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2. Abstract  
The genetic contribution to bladder cancer risk remains undetermined, while the role 
of radiotherapy versus surgery in muscle-invasive bladder cancer (MIBC) treatment 
is hotly debated with the need for predictive biomarkers of treatment response. DNA 
repair pathways are involved in repairing DNA damage from carcinogens thus 
preventing carcinogenesis, but also form one of the 5 R’s of radiobiology for 
determining cancer response to radiotherapy. 
 
The aims of this project were: 
1) To study the contribution of germline DNA repair gene variants, specifically rare 
variants (RV) and 3’-untranslated region (3’UTR) single nucleotide 
polymorphisms (SNP), on bladder cancer risk. 
2) To investigate the predictive value of germline DNA repair gene variants and 
tumour DNA repair protein expression on radiotherapy outcomes in MIBC.  
 
RVs can only be identified by sequencing so a developmental multiplexed next-
generation sequencing (NGS) project was undertaken, identifying two approaches, 
with the choice of method based on balancing costs and labour versus accuracy and 
data needed. Using these methods, candidate RVs were identified in the DNA repair 
genes, MUTYH and XPC, with XPC RVs being associated with an increased bladder 
cancer risk (P=0.008) independent of previously identified GWAS SNPs. Putatively 
functional DNA repair gene 3’UTR SNPs, PARP1 rs8679 and RAD51 rs7180135, 
were found to increase bladder cancer risk (P=0.05) and predict improved survival 
following radiotherapy (P=0.01) respectively. Multiplexed NGS of MRE11A identified 
rs1805363 to be predictive of survival following radiotherapy (P=0.001) but not 
surgery (P=0.89), and to affect MRE11A isoform expression. Tumour DNA repair 
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protein expression of CtIP, MUTYH and XPC were not found to predict survival 
following radiotherapy. 
 
This study demonstrated the contribution of DNA repair gene variants in bladder 
cancer risk and predicting radiotherapy response. These findings could contribute to 
the goal of personalised medicine for targeted primary prevention, early diagnosis 
and treatment individualisation. 
  
 7 
Table of contents 
1. Acknowledgements ............................................................................................. 3 
2. Abstract .............................................................................................................. 5 
3. Glossary ........................................................................................................... 18 
4. Glossary of Next-Generation Sequencing Terminology .................................... 20 
5. Introduction ....................................................................................................... 21 
5.1. Bladder cancer .......................................................................................... 21 
5.1.1. Epidemiology ...................................................................................... 21 
5.1.2. Histopathology and Carcinogenesis .................................................... 22 
5.1.3. Diagnosis and Staging ........................................................................ 27 
5.1.4. Treatment of superficial bladder cancer .............................................. 30 
5.1.5. Treatment of muscle invasive bladder cancer (MIBC) ......................... 31 
5.2. Genetics .................................................................................................... 37 
5.2.1. Common Disease - Common Variant Hypothesis ............................... 37 
5.2.2. Common Disease - Rare Variant Hypothesis ...................................... 41 
5.2.3. DNA sequencing ................................................................................. 45 
5.2.4. MicroRNAs ......................................................................................... 49 
5.3. DNA repair and radiation biology ............................................................... 53 
5.3.1. DNA Repair Pathways ........................................................................ 53 
5.3.2. DNA Repair Variants and Cancer Predisposition ................................ 61 
5.3.3. Ionising Radiation and DNA ................................................................ 62 
5.3.4. Biomarkers of Bladder Cancer and Radiotherapy Outcomes .............. 63 
6. Aims and Objectives ......................................................................................... 67 
7. Materials and Methods ..................................................................................... 69 
7.1. Materials .................................................................................................... 69 
7.2. Study Population ....................................................................................... 69 
7.2.1. Ethical approval .................................................................................. 69 
7.2.2. Leeds Bladder Cancer Study (LBCS) Population ................................ 69 
7.2.3. Muscle Invasive Bladder Cancer (MIBC) Study Population ................. 70 
 8 
7.3. Histopathology ........................................................................................... 71 
7.3.1. Cell lines and culture .......................................................................... 71 
7.3.2. FFPE cell line pellets .......................................................................... 71 
7.3.3. Cell protein lysates and protein concentration quantification ............... 72 
7.3.4. Western Blotting ................................................................................. 73 
7.3.5. Haemotoxylin and Eosin (H&E) Staining ............................................. 74 
7.3.6. Immunohistochemistry (IHC) .............................................................. 74 
7.3.7. Microscopy and Photography and Scoring.......................................... 76 
7.4. Genetics .................................................................................................... 78 
7.4.1. DNA master plate design and alliquoting ............................................ 78 
7.4.2. Reference sequences ......................................................................... 78 
7.4.3. Primer design ..................................................................................... 79 
7.4.4. Polymerase Chain Reaction (PCR) ..................................................... 80 
7.4.5. Gel Electrophoresis ............................................................................ 84 
7.4.6. PCR product purification ..................................................................... 84 
7.4.7. DNA quantification .............................................................................. 85 
7.4.8. Genotyping ......................................................................................... 86 
7.4.9. Conventional DNA sequencing ........................................................... 91 
7.4.10. Next-generation sequencing ........................................................... 92 
7.4.11. MRE11A mRNA isoform expression profiling .................................. 96 
7.5. Bioinformatics ............................................................................................ 98 
7.5.1. Next-generation sequencing ............................................................... 98 
7.5.2. Bioinformatics functional prediction ..................................................... 99 
7.6. Statistical analysis ................................................................................... 101 
7.6.1. Statistical software ............................................................................ 101 
7.6.2. Case-control epidemiological studies ................................................ 101 
7.6.3. Clinical outcome and survival analyses ............................................ 102 
8. Results ........................................................................................................... 103 
 9 
8.1. Developing multiplexed next-generation sequencing for detecting rare 
variants .............................................................................................................. 103 
8.1.1. Unindexed multiplexed next-generation sequencing ......................... 103 
8.1.2. Indexed multiplexed next-generation sequencing ............................. 113 
8.1.3. Unindexed multiplexed next-generation sequencing revisited ........... 118 
8.1.4. Discussion ........................................................................................ 121 
8.2. MUTYH and XPC rare variants in bladder cancer susceptibility ............... 131 
8.2.1. Bladder cancer case-control study population .................................. 131 
8.2.2. Candidate variants for genotyping .................................................... 134 
8.2.3. Rare variants and bladder cancer risk .............................................. 144 
8.2.4. Discussion ........................................................................................ 154 
8.3. DNA repair gene microRNA-binding site SNPs in bladder cancer risk and 
radiotherapy outcomes ....................................................................................... 164 
8.3.1. Bladder cancer case-control study of DNA repair gene miRNA-binding 
site SNPs ........................................................................................................ 164 
8.3.2. DNA repair gene miRNA-binding site SNPs and MIBC radiotherapy 
outcomes ........................................................................................................ 172 
8.3.3. Discussion ........................................................................................ 177 
8.4. Germline MRE11A variants as a biomarker of radiotherapy outcomes in 
muscle-invasive bladder cancer ......................................................................... 183 
8.4.1. Radiotherapy treated MIBC cohort demographics ............................ 183 
8.4.2. Germline MRE11A variants from indexed multiplexed NGS.............. 185 
8.4.3. Validation of rs1805363 .................................................................... 193 
8.4.4. Discussion ........................................................................................ 201 
8.5. Tumour DNA repair protein expression as a marker of radiotherapy 
response ............................................................................................................ 206 
8.5.1. Study population demographics ........................................................ 206 
8.5.2. Antibody specificity validation and optimisation ................................ 208 
8.5.3. Bladder tumour CtIP, MUTYH and XPC expression ......................... 209 
8.5.4. Association with cancer-specific survival .......................................... 211 
 10 
8.5.5. Discussion ........................................................................................ 212 
9. General discussion and future work ................................................................ 218 
10. References .................................................................................................. 224 
11. APPENDICES ............................................................................................. 247 
11.1. Appendix A........................................................................................... 248 
11.2. Appendix B........................................................................................... 268 
11.3. Appendix C .......................................................................................... 295 
11.4. Appendix D .......................................................................................... 305 
11.5. Appendix E........................................................................................... 310 
 
 
 
  
 11 
Table of figures 
Figure 1: Pathways of bladder carcinogenesis ......................................................... 26 
Figure 2 Bladder cancer T-staging ........................................................................... 28 
Figure 3: Treatment algorithm for non-metastatic MIBC ........................................... 32 
Figure 4: Cancer susceptibility loci hits identified by respective cancer site GWAS 
studies up to 2010 ................................................................................................... 39 
Figure 5: Estimated distribution of variants by current population MAFs relative to 
when the variant first arose ...................................................................................... 42 
Figure 6: Predicted distribution of number of rare variant risk alleles carried in a 
case– control population .......................................................................................... 43 
Figure 7: Conventional Sanger sequencing ............................................................. 45 
Figure 8: Illumina Genome Analyzer sequencing workflow ...................................... 48 
Figure 9: MicroRNA biogenesis and its role in mRNA post-transcriptional regulation
 ................................................................................................................................ 50 
Figure 10: Base excision repair of 8-oxoG by MUTYH and OGG1 ........................... 55 
Figure 11: Nucleotide excision repair pathway ......................................................... 57 
Figure 12: DSB repair pathways – NHEJ and HR .................................................... 58 
Figure 13: The MRE11-RAD50-NBS1 complex and its functions in DSB repair 
signalling ................................................................................................................. 60 
Figure 14: Representative sections immunostained for MRE11 demonstrating the 
different staining intensities ...................................................................................... 76 
Figure 15: Blueprint for 96-well master plates for both the LBCS and MIBC study 
germline DNA samples ............................................................................................ 78 
Figure 16: Temperature-shifted, fluorescence-normalised melting curve ................. 91 
Figure 17: PCR Efficiency of MUTYH and XPC amplicons .................................... 104 
Figure 18: Flow chart of sample processing and pooling of purified and unpurified 
PCR products for pilot multiplexed NGS ................................................................ 105 
Figure 19: Relative proportions of each sample in the multiplexed NGS pool and the 
detection of previously identified variants ............................................................... 106 
 12 
Figure 20: Flow chart showing the filtering criteria and identified rare variants by gene 
region .................................................................................................................... 107 
Figure 21: High resolution melting curves for XPC rs3731072 in Pool 24 and 28 ... 108 
Figure 22: Conventional Sanger sequencing electropherogram confirming the 
triallelic XPC rare variants rs3731072 G>C and G>T ............................................. 109 
Figure 23: Allelic discrimination plots using custom Taqman assay AHGI9A3 for XPC 
variant rs3731072 G>C .......................................................................................... 110 
Figure 24: Flowchart of filtered NextGene coding and 3’UTR variants called that were 
selected for confirmation and the number of true variants identified ....................... 111 
Figure 25: Flow chart of candidate XPC variant selection and the number of Sanger 
sequencing confirmed true variants by gene region ............................................... 117 
Figure 26: Flowchart of number of Syzygy variants called, and number of variants at 
each stage of filtering and selection for confirmation .............................................. 120 
Figure 27: Characteristics of variants called by NextGene in each pool in 
chronological order of sequencing ......................................................................... 123 
Figure 28: Receiver operator curve for sensitivity and false discovery rate of 
detecting a variant with unindexed multiplexed NGS ............................................. 125 
Figure 29: Optimum target enrichment strategy relative to number of samples 
sequenced and target size ..................................................................................... 129 
Figure 30: Distribution of variants identified by the 1000 Genomes Exon Pilot Project 
by allele frequency, amino acid change and predicted functional effects by SIFT and 
PolyPhen-2 ............................................................................................................ 156 
Figure 31: The case-control study sample size needed to achieve 80% statistical 
power for a single variant with a MAF of 0.001, 0.025  and 0.05 at different odds 
ratios of effect ........................................................................................................ 158 
Figure 32: Kaplan-Meier graph of cancer-specific survival in combined heterozygotes 
and rare homozygotes of RAD51 rs7180135 (AG+GG) versus wildtype (AA) ........ 175 
Figure 33: Illuminator alignment and coverage data demonstrating regions of poor 
confidence calling .................................................................................................. 185 
Figure 34: MRE11A haplotypes in the study population ......................................... 186 
Figure 35: Linkage disequilibrium plot for all common MRE11A SNPs (MAF>0.01) 
generated using Haploview .................................................................................... 187 
 13 
Figure 36: Kaplan Meier curve of cancer-specific survival for MRE11A rs1805363 
genotypes in the MIBC radiotherapy cohort ........................................................... 188 
Figure 37: Kaplan Meier curve of cancer-specific survival for carriers of at least one 
3’UTR MRE11A rare variant allele in the MIBC radiotherapy cohort ...................... 190 
Figure 38: MRE11A isoform 1 and isoform 2 alternative splicing and the relative 
position of common SNP rs1805363 ...................................................................... 193 
Figure 39: Predicted exonic splice enhancer splice sites in the region surrounding 
rs1805363 using the ESEFinder 3.0 ...................................................................... 193 
Figure 40: Sequence data for genomic DNA from eight bladder cancer and bladder-
derived cell lines .................................................................................................... 194 
Figure 41: MRE11A isoform expression in bladder cancer cell lines and primary 
bladder tumours with different genotypes for rs1805363 ........................................ 195 
Figure 42: Sequencing electropherograms for PCR products corresponding to 
isoform 1 and isoform 2 for RT112 bladder cancer cell line, and primary bladder 
tumours A, B and C ............................................................................................... 197 
Figure 43: Kaplan Meier curve of cancer-specific survival for MRE11A rs1805363 
genotypes in the Aarhus MIBC cystectomy cohort ................................................. 199 
Figure 44: Western blots of cell line extracts for MUTYH, CtIP and XPC ............... 208 
Figure 45: Stained positive control (and negative control in the case of GM15983) cell 
line pellets for MUTYH, CtIP and XPC ................................................................... 208 
Figure 46: Representative images of variation in nuclear CtIP staining and MUTYH 
cytoplasmic staining ............................................................................................... 210 
Figure 47: Kaplan-Meier survival curves of CSS for CtIP, XPC and MUTYH ......... 211 
Figure 48: Western blots using rabbit polyclonal anti-OGG1 antibody on 
manufacturer recommended cell line lysate ........................................................... 216 
  
 14 
Table of tables 
Table 1: 2004 WHO/ 1998 ISUP morphologic classification ..................................... 23 
Table 2: 2010 TNM classification for bladder cancer ................................................ 29 
Table 3: Non-muscle invasive bladder cancer recurrence risk factor weighting, and 
the probability of recurrence by risk group and recurrence score ............................. 30 
Table 4: Comparison of common versus rare disease variant characteristics .......... 41 
Table 5: Comparison between different next-generation sequencing platforms ....... 46 
Table 6: Lesions per Gray of ionising radiation ........................................................ 62 
Table 7: Primary antibody details, IHC conditions and positive control tissue used .. 75 
Table 8: Primer3 settings for primer design according to primer purpose ................. 79 
Table 9: Standard 10 µl long PCR reaction mixes for the different long PCR kits used
 ................................................................................................................................ 81 
Table 10: Standard thermocycling conditions for the different long PCR kits used ... 81 
Table 11: XPC and MUTYH long PCR amplicons and primers for the pilot multiplexed 
NGS study ............................................................................................................... 82 
Table 12: MRE11A long PCR amplicons and primers .............................................. 83 
Table 13: Long PCR amplicons and primers for NGS resequencing of XPC ............ 83 
Table 14: HRM primer sequences and PCR conditions for each variant tested ....... 90 
Table 15: The sensitivity of multiplexed NGS to detect the presence of a true rare 
variant allele relative to Taqman genotyping results ............................................... 112 
Table 16: False positive and true positive rates of potentially functional coding 
variants called by multiplexed NGS successfully validated .................................... 113 
Table 17: Variant calling of the false positive MUTYH rs1140199 variant alleles in the 
original unindexed pool compared to the indexed pool samples ............................ 114 
Table 18: Summary of confirmed MRE11A variants identified by MAF, presence in 
the dbSNP database and gene location. ................................................................ 116 
Table 19: Statistical power of LBCS and combined LBCS and WTCC populations at 
different ORs and MAFs ........................................................................................ 132 
Table 20: Combined LBCS and WTCC case-control study population demographics 
and tumour characteristics ..................................................................................... 133 
 15 
Table 21: MUTYH and XPC rare variants detected by NGS selected for genotyping 
and functional predictions ...................................................................................... 135 
Table 22: Preliminary univariate logistic regression analysis results following Taqman 
genotyping in 750 bladder cancer cases and 706 controls ..................................... 140 
Table 23: Candidate known MUTYH rare variants from the UCSC genome browser 
selected for genotyping in the bladder cancer case-control study population ......... 141 
Table 24: Most significant SNPs from the corresponding bladder cancer GWAS 
publications selected for genotyping in the bladder cancer case-control study ....... 143 
Table 25: List of variants that failed to discriminate on genotyping ......................... 144 
Table 26: Genotyping results for GWAS SNPs with significant associations with 
bladder cancer susceptibility .................................................................................. 146 
Table 27: GWAS SNPs with an independent contribution to bladder cancer 
susceptibility on conditional analyses..................................................................... 148 
Table 28: The number of minor alleles of variants with a control MAF under 0.05 or 
under 0.01 carried by individuals in the combined LBCS and WTCC population .... 149 
Table 29: Genotyping results for MUTYH and XPC variants with significant 
associations with bladder cancer susceptibility ...................................................... 150 
Table 30: Collapsed analyses of MUTYH rs34612342 and rs36053993 from the 
preliminary Taqman genotyping, and the Fluidigm genotyping for the combined LBCS 
and WTCC population and the LBCS population only.............................................152 
Table 31: Associations between bladder tumour phenotype and histological grade 
with GWAS SNPs previously associated with bladder cancer susceptibility ........... 153 
Table 32: Case-control study population demographics and tumour characteristics.
 .............................................................................................................................. 165 
Table 33: List of 20 candidate DNA repair genes investigated for putative miRNA-
binding site SNPs within the gene 3’UTR ............................................................... 167 
Table 34: Candidate DNA repair gene miRNA-binding site SNPs selected for 
genotyping in the bladder cancer case-control study population ............................ 169 
Table 35: Multivariate logistic regression analysis of candidate DNA repair gene 
3’UTR SNPs on bladder cancer risk....................................................................... 171 
Table 36: Multivariate logistic regression analysis of number of unfavourable LIG3 
rs4796030 and PARP1 rs8679 SNP genotypes on bladder cancer risk ................. 172 
 16 
Table 37: Radiotherapy cohort clinical characteristics and Cox multivariate survival 
analysis of the contribution of each variable to cancer-specific survival ................. 174 
Table 38: Cox multivariate analysis of cancer-specific survival and logistic regression 
for late radiation normal tissue toxicity following radical radiotherapy and associations 
with candidate SNPs .............................................................................................. 176 
Table 39: Predicted miRNA bindings sites and predicted ∆G values for MRE11A 
rs2155209.............................................................................................................. 179 
Table 40: Clinical demographics of patients from the MIBC radiotherapy cohort with 
successful long PCR amplification of MRE11A ...................................................... 184 
Table 41: Summary of confirmed MRE11A variants identified................................ 186 
Table 42: Cox proportional hazards multivariate analysis of cancer specific survival in 
covariates, rs1805363, rs13447623 and 3’UTR rare variants................................. 189 
Table 43: Ordered logistic regression of late radiation bladder and rectal toxicity with 
genotype of rs13447623 and rs2155209 ................................................................ 191 
Table 44: MRE11A common SNPs and rare variants with predicted functional effects
 .............................................................................................................................. 192 
Table 45: Overall MRE11A expression normalised to GAPDH expression in bladder 
cancer cell lines and primary bladder tumours A, B and C by MRE11A rs1805363 
genotype ................................................................................................................ 196 
Table 46: Clinical demographics of patients from the MIBC cystectomy cohort ...... 198 
Table 47: Cox proportional hazards multivariate analysis of cancer specific survival 
for rs1805363 in the cystectomy treated cohort ..................................................... 200 
Table 48: Clinical demographics of bladder cancer patients treated by radical RT 
between 2002 and 2005 ........................................................................................ 207 
Table 49: MUTYH long PCR primers and conditions for the pilot multiplexed NGS 
study ...................................................................................................................... 253 
Table 50: XPC long PCR primers and conditions for the pilot multiplexed NGS study
 .............................................................................................................................. 254 
Table 51: MRE11A long PCR primers and conditions ............................................ 254 
Table 52: Long PCR primers and conditions for NGS resequencing of XPC .......... 256 
Table 53: Conventional sequencing primers designed for specific MRE11A and XPC 
variants .................................................................................................................. 257 
 17 
Table 54: Conventional sequencing primers for exons of MUTYH and XPC .......... 262 
Table 55: Applied Biosystems Taqman SNP Genotyping Primers and Probes for 
MUTYH rare variants genotyped ............................................................................ 263 
Table 56: Applied Biosystems Taqman SNP Genotyping Primers and Probes for XPC 
rare variants genotyped ......................................................................................... 264 
Table 57: Applied Biosystems Taqman SNP Genotyping Primers and Probes for 
DNA repair 3’UTR SNPs genotyped ...................................................................... 265 
Table 58: Applied Biosystems Taqman SNP Genotyping Primers and Probes for 
MRE11A rs1805363 .............................................................................................. 265 
Table 59: Illumina sequencing adaptor oligonucleotide sequences and index 
sequences ............................................................................................................. 266 
Table 60: Analysis for all confirmed MRE11A variants for associations with cancer-
specific survival and radiotherapy toxicity .............................................................. 296 
Table 61: Functional predictions for all confirmed MRE11A variants ...................... 300 
Table 62: All DNA repair gene 3’UTR SNPs identified located within a predicted 
miRNA binding site and predicted ∆G values ......................................................... 305 
 
  
 18 
3. Glossary 
G Gibbs binding free energy 
Ago Argonaute 
BER base excision repair 
bp base pairs 
BSA bovine serum albumin 
CDCV Common Disease – Common Variant hypothesis 
CDRV Common Disease – Rare Variant hypothesis 
CI confidence interval 
CSS cause specific survival 
CT computed tomography 
CTV clinical target volume 
DSB double strand breaks 
dsDNA double stranded DNA 
EORTC European Organization for Research and Treatment of Cancer 
FFPE formalin-fixed paraffin-embedded 
FPRP False Positive Reporting Probability 
Gb gigabases 
GGR global genome repair 
GWAS genome wide association study 
H&E haematoxylin and eosin 
HR hazard ratio 
HRM high resolution melting 
HRR homologous recombination repair 
IFC Integrated Fluidic Circuit 
IR ionising radiation 
LBCS Leeds Bladder Cancer Study  
LD linkage disequilibrium 
LIMM Leeds Institute of Molecular Medicine 
LOD logarithm of odds 
LTHT Leeds Teaching Hospitals NHS Trust 
MAF minor allele frequency 
MAP MUTYH-associated polyposis 
Mb megabases 
MIBC muscle-invasive bladder cancer  
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miRNA micro-RNA 
MMEJ microhomology-mediated end joining 
MRI magnetic resonance imaging 
MRN MRE11-RAD50-NBS1 complex 
NCI National Cancer Institute 
ncRNA non-coding RNA 
NER nucleotide excision repair 
NGS next-generation sequencing 
NHEJ non-homologous end joining 
OR odds ratio 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pre-miRNA precursor-microRNA 
pri-miRNA primary-microRNA 
psi pound-force per square inch 
RCT randomised control trial 
RISC RNA-induced silencing complex 
RT radiotherapy 
RTOG Radiation Therapy Oncology Group 
RV rare variant 
SBC streptavidin-biotin complex 
SIR standardised incidence ratio 
SJIO St James’s Institute of Oncology 
SJUH St James’s University Hospital 
SNP single nucleotide polymorphism 
SNV single nucleotide variants 
SQS semi-quantitative score 
TBE Tris/ Borate/ EDTA 
TBS Tris-buffered Saline 
TCR transcription-coupled repair 
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UC urothelial carcinoma 
UCSC University of California Santa Cruz 
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4. Glossary of Next-Generation Sequencing 
Terminology 
Bar-coding The tagging of DNA fragments in each sequencing library with a 
unique six oligonucleotide sequence. Used together with multiplexing. 
Coverage 
(Depth of) 
The average number of times each nucleotide base has been 
sequenced. 
Indexing Same as “Bar-coding”. 
Multiplexing The pooling of multiple different DNA samples together. 
Paired-end 
Reads 
The sequencing of DNA fragments from the 5’- to 3’-end followed by 
sequencing from the 3’- to 5’-end. 
Read Depth Same as “Coverage” 
Read Length The number of contiguous nucleotide bases sequenced for each 
DNA fragment. On the Illumina platform, usually user-defined by the 
number of DNA sequencing-by-synthesis cycles performed (ie. the 
number of cycles labelled nucleotides are added and imaged). 
Sequence 
Alignment 
The lining up of DNA fragment sequences against a reference 
sequence and to each other to determine the DNA sample’s 
sequence. 
Sequencing 
Depth 
Same as “Coverage”. 
Single-end 
Reads 
The sequencing of DNA fragments from the 5’- to 3’-end only. 
Target Size The total length (in nucleotide base pairs) of the DNA sample being 
sequenced. 
Variant 
Calling 
The identification of specific sequence variation in the DNA sample 
compared to the reference sequence used for sequence alignment. 
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5. Introduction 
5.1. Bladder cancer 
5.1.1. Epidemiology 
Bladder cancer is the seventh most common cancer in the United Kingdom (UK) and 
the fourth commonest cancer among men, with approximately 11000 new cases 
diagnosed per year (Cancer Research UK 2010). It is also the eighth highest cause 
of cancer death in the UK killing approximately 5000 people per year and is the sixth 
most common cause of male cancer death. In the United States, bladder cancer has 
the fifth highest healthcare budgetary costs amongst all cancers and the highest 
monitoring and treatment costs per patient from diagnosis to death (Botteman et al. 
2003). Bladder cancer is predominantly seen in men, with a male to female ratio of 
5:2, and the elderly, with 80 percent of cases occurring in people over the age of 65 
years.   
 
In the developed world, tobacco smoking and occupational exposure to industrial 
chemicals, such as from the dye, printing and rubber industries, are major pre-
disposing risk factors for bladder cancer (Glashan and Cartwright 1981; Morrison et 
al. 1984; Kogevinas et al. 1998). The population attributable risk (the additional 
disease risk in a population due to an exposure) of bladder cancer from cigarette 
smoking is about 50% with current smokers having quadruple the bladder cancer risk 
of never smokers (Freedman et al. 2011). In the UK, occupational carcinogen 
exposure was estimated to account for 5.3% (7.1% in men, 1.9% in women) of the 
population bladder cancer attributable risk and 245 attributable deaths per year 
(Brown et al. 2012). However, in Africa especially Egypt, chronic bladder 
inflammation secondary to endemic schistosomiasis parasitic infections is the main 
mechanism of carcinogenesis leading to high bladder cancer rates (Mostafa et al. 
1999). 
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Genetic factors also play a role in bladder cancer pre-disposition as suggested by 
racial differences and the association of family history with bladder cancer risk.  
Caucasian Americans have a higher incidence of bladder cancer compared to 
African Americans with a greater dose-response effect with increasing cigarette 
consumption on bladder cancer risk (Schairer et al. 1988; Harris et al. 1990). Kantor 
et al reported that a family history of a first-degree relative with bladder cancer 
resulted in an increased bladder cancer risk (relative risk = 1.45) in the United States 
(Kantor et al. 1985), while in Sweden, Plna et al observed familial risks of 1.35 to 
2.29 (Plna and Hemminki 2001). Similar findings were then reported by Aben et al in 
a Dutch population (odds ratio (OR) 1.8 [95% confidence interval (CI) 1.3 – 2.7]) 
(Aben et al. 2002) and by the Spanish Bladder Cancer Study (OR 1.32 [95%CI 1.01 - 
1.50]) who also reported an increased risk of developing early onset disease (Murta-
Nascimento et al. 2007).   
 
5.1.2. Histopathology and Carcinogenesis  
5.1.2.1. Histopathology 
In the Western world, urothelial carcinoma (UC) accounts for more than 90% of 
bladder cancer and, as the name denotes, originates from the bladder urothelial 
epithelium. Macroscopically, UC tumours present as flat or papillary lesions while 
microscopic grading is based on cytological and architectural atypia, nuclear 
pleomorphisms and mitoses (Stevens and Lowe 1995; Grignon 2009). The 2004 
WHO/ 1998 ISUP morphologic classification is typically used for histological grading 
and is summarised in Table 1. 
 
Due to the entire bladder urothelium being exposed to causative carcinogens in the 
urine, there is often a “field-change” throughout the urothelium with 25% of cases 
showing dysplasia around primary tumours, and 60% of cases developing 
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recurrences distant to the primary tumours with multi-focal or multiple co-existing UC 
tumours also seen (Harris and Neal 1992; Stevens and Lowe 1995). These co-
existing multi-focal tumours were also found to be predominantly of oligoclonal origin, 
with each tumour having distinctly different genetic alterations (Jones et al. 2005). 
There is frequent divergent differentiation in UCs with a variable proportion of cancer 
cells showing adenomatous, squamous, or small cell differentiation with the latter two 
possibly indicative of a worse prognosis (Lopez-Beltran et al. 2004). 
 
Table 1: 2004 WHO/ 1998 ISUP morphologic classification defining the microscopic 
morphologic appearances of bladder lesions (adapted from (Lopez-Beltran et al. 2004; 
Grignon 2009; Babjuk et al. 2011)). Images from (Lopez-Beltran et al. 2004) 
Flat lesions 
 
Hyperplasia  
(flat lesion without atypia or papillary aspects) 
 
Reactive atypia (flat lesion with atypia) 
 
Atypia of unknown significance 
Dysplasia  
(Intra-Urothelial Neoplasia, low-grade) 
 
Carcinoma in situ  
(Intra-Urothelial Neoplasia, high-grade) 
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Invasive carcinoma 
 
Papillary lesions 
 
Urothelial papilloma (benign lesion) 
 
Papillary urothelial neoplasm of low malignant 
potential 
 
Papillary urothelial carcinoma, low-grade 
 
Papillary urothelial carcinoma, high-grade 
 
 
The remaining approximately 10% of bladder cancers consist of pure squamous cell 
carcinomas (<5%), typically associated with chronic inflammation from calculi or 
schistosomiasis, adenocarcinomas (< 2%) usually originating from urachal remnants, 
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and rarer histological types such as small cell carcinoma, lymphoma and sarcoma.  
This thesis will predominantly focus on UCs of the bladder. 
 
5.1.2.2. Molecular genetics of bladder carcinogenesis 
Carcinogenesis is “the evolution of an invasive cancer cell from a normal cell” (Martin 
1998). The multistep model of carcinogenesis involves sequential mutations resulting 
in down-regulation of tumour suppressor genes and up-regulation of oncogenes, 
genes that are involved in inhibiting or contributing to cancer development and 
progression respectively. These sequential mutations lead to initiation of a tumour, 
promotion of tumour growth and progression to invasive carcinoma (Okey et al. 
2005). Multiple somatic mutations have been identified in bladder tumours affecting 
growth factor receptors, signalling pathways and cell-cycle control genes. 
Chromosomal abnormalities are seen in over 60% of bladder UCs with loss of 
heterozygosity reported in 2q (long arm of chromosome 2) (58%), 5q (6-50%), 8p 
(short arm of chromosome 8) (18-83%), 9p (33-82%), 9q (43-90%), 10q (39-45%), 
11p (9-72%), 18q (36-51%) and the Y chromosome (11%) as well as amplifications 
at 1q (37-54%), 5p (24-25%), 8q (37-54%), and 17q (29-49%) (Lopez-Beltran et al. 
2004; Knowles 2006).  Identification of all the genes responsible for tumour survival 
and growth in these large chromosomal regions remains work in progress.  
 
However, distinct patterns of somatic mutations have been identified in papillary and 
flat/ dysplastic UC lesions with allelic loss of chromosome 9 being more common in 
the former while TP53 mutations and loss of chromosome 17 are more common in 
the latter (Spruck et al. 1994; Knowles 2006).  Two separate bladder tumorigenesis 
pathways have thus been proposed for the development of these two phenotypically 
different UC tumour subtypes (Figure 1) (Castillo-Martin et al. 2010; Goebell and 
Knowles 2010).  
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Figure 1: Pathways of bladder carcinogenesis (adapted from (Goebell and Knowles 
2010)). The genomically stable papillary tumour pathway (blue) involving FGFR3 and 
RAS oncogene mutations, progressing to frequently recurring low grade papillary 
tumours, while the genomically unstable invasive carcinoma pathway (red) with 
mutations in TP53, RB and PTEN tumour suppressor genes, progressing to invasive 
carcinoma. The broken arrows indicate potential alternative pathways of progression. 
 
The papillary tumour pathway, as previously stated, is typically associated with loss-
of-heterozygosity in chromosome 9 and commonly early activating mutations in 
oncogenes such as FGFR3, RAS and in the PI3-kinase pathway (Knowles 2006; 
Castillo-Martin et al. 2010).  FGFR3, fibroblast growth factor receptor 3, is a cell 
surface receptor thought to activate the Ras-MAPK signalling pathway. Activating 
mutations or overexpression of FGFR3 has been reported in 80% of superficial 
papillary tumours compared to 50% of invasive cancers (Goebell and Knowles 2010) 
and is not seen in papillary tumours carrying Ras mutations (Jebar et al. 2005), 
perhaps indicating distinct processes of papillary tumorigenesis. Despite frequent 
recurrences, papillary tumours remain genetically stable. 
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The invasive carcinoma pathway, however, is associated instead with tumour 
initiating deletions or mutations of tumour suppressor genes resulting in inactivation 
of TP53, RB1, and PTEN (Knowles 2006; McConkey et al. 2010). Mutations in TP53, 
a transcription factor involved in cell cycle arrest and apoptosis, are seen in 70% of 
invasive bladder carcinomas, but less than 20% of papillary tumours, with TP53 and 
FGFR3 mutations being almost mutually exclusive (Bakkar et al. 2003; Knowles 
2006). CDKN2A mutations are frequently seen in both superficial and invasive 
tumours (Goebell and Knowles 2010). Invasive tumours are genetically unstable, 
frequently accumulating further genetic aberrations and mutations, thus progressing 
to more advanced disease.  
 
5.1.3. Diagnosis and Staging 
5.1.3.1. Clinical Presentation 
Bladder cancer presents with frank haematuria with or without dysuria in 85% of 
cases (Lopez-Beltran et al. 2004); other patients present with symptoms of cystitis or 
anaemia (Blandy 1998). Tumours at the bladder neck may present with urgency or 
frequency while tumours obstructing the ureteric orifice may cause hydronephrosis 
with resulting flank pain and renal dysfunction. First presentation with extensive 
pelvic or metastatic disease is uncommon in bladder cancer. 
 
5.1.3.2. Diagnosis and staging 
The current gold standard for diagnosis of bladder cancer is by cystoscopy and 
transurethral resection of the bladder tumour (TURBT- see section 5.1.4.1, page 36 ) 
to obtain a biopsy specimen (British Association of Urological Surgeons and British 
Uro-oncology Group 2007). Further investigations and management will be 
dependent on the histological findings, multi-focal nature of the disease and previous 
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history and treatment for bladder cancer. WHO tumour staging is shown in Figure 2 
while the full 2010 TNM (tumour, nodes, metastasis) classification in Table 2.  
 
 
Figure 2 Bladder cancer T-staging (Cancer Research UK 2010) 
 
High risk (large, multifocal or treatment-resistant tumours) or high grade superficial 
disease may require further resection to confirm the extent of disease, random 
biopsies to exclude multifocal disease or intravenous urography/ ultrasonography to 
detect synchronous upper urinary tract tumours (British Association of Urological 
Surgeons and British Uro-oncology Group 2007).  About 80% of bladder cancers 
present as superficial papillary tumours with the remainder presenting as invasive 
disease.  Fifteen percent of superficial disease will progress to become muscle 
invasive disease (Castillo-Martin et al. 2010). In view of this, regular follow-up 
cystoscopy is performed for all patients with superficial bladder cancers for the early 
detection of disease recurrence or progression (Babjuk et al. 2011).  
Muscle-invasive disease consists of WHO T-stage of 2 or greater tumours (Table 2), 
with invasion into the detrusor muscle, the smooth muscle layer of the bladder wall, 
and is associated with access to the lymphatic drainage system, and hence the 
potential for tumour spread to regional lymph nodes and more distant spread (Blandy 
 29 
1998). Staging for muscle-invasive disease requires an overall assessment of patient 
fitness for treatment and magnetic resonance imaging (MRI) of the pelvis and 
computed tomography (CT) of the thorax, abdomen and pelvis to assess the extent 
of bladder wall invasion, local and distant spread (British Association of Urological 
Surgeons and British Uro-oncology Group 2007). Routine blood tests performed are 
a full blood count for anaemia, biochemistry for renal dysfunction, and alkaline 
phosphatase for potential bone involvement. 
 
Table 2: 2010 TNM classification for bladder cancer (adapted from (Edge et al. 2010)). 
2010 Tumour Node Metastases Classification of Urinary Bladder Cancer 
T - Primary Tumour  
Tx Primary tumour cannot be assessed.  
T0 No evidence of primary tumour. 
Superficial 
Disease 
 Ta Noninvasive papillary carcinoma. 
 Tis Carcinoma in situ: "flat tumour." 
T1 Tumour invades subepithelial connective tissue. 
T2 Tumour invades muscularis propria. 
Muscle-
Invasive 
Disease 
(Non-
metastatic) 
 T2a 
Tumour invades superficial muscularis propria (inner 
half). 
 T2b Tumour invades deep muscularis propria (outer half). 
T3 Tumour invades perivesical tissue. 
 T3a Microscopically. 
 T3b Macroscopically (extravesical mass). 
T4 
Tumour invades any of the following: prostatic stroma, seminal 
vesicles, uterus, vagina, pelvic wall, abdominal wall. 
 T4a Tumour invades prostatic stroma, uterus, vagina. 
 T4b Tumour invades pelvic wall, abdominal wall. 
N - Lymph Nodes 
NX Lymph nodes cannot be assessed. 
N0 No lymph node metastasis. 
N1 
Single regional lymph node metastasis in the true pelvis 
(hypogastric, obturator, external iliac or presacral lymph node). 
Advanced 
Disease 
(Metastatic) 
N2 
Multiple regional lymph node metastases in the true pelvis 
(hypogastric, obturator, external iliac or presacral lymph node). 
N3 Lymph node metastases to the common iliac lymph nodes. 
M - Distant Metastases 
M1 Distant metastasis. 
M0 No distant metastasis.  
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5.1.4. Treatment of superficial bladder cancer 
5.1.4.1. Transurethral Resection of Bladder Cancer (TURBT) 
TURBT is the primary method for diagnosis and treatment of all superficial bladder 
tumours (British Association of Urological Surgeons and British Uro-oncology Group 
2007; Babjuk et al. 2011). Under direct visualisation by flexible cystoscopy, the 
bladder tumour is excised down to the detrusor muscle layer of the bladder wall with 
a surrounding resection margin. Complete resection with detrusor muscle seen in the 
resection sample is associated with reduced recurrence rates (Mariappan et al. 
2010). 
 
Table 3: Non-muscle invasive bladder cancer recurrence risk factor weighting, and the 
probability of recurrence by risk group and recurrence score (adapted from (Sylvester 
et al. 2006; Babjuk et al. 2011)). 
Risk Factor Recurrence 
weighting 
score 
 Risk group Recurrence 
score 
Probability of 
recurrence at 1 year 
Number of tumours    % (95% CI) 
Single 0  Low risk 0 15 (10-19) 
2-7 3  Intermediate 
risk 
1-4 24 (21-26) 
> 8 6  5-9 38 (35-41) 
Tumour diameter   High risk 10-17 61 (55-67) 
< 3 cm 0      
> 3 cm 3      
Prior recurrence rate      
Primary 0      
< 1 recurrence/year 2      
> 1 recurrence/year 4      
Category      
Ta 0      
T1 1      
Concurrent CIS      
No 0      
Yes 1      
Grade (WHO 1973)      
G1 0      
G2 1      
G3 2      
Total score 0-17      
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5.1.4.2. Intra-vesical Mitomycin C chemotherapy 
Over 24% of intermediate-risk superficial tumours recur following TURBT (Table 3) 
(Millan-Rodriguez et al. 2000; Babjuk et al. 2011). In this group of patients, adjuvant 
intravesical chemotherapy with a single instillation of Mitomycin C is recommended 
with a  24% relative risk reduction in recurrence rates (British Association of 
Urological Surgeons and British Uro-oncology Group 2007; Babjuk et al. 2011). 
 
5.1.4.3. Local Bacillus Calmette-Guerin (BCG) injection 
BCG immunotherapy is recommended for high risk superficial tumours (Table 3) as 
over 60% of cases recur and are at high risk of progression to muscle-invasive 
disease (British Association of Urological Surgeons and British Uro-oncology Group 
2007; Babjuk et al. 2011). Maintenance BCG treatment with 27 doses over 3 years is 
associated with improved recurrence-free and overall survival (Lamm et al. 2000).  
 
5.1.5. Treatment of muscle invasive bladder cancer (MIBC) 
Curative treatments for MIBC in the United Kingdom consist of either radical 
cystectomy or radical RT with / without neoadjuvant chemotherapy (Figure 3) (British 
Association of Urological Surgeons and British Uro-oncology Group 2007). 
 
5.1.5.1. Neoadjuvant, concurrent and adjuvant chemotherapy 
Neoadjuvant cisplatin-based chemotherapy prior to curative surgery or radiotherapy 
to downstage disease and eradicate micrometastases is recommended for all non-
metastatic MIBC.  This is based on a Cochrane review meta-analysis of 11 trials 
finding a significant benefit in disease-specific and overall survival at 5 years 
(absolute improvement of 9% and 5% respectively) with platinum-based combination 
chemotherapy (Vale and Advanced Bladder Cancer Meta-analysis Collaboration 
2004; Vale and ABC Meta-analysis Group 2005).  
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Figure 3: Treatment algorithm for non-metastatic MIBC (British Association of 
Urological Surgeons and British Uro-oncology Group 2007) 
 
The optimum regimen of concurrent chemo-radiotherapy remains unclear.  Until 
recently, there has been only one published small randomised trial (99 patients only) 
comparing radiotherapy with or without concurrent cisplatin chemotherapy, which 
found a significant improvement in control of pelvic disease but not survival although 
its power was very limited (Coppin et al. 1996).  In a single centre study looking at 
four consecutive patient cohorts with gradual introduction of different platinum-based 
chemotherapy regimens between 1982 and 2006, the authors found improvement in 
5-year overall survival in the concurrent chemotherapy cohorts though this could be 
confounded by advancements in patient care and RT techniques (Ott et al. 2009).  A 
recent Phase II trial using concurrent gemcitabine with hypofractionated RT has 
generated promising results with 3-year overall survival rates of 75% compared to 
46% in previously reported RT-only results (Hoskin et al. 2010; Choudhury et al. 
2011). The recently published BC2001 phase III randomised control trial (RCT) 
comparing radical radiotherapy versus radiotherapy with synchronous Mitomycin C 
and 5-fluorouracil has reported a significant improvement in loco-regional control, 
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with no increase in treatment morbidity, but no significant difference in cancer-
specific survival or overall survival although this may have been an issue of statistical 
power with subjective separation of the survival curves (James et al. 2012).  
 
The BCON phase III RCT (Hoskin et al. 2010) explored the addition of concurrent 
carbogen (a normobaric 98% oxygen/ 2% carbon dioxide gas mixture), and 
nicotinamide as radiosensitisers to RT treatment. These radiosensitisers were to 
overcome chronic diffusion-limited tumour hypoxia by enhancing oxygen delivery, 
and to stabilise oxygen delivery by reducing intermittent tumour blood flow closure 
thus overcoming acute perfusion-limited tumour hypoxia respectively (Chaplin et al. 
1991). In this trial, use of concurrent carbogen and nicotinamide with RT resulted in 
an absolute 11% improvement in 3-year relapse-free survival and 13% improvement 
in 3-year overall survival with no increase in radiotherapy toxicity. 
 
The role of adjuvant chemotherapy in advanced localised disease (T3 and T4) 
remains unclear due to small study sizes and failure of recruitment in trials (Calabro 
and Sternberg 2009).  A meta-analysis of six trials using cisplatin-based 
chemotherapy found a significant 25% relative risk reduction of death with 
chemotherapy (P=0.02).  However, this meta-analysis was limited by small numbers, 
poor treatment arm compliance, and trials closing early (Vale and ABC Meta-analysis 
Group 2005). 
 
5.1.5.2. Radical radiotherapy 
Radical RT is a curative treatment modality for non-metastatic MIBC allowing the 
preservation of the bladder thus maintenance of urinary continence in most cases. In 
the UK, besides patient choice, factors favouring radiotherapy treatment are related 
to fitness for surgical treatment, successful technical delivery and safety of 
radiotherapy, concurrent co-morbidities, bladder function and the presence of ureteric 
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obstruction and hydronephrosis (British Association of Urological Surgeons and 
British Uro-oncology Group 2007).  
 
Maximal TURBT is preferred for maximum tumour debulking prior to RT (Efstathiou 
et al. 2012; Hindson et al. 2012). A planning CT scan is performed with the patient 
supine. The clinical target volume (CTV) is delineated encompassing the entire 
bladder and a 0.5 cm margin around the tumour bearing wall and regions clinically or 
radiologically suspect for extra-vesicular extension. A further 1.5 to 2 cm margin is 
added to the CTV to generate the planning target volume (PTV) (James and Zarkar 
2006). The PTV receives at least 95% of the total prescribed radiotherapy dose of 64 
Gy in 32 fractions using conventional fractionation or a hypofractionated schedule of 
52.5 - 55Gy in 20 fractions (James and Zarkar 2006; Hindson et al. 2012).  
 
Acute radiotherapy toxicity, which occurs during treatment and for several weeks 
afterwards, includes lethargy, radiation dermatitis, diarrhoea, tenesmus, proctitis and 
cystitis (British Association of Urological Surgeons and British Uro-oncology Group 
2007), with the majority of patients developing bowel and/or urinary symptoms, 
although reported severe toxicity rates (Radiation Therapy Oncology Group (RTOG)/ 
European Organization for Research and Treatment of Cancer (EORTC) radiation 
toxicity score ≥ 3) are low (3% and 5% respectively)  (Sengelov and von der Maase 
1999; Majewski and Tarnawski 2009). Late radiotherapy side-effects, which develop 
three or more months post-RT treatment, include bladder fibrosis and shrinkage, 
haematuria from bladder telangiectasia, impotence, radiation proctitis, and, more 
uncommonly, ileus or fistula formation and, rarely, secondary malignancies. Of the 
60% of male patients with sexual dysfunction post-RT, 75% of these reported that 
this was secondary to other factors and not just RT per se (Fokdal et al. 2004).  Five-
year risk of severe late radiation bladder or bowel toxicity is between 3-8% (Sengelov 
and von der Maase 1999; Majewski and Tarnawski 2009). 
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5.1.5.3. Radical and salvage cystectomy 
Radical cystectomy is the curative surgical option for MIBC; it involves the excision of 
the whole bladder, with any macroscopic tumour extension beyond the bladder wall, 
the adjacent distal ureters and pelvic lymph nodes (Blandy 1998; British Association 
of Urological Surgeons and British Uro-oncology Group 2007; Stenzl et al. 2011). In 
men, the prostate gland is also resected, with over 65% of patients found to have an 
unsuspected prostate adenocarcinoma or urothelial cancer (Stenzl et al. 2011).  
Salvage cystectomy involves the same surgical technique but is performed in the 
setting of local treatment failure or relapse following radical radiotherapy. Post-
cystectomy, there are three main options for urinary diversion: 1) via an abdominal 
stoma by direct diversion of the ureters, through an ileal conduit or a continent 
abdominal pouch, 2) by drainage into the large bowel via a rectosigmoid diversion, 
and, 3) via the urethra by construction of an orthotopic neobladder using a section of 
bowel (Blandy 1998; Stenzl et al. 2011). 
 
Common early surgical complications are prolonged ileus after surgery, anastamotic 
leakage or suture breakdown of urinary diversions and reconstructed bladders (with 
associated risk of peritonitis), thromboembolic events, and respiratory infections 
(Blandy 1998). About 50% of cystectomy patients develop a surgical complication, 
with the rate being even higher in salvage cystectomy cases (Stenzl et al. 2011; 
Eswara et al. 2012). Long-term morbidity is mainly related to complications of the 
urinary diversion and includes urinary tract infections and incontinence, but also 
includes male impotence and erectile dysfunction (Stenzl et al. 2011). 
 
5.1.5.4. Radical cystectomy versus radical radiotherapy 
There are no definitive international guidelines on the curative treatment modality of 
choice for MIBC with guidelines and practices varying between countries and centres 
(British Association of Urological Surgeons and British Uro-oncology Group 2007; 
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Stenzl et al. 2011; Efstathiou et al. 2012; Hindson et al. 2012).  The gold standard in 
the United States of America (USA) and Europe remains radical cystectomy while in 
the UK and a few centres in Europe and at the Massachusetts General Hospital, the 
preferred treatment option is radical radiotherapy (RT) with or without concurrent 
chemotherapy (James and Hussain 2005; Rodel et al. 2005; Efstathiou et al. 2012).  
There has been only one randomised Phase III clinical trial comparing radical 
cystectomy versus radical RT but this trial was closed early due to poor accrual, 
partly due to those patients declining randomisation preferring bladder preservation, 
and hence RT (Huddart et al. 2010).  A Cochrane review covering only three trials (all 
prior to 1995, with two trials before 1980) comparing pre-operative RT and radical 
cystectomy versus radical RT and salvage cystectomy found a small survival benefit 
with surgery (Shelley et al. 2008).  However, all three trials were relatively small, and 
both surgical and RT techniques have advanced significantly since then, with 
orthotopic bladder reconstruction in surgery and, for RT, CT planning, improved dose 
delivery, conformal and image-guided adaptive RT (Pos and Remeijer 2010; 
Lalondrelle et al. 2011; Thariat et al. 2012).  In an audit in Leeds looking at MIBC 
patients treated by cystectomy or RT between 1995 and 2000, there was no 
significant difference seen in 5-year disease specific survival (53.4% versus 56.8% 
respectively) (Kotwal et al. 2008).  A recent study of the Surveillance, Epidemiology, 
and End Results database of MIBC patients between 1988 and 2006 in the USA also 
found no significant difference in overall survival between radical cystectomy or RT 
after adjusting for confounding factors (Kozak et al. 2012). 
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5.2. Genetics 
Understanding the genetics of inherited bladder cancer risk is important to improve 
knowledge of the underlying mechanisms of bladder carcinogenesis which in turn 
could lead to the discovery of new therapeutic targets. Knowledge of the genetic 
determinants of bladder cancer inherited risk could also potentially allow the prospect 
of estimating individual cancer risk, thus providing targeted lifestyle advice for 
primary prevention or for targeted screening. 
 
5.2.1. Common Disease - Common Variant Hypothesis 
Single nucleotide polymorphisms (SNP) are common single base DNA variations that 
have a minor allele frequency (MAF) of more than one percent.  The “common 
disease - common variant” (CDCV) hypothesis proposes that a few common SNPs 
sited at a few specific disease loci are predominantly responsible for the genetically 
attributable risk of common diseases such as cancer (Reich and Lander 2001).   
 
Previously, the acetylator activity status of N-acetyltransferase,  a gene involved in 
detoxifying aromatic hydrocarbons such as those from tobacco smoke, was  
demonstrated to be associated with bladder cancer risk (Cartwright et al. 1982), with 
acetylator status being known to be related to SNPs in this gene (Evans and White 
1964). Candidate SNP studies by the Spanish Bladder Cancer Study proceeded to 
demonstrate that SNPs resulting in deletion of the glutathione-S-transferase M1 
(GSTM1) gene (also involved in detoxifying aromatic hydrocarbons ) and slow N-
acetyltransferase acetylator (NAT2) status resulted in an overall increased risk (OR 
4.21 [95%CI 1.26-14.14] and OR 4.76 [95%CI 1.25-18.09]) of bladder cancer 
(Garcia-Closas et al. 2005). 
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Genome wide association studies (GWAS) explore the CDCV hypothesis further by 
unbiased high-throughput genotyping of hundreds of thousands of SNPs spread 
throughout the genome in large case-control studies. Geographically close SNPs 
tend to be in “linkage”, that is they tend to be inherited together, and “tag” SNPs are 
SNPs which provide representative information of the presence of surrounding linked 
SNPs. Thus by targeting tag SNPs, the GWAS approach is able to detect the effects 
of SNPs not genotyped and, with sufficiently dense SNP spacing, is able to provide 
information on the majority of SNPs in the whole genome (Iles 2008). Multiple cancer 
GWAS have been conducted with many positive cancer disease-susceptibility loci 
discovered (Figure 4) (Cooper and Shendure 2011).  However, not all associations 
were replicated (Lohmueller et al. 2003) and the majority of successfully replicated 
SNPs had low penetrance (ie. only a small proportion of carriers go on to develop 
cancer) with small effect sizes (mean OR between 1.2 and 1.5) with only a few 
having ORs greater than two (Bodmer and Bonilla 2008; Iles 2008; Schork et al. 
2009; Carvajal-Carmona 2010).   
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Figure 4: Cancer susceptibility loci hits identified by respective cancer site GWAS 
studies up to 2010 (red asterisk for GWAS bladder cancer loci) (Hindorff et al. 2011). 
 
5.2.1.1. Genome wide association studies in bladder cancer 
The three initial bladder cancer GWAS completed in Europe and the USA identified 
eight disease loci, with replication of disease loci on chromosomes 3q28 (closest 
gene TP63), 4p16.3 (FGFR3), 8q24.21 (MYC) and 8q24.3 (PSCA) in all three 
studies, with allelic ORs of about 1.2 (Kiemeney et al. 2008; Wu et al. 2009; Rothman 
et al. 2010; Fu et al. 2012).  The roles of these genes in bladder carcinogenesis is 
biologically feasible: FGFR3 mutations are commonly seen in superficial tumours as 
mentioned earlier (Goebell and Knowles 2010), PSCA is overexpressed with 
increasing grade of bladder tumour, with PSCA mRNA expression levels being 
predictive of superficial tumour recurrence, the transcription factor MYC is involved in 
cell proliferation and is associated with other malignancies, and the tumour 
suppressor TP63 is involved in cell cycle arrest and apoptosis (Kiltie 2010). Wu et al 
demonstrated that the different alleles of the GWAS SNP hit PSCA rs2294008 
* 
* 
* 
* 
* 
* 
* 
* 
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resulted in alterations in the transcriptional promoter activity of PSCA, while 
resequencing the PSCA gene identifed seven common PSCA SNPs all in strong 
linkage disequilibrium (LD) with rs2294008 and having similar effects on bladder 
cancer risk (Wu et al. 2009). 
 
Pathway based analysis of the National Cancer Institute (NCI) GWAS identified 
signals in three main cellular processes – vesicle biogenesis and budding involved in 
intra- and extra-cellular signalling, mitosis, and metabolic detoxification including 
aromatic amine metabolism (Menashe et al. 2012). As mentioned earlier, aromatic 
amine metabolism is implicated in bladder cancer risk from candidate gene SNP 
studies of NAT2 and GSTM1 genes (Garcia-Closas et al. 2005).  By imputation and 
targeted Sanger sequencing of the NCI GWAS hit rs11892031 within intron 1 of the 
UGT1A gene (coding for an enzyme involved in aromatic amine detoxification) 
located on chromosome 2q37.1, an uncommon synonymous coding UGT1A SNP, 
rs17863783 (MAF 2.5%), was identified. This SNP explained the genetic association 
seen with rs11892031, and was found to be protective for bladder cancer risk (allelic 
OR 0.55) and associated with increased mRNA expression of the UGT1A functional 
splicing isoform (Tang et al. 2012). Further imputation of newly discovered SNPs 
from the 1000 Genomes project (The 1000 Genomes Project Consortium 2010) in 
the European GWAS has further identified an additional locus in SLC14A, a urea 
transporter gene involved in urine production (Rafnar et al. 2011).  
 
However despite these efforts in bladder cancer and in other diseases, only about 
five percent of inheritable risk in complex diseases has been explained by GWAS 
and the CDCV hypothesis (Schork et al. 2009; Bodmer and Tomlinson 2010; Cirulli 
and Goldstein 2010; Gorlov et al. 2011).  An alternative hypothesis was thus needed 
to explain this “missing heritability” (Manolio et al. 2009). 
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5.2.2. Common Disease - Rare Variant Hypothesis 
The “common disease-multiple rare variants” (CDRV) hypothesis proposes that a 
significant proportion of inherited cancer susceptibility is due to the summation of 
several different rare gene variants each having a significant effect on disease risk 
(Bodmer and Bonilla 2008).   Rare variants are base variations with a MAF between 
0.1 and 1% (Table 4) (Cirulli and Goldstein 2010) but they make up to 50% of 
variants in the dbSNP database (http://www.ncbi.nlm.nih.gov/snp) (Gorlov et al. 
2011).   
Table 4: Comparison of common versus rare disease variant characteristics (adapted 
from (Bodmer and Bonilla 2008). 
Common disease variants Rare disease variants 
Discovery by population association, case-
control studies, using genome-wide markers 
(WGA) 
Discovery by DNA resequencing of 
candidate genes, preferably in early onset 
cases with one or more relatives affected 
Mostly MAF > 5% MAF > 0.1% to 1% 
 
Higher than rare familial mutations, lower 
than polymorphisms. Often population 
specific 
Explained by LD with functional variant Not detected by WGA 
OR mostly between 1.2 and 1.5 OR mostly ≥ 2 
Need large studies with control for ethnic 
heterogeneity to achieve statistical 
significance and minimise false positives 
Assess significance by increased 
frequencies in cases vs. controls and by 
functional analysis of variant 
Make substantial contribution to population 
attributable risk 
Summation of effects of several variants 
make significant contribution to population 
attributable risk 
Low penetrance makes prophylactic 
intervention unlikely 
Penetrance often high enough to justify 
prophylactic interventions 
Hard to find functionally relevant variant Variants identified are functionally relevant 
Contribution to disease aetiology 
questionable 
Make a contribution to understanding 
disease aetiology 
May suggest candidates for rare variant 
search 
Effect may be modified by common variants 
 
They represent recent germline genetic mutations arising within the last 100 
generations (Figure 5). Thus, the rapid population growth over the last 2000 years 
has resulted in the abundance of rare variants detected with many variants being 
population-specific (Coventry et al. 2010; Ju et al. 2011). Due to genetic selection 
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having insufficient time to influence these recent variations, rare variants are 
predicted to have a larger effect on disease risk and to be more likely to have a 
functional effect than common SNPs (Coventry et al. 2010; Gorlov et al. 2011).  
 
Figure 5: Estimated distribution of variants by current population MAFs relative to 
when the variant first arose in log 10 number of generations ago (adapted from 
(Coventry et al. 2010). 
 
Rare variant alleles are predicted to have dominant effects due to loss of 
heterozygosity or gain of function, with each rare variant allele at least doubling 
disease risk (Gibson 2011). For a disease with low population incidence, it has been 
predicted that many individuals may carry a few different disease risk rare variants 
without developing disease (Figure 6). It is also proposed that a potentially large 
proportion of GWAS common SNP hits may be secondary to “synthetic associations” 
with causal rare variants within several megabases (Mb) of the GWAS significant 
SNP (Dickson et al. 2010). 
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Figure 6: Predicted distribution of number of rare variant risk alleles carried in a case– 
control population. Distribution of cases (blue) and controls (red) assume a rare 
variant allele frequency of one percent, a background population disease risk of 0.2% 
and 100 rare variant disease loci each conferring a genotype relative risk of 2.2 (Gibson 
2011). 
 
5.2.2.1. Rare variants in common diseases 
Highly penetrant rare germline variants are known to be associated with several rare 
familial disorders such as maturity onset diabetes of the young (Weedon and Frayling 
2007), familial BRCA1/ BRCA2 related breast cancers (Easton et al. 2007) and 
MUTYH-associated polyposis (Al-Tassan et al. 2002). Fearnhead et al first 
demonstrated the role of rare variants in common diseases by identifying 13 rare 
variants with a combined OR of 2.2 involved in the inherited susceptibility of 
colorectal adenomas (Fearnhead et al. 2004). In hypertriglyceridaemia, targeted 
sequencing of four GWAS loci found a significantly increased rare variant carrier 
frequency in cases compared to controls (Johansen et al. 2010). In the WECARE 
population-based breast cancer study, a greater risk of developing a second, 
contralateral breast cancer was described in carriers of rare BRCA1 and BRCA2 
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variants of unknown significance as well as an increased risk of breast cancer in their 
first degree relatives (Capanu et al. 2011). In colorectal cancer genetic susceptibility, 
carriers of rare variants in the cell cycle regulation gene, Cyclin D1, had an increased 
risk of developing multiple adenomas and colorectal cancer while MUTYH rare 
variants have been associated with early onset colorectal cancer with all identified 
rare variants in these two studies reported having per-allele odds ratios greater than 
two (Farrington et al. 2005; Bonilla et al. 2011). 
 
GWAS are not adequately powered to detect rare variants due to their low allele 
frequency, high allelic heterogeneity and being population specific (Iles 2008; Schork 
et al. 2009; Bodmer and Tomlinson 2010). Thus, reliable rare variant discovery can 
only be achieved by direct DNA resequencing of the whole genome, whole exome or 
candidate genes (Bodmer and Tomlinson 2010; Cirulli and Goldstein 2010). Most 
strategies proposed for the study of rare variants involve a two-stage approach of 
sequencing a study sub-set or population enriched for rare variants, followed by 
confirmation in a large case-control study using standard genotyping techniques 
(Cirulli and Goldstein 2010; Kim et al. 2010; Yang and Thomas 2011).  
 
However, standard conventional Sanger sequencing is too costly and labour 
intensive to use for extensive DNA resequencing for rare variants but the advent of 
next-generation sequencing technologies has now made such studies feasible. 
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5.2.3. DNA sequencing 
5.2.3.1. Conventional Sanger sequencing 
 
 
 
 
 
Conventional sequencing is performed using capillary-based Sanger sequencing, 
involving the incorporation of chain-terminating fluorescently-labelled 
dideoxynucleotides during DNA strand elongation. As each complementary fragment 
is terminated at different points, capillary electrophoresis separates each fragment by 
size while laser excitation of the fluorescent label generates an electropherogram for 
Figure 1: Conventional Sanger sequencing. Using a primer upstream of the DNA 
template, standard deoxynucleotides (dNTP), DNA polymerase and chain-terminating 
dideoxynucleotides (ddNTP) labelled with a different fluorescent dye for each nucleotide 
are added for DNA strand elongation resulting in DNA fragments of varied sizes which, 
based on size, travel at different speeds in an electric field during capillary 
electrophoresis. Laser excitation of the fluorescent dye and capture of this fluorescence 
generates an electropherogram with each fluorescent peak denoting the respective 
ddNTP with the complement being the sequence of the original DNA template. 
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interpretation of the DNA sequence (Figure 7).  Conventional sequencing is capable 
of sequencing up to about 1 kilobase at a cost of $500 per megabase (Shendure and 
Ji 2008; Tucker et al. 2009). 
 
5.2.3.2. Next-generation sequencing 
There are currently three commercially available second generation next-generation 
sequencing (NGS) platforms: Illumina Genome Analyzer’s polymerase-based 
“sequencing by synthesis” platform, Applied Biosystems SOLiD Sequencer ligation-
based platform and Roche GS-FLX 454 Genome Sequencer pyrosequencing-based 
platform (Table 5). Using these platforms, it is now possible to sequence a whole 
genome within a week. 
 
Table 5: Comparison between different next-generation sequencing platforms (adapted 
from (Tucker et al. 2009). * Cost quoted is as reported in 2009. 
Platform Amplification  Approach  
Read 
Length 
(bp) 
Run Time 
and 
Throughput  
Raw 
Accuracy 
 Cost 
(US$/Mb)* 
Illumina 
Genome 
Analyzer 
polymerase-based 
sequencing by 
synthesis 
bridge 
PCR  
75-150   
17 gigabases 
(Gb) 
in 7 days  
98.50% 6.00 
ABI SOLiD 
Sequencer 
ligation-based  
emulsion 
PCR  
50 
10–15 Gb  
in 3-7 days  
99.94% 5.80 
Roche 454 
Sequencer 
pyrosequencing  
emulsion 
PCR  
400 
400–600 Mb  
in 10 hr  
99% 84.40 
 
Focusing on the Illumina platform used in this thesis, the DNA sequence of interest is 
fragmented and ligated with oligonucleotide adaptors to form sequencing libraries.  
Fragments are hybridised to complementary adaptors coated on the flow cell surface. 
Bridge amplification of hybridised fragments result in the formation of clusters of each 
fragment sequence. Fluorescently-labelled nucleotides with reversible chain-
terminating inhibitors are added to the 5’-end and the surface imaged to determine 
the first base. The terminator and label are enzymatically removed and the next base 
 47 
added and imaged and so on for currently up to a read length of 150 bases (Figure 
8).   
 
As the cost for whole genome sequencing of a single sample to a high read depth 
remains relatively high, sequencing a large cohort would prove excessively 
expensive.  However, by sequencing only a target-enriched region of interest, it is 
possible to sequence pools of multiple samples, termed multiplexing, while 
maintaining high read depths and improving cost-effectiveness.  Several studies 
have thus recently been exploring the feasibility and the various strategies of 
multiplexing with regards to target size, amplification processes and the ideal pooling 
strategies (Out et al. 2009; Harris et al. 2010; Kim et al. 2010; Harakalova et al. 2011; 
Lee et al. 2011).  
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DNA Fragmentation 
 
Adaptor Ligation 
Flow Cell Hybridisation, 
Bridge Amplification  
and  
Cluster Formation 
Sequencing by Synthesis 
and 
Flow Cell Imaging 
Figure 8: Illumina Genome Analyzer sequencing workflow (Tucker et al. 2009). The DNA 
sequence of interest is randomly fragmented into 200 base pair (bp) fragments 
followed by ligation to oligonucleotide adaptors at both the 3’- and 5’-ends. Fragments 
are then hybridised to a flow cell coated with complementary oligonucleotides to the 
adaptors (A) resulting in the formation of “bridges” between hybridised fragments and 
complementary oligonucleotides and amplification from the 3’ to the 5’-end (B). By 
repeated bridge amplification of hybridised fragments and newly synthesised 
fragments (C), discrete clusters of each fragment are formed (D). Sequencing by 
synthesis is then performed from the 5’-end using fluorescently labelled nucleotides 
with reversible chain-terminating inhibitors and imaging of each consecutive base with 
each cycle. The number of cycles is equivalent to the read length. 
 
A 
B 
C 
D 
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5.2.4. MicroRNAs 
5.2.4.1. Biology and post-transcriptional regulation 
Non-coding RNAs (ncRNA), which include microRNAs (miRNAs), small nucleolar 
RNAs, Piwi protein-interacting RNAs and large intergenic non-coding RNAs, are a 
recently discovered group of endogenous RNAs involved in epigenetic, ribosomal 
and post-transcriptional regulation (Esteller 2011). miRNAs are the most extensively 
studied of these. They are small ncRNAs of approximately 22 to 27 nucleotides, 
accounting for 1% of all genes, and are believed to regulate more than 60% of coding 
genes (Brennecke et al. 2005; Friedman et al. 2009; Esteller 2011). miRNA genes 
are either independent genes or are located within introns of coding genes known as 
mirtrons. They are transcribed by RNA polymerase II into primary-miRNA (pri-
miRNA) which is processed by the Drosha complex into precursor-miRNA (pre-
miRNA) which is then exported out of the nucleus by Exportin-5 (Figure 9) (Krol et al. 
2010; Esteller 2011; Pasquinelli 2012). The loop region is excised by Dicer and the 
miRNA duplex loaded onto the catalytic RNA endonuclease protein Argonaute (Ago) 
to form an RNA-induced silencing complex (RISC). 
 
RISC regulates post-transcriptional gene regulation by pairing with complementary 
binding sites predominantly in the 3’untranslated region (3’UTR) of messenger RNA 
(mRNA), with perfect complementation resulting in mRNA degradation while 
imperfect pairing causes inhibition of mRNA translation (Zeng et al. 2003; Liu et al. 
2008). High complementation of the second to eighth nucleotide from the 5’ end of 
the miRNA known as the miRNA “seed” site, is required for functional miRNA-mRNA 
pairing (Brennecke et al. 2005; Chi et al. 2012; Pasquinelli 2012). Multiple bio-
informatics algorithms have thus been developed using these “seed pairing rules” for 
predicting miRNA targets (Lewis et al. 2003; John et al. 2004; Kiriakidou et al. 2004; 
Krek et al. 2005; Rusinov et al. 2005; Griffiths-Jones et al. 2006). However, functional 
non-canonical miRNA binding sites have recently been described: “centered pairing” 
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with highly contiguous pairing between miRNA nucleotides four to fifteen (Shin et al. 
2010); 3’-end pairing (Lal et al. 2009; Pasquinelli 2012); and “pivot-pairing” involving 
the formation of a transitional nucleation state of complementary seed pairing 
between nucleotides two to six followed by a bulge in the mRNA to allow downstream 
base-pairing (Chi et al. 2012).  
 
Figure 9: MicroRNA biogenesis and its role in mRNA post-transcriptional regulation 
(adapted from (Esquela-Kerscher and Slack 2006). miRNA genes are transcribed by 
RNA polymerase II into pri-miRNAs which in turn are processed by DGCR8 double-
stranded RNA binding protein and Drosha RNAase II enzyme into a ~70 nucleotide pre-
miRNA stem-loop hairpin structure. The pre-miRNA is exported out of the nucleus by 
Exportin-5 and Ran-GTP and the loop excised by Dicer to form a miRNA duplex.  The 
mature miRNA is incorporated into the RISC complex with Argonaute and, depending 
on perfect or imperfect complementation with target mRNA, results in mRNA 
degradation or inhibition of mRNA translation. 
 
5.2.4.2. MicroRNAs in carcinogenesis and cancer susceptibility 
miRNAs are commonly dysregulated in cancers with differential expression between 
normal tissues, tumours, and across cancer types (Esteller 2011). Fifty percent of 
miRNA genes are localised to cancer-associated “fragile sites” of the genome with 
miRNA dysregulation caused by genetic mutation of miRNA or miRNA biogenesis 
genes, by epigenetic changes such as CpG island hypermethylation of miRNA or 
mirtron associated gene promoters, or by gene copy number variations (Esquela-
Kerscher and Slack 2006; Zhang et al. 2006; Krol et al. 2010; Esteller 2011). miRNAs 
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can act both as oncogenic miRNAs (or “oncomirs”), or as tumour suppressors. 
miRNAs commonly associated with malignancy are miR-15, miR-16-1, miR-17-92, 
miR-21, miR-125 and miR-145 and the let-7 miRNA family (Esquela-Kerscher and 
Slack 2006; Hammond 2007; Esteller 2011).  
 
In bladder cancer, genomic miRNA profiling has demonstrated differences in miRNA 
expression not only between normal urothelium and bladder cancer but differences 
between low-grade, high grade and invasive tumours (Catto et al. 2009; Dyrskjot et 
al. 2009; Catto et al. 2011). The differential expression of several miRNAs in low 
grade tumours is also associated with risk of progression to a high grade phenotype 
(Catto et al. 2009; Dyrskjot et al. 2009). Transfection of various miRNAs 
downregulated in bladder tumours, such as miR-125, miR-129 and miR-145, into 
bladder cancer cell lines have resulted in cell growth and colony formation inhibition, 
apoptosis and cancer cell death, highlighting the tumour suppressor roles of these 
miRNAs (Dyrskjot et al. 2009; Ichimi et al. 2009; Ostenfeld et al. 2010; Huang et al. 
2011). 
 
SNPs in miRNA and miRNA biogenesis genes are associated with cancer 
predisposition by affecting miRNA-mRNA binding, miRNA maturation or RISC 
stability (Horikawa et al. 2008; Krol et al. 2010; Liu et al. 2010; Yang et al. 2010). In 
bladder cancer, homozygote carriers of the miRNA processing gene GEMIN3 SNP 
rs197414 rare allele had a significantly increased risk of developing bladder cancer 
(Yang et al. 2008).  SNPs within miRNA-target binding sites may also alter miRNA-
mRNA binding and Yu et al reported a negative selection against SNPs within these 
predicted 3’UTR miRNA “seed” sites compared to other SNPs within the 3’UTR, 
potentially due to their deleterious effects (Yu et al. 2007).  Bioinformatics predictions 
for these 3’UTR SNPs affecting miRNA-mRNA binding have since been successful in 
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identifying breast cancer and colorectal cancer susceptibility alleles (Landi et al. 
2008; Nicoloso et al. 2010). 
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5.3. DNA repair and radiation biology 
Maintaining cellular genetic integrity is crucial in preventing somatic mutations and 
carcinogenesis. Cellular DNA is constantly assailed by both intrinsic agents, such as 
free radicals generated from metabolic processes, and extrinsic agents such as 
chemical carcinogens, carcinogens derived from tobacco smoking and ionising 
radiation. Following DNA damage, DNA repair, cell cycle arrest and apoptotic 
pathways are activated rapidly with the purpose of repairing these DNA lesions or if 
not possible, inducing cell death. These pathways are thus important in determining 
carcinogenesis in normal tissues and cancer cell death or survival following 
radiotherapy treatment. 
 
5.3.1. DNA Repair Pathways 
There are five main DNA repair pathways: mismatch repair (MMR), base excision 
repair (BER), nucleotide excision repair (NER), and the two double strand break 
(DSB) repair pathways – homologous recombination and non-homologous end 
joining. 
 
5.3.1.1. Mismatch Repair 
Errors in DNA replication due to “DNA polymerase slippage” can result in 
mismatched nucleotides or DNA insertion-deletion loops in regions of repetitive DNA 
(Bristow and Harrington 2005; Hall and Giaccia 2006; Jalal et al. 2011).  These errors 
are recognised, excised and repaired by MMR. Mutations in the MMR gene families, 
MSH, MLH and PSM, result in insertions or deletions of short DNA repeats termed 
microsatellite instability and is associated classically with hereditary non-polyposis 
colorectal cancer but also seen in a variety of other malignancies. MMR deficiency is 
also predictive of sensitivity to topoisomerases and resistance to cisplatin and 
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fluorouracil chemotherapy (Ribic et al. 2003; Bristow and Harrington 2005; 
Bertagnolli et al. 2009). 
 
5.3.1.2. Base excision repair 
BER is required to repair DNA base lesions, including methylated bases from 
industrial carcinogens or chemotherapeutics, and oxidative base damage from 
reactive oxygen species, such as that from smoking-related carcinogens and from 
ionising radiation, and also DNA SSBs (Hegde et al. 2008).  Different DNA 
glycosylases recognise and excise specific base lesions with a level of cross-activity 
between glycosylases and target base lesions (David et al. 2007). The most common 
oxidative base lesion is 7,8-dihydro-8-oxyguanine (8-OxoG) which is particularly 
deleterious, as it is able to mimic thymine (T) in base pairing with adenine (A) during 
DNA replication, resulting in a guanine (G) to T transversions if unrepaired (Figure 
10).  OGG1 detects and excises 8-oxoG resulting in an apurinic site, which in turn is 
excised by APE1 leading to repair by either the short-patch or long-patch BER. 
Short-patch BER involves the removal of only the damaged nucleotide while long-
patch BER involves the excision of 2 to 13 (Evans et al. 2000). Both pathways 
generate an SSB and results in poly-ADP-ribosylation of the SSB by PARP1 and 
recruitment of the downstream repair proteins DNA polymerase β, LIG3 and XRCC1 
(Bristow and Harrington 2005; Hall and Giaccia 2006; David et al. 2007; Hegde et al. 
2008; Jalal et al. 2011).   
 
MUTYH, like OGG1, screens DNA for 8-oxoG but then locates and excises the 
mispaired A instead, thus restoring the 8-oxoG:C substrate for OGG1 repair and 
preventing the G to T transversion (Figure 10).  It is a unique glycosylase with no 
“backup” glycosylase recognising the same lesion (David et al. 2007; Kundu et al. 
2009). In MUTYH-associated polyposis (MAP), carriage of MUTYH rare missense 
variants result in increased somatic G to T transversions in the APC and KRAS 
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genes and accounts for approximately 1% of all colorectal cancers (Al-Tassan et al. 
2002; Lipton et al. 2003; Fleischmann et al. 2004).  MAP patients have also been 
noted to have an increased risk in extra-colonic tumours (including bladder cancer) 
(Vogt et al. 2009). Colorectal cancer epidemiology studies of  two rare MUTYH 
variants Y179C (rs34612342) and G396D (rs36053993), have found a 100% 
penetrance of developing colorectal cancer by the age of 65 in individuals with 
biallelic MUTYH defects, as well as an increased risk in heterozygous carriers 
(Farrington et al. 2005; Theodoratou et al. 2010).  Increased rates of breast, gastric 
and endometrial cancers have also been observed in heterozygote carriers of 
MUTYH variants (Win et al. 2011; Rennert et al. 2012).  
 
 
Figure 10: Base excision repair of 8-oxoG by MUTYH and OGG1 (David et al. 2007). 
Oxidative stress results in the formation of 8-oxoG which is detected and excised by 
OGG1 and repaired (left pathway). If unrepaired prior to replication, 8-oxoG mispairs 
with A and results in a G:C to T:A mutation (middle pathway). MUTYH detects 8-oxoG:A 
mispairing and excises A (right pathway),  restoring the 8-oxoG:C substrate for OGG1 
repair. 
 
5.3.1.3. Nucleotide excision repair 
NER targets DNA helix-distorting lesions such as ultraviolet-induced photolesions 
and bulky DNA adducts from a variety of compounds including aromatic carcinogens 
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from industrial chemicals and cigarette smoke, and chemotherapy agents.  It consists 
of two sub-pathways: global genome repair (GGR) and transcription-coupled repair 
(TCR) (Figure 11). Following lesion recognition, GGR and TCR activate a common 
pathway with unwinding of the DNA helix, excision of the lesion with 24 to 34 
surrounding nucleotides, gap filling by DNA polymerase and finally ligation of the re-
synthesised DNA (Sugasawa 2008; Bergink et al. 2012).  
 
XPC is crucial in GGR for the surveillance of the whole genome for DNA distorting 
lesions by searching for non-hydrogen bonded nucleotides within the genome, 
binding to them and recruiting downstream repair factors (Camenisch et al. 2009).  
XPC exists as a heterotrimer complex with HR23B and Centrin 2, which are essential 
for stabilising XPC by regulating ubiquitinylation and enhancing stable XPC binding 
to DNA (Sugasawa 2008; Sugasawa 2010; Bergink et al. 2012).  There is also 
evidence that XPC modulates DSB repair (Despras et al. 2007; Zhang et al. 2009), 
acts as a co-factor for OGG1 in BER (D'Errico et al. 2006), regulates gene 
transcription (Le May et al. 2010),  and activates a p-53 independent apoptosis 
pathway (Wang et al. 2012). 
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Figure 11: Nucleotide excision repair pathway (adapted from (Sugasawa 2008). NER is 
initiated by the detection of DNA helix-distorting lesions in global genomic repair by 
the XPC-HR23B(RAD23)-Centrin2  or in the case of ultraviolet-induced lesions or in 
transcription coupled repair by the detection of a translocation blockage during 
transcription by RNA polymerase II and recruitment of the Cockayne syndrome 
proteins, CSA and CSB. The TFIIH complex is recruited by both XPC and CSA/ CSB 
resulting in initiation of a common repair pathway with DNA helix unwinding and 
excision of the damaged DNA at two incision sites by the incision complex generating 
a 24 to 34 base gap. The gap is filled by DNA synthesis using the undamaged DNA 
strand as a template and finally rejoined by DNA ligase I. 
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5.3.1.4. DSB repair 
Depending on the cell cycle phase, either of two DSB repair pathways are activated:  
homologous recombination repair (HR) in cells in S/G2 phase, or the classical or 
alternative non-homologous end joining (NHEJ) pathways in cells in the G0/G1 phase 
(Figure 12) (Williams et al. 2007; Iijima et al. 2008). Phosphorylation of CtIP by ATM 
and CDK has been reported to influence the cell-cycle dependent choice of pathway 
activated (Iijima et al. 2008; Yun and Hiom 2009; Kass and Jasin 2010). 
 
 
Figure 12: DSB repair pathways – NHEJ and HR (Iijima et al. 2008). In NHEJ, the 
Ku70/80 heterodimer binds to the DSB ends and recruits DNA-PKcs, which in turn 
phosphorylates and recruits the MRE11-RAD50-NBS1 (MRN) complex or Artemis for 
DSB end-processing. The DSB is then ligated by the XRCC4/LIGIV heterodimer with 
potential loss or gain of a few nucleotides. In HR, MRN detects and binds to the DSBs, 
initiates end-processing facilitated by CtIP and amplifies the repair signal by 
phosphorylating ATM. RAD51 and BRCA2, regulated by CDK, Chk1, RAD52 and 
Fanconi anaemia proteins, substitutes RPA at the processed DNA ends, initiating 
sister chromatid strand invasion and Holliday junction formation. The damaged DNA is 
then repaired by DNA synthesis using the sister chromatid template for error-free 
repair. 
 
MRN 
MRN 
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5.3.1.5. Homologous recombination 
HR is a high fidelity error-free repair process for DNA DSBs due to the availability of 
a sister chromatid template for repair (Figure 12). The MRE11-RAD50-NBS1 (MRN) 
complex detects DSBs and binds to the DNA ends forming a scaffold to tether the 
broken ends, and recruits and phosphorylates ATM (Figure 13). This in turn 
phosphorylates H2AX, resulting in a cascade of phosphorylation events amplifying 
the repair signal leading to end resection and processing by CtIP and MRE11, 
histone modification and chromatin remodeling, activation of cell cycle checkpoints 
and initiation of HR (Lavin 2007; Sartori et al. 2007; Williams et al. 2007; Iijima et al. 
2008; Zha et al. 2009; Eid et al. 2010). RAD51 and BRCA2 are then recruited and 
promote sister chromatid strand invasion and formation of Holliday junctions. DNA 
repair synthesis using the sister template is completed by DNA polymerases followed 
by ligase sealing of the strand breaks, Holliday junction disengagement and 
resolution of repair (Figure 12) (Bristow and Harrington 2005; Hall and Giaccia 2006; 
Kass and Jasin 2010). PARP1 has also been implicated in promoting MRN 
recruitment and binding to DSBs (Haince et al. 2008). 
 
5.3.1.6. Non-homologous end-joining  
NHEJ is an error-prone DSB repair pathway that does not require sequence 
homology. Classical NHEJ requires recognition of DSBs by the DNA-dependent 
protein kinase complex (DNA-PK) consisting of Ku70, Ku86 and DNA-PKcs. Ku 
competes competitively with MRN and PARP1 to bind to DSB ends thus inhibiting 
DNA end resection, HR and microhomology-mediated end joining (MMEJ) (see 
below) (Fattah et al. 2010; Kass and Jasin 2010; Cheng et al. 2011). DNA-PK 
activates Artemis for end-processing and gap-filling usually resulting in short 
nucleotide insertions or deletions, followed by bridging and ligation of DSB ends by 
XRCC4 and LIG4. 
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Figure 13: The MRE11-RAD50-NBS1 (MRN) complex and its functions in DSB repair 
signalling (Zha et al. 2009). (a) The MRN complex binds to DNA DSB ends and 
phosphorylates ATM thus, (b) activating the DNA damage response with downstream 
ATM phosphorylation targets, and (c) as well as binding to the DSB ends, the MRN 
complexes tethers the two broken ends together and initiates end-resection and 
processing with CtIP. 
 
The alternative or back-up NHEJ pathway also known as MMEJ, is less efficient and 
more error-prone than classical NHEJ, and is predominantly seen in the event of 
defective classical NHEJ. MMEJ requires short homologous sequences 
(microhomologies) near the DSB break which are paired for DNA repair resulting in 
large deletions. MRN and PARP1 detect the lesion and undertake end-resection to 
the sites of microhomology with the DSB ends finally joined by XRCC1 and LIG3 
(Audebert et al. 2004; Fattah et al. 2010; Cheng et al. 2011; Della-Maria et al. 2011). 
MMEJ has been implicated in chromosomal translocations and has a greater role in 
DSB repair in cancer cells compared to normal cells (Della-Maria et al. 2011). High-
grade and muscle-invasive bladder tumours have been found to preferentially repair 
microhomology related DSBs by MMEJ over the classical pathway (Bentley et al. 
2004; Bentley et al. 2009). 
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5.3.2. DNA Repair Variants and Cancer Predisposition 
DNA damage repair mechanisms are crucial for the prevention of the fixation of 
somatic mutations caused by carcinogens and hence tumorigenesis (Wu et al. 2006). 
DNA repair gene SNPs may impair DNA repair capacity and, from multiple case-
control studies, GWAS and meta-analyses, have been found to be associated with 
cancer susceptibility in most cancer sites (Berwick and Vineis 2000; Goode et al. 
2002; Hung et al. 2005; Landi et al. 2006; Shen et al. 2010; Ricceri et al. 2011; Yu et 
al. 2011). These studies have focused predominantly on candidate common coding 
SNPs and, as with other common SNP studies, effects sizes have been small. 
Studies of DNA repair rare variants have focused on candidate genes implicated in 
familial cancer disorders such as in BRCA1 and MUTYH, as previously mentioned 
(Theodoratou et al. 2010; Capanu et al. 2011). 
 
In bladder cancer, epidemiological studies have found associations between coding 
single nucleotide polymorphisms (SNP) in BER, NER and DSB repair genes and 
bladder cancer susceptibility (Garcia-Closas et al. 2006; Figueroa et al. 2007; 
Figueroa et al. 2007; Kiltie 2009).  In a pooled analysis by the International 
Consortium on Bladder Cancer, three DNA repair gene coding SNPs: ERCC2 D312N 
(rs1799793); NBS1 E185Q (rs1805794) and XPC A499V (rs2228000), were 
confirmed to significantly increase bladder cancer risk, though their effect sizes were 
small (OR ~1.10) (Stern et al. 2009).  Analysis of tagging SNPs of all known NER 
genes identified SNPs in six genes modifying bladder cancer risk with SNP-SNP and 
SNP-smoking interactions (Xing et al. 2012).  Dr Kiltie’s group investigating the role 
of rare variants in bladder cancer predisposition, have recently identified four new 
rare XPC risk variants (OR=3.1, 95%CI 1.0-9.8, p=0.048) that alter gene regulation 
and in vivo function (Qiao et al. 2011). 
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5.3.3. Ionising Radiation and DNA 
Ionising radiation (IR), such as radiotherapy, damages DNA directly or indirectly by 
ionizing water and generating free radicals, resulting in base damage, single-strand 
breaks (SSB) and double-strand breaks (DSB) (Table 6), usually with a cluster of 
DNA lesions within a few nanometers of each other (Steel 2002). DNA DSBs are the 
most lethal form of ionising radiation-induced DNA damage and it is the failure to 
repair these DSBs that results in cancer cell death. 
 
Table 6: Lesions per Gray of ionising radiation (Steel 2002) 
 Number of lesions per Gy 
DNA crosslinks 2000 
Base damage 1000 
Single-strand breaks 1000 
Double-strands breaks 40 
 
5.3.3.1. DNA Repair in Radiobiology 
The five R’s of radiation biology describe the principles determining the response of 
cancer and normal cells to ionising radiation. They are: 1) Repair, the cellular 
capability to repair radiation induced DNA damage, 2) Redistribution or reassortment, 
the movement of cells through the cell cycle phases from radioresistant (S) to more 
radiosensitive (late G2 / M) phases, 3) Repopulation, regrowth due to cell division, 4) 
Reoxygenation, the oxygen availability in cells which is crucial for the fixation of 
indirect DNA damage from ionising radiation, and, 5) Radiosensitivity, the intrinsic  
radiosensitivity of different cell types (Steel 2002). DNA repair, forming one of the 5 
R’s, influences RT cancer cell kill by its role in repairing both lethal DSBs and 
sublethal/ potentially lethal DNA damage - lesions that could potentially generate 
DSBs from stalled replication forks. The repair of these latter DNA lesions is also 
important in acute normal tissue radiation toxicity, with one of the rationales for RT 
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treatment fractionation being to allow sufficient time for normal tissue cells to repair 
these lesions prior to the delivery of the next RT fraction. 
 
5.3.4. Biomarkers of Bladder Cancer and Radiotherapy Outcomes 
5.3.4.1. Predictive and prognostic markers in bladder cancer 
With adoption of the concept of personalised cancer medicine, predictive and 
prognostic markers are vital for treatment individualisation (La Thangue and Kerr 
2011; Mirnezami et al. 2011). Predictive markers indicate the likelihood of cancer 
response to a specific treatment, while prognostic markers indicate the likely disease 
outcomes for an individual. Clinical prognostic markers in bladder cancer are TNM 
staging, tumour grade and multifocality, hydronephrosis and concurrent carcinoma in 
situ, and have been used to identify individuals who may gain from increased 
surveillance, treatment intensification or adjuvant treatment (Lopez-Beltran et al. 
2004). Several clinical nomograms for MIBC post-radical cystectomy have been 
generated, though these are not yet in routine clinical use (Karakiewicz et al. 2006; 
Shariat et al. 2006; Nuhn et al. 2012).  
 
A molecular biomarker is a biochemical “characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention” (Biomarker Definitions 
Working Group 2001).  Several predictive and prognostic biomarkers are already in 
routine clinical use such as HER2 and oestrogen receptor status in breast cancer, 
BCR-ABL translocations in chronic myeloid leukaemia, and BRAF mutations in 
melanoma (La Thangue and Kerr 2011).  
 
Biomarker studies in bladder cancer have predominantly employed 
immunohistochemistry methods (Matsushita et al. 2011). FGFR3, p53 and Ki-67 (a 
marker of cell proliferation) expression, have been associated with tumour grade, 
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progression, recurrence and cancer survival (Hernandez et al. 2006; Mhawech-
Fauceglia et al. 2006; Margulis et al. 2009; Goebell et al. 2010; van Rhijn et al. 
2012). Though TP53 mutations have been reported to be predictive of cisplatin-
based chemosensitivity (Nishiyama et al. 2008), a recent phase III RCT failed to 
detect any prognostic or predictive value of TP53 protein expression in MIBC patients 
receiving adjuvant chemotherapy (Stadler et al. 2011). Immunohistochemistry studies 
of proteins involved in cell cycle regulation, apoptotic signalling, growth factor 
receptors and angiogenesis as potential biomarkers have so far been inconclusive 
(Lopez-Beltran et al. 2004; Proctor et al. 2010; Matsushita et al. 2011). Genetic 
studies have also identified gene expression signatures, epigenetic histone 
methylation marks and miRNAs as potential prognostic biomarkers (Catto et al. 2009; 
Dyrskjot et al. 2009; Schneider et al. 2011; Riester et al. 2012). However, none of the 
above markers has been successfully implemented clinically to date. 
 
5.3.4.2. Biomarkers of radiotherapy 
Radiotherapy biomarker research has so far aimed to identify predictors of normal 
tissue and tumour radiosensitivity, which may identify potential drug targets or allow 
individualisation of radiotherapy dosimetry, dose-fractionation or concurrent 
chemotherapy or radiosensitiser treatments (Alsner et al. 2008; Mukherjee et al. 
2010; Sak and Stuschke 2010; Toustrup et al. 2012). High tumour EGFR expression 
or EGFR mutation, and a hypoxic gene expression profile have been associated with 
cancer radioresistance and worse outcomes in a variety of cancer sites (Mukherjee 
et al. 2010; Klopp and Eifel 2012; Toustrup et al. 2012). Positive human papilloma 
virus infection status in HPV-related squamous cell carcinomas are both prognostic 
and predictive of good radiotherapy response (Begg 2012; Klopp and Eifel 2012) 
while γ-H2AX assays of normal patient lymphocytes during radiotherapy have had 
moderate success in predicting normal tissue radiation toxicity (Sak and Stuschke 
2010).  
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In MIBC, high tumour MRE11 expression in a test and validation cohort was found to 
be predictive of improved cancer specific survival (CSS) following radical RT but not 
radical cystectomy (Choudhury et al. 2010). This result has recently been 
independently validated (Laurberg et al. 2012). High MRN expression has been 
correlated with reduced local recurrence following post-operative radiotherapy for 
early breast cancer while overexpression of NBS1 in head and neck squamous cell 
carcinomas was associated with radiosensitisation (Rhee et al. 2007; Soderlund et 
al. 2007). Further validation is currently underway, testing MRE11 as a clinical 
biomarker to identify patients best managed with bladder preserving treatment. Other 
MIBC studies have also indicated associations of APE1 and XRCC1 expression and 
ERCC1 mRNA levels with RT and chemo-RT response (Sak et al. 2005; Kawashima 
et al. 2011). 
 
The new field of radiogenetics aims to identify the genetic determinants of individual 
clinical radiosensitivity (Burnet et al. 2006; Alsner et al. 2008).  Multiple studies have 
demonstrated links between DNA repair gene SNPs with acute and late radiation 
normal tissue toxicity (Pugh et al. 2009; Parliament and Murray 2010) and the multi-
centre RAPPER radiogenomics study is currently underway to investigate the role of 
common SNPs in radiation toxicity using GWAS techniques (Burnet et al. 2006; 
Barnett et al. 2012). The role of germline SNPs in predicting radiotherapy outcomes 
has been less extensively investigated.  Candidate SNP studies have found 
associations of DNA repair gene SNPs with pathological response or survival in 
several cancer sites following radiotherapy treatment, predominantly in combination 
with concurrent chemotherapy (Parliament and Murray 2010; Yin et al. 2011; Yoon et 
al. 2011). In MIBC, Sakano et al (2006) identified coding ERCC2 and XRCC1 SNPs 
as potential prognostic markers following platinum-based chemoradiotherapy 
(Sakano et al. 2006). However, all these small sized, positive studies remain focused 
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on selected candidate common coding SNPs which as previously discussed are less 
likely to have clinically significant functional effects. 
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6. Aims and Objectives 
The two main aims of this project were: 
 
1) To study the contribution of DNA repair gene variants on bladder cancer risk, with 
the ultimate goal of improving the understanding of inherited risk in bladder 
cancer. 
 
The following objectives were set to achieve this aim: 
i. To develop a protocol for multiplexed NGS to allow the cost-effective 
targeted sequencing of multiple samples for the identification of rare 
germline variants, exploring issues of target amplification, optimum 
sample pooling, rare variant calling and selection, and sensitivity and 
specificity of the method. 
 
ii. To test the CDRV hypothesis in two candidate DNA repair genes, 
XPC and MUTYH, by undertaking a pilot multiplexed NGS study to 
identify rare germline variants in XPC and MUTYH that may influence 
bladder cancer susceptibility in an enriched case-control population 
followed by confirmation of candidate, putatively-functional variants in 
a larger case-control study. 
 
iii. To investigate in a large case-control study the association of DNA 
repair gene 3’UTR SNPs predicted to affect miRNA binding in silico on 
bladder cancer risk. These SNPs would also be investigated for 
associations with clinical outcomes in MIBC treated with radical RT. 
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2) To investigate DNA repair as a potential marker of RT response and outcomes in 
MIBC to allow future treatment individualisation, aid patient choice of the most 
effective treatment, and potentially improve overall bladder cancer survival.  
 
The following objectives were set to achieve this aim: 
i. To use novel bar-coded multiplexed next-generation sequencing 
technology to identify germline MRE11A variants associated with RT 
outcomes in MIBC patients treated with radical RT.  
 
ii. To examine tumour protein expression of several DNA repair proteins 
involved in DSB processing, NER and BER as potential predictive 
biomarkers of RT response in MIBC. 
 
 69 
7. Materials and Methods 
7.1. Materials 
Reagents and kits are listed in Appendix A. 
 
7.2. Study Population 
7.2.1. Ethical approval 
Local ethical approval was obtained from Leeds (East) Local Research Ethical 
Committee (studies 02/060, 02/192 and 04/Q1206/62) (Appendix B). 
 
7.2.2. Leeds Bladder Cancer Study (LBCS) Population 
As previously described (Choudhury et al. 2008), between August 2002 and October 
2009, bladder cancer cases (N = 853) were recruited from the Pyrah Department of 
Urology, St James's University Hospital, Leeds (SJUH). All recruited cases had 
urothelial carcinomas except for two cases that also had synchronous squamous cell 
carcinomas. Hospital-based controls (N = 546) were recruited specifically for this 
study from the ophthalmology, and ear, nose and throat (ENT) outpatient 
departments, SJUH. Community controls (N = 227) were previously recruited for a 
colorectal cancer case-control study undertaken by the Leeds Cancer Research UK 
Centre (Barrett et al. 2003). Controls had no history of cancer or haematuria, with 
attempts made to frequency match for age and gender. As both recruited control 
groups were cancer-free, of similar age and gender frequencies, and from the same 
georgraphical region and ethnic distribution (over 97.8% Caucasian), it was deemed 
unlikely that the community recruited control group would incur any genetic biases. 
Each participant was provided with a patient information leaflet, consent form and a 
questionnaire covering smoking, and occupational and family history, which were 
then discussed and completed (Appendix B). Five millilitres of blood was collected in 
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an EDTA tube for DNA extraction. DNA extraction from peripheral blood leucocytes 
was performed by the Yorkshire Regional Genetics Service, SJUH, using a salting-
out protocol involving isolation of cell nuclei by centrifugation, lysis of nuclei and use 
of a high concentration sodium chloride solution to precipitate out proteins. The DNA 
supernatant was then purified by ethanol precipitation and eluted in Tris-EDTA buffer. 
Sample concentrations were measured by spectrophotometry (Nanodrop, Thermo 
Scientific, USA) and stored at -20°C. 
 
7.2.3. Muscle Invasive Bladder Cancer (MIBC) Study Population 
7.2.3.1. Germline DNA 
Between August 2002 and October 2009, 201 bladder cancer patients referred for 
radical RT were recruited in the Pyrah Department of Urology, SJUH. Consent was 
obtained for the study at their first oncology outpatient’s appointment and a blood 
sample for germline DNA extraction (as described above) was collected prior to 
initiating any treatment. All patients had MIBC (WHO T-stage 2 or greater) on pre-
treatment transurethral biopsy specimens and no evidence of metastases on 
radiological staging. Patients were treated using three-dimensional conformal 
external beam radiotherapy (52.5 – 55 Gy in 20 fractions over four weeks), initially at 
Cookridge Hospital and latterly at St James’s Institute of Oncology (SJIO), Leeds, UK 
(Kotwal et al. 2008). Clinical outcomes and follow-up data were collected from clinic 
letters and electronic medical notes prospectively. Radiation Therapy Oncology 
Group (RTOG)/European Organisation for Research and Treatment of Cancer 
(EORTC) scores (Cox et al. 1995) for late bladder and bowel radiation toxicity were 
collected at each follow-up visit using a set proforma (Appendix B). 
 
7.2.3.2. Formalin Fixed Paraffin Embedded (FFPE) TURBT Blocks 
This previously described population (Choudhury et al. 2010) consisted of non-
metastatic MIBC patients treated by radical RT between 2002-2005 for MIBC at 
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Cookridge Hospital and SJIO, Leeds, UK. Clinical FFPE tumour blocks taken at pre-
treatment TURBT were available for 88 individuals. Patient treatment details were the 
same as above with clinical data also collected prospectively. 
 
7.3. Histopathology 
7.3.1. Cell lines and culture 
The RT112 bladder urothelial carcinoma cell line was a generous gift from Prof M 
Knowles; the Daudi Burkitt lymphoma cell line was generously provided by Dr G 
Doody. The HeLa cervical squamous cell carcinoma cell line and GM15983 XPC 
SV40-transformed fibroblasts were obtained from American Type Culture Collection 
(LGC Standards, UK). RT112 and Daudi cells were cultured in RPMI 1640 (Sigma-
Aldrich, UK) growth medium, and GM15983 and HeLa cell lines in MEM Eagle 
growth medium (Sigma-Aldrich, UK). Both media were supplemented with 10% v/v 
foetal bovine serum (Sigma-Aldrich, UK) and 1% 2 mM L-glutamine (Sigma-Aldrich, 
UK) and all cell lines were incubated in a 37°C 5% CO2 humidified atmosphere. 
 
7.3.2. FFPE cell line pellets 
Over 1 x 107 cells in solution were needed to generate a cell pellet. Daudi cell lines 
were used directly. For adherent cell lines (RT112, HeLa and GM15983), the growth 
medium was discarded and the cells washed with 10 ml phosphate buffered saline 
(PBS): 0.1% EDTA for 10 minutes. The wash was discarded and the cells were then 
incubated with 0.25% Trypsin-EDTA solution at 37°C for five minutes. Cells were 
suspended in growth medium and 20 µl of suspended cells pipetted onto a 
haematocytometer to determine cell concentration. The appropriate volume of 
suspended cells were transferred into a conical tube and centrifuged at 2000 rpm at 
4°C for four minutes. The supernatant was removed without disturbing the pellet and 
the cells resuspended and washed with PBS, and recentrifuged at 2000 rpm at 4°C 
for four minutes. The PBS was then discarded (without disturbing the pellet) and the 
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cell pellet fixed in 5 ml 4% Formalin in PBS pH 9 overnight. The next day, the 
formalin was removed and 5 ml 70% ethanol added to the fixed cell pellet with the 
cell pellet. The cell pellet was then brought to the Histopathology laboratory for 
paraffin embedding. 
 
7.3.3. Cell protein lysates and protein concentration quantification 
Cells were grown to 80-90% confluence for adherent cells in a 50cm2 cell culture 
flask, incubated with 0.25% Trypsin-EDTA solution as described above, suspended 
in growth medium, and transferred to a 50 ml centrifuge tube. The cell suspension 
was centrifuged at 450 g for five minutes. The medium was then carefully aspirated 
without disturbing the cell pellet and discarded. The cell pellet was then washed three 
times by resuspending in ice cold PBS, centrifuging at 450 g for five minutes and 
discarding as much of the supernatant as possible. The cell pellet was then 
resuspended in 1 ml PBS, transferred to an Eppendorf tube, centrifuged again at 
13000 rpm for one minute, and the supernatant discarded. The cell pellet was then 
incubated on ice with a mixture of 100 µl RIPA buffer (Sigma-Aldrich, UK), 1 µl 
phosphatase inhibitor (Roche, Switzerland) and 1 µl proteinase inhibitor (Roche, 
Switzerland) for 20 minutes, then centrifuged at 13000 rpm for one minute. The cell 
lysate was then transferred to a fresh Eppendorf tube for quantification. 
 
Cell lysate protein concentration was determined using the Bradford protein assay. 
By diluting bovine serum albumin (BSA) (Sigma-Aldrich, UK) in sterile water, 50 µl 
protein standards containing 0 µg, 2 µg, 4 µg, 6 µg, 8 µg and 10 µg of BSA were 
made. One millilitre of Bradford solution (Sigma-Aldrich, UK) was added and the 
mixture transferred into a transparent cuvette. The absorption spectrum was 
measured for each protein standard at 595 nm using a spectrophotometer (Jenway, 
UK) to generate a standard curve. In triplicate, one microlitre of the cell lysate sample 
was diluted in 49 µl sterile water, 1 ml Bradford solution was added, and the mixture 
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transferred to a cuvette. The absorption spectrum was then measured for each 
triplicate sample and the mean absorption spectrum of the three samples used to 
determine the sample protein concentration using the generated standard curve. Cell 
lysate samples were stored at -20°C. 
 
7.3.4. Western Blotting 
All primary antibodies were tested by western blotting to confirm target specificity on 
cell lysates from Daudi, HeLa and RT112 cell lines. A 10%  acrylamide gel was made 
using the recipe below. 
Resolving Gel  Stacking gel 
Reagent Volume  Reagent Volume 
2M Tris pH 8.8 1.87 ml  2M Tris pH 6.8  
10% sodium dodecyl sulfate 100 µl  10% sodium dodecyl sulfate 100 µl 
Protogel 3.33 ml  Protogel 1.33 ml 
Sterile distilled water 4.7 ml  Sterile distilled water 7.94 ml 
TEMED 6 µl  TEMED 6 µl 
10% ammonium persulphate 30 µl  10% ammonium persulphate 30 µl 
 
50 µg of cell lysate protein sample was mixed with 2x sodium dodecyl sulphate and 
20% mercaptoethanol loading buffer, heated to 95°C for five minutes and placed on 
ice.  Samples were then loaded onto the  acrylamide gel alongside 10 µl of a dual 
colour protein marker (Bio-Rad Laboratories, UK) and run at 130 V in Tris-Glycine-
SDS running buffer (Bio-Rad Laboratories, UK) for two hours. Proteins were then 
transferred onto a nitrocellulose supported membrane (Amersham Pharmacia 
Biotech, UK) at 100 V for one hour in ice-cold Tris-Glycine transfer buffer (Bio-Rad 
Laboratories, UK). Protein transfer was checked by staining with Ponceau Red 
(Sigma-Aldrich, UK). Membrane blocking was performed by incubation in 50% 
Odyssey Blocking Buffer (Licor, USA) in PBS for one hour at room temperature. The 
membrane was then incubated with the primary antibody at the manufacturer 
recommended dilution overnight at 4C, washed four times with PBS-0.01% Tween 
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20 (Sigma-Aldrich, UK), followed by incubation with the appropriate fluorescent 
secondary antibody, Alexa Fluor 680 anti-rabbit (Molecular Probes, UK) or IR Dye 
800 Anti-mouse (Rockland Inc, USA), for one hour at room temperature.  The 
membrane was washed again four times with PBS-0.01% Tween 20 then imaged on 
an Odyssey Infrared Imaging System (Licor, USA). 
 
7.3.5. Haemotoxylin and Eosin (H&E) Staining 
For each patient, a 4 µm FFPE tissue section was stained with haematoxylin and 
eosin (H&E). Sections were deparaffinised in three changes of xylene for five 
minutes each, then rehydrated in two changes of absolute alcohol for two minutes 
each then 90% alcohol for two minutes and 70% alcohol for two minutes followed by 
washing in tap water. The sections were then stained in haematoxylin (Sigma-
Aldrich, UK) for three minutes, Scott’s tap water (Sigma-Aldrich, UK) for one minute 
and eosin (Sigma-Aldrich, UK) for three minutes. Finally, the sections were 
dehydrated in three changes of absolute alcohol and two changes of Xylene for one 
minute each and mounted with a coverslip using DPX mountant (Sigma-Aldrich, UK). 
Slides were reviewed by a consultant uropathologist and areas of muscle-invasive 
urothelial carcinoma were outlined. 
 
7.3.6. Immunohistochemistry (IHC) 
As per Table 7, immunohistochemistry was undertaken using a standard streptavidin-
biotin complex (SBC) method or the MenaPath X-Cell Plus HRP-Polymer Detection 
Kit (Menarini Diagnostics, UK). FFPE tissue section slides were deparaffinised, 
rehydrated and washed as described above. Endogenous peroxidases were blocked 
using 3% hydrogen peroxide (Sigma-Aldrich, UK) for 20 minutes, followed by tissue 
section antigen retrieval by pressure-cooking at 15 psi for two minutes in the 
appropriate buffer (see Table 7). Slides were then stained vertically using a Shandon 
coverplate assembly (ThermoFisher Scientific, UK). For antibodies using the SBC 
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method, endogenous avidin binding sites, biotin and biotin receptors were blocked 
using an Avidin/ Biotin Blocking kit (Vector Laboratories, USA) with an initial avidin 
block for 15 minutes, two washes with Tris-buffered saline (TBS) followed by a biotin 
block for 15 minutes. This step was not needed for the MenaPath kit. The slides were 
then washed twice with TBS and incubated for 30 minutes with 10% normal goat 
serum (for SBC protocol) or casein (for the Menapath kit) diluted in TBS to block non-
specific antibody binding. Slides were then incubated with the optimised 
concentration for the respective primary antibody for 60 minutes at room temperature 
or overnight at 4C (Table 7).   
Table 7: Primary antibody details, IHC conditions and positive control tissue used. 
Primary Antibody 
Antigen 
Retrieval Buffer 
IHC kit/ 
protocol 
Dilution 
Incubation 
time 
Positive 
control 
tissue 
Anti-CtIP 
Mouse monoclonal 
Supplied by R Baer (Yu 
and Baer 2000) 
10 mM citrate 
buffer pH 6.0 
SBC 1:50 
Overnight at 
4C 
Daudi cell 
pellet 
Anti-XPC 
Rabbit polyclonal 
Sigma C-terminus X1129  
10 mM citrate 
buffer pH 6.0 
SBC 1:8000 
60 minutes 
at room 
temperature 
Daudi cell 
pellet 
Anti-MUTYH 
Mouse monoclonal 
Abcam ab55551 
10 mM Tris-  
1 mM EDTA 
buffer pH 8.0 + 
0.05% Triton X-
100 
Menapath 1:200 
60 minutes 
at room 
temperature 
HeLa cell 
pellet 
 
For the SBC method, sections were incubated in biotinylated secondary antibody for 
30 minutes, washed twice with TBS, incubated with streptavidin peroxidase 
(Dakocytomation, Denmark) for a further 30 minutes and washed again twice with 
TBS. For the Menapath kit, sections were incubated with the Universal Probe for 30 
minutes, washed twice with TBS-0.1% Triton X-100 (Promega, USA), incubated with 
the HRP-Polymer for a further 30 minutes and washed again twice with TBS-0.1% 
Triton X-100. For both protocols, bound antibodies were visualised by incubation with 
diaminobenzidine (Dakocytomation, Denmark) for 10 minutes then washed in tap 
water. Sections were then counterstained in haematoxylin (Sigma-Aldrich, UK) for 15 
seconds and Scott’s tap water (Sigma-Aldrich, UK) for one minute. Finally, the 
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sections were dehydrated in three changes of absolute alcohol and two changes of 
Xylene for one minute each and mounted with a coverslip using DPX-Mountant 
(Sigma-Aldrich, UK). 
 
Primary antibodies were tested and concentrations optimised against sections from a 
panel of tissue (normal breast, skin, placenta, tonsil and papillary bladder tumour) as 
well as cell line pellets (HeLa, RT112 and Daudi cell lines) to identify the ideal 
positive control. The final primary antibody dilution was chosen by two observers so 
that on a scale of 0 - 3 (Figure 14) the nuclear staining in the positive control scored 
2. Negative controls consisted of the positive control tissue with the primary antibody 
omitted.  
 
For the anti-XPC antibody, due to the presence of a second unspecified band on 
Western blotting, a cell pellet made from the XPC non-expressing GM15983 cell line 
was used as a separate negative control tissue. The optimum antibody concentration 
was the highest concentration with no staining in the GM15983 cell pellet but positive 
staining in the Daudi cell pellet positive control. A GM15983 negative control was 
used for all anti-XPC IHC staining runs. 
 
Staining 
Intensity 
    
0 1 2 3 
Figure 14: Representative sections immunostained for MRE11 (Abcam mouse 
monoclonal ab214, UK) demonstrating the different staining intensities. 
 
7.3.7. Microscopy and Photography and Scoring 
Using the H&E-stained slides as a reference, areas of muscle-invasive tumour were 
demarcated on the IHC stained slides.  Digital images were taken of 10 random fields 
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from within these areas using an Olympus BX50 microscope and c-3030 camera 
(Olympus UK, UK) at 600x magnification. A “quickscore” method was used for semi-
quantitative assessment of protein expression (Reiner et al. 1990; Detre et al. 1995). 
For each field, the proportion of bladder cancer cells staining positive was scored 
from 1 to 4 (1 = 0 – 10%, 2 = 11 – 30%, 3 = 31 – 70%, 4 = 71 – 100%) as well as the 
nuclear staining intensity which was scored 0 to 3 as per Figure 14. The nuclear 
staining intensity was scored independently by two observers, and discordant scores 
reviewed together and a consensus reached. A semi-quantitative score (SQS) was 
used to assess overall tumour DNA repair protein expression based on the product of 
the median score of the proportion of positive staining cells and the modal intensity. 
For MUTYH, due to its expression in mitochondria (Ohtsubo et al. 2000), bladder 
cancer cytoplasmic staining was also scored as present (1) or absent (0) as 
previously described by Gao et al (2004) (Gao et al. 2004). 
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7.4. Genetics 
7.4.1. DNA master plate design and alliquoting 
 
Figure 15: Blueprint for 96-well master plates for both the LBCS and MIBC study 
germline DNA samples. The empty well for orientation/ identification (red) is changed 
for each master plate to aid plate identification. 
 
Ninety six-well master DNA plates were designed for germline DNA samples from 
both the LBCS and MIBC study populations using the blueprint shown in Figure 15. 
For alliquoting, stock DNA tubes were arranged in 96 tube racks based on the 
corresponding 96-well plate design. Two different identifiers were checked by two 
people for each sample to ensure accurate layout. Samples were then alliquoted 
using an automated robotic liquid handling workstation (Corbett Robotics, Australia) 
and diluted with molecular grade water to produce 100 µl of 50 ng/ µl germline DNA 
for each sample.  
 
7.4.2. Reference sequences 
The wildtype genomic sequences and gene annotations for the candidate genes 
were obtained from the University of California Santa Cruz (UCSC) genome browser 
(http://genome.ucsc.edu): MUTYH (NCBI Accession NG_008189 human genome 
build 18 accessed October 2008), XPC (NCBI Accession NT_022517 human 
genome build 18 accessed August 2008 and NCBI Accession NG_011763.1 human 
1 2 3 4 5 6 7 8 9 10 11 12
A
Empty for 
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identification
Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
B Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
C Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
D Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
E Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
F Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
G Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample
Empty for 
Assay 
Controls
H Sample Sample Sample Sample Sample Sample
Replicate/ 
Control 
sample
Replicate/ 
Control 
sample
Replicate/ 
Control 
sample
Replicate/ 
Control 
sample
Replicate/ 
Control 
sample
Empty for 
Assay 
Controls
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genome build 19 accessed March 2011), and MRE11A (NCBI Accession ng_007261 
human genome build 19 accessed January 2010). Reference protein sequences 
were obtained from the NCBI protein database (http://www.ncbi.nlm.noh.gov/protein) 
for MUTYH isoform 1 (NP_036354.1 accessed February 2009), XPC isoform 1 
(NP_004619.3 accessed February 2009) and MRE11A isoform 1 (NP_005582.1 
accessed June 2010). 
 
7.4.3. Primer design 
PCR primers were designed using Primer3 (http://frodo.wi.mit.edu/primer3/) using the 
default settings with some alterations depending on primer function (Table 8). The 
respective wildtype reference genomic sequence was used for primer design with 
surrounding common SNPs annotated.  
 
Table 8: Primer3 settings for primer design according to primer purpose. 
Settings 
Conventional 
Sequencing Primers 
High Resolution 
Melting Primers 
Long PCR 
Primers 
Product Size 100-800 bases 150-300 bases Up to 15 kb 
Primer Size 
18-25 bases 
Optimum: 20 bases 
18-25 bases 
Optimum: 20 bases 
22-27 bases 
Optimum: 25 bases 
Primer Melting 
Temperature 
52-63°C 
Optimum: 55°C 
57-65°C 
Optimum: 63°C 
55-65°C 
Optimum: 60°C 
Maximum 
melting 
temperature 
difference 
100°C (Default) 1°C 100°C (Default) 
CG Clamp 0 0 1-2 
Other 
Variant of interest not 
within 20 bases of at 
least one of the primers 
Variant of interest 
not within 20 bases 
of at least one of 
the primers 
No other common 
SNPs within the 
fragment 
Primer not located 
within 200 bases 
5’- or 3’ of an exon. 
Primer not sited on 
a common SNP or 
within a known 
DNA repeat region. 
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7.4.4. Polymerase Chain Reaction (PCR) 
7.4.4.1. Standard PCR 
Standard PCR was carried out using the HotStarTaq master mix kit (Qiagen, UK) in a 
10 µl reaction mix using 40 pmol of each primer, 10 ng of genomic DNA, 5 µl of 2x 
HotStarTaq master mix and made up to 10 µl with molecular grade water.  Reaction 
conditions were – initial denaturation: 95°C for 15 minutes, 36 cycles of [denature: 
95°C for 30 seconds; anneal: 50-65°C for 30 seconds; extend: 72°C for 30 seconds], 
followed by a final extension of 72°C for 10 minutes. The optimum annealing 
temperature for each primer pair set was determined by amplifying control germline 
DNA samples using an annealing temperature gradient followed by gel 
electrophoresis of PCR products. 
 
7.4.4.2. Long Polymerase Chain Reaction (PCR) Amplification 
For the initial pilot NGS study, MUTYH was divided into two amplicons and XPC into 
nine amplicons. MRE11A was divided into 12 amplicons, while for the resequencing 
of XPC, the gene was divided into four amplicons. Several proof-reading capable 
long PCR kits, ABgene Extensor Long PCR Master Mix (ThermoFisher Scientific, 
UK), Bio-X-act (BioLine, UK), Invitrogen SequelPrep (Life Technologies, UK) and 
Fermentas Phusion Flash (ThermoFisher Scientific, UK), were tested for each primer 
set using control germline DNA samples on an annealing temperature gradient for 
successful PCR amplification with PCR products imaged following gel 
electrophoresis. Standard 10 µl reaction mixes and thermocycling conditions are 
shown in Table 9 and Table 10. 
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Table 9: Standard 10 µl long PCR reaction mixes for the different long PCR kits used. 
Reagent 
ABgene 
Extensor 
Long PCR 
Master Mix kit 
Bioline  
Bio-X-act kit 
Invitrogen 
SequelPrep 
kit 
Fermentas 
Phusion 
Flash kit 
DNA sample 
(25 ng/ µl) 
2 µl 2 µl 2 µl 2 µl 
Long PCR kit 
reagent 1 
5 µl 2x master 
mix 1/2 
5 µl 2x master 
mix 
1 µl 10x buffer 
5 µl 2x master 
mix 
Long PCR kit 
reagent 2 
  
0.5-1 µl 10x 
Enhancer A/B 
 
Long PCR kit 
reagent 3 
  
0.18 µl Long 
Polymerase 
 
Forward 
Primer (100 
µM) 
0.05 µl 0.05 µl 0.05 µl 0.05 µl 
Reverse 
Primer (100 
µM) 
0.05 µl 0.05 µl 0.05 µl 0.05 µl 
DMSO   0.2 µl  
Molecular 
grade water 
Made up to  
10 µl 
Made up to  
10 µl 
Made up to  
10 µl 
Made up to  
10 µl 
 
Table 10: Standard thermocycling conditions for the different long PCR kits used. 
Thermocycling 
Step 
ABgene 
Extensor 
Long PCR 
Master Mix kit 
Bioline 
Bio-X-act kit 
Invitrogen 
SequelPrep 
kit 
Fermentas 
Phusion 
Flash kit 
Initial 
Denaturation 
92°C for 2 
minutes 
95°C for 3 
minutes 
94°C for 2 
minutes 
98°C for 10 
seconds 
Phase 1: 15 cycles 35 cycles 10 cycles 35 cycles 
Denaturation 92°C for 10 
seconds 
95°C for 30 
seconds 
94°C for 10 
seconds 
98°C for 3 
seconds 
Annealing 50-68°C for 30 
seconds 
50-68°C for 45 
seconds 
50-68°C for 30 
seconds 
55-72°C for 5 
seconds 
Extension 68°C for 1 
minute/ kb 
72°C for 1 
minute/ kb 
68°C for 1 
minute/ kb 
72°C for 30 
seconds/ kb 
Phase 2: 20 cycles  25 cycles  
Denaturation 92°C for 10 
seconds 
 94°C for 10 
seconds 
 
Annealing 50-68°C for 30 
seconds 
 50-68°C for 30 
seconds 
 
Extension 68°C for 1 
minute/ kb + 
10 seconds 
per cycle 
 68°C for 1 
minute/ kb + 
20 seconds 
per cycle 
 
Final Extension 68°C for 7 
minutes 
72°C for 10 
minutes 
72°C for 5 
minutes 
72°C for 1 
minute 
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PCR amplification conditions were further optimised to maximise PCR yield by 
adjusting the duration of thermocycling steps and/or the number of thermocycling 
cycles accordingly. Details for each candidate gene amplicons are shown below in 
Table 11 to Table 13 with full long PCR conditions in Appendix A. All candidate gene 
amplicons were amplified individually for each study sample. 
 
Table 11: XPC and MUTYH long PCR amplicons and primers for the pilot multiplexed 
NGS study. 
Gene Amplicon Exons 
Forward PCR 
Primer 
Reverse PCR 
Primer 
Amplicon 
Size (bp) 
XPC 
1 1 
TGAATAAATAATTGT
TGCGCTCAC 
GGAGGAAAGCATA
GATTTAAAGAGG 
1265 
2 2 - 3 
GAGGTTAGCTGACA
TTTAAGATCTGG 
TACTCACTCACACT
GCCACCTAAG 
3261 
3.1 4 - 5.1 
TCTAAAGACTGTCT
GGGTTGTGTG 
TCTAATCCTTTCCC
CTACATAAAGC 
1994 
3.2 5.2 - 6 
AAGCAATTTGTATTT
TGAAGCTTTG 
TAGCACATCTGACC
AAAAACTACG 
1316 
4.1 7 - 8 
TAGCACTAGACTGT
TTCCAGAGTCC 
GACAGTATCATGTC
TGTCTCATTCC 
3434 
4.2 9 
AGTGAATTGCCTAC
TGAGAAATGAG 
AGAGACAGGGTTTC
ATCGTGTTAG 
1255 
5 10 
AATCATTTGACTGTT
CCATGTGC 
GTGTCCTGTGAATA
GTCTCTGTGG 
1269 
6.1 11 - 14 
ACAGGCTCTACTGA
TGGACAGTTAC 
AGACAGAAGACTGA
GGTGTCCTAAC 
2111 
6.2 15 - 16 
AAAAGCCCTTCATC
TGACTTTATG 
GTCTGTTTCTCAAC
AAGAGGTTCC 
1987 
MUTYH 
1 1 - 4 
GTATGAGCCTGGGT
AAATTACTTCC 
TTCAGTAAATAAAA
CATCAAAAGTTCC 
3049 
2 5 - 9 
TAACAGTTAGGGAG
CAGTGAAAATC 
ATTAGAGCTGACCT
GAGACGTAAAC 
6583 
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Table 12: MRE11A long PCR amplicons and primers. 
Gene Amplicon Exons 
Forward PCR 
Primer 
Reverse PCR 
Primer 
Amplicon 
Size (bp) 
MRE11A 
1 1 - 3 
CAGACGTTCTAATT
CAAAAGTTCTAC 
AGCTTTGACAGTCA
CCTTACATTTC 
3960 
2 4 
TAACAGTTTGCCTC
TTCCATTAGAG 
TGTCAACAAGAGTC
CATAAACAAAG 
1250 
3 5 - 7 
TCAAACTAATTGAA
ATGAATTGTCG 
TCTACCTTTTTGTTG
AATTGAGGAG 
3903 
4 8 - 9 
CACTTGTCTGTGTC
CAATAAGTTTG 
TCCAGTATTCCTCT
CTCTCAATGAC 
1701 
5 10 
AGGAAAGCCTTATT
GAAACATGAG 
AGACTGTGAGTGGT
GCTATAAGAGG 
2233 
6 11 
CTTTCTCTTGAGGC
ACATCTCTAAG 
GAGGCCTCAGAAAT
AACAATGC 
2068 
7 12 - 13 
TATGAACGAGAAAT
ACTGACTGTGG 
AGAGAAGATACTAT
CCATGGGGAAC 
2067 
8 14 
ACGATAATATATGG
CACATTGAAGG 
GGTTGCTAACTTGT
AGATTCAAACC 
1394 
9 15 - 16 
ATAGCTCACTGCAG
CCTGTATCTC 
CTCTCTCTGTTGCT
AGGGTAGAGTC 
2448 
10 17 - 18 
TCTCAATAAGCTGG
GAAATAATGAG 
GGAGAGAACACAG
TCTTCCATTAAG 
2223 
11 19 
TTTTCAGAAGTGGA
AGATGGTAATG 
AGGCACATTACAAA
GAAGAAGACAC 
1369 
12 20 
AAAATTACAGCTGT
TTCTGAGTTGG 
TTGAGATTGAGTTT
CACTCTTGTTG 
3620 
 
 
 
Table 13: Long PCR amplicons and primers for NGS resequencing of XPC. 
Gene Amplicon Exons 
Forward PCR 
Primer 
Reverse PCR 
Primer 
Amplicon 
Size (bp) 
XPC 
1 1 - 3 
TAACCTAACTCAAC
TGGTCCCTATG 
GTAAACAGCCTTCT
TTGGTAACTTG 
9800 
2 4 - 7 
GCTACTGTATACAA
GCAACGTAGGG 
TGTTTTATTCAGACA
GAGCCTTACC 
4649 
3 8 - 10 
ACCCATAACCCAGT
ATATGGATGC 
TGTGGGGTGTGTTT
TATACTGC 
4394 
4 11 - 16 
CTTTACCCCATCCT
GATAGTCTGC 
GTCTGTTTCTCAAC
AAGAGGTTCC 
8079 
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7.4.5. Gel Electrophoresis 
Successful PCR amplification was confirmed by running PCR products on a 1% 
agarose gel. The gel was made by heating and dissolving 1 g of molecular grade 
agarose in 100 ml of Tris/Borate/EDTA (TBE) buffer (Bio-Rad Laboratories, UK). One 
microlitre of ethidium bromide was dissolved in the liquid agarose gel then the gel 
poured into a mould with the appropriate sized comb in situ and the gel left to set. 
Four microlitres of each PCR product was mixed with 1 μl sterile water and 1 μl 6x 
loading dye (Norgen Biotek, Canada). The set agarose gel was submerged in TBE 
buffer in a gel electrophoresis tank. PCR products were then loaded into each well 
alongside an appropriate sized DNA ladder: <1 kb ladder (New England Biolabs, 
USA), <10 kb ladder (Norgen Biotek, Canada), and >10 kb ladder (Invitrogen, UK). 
The samples were electrophoresed in a 100-150 V electric potential for 60-90 
minutes and the PCR product bands visualised using a gel documentation ultraviolet 
imager (Bio-Rad Laboratories, UK). 
 
7.4.6. PCR product purification 
PCR products were purified to remove excess nucleotides, primers, enzymes and 
salts prior to downstream application. 
7.4.6.1. Column purification 
Column purification was performed using the standard QIAquick PCR Purification Kit 
(Qiagen, UK) protocols with the DNA eluted in 30 µl of 10 mM Tris-Cl (pH 8.5) buffer.  
7.4.6.2. Exonuclease – Shrimp Alkaline Phosphotase 
This PCR product purification process was used only for clean up prior to 
conventional dye terminator sequencing as the exonuclease – shrimp alkaline 
phosphatase reagents were found to interfere with DNA fragmentation during NGS 
library preparation. One microlitre of ExoSAP-IT (Affymetrix, USA), or 1 µl of 
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exonuclease 1 and 2 µl of shrimp alkaline phosphatase were added to 2.5 µl of PCR 
product to digest excess primers, degrade excess nucleotides and dephosphorylate 
enzymes. The mixture was incubated at 37°C for 30 minutes followed by enzyme 
inactivation at 80°C for 15 minutes. The treated sample was then diluted with 4 µl 
molecular grade water. 
7.4.6.3. Polymer-based purification 
The microCLEAN DNA clean-up reagent (Web Scientific, UK) was used for 96-well 
plate-based PCR product purification. Equal volumes of the microCLEAN reagent 
and PCR product were mixed in a 96-well plate and left at room temperature for five 
minutes. The plate was centrifuged at 4000 rpm for 40 minutes then centrifuged 
again upside down on tissue paper at 200 rpm for 30 seconds. Finally, the DNA was 
eluted in 30 µl of molecular grade water for five minutes and transferred to a fresh 
microcentrifuge tube. 
 
7.4.7. DNA quantification 
The concentrations of each purified amplicon were determined using a DNA standard 
curve assay. The Invitrogen Quant-IT BR PicoGreen Kit (Life Technologies, UK) was 
used. Two microlitres of each sample and lambda DNA standards (supplied at 0 ng/ 
µl, 5 ng/ µl, 10 ng/ µl, 20 ng/ µl, 40 ng/ µl, 60 ng/ µl, 80 ng/ µl and 100 ng/ µl) were 
mixed with 1 µl of Picogreen dsDNA reagent (a 502/523 nm fluorescent double-
stranded DNA (dsDNA) binding compound) and 199 µl of 20x Tris-EDTA buffer on a 
black 96-well assay plate. The fluorescence intensity was then measured for each 
well using a spectrofluorometer (excitation 480 nm, emission 520 nm) (BMG 
LABTECH, Germany). A DNA standard curve was plotted using the fluorescence 
measurements of the lambda DNA standards and from this plot, the sample 
concentrations calculated. 
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7.4.8. Genotyping 
7.4.8.1. High-throughput Taqman SNP genotyping 
Genomic DNA samples were sent for genotyping using the Taqman SNP Genotyping 
Assay (Applied Biosystems, USA) by Gen-Probe Life Sciences (West Lothian, 
Scotland) or by the Leeds Cancer Research UK Genomics Facility. For each sample, 
five nanograms of germline DNA was dried on a 384-well plate and resuspended in 2 
µl of reaction mix consisting of 1x Taqman Universal PCR Master Mix (Applied 
Biosystems, UK), which incorporates a Taq polymerase, and 1x SNP Genotyping 
Assay (Applied Biosystems, UK) containing the target specific forward and reverse 
primers, and two allele specific probes labelled with a VIC or FAM fluorescent dye 
linked to a fluorescence quenching molecule. All primers and probes used are listed 
in Appendix A. Blind duplicates from five percent of samples were included to ensure 
concordance of genotyping calls. 
 
The sample mixtures were PCR amplified using the following thermocycler 
conditions: enzyme activation 95°C for 10 minute, 40 cycles of [denature: 92°C for 15 
seconds; anneal and extend: 60°C for one minute]. During PCR amplification and 
DNA elongation, on reaching a perfectly complementary probe bound to the SNP of 
interest, the 5’-nuclease activity of Taq polymerase cleaves the probe separating the 
fluorescent dye from the quencher. Imperfectly bound probes are displaced but not 
degraded by the Taq polymerase. Fluorescence measurements were carried out 
using an Applied Biosystems 7900 real-time PCR machine (Applied Biosystems, UK) 
and a fluorescence plot of each sample measurement generated. SDS 2.2 software 
(Applied Biosystems, UK) was used for allelic discrimination and genotype calling of 
each sample. 
 
In the study of DNA repair gene 3’UTR SNPs, as the ATM SNPs rs1137918 and 
rs227091 failed Taqman genotyping due to being located within Alu repeats, Taqman 
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genotyping was performed on a nested PCR product.  PCR primers located in unique 
sequence flanking the Alu repeat were designed using Primer3 as previously 
described. Primers for rs1137918 were AAGGAACATCTCTGCTTTCACTC and 
GAGTGATCTTACTAGGAAAAATCCAAA (398 bp product) and for rs227091 were 
TGCACACAAGCCCATTCTTA and AGCTGGGGGACAGAGAAATG (842 bp 
product).  PCR was carried out using the HotStarTaq master mix (Qiagen, UK) in a 
10 µl reaction mix as previously described with a 58°C annealing temperature. Two 
microlitres of diluted 1:10 PCR product was then dried on a 384-well plate and 
Taqman SNP genotyping performed as described above.  Conventional DNA 
sequencing was used to confirm the genotype. For sequencing, the primers 
GGAGTTTCGCTCTTGTCACC (rs1137918) and GTGCAGTGGCATGATCTCAG 
(rs227091) were used.  There was complete concordance of genotype by 
sequencing and Taqman in all samples tested. 
 
7.4.8.2. Fluidigm SNP genotyping 
The Fluidigm 96.96 Dynamic Array Integrated Fluidic Circuit (IFC) system with 
custom Fluidigm SNPtype Assays (Fluidigm, USA) were used for SNP genotyping of 
genomic germline DNA samples. Each DNA sample was first pre-amplified in a 5 µl 
reaction mix of 1.25 µl germline DNA (at 10 ng/ µl to 90 ng/ µl), 2.5 µl of Qiagen 2x 
Muliplex PCR Master Mix (Qiagen, UK), 0.5 µl of 10x SNPtype Specific Target 
Amplification primer pool (consisting of 500 nM of each SNPtype Assay STA primer 
and SNPtype Assay LSP Primer combined from all 96 SNP assays) (Fluidigm, USA)  
and 0.75 µl of molecular grade water, and using the following thermal cycling 
conditions: initial denaturation: 95°C for fifteen minutes and 14 cycles of [denature: 
95°C for 15 seconds; anneal and extend: 60°C for four minutes].  
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Pre-amplified samples were then diluted 1:100 in Tris-EDTA buffer. A sample mix 
was then made by combining 2.5 µl of each diluted pre-amplified sample with 3.5 µl 
of a master mix containing 3 µl Biotium 2x Fast Probe Master Mix (Biotium, USA), 0.3 
µl SNPtype 20x Sample Loading Reagent (Fluidigm, USA), 0.1 µl SNPtype Reagent 
(Fluidigm, USA), 0.036 µl 50x ROX Reference Dye (Invitrogen, UK) and 0.064 µl of 
molecular grade water. A 10x assay mix was made for each assay by mixing 2.5 µl 
2x Assay Loading Reagent (Fluidigm, USA), 1.5 µl molecular grade water and 1 µl of 
SNPtype Assay Mix (consisting of 7.5 µM SNPtype Assay ASP1/ASP2 and 20 µM 
SNPtype Assay LSP Primer for each SNP assay) (Fluidigm, USA). 
 
Using the Fluidigm IFC Controller HX (Fluidigm, USA), the Fluidigm 96.96 Dynamic 
Array IFC chip was loaded with 4 µl of each 10x assay mix and 5 µl of each sample 
mix in the corresponding assay and sample inlets respectively. The IFC chip was 
then loaded onto the Biomark HD system (Fluidigm, USA) for PCR amplification and 
fluorescence image capture. Allelic discrimination and genotype calling of each 
sample was performed using the Fluidigm Genotyping Analysis software (Fluidigm, 
USA). 
 
7.4.8.3. High resolution melting mutation scanning 
High resolution melting (HRM) mutation scanning in genotyping works by measuring 
the differences in the melting temperature of dsDNA due to DNA sequence variation 
(Taylor 2009). Forward and reverse primers were designed using Primer3 as 
described earlier. PCR amplification was performed using 5 µl 2x HotShot Diamond 
PCR Master Mix (Clent Life Science, UK), 1 µl LCGreen PLUS dye (Idaho 
Technology, USA), 40 pmol of each primer, and 1 ng of genomic DNA made up to a 
10 µl reaction with molecular grade water and with 1 µl DMSO added as required. 
Thermal cycling conditions were: initial denaturation: 95°C for five minutes, 45 cycles 
of [denature: 95°C for 30 seconds; anneal: 50-65°C for 30 seconds; extend: 72°C for 
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15 seconds], followed by a final denaturation step of 95°C for 30 seconds. The PCR 
annealing temperature was optimized for each primer pair using a control genomic 
DNA sample on a temperature gradient. HRM primers for each variant tested are 
listed in Table 14. 
 
The LCGreen PLUS dsDNA intercalating fluorescent dye only fluoresces when 
bound to dsDNA. Thus, using the LightScanner (Idaho Technology, USA), the 
fluorescence of each sample was measured as each PCR sample was gradually 
heated over a temperature gradient of 70°C to 95°C with the fluorescence intensity 
falling off rapidly with dsDNA denaturation (Figure 16). Analysis of these different 
melting curve profiles on the LightScanner allowed identification of any samples 
containing variant alleles. These variant calls were confirmed by conventional DNA 
sequencing, using the above PCR products directly in the cycle sequencing reaction 
following Exonuclease – Shrimp Alkaline Phosphatase PCR purification. 
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Table 14: HRM primer sequences and PCR conditions for each variant tested. 
Gene 
HG19 reference 
position/  
dbSNP rs 
number 
Variant 
base 
change 
Forward Primer Reverse Primer 
Amplicon 
Size (bp) 
Annealing 
Temp (°C) 
DMSO 
MUTYH Chr1: 45795058 T>A GAGTCGGGGAAAGGGAGAGA GTCACTGGGCTGCACTGTTG 222 60 + 
MUTYH Chr1: 45805788 C>T GCCTGAGTCGTCTGTGGGTA GGCCAGCACAGGCCAATAGGCAAT 184 60 + 
MUTYH rs1140199 G>A GGTCCGGAGTTCAAAACC AGGCTGAAGTGCAAAATGG 192 60 - 
MUTYH rs3219495 G>A CGTGTGTATCAGGGCCAACA TCTACCCTGCACCCCACAAT 202 57 + 
MUTYH rs3219497 C>T GAGTCGGGGAAAGGGAGAGA GTCACTGGGCTGCACTGTTG 222 60 + 
XPC Chr3: 14186418 C>T GGGAAACAGTCCCAGCTCCT TCCAGCCTCCATGAAAACAAA 161 57 - 
XPC Chr3: 14186922 A>C TTCATCTGTCCGACAAGTTCACTC TCCCAGCAGATGACCTGTACTTC 156 57 - 
XPC Chr3: 14187269 T>G AAGGCAAACTGAGGCAGCAT GGTGAGTGGGCTTTGGTAGC 150 56 + 
XPC Chr3: 14189405 T>G TCCCCACAGGACTGATGGATAC AGTGTTGCTTCCAGCTTCTG 152 58 - 
XPC Chr3: 14190068 A>C CTGCCCAGCATGATGCCTAT TTTCCATCCCCATCTCTGGA 206 55 + 
XPC Chr3: 14190169 T>G CTGCCCAGCATGATGCCTAT TTTCCATCCCCATCTCTGGA 206 55 + 
XPC Chr3: 14190324 T>G TCCTCTGGTGCAGATGGTGA CTGGTCCTGAGCCCTTCTGA 180 57 + 
XPC Chr3: 14199728 T>G AGCGATGGTGAGAAGGCAGA TCACTGTCAATGCCCACCAC 182 60 - 
XPC Chr3: 14199759 T>G AGCGATGGTGAGAAGGCAGA TCACTGTCAATGCCCACCAC 182 60 - 
XPC Chr3: 14200112 T>G TGCCAAAGGGAAGAGGAACA CCAGCCTCATCACTCCCACT 180 60 - 
XPC Chr3: 14219968 
del 
AGGG 
ATCCAAGGCCAAGAGCAAGG CGCAGCAACCTCCACCAG 151 58 + 
XPC Chr3: 14220193 C>T CTACGTCGTCCGCCATGTTT CCCTTCGTTGGAGGCCTAGT 211 58 - 
XPC rs3731069 G>T TCAGAGGGCTGGAACCATGT TGTTCCCTGGGCTCATAATCA 153 60 - 
XPC rs3731072 G>C CTGCCTCCTAAGAAAGTTGA TGTGCCCTCTACTGGACTAC 150 55 - 
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Figure 16: Temperature-shifted, fluorescence-normalised melting curve (adapted from 
(Taylor 2009). At lower temperatures, the fluorescence intensity remains high with the 
fluorescent dye bound to the dsDNA molecules. As the temperature increases, the 
dsDNA molecules denature to ssDNA releasing the fluorescent dye with a rapid fall in 
the fluorescence measured until complete denaturation of all dsDNA molecules. The 
different sequence of Allele 1 compared to Allele 2 results in the different melting curve 
profile observed.  
 
7.4.9. Conventional DNA sequencing 
A standard dye terminator chemistry protocol was used. In brief, forward and reverse 
primers were designed using Primer3 as previously described.  Primers used are 
detailed in Appendix A. PCR amplification was carried out as described earlier in a 
10 µl reaction mix of HotStarTaq master mix (Qiagen, UK) and 5 ng of genomic DNA. 
Successful PCR was confirmed by gel electrophoresis. PCR products were purified 
using the Exonuclease - Shrimp Alkaline Phosphatase (Exo-SAP) protocol. The cycle 
sequencing reaction was performed using standard BigDye® Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems, UK) protocols.  A 10 µl reaction mix of 4 µl 
molecular grade water, 1 µl of purified PCR product, 0.5 µl of BigDye® Terminator 
v1.1 Ready Reaction Mix, 3.5 µl of 5x Sequencing buffer and 1 µl of either the 
forward or reverse PCR primer (1.6 µm). Two cycle sequencing reactions were 
performed for each sample PCR product: one with the forward and one with the 
reverse primer. Thermocycling conditions were: initial denaturation: 96°C for one 
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minute and 25 cycles of [denature: 96°C for 10 seconds; anneal: 55°C for five 
seconds; extend: 60°C for four minutes]. 
 
Sequencing extension products were purified using a standard ethanol precipitation 
protocol. DNA was precipitated by incubating each product sample with 1 µl of 3M, 
pH5.3 sodium acetate and 25 µl of 95% ethanol for 30 minutes at room temperature. 
Samples were then centrifuged at 2250g for 30 minutes followed by centrifuging 
inverted on tissue paper at 180g for one minute. The samples were then washed with 
70 µl of 70% ethanol and centrifuged at 1650g at 4°C for 15 minutes, followed by 
centrifuging inverted on tissue paper at 180g for one minute. The invisible DNA pellet 
was then dried at 95°C for one minute. 
 
The pellet was resuspended in 15 µl of Hi-Di formamide (Life Technologies, UK) and 
heated at 95°C for one minute then cooled on ice. Samples were loaded on a 3130xl 
Genetic Analyser (Applied Biosystems, UK) for capillary electrophoresis 
electrophoresis and sequence data collection. Data analysis was by visual inspection 
of generated electropherograms using Sequencing Analysis Software version 5.1 
(Applied Biosystems, UK). 
 
7.4.10. Next-generation sequencing 
7.4.10.1. Long PCR product normalisation 
The concentrations of each purified amplicon were measured using the Quant-IT BR 
PicoGreen Kit (Life Technologies, UK) as described earlier. For each individual, all 
their amplicons were normalised based on the relative size of each amplicon to 
produce one microgramme of the amplified candidate gene/genes containing 
equimolar quantities of each amplicon. Thus, the volume needed of each amplicon 
for each sample was calculated using the following formula: 
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For each sample, all the amplicons were pooled and made up to 50 µl with 10 mM 
Tris-Cl (pH 8.5) buffer. For the pilot study sequencing XPC and MUTYH, the 
normalised samples were pooled immediately into pools of 20 case or 20 control 
samples prior to standard Illumina sequencing library preparation. For the indexed 
sequencing of MRE11A and XPC, each sample underwent library preparation 
individually. 
 
7.4.10.2. Illumina sequencing library preparation and indexing 
Illumina sequencing libraries were prepared using the standard LIMM Next 
Generation Sequencing Facility protocol. Samples were made up to 250 µl with 
molecular grade TE buffer, transferred to a shearing tube then fragmented to 150-
200 bp using adaptive focused acoustics on a Covaris S2 Sonicator ( KBiosciences, 
UK). Sheared samples were purified with fragment size selection using the MinElute 
PCR Purification Kit (Qiagen, UK) – the protocol was as per column purification 
above but instead a MinElute column (instead of a Qiaquick column) was used and 
the DNA was eluted in 10 µl (instead of 30 µl) of 10 mM Tris-Cl (ph8.5) buffer. 
Successful fragmentation was confirmed by running 1 µl of each purified sample on 
an Agilent 2100 Bioanalyzer (Agilent Technologies, USA) using the DNA 1000 Kit 
(Agilent Technologies, USA) for sizing and quantification of DNA fragments.  
 
DNA fragment ends were then repaired using the End-It DNA End Repair kit 
(EpiCentre, USA). At room temperature, 9 µl of each sample was incubated with 5 µl 
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10x End-Repair buffer, 5 µl dNTP mix, 5 µl ATP, 1 µl End-Repair Enzyme mix and 
made up to a 50 µl reaction with molecular grade water, for 45 minutes. Each sample 
was then purified using the QIAquick PCR Purification Kit (Qiagen, UK) as described 
earlier but instead eluted in 34.45 µl of 10 mM Tris-Cl (ph8.5) buffer. A 3’-
deoxyadenosine was then added by incubating each sample at 37°C for 30 minutes 
with a master mix containing 5 µl DNA Polymerase 10x buffer (Promega, USA), 10 µl 
1 mM dATP and 0.55 µl of 9 Unit/ µl DNA Polymerase I Large (Klenow) Fragment 
Exonuclease Minus (Promega, USA) for each sample. Samples were then purified 
again using the MinElute PCR Purification Kit (Qiagen, UK) and eluted in 10 µl of 10 
mM Tris-Cl (pH 8.5) buffer. 
 
Either standard Illumina sequencing adaptor oligonucleotides for unindexed NGS 
runs or adaptors with a unique six nucleotide bar-code attached for indexed NGS 
runs, were then ligated to the DNA fragments for each sample using the LigaFast 
Rapid DNA Ligation System kit (Promega, USA). Ten microlitres of each sample was 
mixed with 15 µl 2x Rapid Ligation Buffer, 0.5 µl standard or indexed adaptors, 3 µl 
T4 DNA Ligase and 2 µl molecular grade water and incubated at room temperature 
for 15 minutes then 65°C for 20 minutes to inactivate the enzyme. The sequencing 
adaptor oligonucleotides and six nucleotide bar-codes are shown in Appendix A. 
Each bar-code has a minimum of two bases difference between indexes to reduce 
the risk of sequencing error resulting in mis-assignment of DNA fragment sequences. 
 
Adaptor-ligated samples were then purified and size selected using the Agencourt 
AMPure XP magnetic bead system (Beckman Coulter, USA). The ligation reaction 
mix was mixed thoroughly with 27 µl of AMPure XP and incubated for five minutes at 
room temperature to allow DNA binding to the magnetic beads. The beads were then 
separated from solution by placing samples on a magnetic separator rack (Invitrogen, 
UK) for 10 minutes until the solution clears. While still on the magnetic rack, the 
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solution was discarded and the beads washed twice with 200 μl 70% ethanol. All the 
ethanol was aspirated and the beads dried at 37°C until all excess ethanol has 
evaporated. The beads were resuspended in 40 µl 10 mM Tris-Cl (pH 8.5) buffer to 
elute the DNA then separated from solution by placing back on a magnetic rack for 
10 minutes. The eluted DNA solution was then transferred to a new microcentrifuge 
tube. 
 
 NGS libraries were then generated by amplifying the eluted DNA by PCR in a 50 µl 
reaction containing 2 µl purified DNA, 25 µl Fermentas Phusion High Fidelity Master 
Mix (ThermoFisher Scientific, UK) and 1 µl each of the Illumina library amplification 
forward and reverse primers (CAAGCAGAAGACGGCATACGAGATCGGTCTCGGC 
ATTCCTGCTGAACCGCTCTTCCGATCT and AATGATACGGCGACCACCGAGAT 
CTACACTCTTTCCCTACACGACGCTCTTCCGATCT respectively). Thermocycling 
conditions were: initial denaturation: 96°C for one minute, 12 cycles of [denature: 
98°C for 30 seconds; anneal: 65°C for 30 seconds; extend: 72°C for 30 seconds], 
and final extension: 72°C for five minutes. PCR products were purified again using 
the Agencourt AMPure XP magnetic bead system (Beckman Coulter, USA) but 
instead using 90 µl of AMPure XP. Finally, the library quality was checked on an 
Agilent 2100 Bioanalyzer (Agilent Technologies, USA) using the DNA 1000 Kit 
(Agilent Technologies, USA) and library concentration measured using the Invitrogen 
Quant-IT BR PicoGreen Kit (Life Technologies, UK). For indexed NGS, equal 
quantities of each indexed library were pooled in groups of 20 to 25 samples per pool 
for a total of 1 µg of DNA library. 
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7.4.10.3. Illumina sequencing 
Libraries were sent for sequencing at the LIMM Next-Generation Sequencing facility. 
Flow cell cluster generation and sequencing by synthesis using the Illumina GA II 
was performed following standard Illumina protocols with single end reads. The pilot 
multiplexed NGS study of XPC and MUTYH used 36 bp reads while the indexed 
NGS of MRE11A and XPC used 100 bp reads. 
 
7.4.11. MRE11A mRNA isoform expression profiling 
For RNA extraction, macrodissection was undertaken on five 10 µm FFPE tissue 
sections from each corresponding patient tumour blocks for regions of muscle-
invasive bladder cancer. Tissue from the muscle-invasive tumour regions were 
placed in a microcentrifuge tube, deparaffinised in one millilitre of Xylene, vortexed, 
then centrifuged at 13200 rpm for two minutes. The supernatant was discarded and 
the tissue pellet washed with one millilitre of 100% ethanol, vortexed again, and 
centrifuged at 13200 rpm for two minutes. The supernatant was discarded and the 
pellet dried at 37°C for 10 minutes. 
 
Tumour RNA was extracted using the AllPrep DNA/RNA FFPE Kit (Qiagen, UK) 
following standard protocols. The RNA sample was then quantified using a 
NanoDrop 1000 spectrophotometer (ThermoScientific, UK). Reverse transcription of 
RNA to cDNA was performed following standard protocols using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, UK). A 10 µl master mix of 2 µl 
10X RT Buffer, 0.8 µl 25X 100 mM dNTP Mix, 2 µl 10X RT Random Primers, 1 µl 
MultiScribe Reverse Transcriptase, 1 µl RNase Inhibitor and 3.2 µl molecular grade 
water was mixed with 2 µg of RNA made up to 10 µl with molecular grade water. 
Thermal cycling conditions were: 25°C for 10 minutes, 37°C for two hours, and 85°C 
for five minutes. A negative control sample for later steps underwent the same 
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process and thermal cycling but the master mix contained no reverse transcriptase. 
The reverse transcription product was then diluted 1:5 with molecular grade water. 
 
Primers were designed using Primer3 for cDNA sequence flanking MRE11A 
rs1805363 with forward and reverse primers sited in common sequence for both 
MRE11A isoforms in exon 1 and exon 2 respectively. The PCR primers used were 
AAACGGACGCCGTTCTCT and GGGACCAGGTTCTTCTCCAA (139 bp product for 
isoform 1 and 246 bp product for isoform 2). PCR amplification was performed on 2 
µl cDNA with Fermentas Phusion Flash (ThermoFisher Scientific, UK) PCR kit 
following standard thermocycling protocols as mentioned earlier except with a 65°C 
annealing temperature, 10 second extension time, and for 40 cycles. The GAPDH 
housekeeper gene was also amplified in parallel as a normalization control in a 10 µl  
reaction mix containing  2 µl cDNA, 5 µl 2x Taqman Universal PCR Master Mix 
(Applied Biosystems, UK) and 0.5 µl Taqman GAPDH Control Reagents (Human) 
(Applied Biosystems, UK). Thermocycling conditions were: enzyme activation 50°C 
for 2 minutes, denaturation 95°C for 10 minutes, 40 cycles of [denature: 95°C for 15 
seconds; anneal and extend: 60°C for one minute]. Both PCR products were 
electrophoresed in parallel on a 2% agarose gel with a 1 kb ladder (New England 
Biolabs, USA) in a 100V electric potential for two hours. Bands were visualised using 
a gel documentation ultraviolet imager (Bio-Rad Laboratories, UK) and images taken. 
Images were analysed using Quantity One 1-D Analysis Software (Bio-Rad 
Laboratories, UK) to measure for each band the intensity per mm2.  
 
The bands with corresponding sizes for the PCR products of isoform 1 and isoform 2 
were excised with a sterile scalpel and placed into separate microcentrifuge tubes for 
conventional Sanger sequencing to confirm the identity of each band. The PCR 
products were then extracted using the Qiaquick Gel Extraction Kit (Qiagen, UK) as 
per manufacturer’s instructions. One microlitre of each purified sample was then 
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used direct in the cycle sequencing reaction as previously described for the 
conventional Sanger sequencing of each sample. 
 
7.5. Bioinformatics 
7.5.1. Next-generation sequencing 
7.5.1.1. Illumina Genome Analyser Pipeline image analysis and base calling 
The standard Illumina Pipeline software (Illumina, USA) was used for interpretation of 
signal intensities for each cluster captured images by the Illumina GA II and base 
calling of each cluster for each cycle. Cluster read sequences were ouput as a 
_prb.txt file (Pipeline software version 1.1) for the initial six NGS runs for the pilot 
multiplexed NGS study of XPC and MUTYH, then as a _qseq.txt file for later runs 
due to an update in the Pipeline software (Pipeline software version 1.3+).  
 
7.5.1.2. Sequence alignment and variant calling 
NextGene version 1.10 (SoftGenetics, USA) was used for sequence alignment and 
variant calling for the pilot multiplexed NGS of XPC and MUTYH study. Reads were 
aligned using the _prb.txt and _qseq.txt files against reference sequences MUTYH 
(NG_008189) and XPC (NT_022517) from build 18 of the Human Genome assembly. 
NextGene alignment and mutation calling settings were: Condensation method: 
Elongation, Coverage Index: 2500, and Mutation Filter: 2.0%. 
 
Illuminator (written by Ian Carr, LIMM (Carr et al. 2011)) was used for index sorting, 
sequence alignment and variant calling for all the indexed multiplexed NGS studies. 
Index sorting was first performed using the Illuminator Data Extractor by inputting the 
_qseq.txt files and a list of the six nucleotide index sequences used in the 
corresponding pool.  This generated a .fasta file for each sample index containing the 
corresponding sample index read data. Sequence alignment was performed for each 
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.fasta file against either the reference sequence human genome build 19 XPC 
(NG_011763.1) or MRE11A (NG_007261). The default heterozygous cut-off of 20% 
was used for mutation calling. 
  
Analysis using Syzygy (http://www.broadinstitute.org/software/syzygy/) was 
undertaken by the University of Leeds Biomedical Health Research Centre 
Bioinformatics Technology Group. In short, a binary sequence alignment .bam data 
file was generated using SAMtools (http://samtools.sourceforge.net/) for each pool 
sequenced from the corresponding _prb.txt and _qseq.txt files of the pilot multiplexed 
NGS of XPC and MUTYH study. Sequence alignment was performed using these 
.bam files against the reference sequences MUTYH (NG_008189) and XPC 
(NT_022517) and mutation calling undertaken using default settings. 
 
7.5.2. Bioinformatics functional prediction 
7.5.2.1. Coding variants 
Non-synonymous coding variants and amino acid changes were determined using 
the UCSC genome browser and these were analysed for potential functional effects 
using Polyphen (http://coot.embl.de/PolyPhen/) and SIFT (http://sift.jcvi.org/), 
changes to protein secondary structure with NPS@ (http://pbil.ibcp.fr/), lost of 
conservation in active sites using Pfam (http://pfam.sa nger.ac.uk/) as well as looking 
for significant changes in amino acid chemical properties. Reference protein 
sequences used have been detailed earlier (Section 7.4.2). 
 
7.5.2.2. Predicting miRNA binding sites 
For 5’UTR and 3’UTR variants identified by next-generation sequencing, variants 
were checked if they were sited at predicted miRNA binding sites using miRbase 
(http://www.mirbase.org/) and miRanda (http://www.microrna.org/microrna/) and if so, 
the G was calculated using RNAhybrid (http://bibiserv.techfak.uni-
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bielefeld.de/rnahybrid/) (Kruger and Rehmsmeier 2006).  UTRscan 
(http://itbtools.ba.itb.cnr.it/utrscan) (Mignone et al. 2005) was used to predict if a new 
miRNA binding site may have been generated by the variant. 
 
For the identification of DNA repair gene miRNA binding site SNPs, twenty DNA 
repair genes involved in NER, BER, NHEJ, HR and DSB signalling and end-
processing pathways were selected for investigation. In July 2009, in collaboration 
with Dr S Landi’s group (Landi et al. 2008), the 3’UTR genomic sequence for all 
genes were obtained from the UCSC genome browser (http://genome.ucsc.edu) and 
putative miRNA-binding sites within these regions were then predicted using the 
miRBase (Griffiths-Jones et al. 2006), miRanda (John et al. 2004), PicTar (Krek et al. 
2005), MicroInspector (Rusinov et al. 2005), Diana-MicroT (Kiriakidou et al. 2004) 
and TargetScanS (Lewis et al. 2003) algorithms. Using the dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP), BLAST (http://www.ncbi.nlm.-
nih.gov/BLAST/Blast.cgi) and BLAST-SNP (http://www.ncbi.nlm.nih.gov/SNP/ 
snpblastByChr.ht ml) algorithms, common SNPs (MAF>0.10) sited within these 
putative miRNA-binding sites were identified. Using miRanda, the Gibbs binding free 
energy (G, expressed in KJ/mol) for both common and variant alleles of each SNP 
was calculated with G being the difference in G of the two alleles. As some SNPs 
may be predicted to reside in more than one miRNA binding site increasing the 
likelihood of a true binding site existing, the sum of all |G|s for each SNP (|Gtot|) 
was used to grade the impact of the SNP on miRNA binding. The eight SNPs with 
the highest |Gtot| not previously studied were selected for genotyping.  
 
7.5.2.3. Intronic variants 
Intronic variants located in canonical GT donor and AG acceptor splice sites were 
identified manually.  NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) and 
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ESEFinder 3.0 (http://rulai.cshl.edu/tools/ESE3/) were used to predict potential 
generation of new splice sites. Using chromatin immunoprecipitation sequencing data 
from the UCSC genome browser (http://genome.ucsc.edu), consistent epigenetic 
regulatory regions across all cell lines, such as transcription factor binding sites, 
histone modifications, and predicted chromatin state segmentation regions, were 
identified. 
 
7.6. Statistical analysis 
7.6.1. Statistical software 
Statistical analysis was performed using STATA version 10 (StataCorp, USA), SPSS 
version 18 (IBM, USA) and GraphPad Prism version 5 (GraphPad Software, USA). 
Haploview (Broad Institute, USA) was used for generating linkage disequilibrium 
plots and haplotype block analysis. 
 
7.6.2. Case-control epidemiological studies 
Power calculations were calculated for the relevant study populations. Hardy-
Weinberg equilibrium was assessed for the variant genotype frequency in the control 
samples at a significance threshold of P = 0.05 for common SNPs. A Cochrane-
Armitage trend test for common SNPs and Fisher’s exact test for trend for rare 
variants was used to test for association of each variant with bladder cancer risk 
estimating the odds ratio (OR) for each genotype with the respective 95% confidence 
interval (95%CI). A multivariate logistic regression analysis was also performed for 
each variant adjusting for gender, age, smoking status (ever versus never) and 
occupational dye exposure (ever versus never). Trend tests were used as the genetic 
inheritance model was unknown and this test was deemed to provide the best power 
for detecting an association (Li et al. 2009). Gene-environment and gene-gene 
interactions were assessed using the multiplicative model of interaction with P-values 
less than 0.05 considered to be significant. 
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In the DNA repair gene miRNA binding site SNP study, SNPs showing a significant 
risk effect were incorporated into a secondary analysis for the total number of 
unfavourable genotype groups carried, adjusting for the same factors listed above. 
The rare variant collapsed analysis was performed using a simple single-direction 
collapsed variant analyses (Barrett and Nsengimana 2011; Konig et al. 2011). This 
method involves for each gene, the number of copies of each minor allele for all 
variants with a MAF less than 0.05 being counted for each individual and each gene 
(according to the number of rare variants carried per individual) being tested for 
association with bladder cancer risk tested using a Bonferroni-corrected significance 
level (P = 0.05 / No of genes tested). 
 
7.6.3. Clinical outcome and survival analyses 
Survival power calculations were calculated for the relevant studies. D’ and r2 values 
of linkage disequilibrium were calculated for all common SNPs. Kaplan Meier curves 
were plotted for cancer-specific survival (CSS; deaths due to bladder cancer only 
with other deaths censored) for the relevant categories of protein expression levels or 
germline variant genotype status. CSS was used as bladder cancer patients treated 
by radiotherapy tend to be elderly thus more likely to die of other causes (Kotwal et 
al. 2008). A log-rank statistic or a survival-adjusted trend test was used to compare 
CSS times across categories of protein expression levels or germline variant 
genotype status respectively. Cox Proportional Hazard models were used to estimate 
hazard ratios (HRs) and 95% confidence intervals and multivariate analysis adjusting 
for age, gender, tumour and nodal stage, tumour grade, hydronephrosis and 
neoadjuvant or concurrent chemotherapy or radiosensitiser use. Ordered logistic 
regression was used to test for genotype associations with late bladder and bowel 
radiation toxicity.  
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8. Results 
8.1. Developing multiplexed next-generation sequencing for 
detecting rare variants 
8.1.1. Unindexed multiplexed next-generation sequencing 
In 2008, technical experience in multiplexing, the sequencing of multiple samples in a 
single pool, for NGS internationally was very limited while indexing or bar-coding 
technology had yet to be developed. This project, which started in October 2008, 
thus aimed to develop protocols for multiplexed NGS for the cost-effective targeted 
sequencing of multiple pooled samples for the identification of rare germline variants. 
 
8.1.1.1. Candidate Gene Amplification 
Long range PCR amplicons were successfully generated for the target candidate 
genes MUTYH (two amplicons) and XPC (nine amplicons) (total 33 kb) (see Methods 
chapter 7.4.4.2). The youngest 280 cases and 280 controls of the LBCS were 
selected to enrich for genetic influences, and were alliquoted in eight 96-well PCR 
plates comprising four case plates and four control plates. Each of the MUTYH and 
XPC amplicons were amplified individually for each sample.  For quality control 
purposes, each amplicon of twelve samples from Row A of each PCR reaction plate 
were checked by gel electrophoresis; a PCR efficiency of greater than 95% was 
achieved in nine out of eleven amplicons (Figure 17). 
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Gene Amplicon Exons 
Gel Image of 
Row A Case Plate 3 
PCR 
efficiency (%) 
XPC 
1 1 
 
92 
2 2, 3 
 
94 
3.1 4, 5.1 
 
96 
3.2 5.2, 6 
 
98 
4.1 7, 8 
 
97 
4.2 9 
 
98 
5 10 
 
97 
6.1 
11, 12, 
13, 14 
 
98 
6.2 15, 16 
 
98 
MUTYH 
1 1,2,3,4 
 
98 
2 
5, 6, 7, 
8, 9 
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Figure 17: PCR Efficiency of MUTYH and XPC amplicons. Sample gel electrophoresis 
image  of Case plate 3 with persistent PCR failure for the same sample (red box) in all 
amplicons, except XPC amplicon 1, suggestive of variations in germline DNA quality or 
elution buffer conditions. 
 
8.1.1.2. Optimum sample pooling 
It was necessary to determine the optimum number of pooled samples per Illumina 
Genome Analyzer flow cell lane while maintaining sensitivity to detect a rare variant.  
Equimolar pooled amplicons from four previously conventionally-sequenced case 
samples of differing XPC heterozygous genotypes were thus NGS sequenced 
together at 1:1.2, 1:10, 1:20 and 1:50 dilutions respectively, as a pilot multiplexed 
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experiment. This pilot multiplexed NGS experiment was performed twice on two 
separate lanes on the same Illumina flow cell, either with PCR product samples 
purified prior to normalisation to generate equimolar pooled amplicons for each 
sample or with samples not purified prior to normalisation (Figure 18). This was done 
to establish whether PCR product purification was required prior to normalisation, as 
if not required, this would reduce the workload involved in individual sample 
processing. DNA concentration quantification using Picogreen® was performed prior 
to normalisation for each sample amplicon, and post-purification in the appropriate 
samples. 
 
Figure 18: Flow chart of sample processing and pooling of purified (blue arrows) and 
unpurified (red arrows) PCR products for pilot multiplexed NGS. 
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From these two NGS experiments as shown in Figure 19, firstly, the sensitivity of 
detecting the respective variants by multiplexed NGS were equivalent if not better in 
the unpurified samples compared to the purified samples. Secondly, 1:20 was the 
highest dilution at which the variant allele was still detectable. Thus, for subsequent 
multiplexed NGS, 20 normalised samples were pooled per lane in 14 case and 14 
control pools. For rare variants, in 20 samples, we would expect only one 
heterozygote sample or one variant allele (2.5%) of 40 alleles.  Based on this and the 
pilot experiment above (Figure 19, Sample 3), a minimum threshold of 2% was set as 
a filter for the minimum percentage of reads containing a variant detectable by the 
SoftGenetics NextGene software. 
 
 
Figure 19: Relative proportions of each sample in the multiplexed NGS pool and the 
detection of previously identified variants (detection in both purified and unpurified 
samples (red), unpurified sample only (green) and undetected in both samples (blue)). 
The expected reads were the expected percentage of reads the SNP minor allele would 
be detected in taking into account the relative concentrations of that sample within the 
pool. The discrepancy in expected and actual read proportions for Sample 1 and 
Sample 2 was thought to be probably secondary to a systematic pipetting inaccuracy 
for Sample 2 during pooling resulting in a greater proportion of Sample 2. 
 
Sample 1: Ratio 1:1.2 (83%)
Heterozygote XPC rs3731062
(expected 41.5% reads) 
Detected in both samples
Unpurified: 32% of reads
Purified: 31.3% of reads
Sample 4: Ratio 1:50 (2%)
Heterozygote XPC rs2227999
(expected 1% of reads)
Undetected in both samples
Sample 3: Ratio 1:20 (5%)
Heterozygote XPC rs2733533
(expected 2.5% of reads)
Detected in unpurified sample
Unpurified: 2.1% of reads
Purified: Undetected
Sample 2: Ratio 1:10 (10%)
Heterozygote XPC rs1211965090
(expected 5% of reads)
Detected in both samples
Unpurified 15% of reads
Purified: 17.4% of reads
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8.1.1.3. Multiplexed NGS rare variant calling and candidate variant selection 
All 14 case and 14 control pools were sequenced using single-end 36bp reads on the 
Illumina platform, this being the longest available read length at the time (now up to 
150bp). Overall mean sequencing depth and base coverage per pool were 152x and 
8969 reads respectively (MUTYH: 136x and 8629 reads, XPC: 163x and 9191 reads) 
with an overall mapped base count of 45 Gb per pool indicating good sequencing 
depth and coverage of the two genes.  This compared favourably with the mapped 
base count seen in the 1000 Genomes Project for single end reads with the Illumina 
platform (12.8 Gb per sample) (The 1000 Genomes Project Consortium 2010).   
 
A total of 313 MUTYH and 528 XPC variants were called following sequencing of all 
28 pools.  Further filtering criteria were applied: having a high base calling quality 
(Phred score greater than 20), good sequencing coverage (greater than 5000 reads), 
and likelihood of being a rare variant (seen in under 15% of reads within a pool or if 
reported in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP), a reported MAF of 
under 1%) (Figure 20); with the aim of reducing the number of variants to a more 
practical number for bioinformatics analysis and candidate variant selection.  
 
 
 
 
 
 
 
 
 
Figure 20: Flow chart showing the filtering criteria and identified rare variants by gene 
region. The filtering criteria used to reduce the number of variants identified were good 
coverage, good base calling quality scores and those likely to be rare variants.  
 MUTYH XPC 
Gene Region dbSNP New dbSNP New 
Coding 3 15 4 54 
3’UTR 0 0 2 13 
Intronic 8 157 29 203 
313 MUTYH 
528 XPC 
183 MUTYH 
305 XPC 
Variant reads 
<15% 
Coverage 
>5000 
Phred 
Score >20 
dbSNP 
MAF <1% 
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Filtered variants were then divided into coding, 3’UTR and intronic for bioinformatics 
functional analysis.  Eighteen candidate variants, six intronic (3 MUTYH, 3 XPC), ten 
coding (4 MUTYH, 6 XPC) and two 3’UTR (both XPC), were selected for further 
investigation, based on their (i) being predicted to have a significant effect on protein 
function or alteration of miRNA binding energies, or (ii) being sited in a canonical 
splice site and (iii) the relative number of case to control pools in which the variant 
was detected. 
 
8.1.1.4. Accuracy of rare variant calling 
Preliminary high throughput Taqman genotyping was performed in 750 cases and 
706 controls by Gen-Probe Life Sciences (West Lothian, Scotland).  Unexpectedly, 
custom Taqman assays for all 11 XPC variants and one of the intronic MUTYH 
variants failed to discriminate. Therefore, high resolution melting (HRM) mutation 
scanning of individual samples from two NGS pools positive for each of these 
variants was performed to determine if this was due to custom Taqman assay failure 
or was due to false positive calls. Only the triallelic XPC rare variants rs3731072 G>C 
and G>T were found to be true variants (Figure 21) with confirmation by direct 
Sanger sequencing (Figure 22).  
 
 
Figure 21: High resolution melting curves for XPC rs3731072 in Pool 24 and 28 
demonstrating a different genotype in one sample of each pool (Red arrow: Pool 24 - 
purple and Pool 28 - brown line) compared with the other samples (blue lines).  Brown 
line (black arrow) in Pool 24 represents a sample that failed to PCR amplify. 
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Figure 22: Conventional Sanger sequencing electropherogram confirming the triallelic 
XPC rare variants rs3731072 G>C and G>T. 
 
 
Repeat genotyping using the same custom assay for rs3731072 G>C in several 
sequenced samples locally indicated that the failure to discriminate this rare allele in 
the original genotyping was due to technical failures with the genotyping itself rather 
than the assay (Figure 23). 
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a) 
 
b) 
 
Figure 23: Allelic discrimination plots using custom Taqman assay AHGI9A3 for XPC 
variant rs3731072 G>C: a) Original genotyping in 750 cases and 706 controls showing a 
mono-cluster; b) Repeat genotyping in NGS pools 24 and 28 with the known sample 
heterozygous for the C-allele (green circle) clear discriminated and the T-allele (blue 
circle) heterozygote sample clustering with the wildtypes. 
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Figure 24: Flowchart of filtered NextGene coding and 3’UTR variants called that were 
selected for confirmation and the number of true variants identified. 
 
All remaining 42 putatively functional coding variants (6 MUTYH and 36 XPC) and 
remaining 13 XPC 3’UTR variants called by NextGene underwent confirmatory 
conventional sequencing in their respective pools, confirming a further six coding 
variants (4 MUTYH and 2 XPC) only (Figure 24).  The sensitivity of multiplexed NGS 
to detect the presence of a true rare variant allele was estimated by using the 
successful rare variant Taqman genotyping results as the gold standard test and the 
following formula: 
 
Sensitivity  =   No of true positive calls    
     (No of true positive calls + No of false negative calls) 
 
A true positive call was hence defined as the detection of a rare variant in a 
multiplexed NGS pool containing a rare variant heterozygote / homozygote individual 
genotyped on Taqman, while a false negative call was the failure of detecting a rare 
variant in a multiplexed NGS pool containing a rare variant heterozygote / 
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homozygote individual genotyped on Taqman. The number of true positive and false 
positive calls was thus summed up for all variants successfully genotyped by 
Taqman at several different variant calling thresholds and the sensitivity calculated 
accordingly (Table 15). At a 2% variant calling threshold, there was a sensitivity of 
73% for detecting a true rare variant with the sensitivity rising or falling as the variant 
calling threshold is increased or decreased. The true negative rate (thus specificity) 
could not be calculated without resequencing all samples by conventional 
sequencing. 
 
Table 15: The sensitivity of multiplexed NGS to detect the presence of a true rare 
variant allele relative to Taqman genotyping results and the effect of varying the NGS 
variant calling thresholds. 
NGS variant calling threshold 
1% 2% 2.5% 
Rare variant allele detected 24 19 15 
Rare variant allele undetected 2 7 11 
Sensitivity 92% 73% 58% 
 
However, on examining only the potentially functional coding variants selected for 
validation, this sensitivity is tempered by a high false positive rate (Table 16) of 
80.8% at the 2% variant calling threshold only decreasing to 54.5% at the 2.5% 
variant calling threshold. As discussed later, these results actually compared 
favourably with the only contemporary published report at that time using unindexed 
multiplexed NGS that attempted to validate their variants, with that study having all 
false positive calls (Harakalova et al. 2011). However, assuming an equivalent false 
positive rate among the intronic variant calls, identifying further candidate intronic 
variants for further investigation would prove to be very labour intensive and non-cost 
effective due to the large number of variants and hence samples needed to be 
tested. 
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Table 16: False positive and true positive rates of potentially functional coding variants 
called by multiplexed NGS successfully validated. 
 NGS variant calling threshold 
 2% 2.5% 
Total coding variants called 52 22 
No of True +ve coding variants 10 10 
No of False +ve coding variants 42 12 
False positive rate (%) 80.8 54.5 
True positive rate (%) 19.2 45.5 
 
 
8.1.2. Indexed multiplexed next-generation sequencing 
After this initial work was undertaken on unindexed multiplexed NGS, NGS 
technology had advanced significantly, with improvements in reagents and 
amplification accuracy, higher flow cell adaptor density, read lengths and the 
development of paired-end sequencing for greater coverage.  Indexing/ bar-coding 
technology was also developed, which involves the labelling of each individual 
multiplexed sample with a unique 6 nucleotide “bar-code” tag (Craig et al. 2008; 
Kenny et al. 2010). This allows the identification of the sample source of each read 
fragment during NGS and the analysis of each sample separately, thus enabling the 
use of a higher variant calling threshold for greater accuracy and accurate sample 
genotype determination.   
 
8.1.2.1. Pilot indexed multiplexed next-generation sequencing of XPC and 
MUTYH 
In order to assess the impact of these advances, XPC and MUTYH were 
resequenced in the samples from one pool, using single-end 90-base reads with 
indexing of all 20 samples. Using a default 30% variant calling threshold for each 
sample and filtering for low-base calling quality or coverage, the two confirmed 
MUTYH variants previously detected were detected again as well as five novel 
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variants (four intronic and one 3’UTR).  These were, in fact, called in the original 
unindexed pool but were not selected for further investigation as they either had no 
predicted functional effects or were seen in most pools (hence, were not rare).  All of 
these five variants were successfully confirmed by conventional sequencing.   
 
Only one of the false positive intronic MUTYH “variant” rs1140199 A allele from the 
untagged NGS experiment was detected though in a small percentage of reads in six 
of the tagged samples (Table 17). Rs1140199 is sited at the end of a short 
homopolymer stretch of four A bases which may account for the false positive call. 
Without indexing, this low level of sequencing or alignment error would have reached 
the variant calling threshold but with indexing, was easily identified and excluded.   
 
Table 17: Variant calling of the false positive MUTYH rs1140199 variant alleles in the 
original unindexed pool compared to the indexed pool samples. 
 
Original 
Pool 
Indexed Samples 
1 2 3 4 5 6 
MUTYH 
rs1140199 
% variant 
reads 
2.24 3.0 6.1 6.4 6.6 10.7 21.6 
Coverage 5653 1191 2458 882 897 979 527 
 
This newer, improved method was thus used in subsequent NGS projects. As there 
were sufficient rare variant hits in MUTYH, only XPC was chosen for resequencing in 
a smaller subset of the bladder cancer case-control for rare variants especially in 
view of the low number of true positive rare variants identified compared to previous 
work done by the group (Qiao et al. 2011). MRE11A was also sequenced using 
indexed multiplexed NGS to look for genetic markers of radiotherapy response in a 
set of germline DNA from MIBC patients treated with radiotherapy (see Results 
chapter 8.4). 
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8.1.2.2. Target Amplification of MRE11A and XPC 
Both MRE11A and XPC genes were amplified by long range PCR, MRE11A in 12 
amplicons (total 28.2 kb) in 186 RT-treated MIBC cases, and XPC, using newer long 
range PCR kits, in just four amplicons (total 26.9 kb) in the youngest 100 bladder 
cancer cases and 100 controls. All PCR amplicons were purified, quantified and 
normalised to generate equimolar pooled amplicons for each sample. 
 
8.1.2.3. Summary of indexed multiplexed NGS of MRE11A and XPC 
Separate indexed NGS libraries were prepared for each sample prior to multiplexing 
in equimolar quantities of 20 to 24 indexed libraries per pool for MRE11A and 25 
indexed libraries per pool for XPC. Each pool was single-end sequenced for 90 
cycles (ie. 90 base read length) on a single flow-cell lane of an Illumina GAII. 
Illuminator, an in-house developed software (Carr et al. 2011), was used to sort 
indexed reads according to sample origin and sequence alignment of the reads from 
each sample against the reference wildtype genomic sequence. For MRE11A, a total 
of nine pools were sequenced with a median coverage of 2507x per sample (range 
673 – 9891) and 95% of target candidate gene regions were sequenced at greater 
than 221x coverage per sample. XPC was resequenced in eight pools with a median 
coverage of 1719x per sample (range 727 – 3579) and 95% of target candidate gene 
regions sequenced to 201x coverage.  
 
8.1.2.4. Accuracy of rare variant calling 
Illuminator was also used for variant calling, with a default 30% variant calling 
threshold and a minimum coverage of 200x. Poor confidence and high-confidence 
variant calls were identified based on visual inspection of sequence alignment and 
read coverage data. A total of 121 MRE11A variants were called, 85 variant calls 
were deemed high confidence variants and 36 poor confidence. Confirmatory 
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sequencing of all 121 variants successfully validated all 85 high confidence calls and 
only 3 of the 36 poor confidence calls (Table 18). 
 
Table 18: Summary of confirmed MRE11A variants identified by MAF, presence in the 
dbSNP database and gene location. 
 dbSNP New 
MRE11A Variant type (MAF)  No of variants No of variants 
SNP (>0.01)  40 3 
Intronic  37 3 
3’UTR  3 0 
Rare Variant (≤0.01)  14 31 
Intronic  10 25 
Coding  3 1 
3’UTR  1 5 
 
On resequencing XPC, a total of 188 variants were called, of which 150 variants had 
an overall MAF less than 10% in the 100 bladder cancer cases and 100 controls 
(Figure 25). 119 of these were high confidence calls and 31 low confidence calls. 
Twenty eight of the high confidence variants were then selected for confirmatory 
sequencing of the respective indexed sample, specifically all 3’UTR, 5’UTR and 
coding variants, and variants within 200bp of a splice site, with 27 being successfully 
validated. The false positive “variant” was sited within a SINE repeat region which 
could suggest an issue with sequence alignment. 
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 dbSNP New 
XPC Variant type No of variants No of variants 
5’UTR  0 1 
Intronic  10 5 
Coding  2 7 
3’UTR  0 2 
Figure 25: Flow chart of candidate XPC variant selection and the number of Sanger 
sequencing confirmed true variants by gene region.The 91 high confidence XPC 
variants excluded were intronic variants with minimal predicted functional effects so 
were not selected for further confirmation (see Appendix C for full details of all 
variants). 
 
Based on the high confidence calls only, indexed multiplexed NGS had a true 
positive rare variant call rate of 98.6% for all MRE11A and XPC rare variants 
selected for confirmatory Sanger sequencing, with only one of 70 rare variants (42 
MRE11A and 28 XPC rare variants) being a false positive call. This marked 
improvement has resulted in these methods being instigated as the standard 
multiplexing protocol for candidate gene resequencing at the Leeds Institute of 
Molecular Medicine’s (LIMM) NGS facility. 
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8.1.3. Unindexed multiplexed next-generation sequencing revisited 
In 2011, Rivas et al at the Broad Institute, USA, investigating GWAS loci in 
inflammatory bowel disease, published the first successful unindexed multiplexed 
NGS for disease susceptibility rare variants (Rivas et al. 2011). Using a custom-
designed variant discovery software, Syzygy, which uses various error-modelling 
algorithms to account for sequencing errors and uneven variant read frequency, they 
identified 429 high-confidence variant calls, of which 137 were selected for validation, 
with 91.2% of these being true positive calls. Despite some differences in their 
protocols compared to this project (germline DNA pooling prior vs post PCR 
amplification respectively, 50 samples vs 20 samples per pool, 107.5 kb vs 33 kb 
target size and single-end 76bp vs single-end 36bp read length), the NGS variant 
calling issues of potentially uneven PCR amplification between individual samples 
and achieving adequate coverage taking into account the sequencing depth, target 
size and pooling size differences were relatively similar. Therefore, the original data 
from the unindexed multiplexed NGS of MUTYH and XPC was reanalysed using 
Syzygy. 
 
8.1.3.1. Syzygy software and accuracy 
The Syzygy software was installed by the LIMM Bioinformatics Group and the data 
from all 14 bladder cancer case pools and 14 control pools analysed. Syzygy called 
398 variants and estimated the MAF for each variant based on the variant allele read 
frequency in case pools and in control pools. Using this MAF estimation, Syzygy 
performs a weighted association likelihood ratio test for each individual variant and 
generates a Chi2-statistic which could be a potential tool for prioritising variants for 
further investigation.  
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Of note, three MUTYH rare variants found to be significantly associated with bladder 
cancer susceptibility in the preliminary Taqman genotyping, as well as the common 
XPC SNP rs2228000 previously associated with bladder cancer risk (Stern et al. 
2009), were all observed to have a Chi2-statistic value greater than two (Appendix C). 
Thus, a filter of a Chi2-statistic value of greater than two was used to try aid candidate 
variant selection resulting in 15 MUTYH and 25 XPC variants (Figure 26), of which 
11 had an estimated population MAF greater than 5%, while four MUTYH rare 
variants had previously been validated in the original work. Of the remaining 25 “rare” 
variants, four MUTYH and three XPC variants were selected, based on predicted 
functional effects and the Chi2-statistic value, for validation by HRM mutation 
scanning and Sanger sequencing of the corresponding sample pools – all were true 
positive. These seven variants were subsequently selected for genotyping in the 
larger case-control study (see Results chapter 8.2). 
 
On cross-referencing all Syzygy variant calls with all previously validated true positive 
variant calls and known false positive variant calls, Syzygy had a predicted true 
positive rare variant call rate of 80.6% and a sensitivity of 89.3% of detecting a true 
positive rare variant. 
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Figure 26: Flowchart of number of Syzygy variants called, and number of variants at 
each stage of filtering and selection for confirmation. Filtering criteria were Syzygy 
Chi
2
-statistic value and estimated population MAF. 
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8.1.4. Discussion 
This project was successful in developing two methods for the identification of rare 
variants in candidate genes using multiplexed NGS at the LIMM. Despite initial high 
false positive call rates with unindexed multiplexed NGS, the use of new custom- 
multiplexed NGS software markedly improved the true positive call rate and the 
sensitivity of detecting rare variants. This project also demonstrated the higher 
accuracy of rare variant detection using indexing technology and current NGS 
reagents in multiplexed NGS. 
 
8.1.4.1. Unindexed multiplexed next-generation sequencing 
In the original analysis using the NextGene software in 2009, despite achieving high 
sequencing depths and coverage, a significant proportion of candidate variants 
selected were false positive calls, with the majority in XPC (Table 16).  In the 1000 
Genomes Project undertaking whole genome sequencing of individual samples using 
contemporary NGS protocols and kits as this project, heterozygote call accuracy for 
SNPs with MAF 2-5% ranged from 83.08% to 99.97% for sequencing depths of 1x to 
16x respectively with overall base call error rates of 1-3% (The 1000 Genomes 
Project Consortium 2010).  Therefore, with multiplexing at a sequencing depth of 
152x per pool, a sequencing depth of about 8x per sample would be expected 
assuming even amplification correlating with a call accuracy of 99.56%.  However, 
the lower variant calling threshold of 2% used would encroach on the Illumina 
platform’s average base call error rates of 1-1.5%, thus searching for variants with 
rarer MAFs likely resulted in the lower accuracy and higher false positive rates seen 
(Shendure and Ji 2008).  This could also explain the relatively higher number of 
“variants” detected in this study (25.5 variants per kb sequenced in 560 individuals) 
compared to the 1000 Genomes Project (6.2 variants per kb in 179 individuals). 
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There was a relatively low number of true XPC rare variants identified compared to 
MUTYH (3 variants vs 10 variants) in the original analysis, which was surprising as in 
our group’s work, conventional sequencing of only 33 case samples identified four 
novel rare variants (Qiao et al. 2011).  There are several possible explanations for 
this.  As individual amplicon PCR products were not purified prior to normalisation, 
unwanted oligonucleotides could distort the quantification of amplicon concentrations 
thus affecting accurate normalisation.  As the XPC amplicons were also relatively 
smaller (1.5 – 3 kb) compared to MUTYH (3 – 6 kb), small volumes (less than 0.5 µL) 
were needed for some amplicons during normalisation.  Any pipetting errors could 
thus result in significantly less DNA normalised and therefore the potential for any 
erroneous sequences to make up a relatively higher proportion of total DNA. 
 
Over the course of sequencing all the pools, there was a drift in the number of 
variants called in the later pools sequenced, with a predominance of variant T>G and 
A>C transversions (Figure 27). These T>G and A>C transversions corresponded to 
the majority of the false positive variants.  This could be due to known changes in 
Illumina NGS kit chemistry or from automatic NextGene software updates (Version 
1.10 in Pools 1 to 19 and Version 1.12 in Pools 20 to 28) over this period.  On 
comparing the read coverage of variants called between Pools 1 to 19 and Pools 20 
to 28, there was a lower mean variant coverage in the latter pools (15182 reads vs 
11294 reads, p<0.001).  There was no significant difference between Pools 1 to 10 
and Pools 11 to 20 (14805 reads vs 15848 reads, p=0.20).  This difference in 
coverage could be due to problems with cluster amplification in the later pools or 
from altered sequence alignment with the software update.  Unfortunately, it was not 
possible to perform a direct comparison between Illumina kit batches or the two 
NextGene versions as earlier kits and software versions were no longer available. 
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a) 
 
 
b) 
 
Figure 27: Characteristics of variants called by NextGene in each pool in chronological 
order of sequencing: a) Number of variants called in each pool, b) Percentage of each 
variant base transversion in each pool. Differences seen in later sequenced pools are 
highlighted in the blue and red squares. 
 
Despite these issues, the number of true rare variants originally detected compared 
favourably with other published unindexed multiplexing studies at that time.  
Harakalova et al used a similar methodology with individual sample amplification 
prior to sample pooling in pools of 20 samples (Harakalova et al. 2011). This study 
sequenced 45 candidate genes (total 500 kb) in 100 patients but found that all twenty 
candidate variants selected were false positive.  Out et al sequenced by NGS the 
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MUTYH gene in 88 previously Sanger-sequenced samples as a single pool, 
detecting two out of the five known rare variants, but they did not investigate for false 
positive calls (Out et al. 2009).  This study pooled 287 genomic samples prior to 
target amplification but no rare variants were detected.  Lupton et al also pooled 
samples prior to target amplification of the Nicastrin gene (3 kb) in 311 cases in one 
case pool and 360 controls in one control pool, but from the variants identified only 
investigated two known coding rare variants (Lupton et al. 2011).  
 
The high false positive rate of rare variant calls observed by Harakalova et al and in 
the original NextGene analysis suggested that unindexed multiplexed NGS was not a 
promising strategy for rare variant detection. However, the success of Rivas et al and 
their development of the Syzygy software as mentioned earlier (Rivas et al. 2011), 
has led to a reassessment of this view. Particularly surprising was the marked 
superiority of its variant-calling algorithm compared to the original analysis (true 
positive rate 80.6% vs 45.5% at best respectively), even when using the same NGS 
raw sequencing data. By incorporating error-modelling and testing of consistency 
between forward and reverse strands, the Syzygy software was successful in 
excluding low-quality base calls and thus identify predominantly true-variant calls. 
 
Recently, Kelleher III et al used a novel multiplexed NGS design with two different 
NGS platforms (Illumina and Helicos) to cross-validate variant calls to identify rare 
variants in 18 autism related genes (total 40 kb) (Kelleher et al. 2012). Of note, their 
Illumina pooling strategy was the same as this project (20 samples per pool) with 
similar false positive rates of greater than 50% (Figure 28). However, by combining 
both platforms for cross-validation, they were able to reduce the false positive rate 
below 10%. Thus, with the development of new custom software and alternative NGS 
study design approaches, unindexed multiplexed NGS remains a feasible option for 
rare variant detection. 
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Figure 28: Receiver operator curve for sensitivity and false discovery rate of detecting 
a variant with unindexed multiplexed NGS as reported by Kelleher et al (Kelleher et al. 
2012). Red squares are results with the Illumina GA2 platform, blue diamonds with the 
Helicos Heliscope platform and green triangles with a combination of both platforms. 
Crosses are the equivalent results on the Illumina GA2 platform reported in this study 
at the 2% (red cross) and 2.5% (orange cross) calling thresholds. 
 
8.1.4.2. Indexed multiplexed next-generation sequencing 
The use of oligonucleotide bar-codes for multiplexed NGS was first demonstrated by 
Craig et al (2008), reporting at best an 88.7% true positive rate and a 90.8% false 
negative rate on multiplexing 46 indexed PCR-enriched samples from previously 
genotyped individuals (Craig et al. 2008). In the last two years, there have been a 
flurry of indexed NGS studies validating this methodology on different NGS platforms 
in previously Sanger sequenced or genotyped samples, demonstrating its use in 
clinical genetic diagnostics and in the investigation of candidate disease-related gene 
variants (Kenny et al. 2010; Morgan et al. 2010; Nijman et al. 2010; Amstutz et al. 
2011; Lotta et al. 2012; Pritchard et al. 2012; Rossetti et al. 2012). Despite using 
different target-enrichment techniques, target sizes, NGS platforms, sequencing 
coverage and numbers of multiplexed samples, results similar to those shown here 
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were reported in all these publications, with all studies having greater than 93% true 
positive rates. Most studies reported sensitivities of over 90% for detecting a true 
single nucleotide variant.  
 
Two papers have reported the potential use of indexed multiplexed NGS in clinical 
genetic diagnostics (Morgan et al. 2010; Pritchard et al. 2012). Pritchard et al 
demonstrated the use of new target enrichment capture arrays for sequencing of all 
colorectal cancer associated genes for pathogenic mutations and variants of 
unknown significance (VUS), by using indexed multiplexing of 96 samples on the 
latest Illumina HiSeq NGS platform. A sensitivity, specificity and accuracy of 99.4% 
was seen on confirmation by Sanger sequencing(Pritchard et al. 2012). Locally, 
diagnostic testing using indexed multiplexed NGS for BRCA1 and BRCA2 mutations 
in breast cancer cases, and TP53 mutations in Li-Fraumeni cases is now routine with 
a 100% sensitivity and zero false positive calls reported (Morgan et al. 2010). 
 
8.1.4.3. Unindexed versus indexed multiplexed NGS 
It is thus feasible to identify rare variants using both unindexed and indexed 
multiplexed NGS. As indexed multiplexed NGS was found to have close to a 100% 
true positive rate with the added benefit of providing information on sample genotype, 
this would seem to be the better NGS option of the two. However, indexing 
techniques require the labour intensive preparation of individual NGS libraries for 
each sample prior to pooling (ie. twenty libraries for twenty samples per pool) 
whereas for non-indexed libraries only one library is needed per pool (ie. one library 
for twenty samples per pool). Unindexed NGS, though, requires confirmation of a 
whole pool of samples for each rare variant detected rather than just two samples 
(one variant carrier and one wildtype) for indexed NGS. Fortunately, this is relatively 
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easy and cost-effective, with minimal added workload using HRM mutation screening 
as an initial sample screening step prior to Sanger sequencing as shown above.  
 
Thus, the choice of unindexed versus indexed multiplexing will be dependent on the 
number of samples to be sequenced and the need for genotyping data. Unindexed 
multiplexing would be more suitable for case-control and rare variant studies where 
large numbers of samples require to be sequenced to maximise the likelihood of 
detecting disease susceptibility variants and where the individual sample genotype is 
not required, as this would be determined in a second stage by large scale 
genotyping. In contrast, indexed multiplexing would be more useful for small to 
medium sized cohort studies, such as biomarker studies  as shown in Results section 
8.4, where the individual sample genotype is needed for correlation with patient-
specific outcome measures, and where analysis of all variants detected rather than 
just selected candidate variants is desirable. 
 
8.1.4.4. Newer Technologies and Study Limitations 
For detection of rare variants, the larger the sample size, the larger the number of 
rare variants that are likely to be detected up to the number of rare variants present 
in the sample set. The high workload of manual library preparation for indexing could 
thus potentially prove prohibitive for some research projects. Recently, several 
commercial automated library preparation kits and systems (Illumina Nextera, Agilent 
Bravo, Bechman Coulter SPRIworks and Fluidigm Access Array) have been 
developed, which are capable of automating the whole process or elements of the 
library preparation process for 10 to 96 samples per run.  However, this reduction in 
hands-on time comes with a consumables cost at least ten-times higher than the 
manual process. Potentially, as costs fall, high-throughput automation could become 
widely available making large multiplexing NGS projects more accessible. 
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NGS technology and platforms continue to develop and improve rapidly with greater 
sequencing depth, more accurate software and newer chemistry. One could predict 
that these newer technologies would improve NGS accuracy, increase multiplexing 
or target sizes, and reduce costs and sequencing time. However, NGS remains a 
relatively new approach with much developmental work still in progress.  Two studies 
have undertaken cross-NGS platform comparisons of the Applied Biosystems SOLiD, 
the Roche 454 GS-FLX and the Illumina GA2 platforms for standard single sample 
NGS (Harismendy et al. 2009; Suzuki et al. 2011). These revealed false positive 
single nucleotide variation call rates of approximately 3%, 7% and 6-16% for each of 
the platforms respectively, and false negative call rates of approximately 3%, 1% and 
0% respectively. These calling errors have been attributed to similar systematic 
errors, typical of the short-read sequencing used by all three platforms and seen at 
regions of repetitive sequences, simple repeats, insertion-deletions within 30bp on 
the variant and homopolymer stretches (Harismendy et al. 2009). It thus remains 
unclear if the greater coverage of advancing NGS technology would be able to 
resolve these issues. 
 
New high-throughput target-enrichment methods have also recently been developed 
using PCR-based assays, molecular inversion probes and hybrid-capture arrays with 
some of these systems capable of incorporating library preparation during the target-
enrichment process though this is usually at the cost of reduced target size 
(Mamanova et al. 2010). These different methods differ in their optimum cost-efficacy 
(Figure 29) with, for example, PCR assays being better suited for sequencing of a 
small target size in a large number of samples, while hybrid-capture arrays are more 
suitable for larger targets. The availability of these high-throughput methods could 
potentially allow megabase sequencing for rare variants in large sample sets. 
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Figure 29: Optimum target enrichment strategy relative to number of samples 
sequenced and target size (adapted from (Mamanova et al. 2010). 
 
One of the limitations of this study is the inability to accurately determine the false 
negative call rate which would require resequencing of the whole target gene by 
conventional Sanger sequencing as a “gold” standard. Potentially pathogenic or 
clinically significant variants could thus be missed. A difficulty also now recognised 
with NGS is the sheer bulk of data generated which requires handling of the large 
number of variants called (Ding et al. 2010). For epidemiology studies, the selection 
of candidate variants for further investigation and second stage genotyping remains 
very subjective, particularly due to the limited validation of bioinformatics functional 
prediction tools and correlation with actual clinical impact. Syzygy’s Chi2-value 
prediction provides a potential objective candidate variant selection tool. Finally, the 
rapid technological developments in NGS has made keeping pace difficult. The 
“novel” developments in this study, such as multiplexed sequencing and target 
enrichment by long PCR for NGS, are now commonplace or outmoded with the 
development of indexing technology and array-based enrichment. It is likely that 
these technologies too will be replaced, especially with the continued development of 
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new “third” generation sequencing platforms such as the Life Technologies Ion 
Torrent semiconductor-based system and the previously mentioned single-molecule 
sequencing Helicos Heliscope (Pareek et al. 2011). 
 
8.1.4.5. Summary 
This study has successfully developed local protocols for unindexed and indexed 
multiplexed NGS and demonstrated its efficacy in rare variant discovery. Both 
approaches have advantages and disadvantages, in terms of cost, accuracy and 
manual workload. The rapid advances in NGS technology, with higher read lengths 
and coverage, and newer automated or high-throughput systems for library 
preparation and target enrichment, will improve the cost-efficacy and accuracy of 
both approaches. This will allow even larger multiplexing projects to be conducted 
and potentially increase the success of identifying rare variants of clinical 
significance. 
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8.2. MUTYH and XPC rare variants in bladder cancer 
susceptibility 
Using the MUTYH and XPC rare variants identified by multiplexed NGS, this study 
aimed to test the common disease – rare variant hypothesis by genotyping candidate 
RVs in a large bladder cancer case-control study population and investigate the 
associations between individual or multiple RVs and bladder cancer risk. The top 
SNP hits reported from the three bladder cancer GWAS (Kiemeney et al. 2008; Wu 
et al. 2009; Kiemeney et al. 2010; Rothman et al. 2010; Garcia-Closas et al. 2011; 
Rafnar et al. 2011; Tang et al. 2012) were also genotyped to determine if risk 
contributions of candidate RVs were independent of these SNPs. 
 
8.2.1. Bladder cancer case-control study population 
Germline DNA samples from 853 cases and 773 controls for the LBCS population 
were collected between 2002 and 2011 at St James University Hospital as described 
in the methods (Methods chapter 7.2.2). A further 1232 controls from the Wellcome 
Trust Case-Control Consortium (WTCC) (The Wellcome Trust Case Control 
Consortium 2007) were also included to try boost statistical power. This resulted in a 
final study population of 853 cases and 2005 controls. The statistical power of this 
study is shown in Table 19 for the LBCS study population on its own (for multivariate 
analyses) and for the whole combined LBCS and WTCC population (for univariate 
analyses) at several ORs and at several different MAFs (either single variant or 
collapsed) at a 5% significance level. 
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Table 19: Statistical power of LBCS and combined LBCS and WTCC populations at 
different ORs and MAFs at a 5% significance level. 
P = 0.05 
LBCS 
(853 cases : 773 controls) 
LBCS + WTCC 
(853 cases : 2005 controls) 
Single variant/ 
Collapsed MAF 
OR 1.5 OR 2.0 OR 3.0 OR 1.5 OR 2.0 OR 3.0 
0.001a 3.7 3.3 9.6 3.7 8.8 25.2 
0.01 15.2 46.4 92.3 26.2 69.0 98.7 
0.05 64.7 99.1 100.0 83.1 99.9 100.0 
0.1 89.2 100.0 100.0 97.5 100.0 100.0 
a Statistical power estimations at small MAFs may be inaccurate. 
 
The study population demographics are shown in Table 20. The control population 
were significantly younger (P < 0.001) with a higher proportion of women (P < 0.001) 
especially as there were no attempts at frequency matching for the WTCC 
population. Between cases and controls for the LBCS population on its own, there 
were no significant differences between the groups for age (Mean 72.1yr v 72.1yr 
respectively, P = 0.96) but there remained significantly more women among the 
controls compared to cases (37.1% v 29.4%, P = 0.001). Among the demographic 
variables, only smoking history was independently associated with an increased 
bladder cancer risk (OR 1.86, 95%CI 1.46 – 2.37, P <0.001) on multivariate analysis. 
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Table 20: Combined LBCS and WTCC case-control study population demographics 
and tumour characteristics. 
Demographic variables 
Case Control OR 
(95% CI)b 
P-
valueb N (%) N (%) 
Age Mean 72.1 53.4  
<0.001c 
 (Range) (21 – 99) (15 – 98)  
Gender Female 251 (29.4) 928 (46.4)  
<0.001d 
 Male 602 (70.6) 1073 (53.6)  
Ethnicitya Non-caucasian 15 (1.8) 18 (2.3) 1 
0.25  Caucasian 838 (98.2) 755 (97.7) 1.52 
(0.75 – 3.09) 
Smoking 
historya 
Never 185 (21.7) 281 (36.4) 1  
Ever 668 (78.3) 492 (63.6) 1.86 
(1.46 – 2.37) 
<0.001 
Family 
historya 
None 809 (95.3) 587 (96.9) 1  
>1 family 
member 
40 (4.7) 19 (3.1) 1.49 
(0.85 – 2.62) 
0.16 
Number of 
occupational 
exposuresa 
0 623 (73.5) 606 (80.0) 1 
 1 183 (21.6) 126 (16.6) 
1.11 
(0.93 – 1.33) 
0.24 
2 31 (3.7) 22 (2.9) 
3 8 (0.9) 3(0.4) 
4 1 (0.1) 1 (0.1) 
6 2 (0.2) 0 (0) 
Bladder tumour characteristicsa       
Tumour 
stage 
Ta 360 (42.2) 
   CIS 15 (1.8) 
T1 200 (23.4) 
   T2 134 (15.7) 
   T3 69 (8.1) 
   T4 13 (1.5) 
   Tx 62 (7.3) 
   Pathological 
grade 
G1 76 (8.9) 
   G2 324 (38.1) 
   G3 412 (48.4) 
   Unrecorded 39 (4.6) 
   Nodal stage N0 203 (23.8) 
   N1 17 (2.0) 
   N2 2 (0.2) 
   N3 1 (0.1) 
   Nx 630 (73.9)       
NB. Missing LBCS data for gender in 4 patients and occupational history in 20 
patients. 
a Data available only for the LBCS population. 
b Multivariate logistic regression adjusting for all demographic variables. 
c Two-tailed T-test. 
d Pearson’s Chi-squared test. 
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8.2.2. Candidate variants for genotyping 
8.2.2.1. MUTYH and XPC rare variants identified by NGS 
In summary from all the unindexed and indexed NGS of MUTYH and XPC, a total of 
14 MUTYH and 34 XPC RVs were identified and confirmed by conventional 
sequencing or Taqman genotyping as follows from the different NGS methods 
development stage as described in the last chapter: i) 10 MUTYH and 4 XPC RVs 
from the initial unindexed multiplexed NGS of 280 cases and 280 controls analysed 
using NextGene; ii) 27 XPC RVs from the indexed multiplexed NGS of 100 cases 
and 100 controls for XPC; and iii) 4 MUTYH and 3 XPC RVs from the reanalysis of 
the unindexed multiplexed NGS of 280 cases and 280 controls using Syzygy. 
 
Candidate RVs were then ranked and selected based on the number of the following 
criteria met: (i) their being predicted to have a significant effect on protein function or 
alteration of miRNA binding energies, (ii) their being sited in or within 100bp of a 
splice site, (iii) the relative number of case to control samples or pools in which the 
variant was detected, (iv) their having a Syzygy Chi2-value greater than two (only for 
RVs identified from the Syzygy analysis as discussed in the last chapter), and (v) 
being able to design a suitable Fluidigm genotyping assay. All the MUTYH (four 
intronic and 10 coding) and 24 XPC (10 intronic, 11 coding, two 3’UTR and one 
5’UTR) RVs were selected for genotyping in the full bladder case-control study and 
these are shown in Table 21 with the bioinformatics functional predictions. The full list 
of all variants identified by NGS is in Appendix C. 
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Table 21: MUTYH and XPC rare variants detected by NGS selected for genotyping and functional predictions. 
Gene 
Variant NCBI 
hg19 position/ 
dbSNP rs 
number 
NGS run 
detected in 
Case: 
Control  
(No of 
pools  
or 
No of 
samples  
or 
Estimated 
MAF)a 
Gene 
Region 
Syzygy 
Chi2 
valueb 
Coding 
Predicted miRNA 
binding 
Splicing/ 
Transcription 
factor binding site/ 
Epigenetics 
Protein 
Change 
Polyphen SIFT 
miRNA-
binding 
site 
ΔΔG 
(kJ/mol) 
MUTYH 
rs3219470 
C>T 
Unindexed 
multiplexed 
(NextGene) 
3 : 0 Intron 1 2.31b Non-coding 
Predicted chromatin 
promoter region & 
H3K27Ac histone 
mark 
MUTYH 
Chr 1: 45803644 
G>C 
Unindexed 
multiplexed 
(NextGene) 
1 : 4 Intron 1 2.39b Non-coding 
Possible 
H3K36Me3 histone 
mark 
MUTYH 
Chr 1: 45805788 
G>A 
Unindexed 
multiplexed 
(Syzygy) 
0.006 : 0a 
Intron  
1 / 2 
3.23 Non-coding 
Exon 2 acceptor 
splice site in 
Isoform Beta 3 
MUTYH 
rs3219495 
C>T 
Unindexed 
multiplexed 
(Syzygy) 
0 : 0.009 a Intron 12 4.66 Non-coding 
73bp 3' from exon 
12 donor splice site 
MUTYH 
rs34612342 
A>G 
Unindexed 
multiplexed 
(NextGene) 
2 : 0 Exon 7 2.16b Y179C 
Probably 
damaging 
Affect protein 
function 
Nil Nil 
MUTYH 
rs149866955 
G>A 
Unindexed 
multiplexed 
(NextGene) 
1 : 0 Exon 10 1.07b R274Q 
Possibly 
damaging 
Affect protein 
function 
Nil Nil 
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MUTYH 
rs138089183 
C>T 
Unindexed 
multiplexed 
(NextGene) 
0 : 2 Exon 10 1.86b R309C Benign Tolerated Nil Nil 
MUTYH 
rs149342980 
G>A 
Unindexed 
multiplexed 
(NextGene) 
1 : 0 Exon 10 1.07b R311K Benign Tolerated Nil 
Exon 10 GA donor 
splice site 
MUTYH 
Chr 1: 45797428 
G>A 
Unindexed 
multiplexed 
(NextGene) 
0 : 1 Exon 12 1.86b R364H 
Possibly 
damaging 
Affect protein 
function (low 
confidence) 
Nil Nil 
MUTYH 
rs36053993 
G>A 
Unindexed 
multiplexed 
(NextGene) 
3 : 0 Exon 13 5.49b G396D 
Probably 
damaging 
Affect protein 
function 
Nil Nil 
MUTYH 
rs140118273  
C>T 
Unindexed 
multiplexed 
(NextGene) 
4 : 1 Exon 16 0.83b S515F Benign Tolerated Nil Nil 
MUTYH 
Chr 1: 45795058 
A>T 
Unindexed 
multiplexed 
(Syzygy) 
0.004 : 0 a Exon 16 2.15 M511L Benign Tolerated Nil Nil 
MUTYH 
rs147923905 
G>T 
Unindexed 
multiplexed 
(NextGene) 
1 : 0 Exon 16 1.07b D530Y 
Possibly 
damaging 
Affect protein 
function 
Nil Nil 
MUTYH 
rs3219497 
G>A 
Unindexed 
multiplexed 
(Syzygy) 
0 : 0.006 a Exon 16 3.02 R534Q Benign Tolerated Nil Nil 
XPC 
rs3731072 
G>T 
Unindexed 
multiplexed 
(NextGene) 
1 : 0 Intron 2 N/A Non-coding 
Predicted chromatin 
transcriptional 
elongation region 
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XPC 
rs3731072 
G>C 
Unindexed 
multiplexed 
(NextGene) 
2 : 1 Intron 2 0.41b Non-coding 
XPC 
Chr 3: 14220193 
G>A 
Unindexed 
multiplexed 
(Syzygy) 
0.004 : 0 a 
5'-
promoter 
region 
2.15 Non-coding 
Predicted chromatin 
promoter region 
with multiple 
transcription factor 
binding sites; CpG 
methylation region 
XPC 
rs3731069 
C>A 
Unindexed 
multiplexed 
(Syzygy) 
0 : 0.009 a Intron 2 4.58 Non-coding 
Predicted chromatin 
transcriptional 
elongation region 
XPC 
Chr 3: 14186418 
G>A 
Unindexed 
multiplexed 
(Syzygy) 
0.01 :  
0.002 a 
3'-post-
gene 
2.99 Non-coding 
Predicted chromatin 
enhancer region & 
H3K27Ac histone 
mark 
XPC 
rs147584831 
C>G 
Indexed 
multiplexed 
(XPC only) 
0 : 4 Intron 1 N/A Non-coding 
Predicted chromatin 
promoter region 
with multiple 
transcription factor 
binding sites; CpG 
methylation region 
XPC 
rs77167750 
A>G 
Indexed 
multiplexed 
(XPC only) 
1 : 3 Intron 10 3.2b Non-coding Nil 
XPC 
rs146126554 
T>C 
Indexed 
multiplexed 
(XPC only) 
3 : 0 Intron 11 N/A Non-coding Nil 
XPC 
Chr 3: 14214734 
G>A 
Indexed 
multiplexed 
(XPC only) 
1 : 0 Intron 1 N/A Non-coding Nil 
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XPC 
rs3731078 
A>G 
Indexed 
multiplexed 
(XPC only) 
4 : 8 Intron 2 N/A Non-coding 
H3K27Ac histone 
mark 
XPC 
Chr 3: 14187236 
A>C 
Indexed 
multiplexed 
(XPC only) 
0 : 1 3'UTR N/A Non-coding Nil Nil 
XPC 
Chr 3: 14186649 
A>G 
Indexed 
multiplexed 
(XPC only) 
0 : 1 3'UTR N/A Non-coding Nil 
3'-transcription end 
site 
XPC 
Chr 3: 14220118 
T>G 
Indexed 
multiplexed 
(XPC only) 
1 : 0 5'UTR N/A Non-coding Nil 
Predicted chromatin 
promoter region 
with multiple 
transcription factor 
binding sites; CpG 
methylation region 
XPC 
Chr 3: 14220032 
G>C 
Indexed 
multiplexed 
(XPC only) 
0 : 1 Exon 1 0.26b G13R 
Possibly 
damaging 
Affect protein 
function 
Nil Nil 
XPC 
rs1870134 
C>G 
Indexed 
multiplexed 
(XPC only) 
1 : 2 Exon 1 N/A L16V Benign 
Affect protein 
function (low 
confidence) 
Nil Nil 
XPC 
Chr 3: 14214527 
C>T 
Indexed 
multiplexed 
(XPC only) 
1 : 0 Exon 2 1.07b L47F Benign 
Affect protein 
function (low 
confidence) 
Nil Nil 
XPC 
rs3731062 
C>T 
Indexed 
multiplexed 
(XPC only) 
4 : 8 Exon 2 1.08b L48F Benign 
Affect protein 
function (low 
confidence) 
Nil Nil 
XPC 
rs183478541 
G>A 
Indexed 
multiplexed 
(XPC only) 
0 : 1 Exon 2 N/A G64E 
Possibly 
damaging 
Affect protein 
function (low 
confidence) 
Nil Nil 
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XPC 
Chr 3: 14206335 
G>A 
Indexed 
multiplexed 
(XPC only) 
1 : 0 Exon 7 1.07b R293Q 
Possibly 
damaging 
Tolerated Nil Nil 
XPC 
Chr 3: 14200154 
A>G 
Unindexed 
multiplexed 
(NextGene) 
1 : 0 Exon 9 1.07b E410G 
Possibly 
damaging 
Affect protein 
function 
Nil Nil 
XPC 
Chr 3: 14199980 
G>C 
Indexed 
multiplexed 
(XPC only) 
0 : 1 Exon 9 0.92b R468T 
Possibly 
damaging 
Affect protein 
function 
hsa-miR-
185-3p 
-6.5 Nil 
XPC 
Chr 3: 14199857 
G>T 
Indexed 
multiplexed 
(XPC only) 
0 : 1 Exon 9 0.92b R509I 
Probably 
damaging 
Tolerated Nil Nil 
XPC 
Chr 3: 14189426 
T>C 
Indexed 
multiplexed 
(XPC only) 
1 : 0 Exon 14 0.28b I832I Synonymous Nil Nil 
XPC 
Chr 3: 14188798 
G>A 
Unindexed 
multiplexed 
(NextGene) 
0 : 1 Exon 15 0.92b G866R 
Possibly 
damaging 
Tolerated Nil Nil 
a The ratio of detection in cases versus controls was dependent on which NGS methods development stage, as described in the last chapter, 
that the RV was detected in. The ratios are thus reported as follows: i)  for unindexed multiplexed NGS (NextGene) detected RVs, the number 
of case pools versus control pools; ii) for indexed multiplexed NGS of XPC detected RVs,  the number of case samples versus control samples; 
or iii) for unindexed multiplexed NGS (Syzygy) detected RVs, the estimated case MAF versus control MAF as calculated by Syzygy. 
b For variants selected from the non-Syzygy analysed runs, the Syzygy Chi2-value is displayed only out of interest if the variant was also 
detected by the Syzygy analysis. 
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8.2.2.2. MUTYH rare variants in bladder cancer risk 
During initial preliminary Taqman genotyping of 750 cases and 706 controls in early 
2010 as mentioned in the last chapter, three MUTYH RVs out of six MUTYH RVs 
genotyped looked suggestive of an influence on bladder cancer risk though only one 
(Chr 1: 45803644 G>C) reached statistical significance (Table 22). As MUTYH RVs 
had been previously associated with several different cancers (especially 
rs34612342 (Y179C) and rs36053993 (G396D) in colorectal cancer) (Vogt et al. 
2009; Win et al. 2011; Castillejo et al. 2012; Rennert et al. 2012) but not investigated 
directly in bladder cancer, it was decided to also genotype all known MUTYH RVs 
that were potentially functional. Using the UCSC genome browser (accessed October 
2011) with MAF details from the dbSNP database, there were 43 known variants in 
MUTYH with reported MAFs less than 0.01 or unknown. From these, 22 RVs were 
selected: 14 non-synonymous coding variants and eight intronic variants within 
predicted epigenetic or splice regions (Table 23). 
 
Table 22: Preliminary univariate logistic regression analysis results following Taqman 
genotyping in 750 bladder cancer cases and 706 controls for select candidate MUTYH 
rare variants. 
MUTYH Varianta 
Case Control Per-allele OR 
(95%CI) 
P-
valuec VVb VWb WWb VVb VWb WWb 
rs3219470 C>T 
 
0 12 646 1 8 620 
1.14 
(0.51-2.56) 
0.66 
Chr 1: 45803644 
G>C 
0 1 740 0 7 690 
0.13 
(0.02-1.09) 
0.03 
rs34612342 A>G 
(Y179C) 
0 4 738 0 0 701 
Variant not 
seen in controls 
0.13 
rs138089183 C>T 
(R309C) 
0 1 742 0 2 701 
0.47 
(0.04-5.22) 
0.62 
rs36053993 G>A 
(G396D) 
0 11 726 0 4 692 
2.62 
(0.83-8.27) 
0.09 
rs140118273 C>T 
(S515F) 
0 14 673 0 13 648 
1.04 
(0.48-2.25) 
0.93 
a 
MUTYH RVs subjectively suggestive of an effect on bladder cancer risk on comparing 
number of carriers among cases versus controls are in bold. 
b
 VV – homozygote variant, VW – heterozygote variant, WW – homozygote wildtype 
c
 Significant Fishers exact test P-values (P ≤ 0.05) are in bold. 
  
 141 
Table 23: Candidate known MUTYH rare variants from the UCSC genome browser 
selected for genotyping in the bladder cancer case-control study population. 
Gene 
Variant dbSNP rs 
number 
dbSNP 
MAF 
Predicted functional effects 
MUTYH 
rs3219496 C>A 0.006 Missense : L529M 
rs3219494 G>A 0.003 Missense : G503E 
rs121908381 G>T Unknown Nonsense : E480X 
rs121908383 A>G Unknown Missense : Q414R 
rs121908382 C>T Unknown Missense : P405S 
rs35352891 C>T 0.005 Missense : A373V 
rs112422930 T>G Unknown Missense : L257R 
rs34126013 C>T Unknown Missense : R241W 
rs11545695 C>T Unknown Missense : A227V 
rs121908380 C>A Unknown Nonsense : Y104X 
rs1140507 T>C Unknown Missense : W103R 
rs75321043 G>A Unknown Missense : G25D 
rs3219484 G>A 0.001 Missense : V22M 
rs79777494 C>T Unknown Missense : P18L 
rs7522089 C>T 0.002 Intron 1/2: H3K36me3 histone mark 
rs3219471 G>A 0.009 Intron 1/2: H3K36me3 histone mark 
rs74688071 C>A Unknown Intron 1: H3K4Me2 histone mark 
rs115058761 C>T 0.008 Intron 1: H3K4Me3 histone mark 
rs115629902 G>A 0.008 
Intron 1: Predicted chromatin promoter 
region with multiple histone marks 
rs3219469 C>G 0.006 
Intron 1: Predicted chromatin promoter 
region with multiple histone marks and 
transcription factor binding sites 
rs77949009 C>T Unknown 
Intron 1: Predicted chromatin promoter 
region with multiple histone marks and 
transcription factor binding sites 
rs3219468 C>G 0.005 
Intron 1: 3 bp 3' from Exon 1 donor splice 
site; decreased MUTYH expression 
reported in carriers (Plotz et al. 2012) 
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8.2.2.3. CDRV versus CDCV hypothesis 
To test the relative contributions of the CDRV hypothesis versus the CDCV 
hypothesis on bladder cancer risk, up to the top 10 (if reported) most significant 
SNPs from each of the published papers from the bladder cancer GWAS studies 
(Kiemeney et al. 2008; Wu et al. 2009; Kiemeney et al. 2010; Rothman et al. 2010; 
Garcia-Closas et al. 2011; Rafnar et al. 2011; Tang et al. 2012) were selected to be 
genotyped alongside the above RVs in the LBCS study population resulting in a total 
of 36 SNPs (Table 24). The XPC SNP rs2228000 previously associated with an 
increased bladder cancer risk was also included (Stern et al. 2009). Inclusion of 
these SNPs would allow identification of indirect or synthetic associations of GWAS 
common SNP bladder cancer loci in linkage association with causal rare variants 
(which can potentially be over 9 Mb apart (Dickson et al. 2010)), and the independent 
risk contributions of candidate RVs and known bladder cancer risk SNPs. 
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Table 24: Most significant SNPs from the corresponding bladder cancer GWAS 
publications selected for genotyping in the bladder cancer case-control study. 
Variant dbSNP rs 
number 
Chromosome 
Closest reported 
genes 
Citation 
rs17418689 A>G 2 THSD7B 
(Kiemeney et al. 2008) 
rs710521 T>C 3 TP63, LEPREL1 
rs10240737 A>G 7 PLXNA4 
rs9642880 G>T 8 MYC 
rs1092116 A>G 10 ZMIZ1 
rs233716 C>T 12 
PTPN11, 
MIR1302-1 
rs233722 G>A 12 
PTPN11, 
MIR1302-1 
rs12584999 G>A 13 DDX6P2 
rs12982672 G>A 19 ARHGAP33 
rs6610426 A>G X ATP6AP2 
rs2819049 A>G 10 TCEB1P3 
(Wu et al. 2009) 
rs11615848 G>T 12 UBA52P7 
rs4902033 C>A 14 
SLC38A6, 
TMEM30B 
rs6100488 T>C 20 PHACTR3 
rs6969519 T>C 7 MEOX2 
rs11782640 C>T 8 TRAPPC9 
rs1584415 C>T 9 CYLC2 
rs16936133 G>A 9 CYLC2 
rs2294008 C>T 8 PSCA 
rs2228000 C>T 3 XPC (Stern et al. 2009) 
rs11892031 A>C 2 UGT1A 
(Rothman et al. 2010) 
rs1495741 G>A 8 NAT2 
rs8102137 T>C 19 CCNE1 
rs1014971 C>T 22 APOBEC3, CBX6 
rs17717312 G>A 10 ABLIM1 
(Garcia-Closas et al. 2011) 
rs10775480 T>C 18 SLC14A1 
rs10853535 C>T 18 SLC14A1 
rs11082469 A>G 18 SLC14A1 
rs11877720 A>G 18 SLC14A1 
rs7238033 T>C 18 SLC14A1 
rs16982241 G>A 19 FUT2 
rs12975781 C>T 19 
RASIP1, IZUMO1, 
FUT1, FGF21 
rs12982115 A>G 19 
RASIP1, IZUMO1, 
FUT1, FGF21 
rs1474680 A>G 20 TGM6 
rs1058396 G>A 18 SLC14A1 
(Rafnar et al. 2011) 
rs17674580 C>T 18 SLC14A1 
rs17863783 G>T 2 UGT1A (Tang et al. 2012) 
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8.2.3. Rare variants and bladder cancer risk 
For the 97 variants, genomic DNA samples with blind duplicates from 7.6% of 
samples were genotyped for 96 variants using custom Fluidigm SNPtype Assays on 
a Fluidigm 96.96 Dynamic Array. XPC Chr 3: 14188798 G>A (G866R) was 
genotyped using a custom Taqman genotyping assay. Fifteen assays failed to 
discriminate (Table 25). Of these, 11 MUTYH variants were identified from the UCSC 
Genome Browser so it is unclear if the failure to discriminate was due to assay failure 
or due to these rare variants not being present in the study population. The remaining 
two MUTYH and two XPC variants identified by NGS had been previously confirmed 
by conventional sequencing in a sub-population thus represented assay failure. Two 
of these variants were previously noted to be in a GC rich region or had another SNP 
in close proximity thus possibly accounting for the assay failure. 
Table 25: List of variants that failed to discriminate on genotyping with details of 
source where the variant was identified and the genotyping assay type used. 
Gene 
Variant NCBI hg19 
position/  
dbSNP rs number 
Variant Source Assay Type 
MUTYH rs3219494 G>A UCSC Genome Browser Fluidigm 
MUTYH rs121908381 G>T UCSC Genome Browser Fluidigm 
MUTYH rs121908383 A>G UCSC Genome Browser Fluidigm 
MUTYH rs121908382 C>T UCSC Genome Browser Fluidigm 
MUTYH rs35352891 C>T UCSC Genome Browser Fluidigm 
MUTYH rs112422930 A>C UCSC Genome Browser Fluidigm 
MUTYH rs11545695 C>T UCSC Genome Browser Fluidigm 
MUTYH rs1140507 T>C UCSC Genome Browser Fluidigm 
MUTYH rs115058761 G>A UCSC Genome Browser Fluidigm 
MUTYH rs115629902 C>T UCSC Genome Browser Fluidigm 
MUTYH rs3219469 C>G UCSC Genome Browser Fluidigm 
MUTYH Chr 1: 45797428 G>A 
Unindexed multiplexed 
NGS (NextGene) 
Fluidigm 
MUTYH rs149866955 C>T 
Unindexed multiplexed 
NGS (NextGene) 
Fluidigm 
XPC Chr 3: 14199857 G>T 
Indexed multiplexed NGS 
(XPC only) 
Fluidigm 
XPC Chr 3: 14188798 G>A 
Unindexed multiplexed 
NGS (NextGene) 
Taqman 
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There was 99.9% concordance of replicates with non-concordant samples dropped 
from analysis. Excluding the above 15 “failed” assays, for the remaining 82 
genotyping assays, the mean assay failure rate was 3.1% with 75 of 82 assays 
having an assay failure rate of less than 5%. Hardy-Weinberg equilibrium was 
maintained for all common SNPs in the controls. Due to the differences in age and 
gender between the case and control populations, all of the following single marker 
analyses were adjusted for age and gender to try correct for these differences. 
Further multivariate analyses adjusting for ethnicity, family history, smoking history 
and occupational exposure was also performed but only included individuals from the 
LBCS study population (where this data was collected). Full analyses results for all 
variants are in Appendix C.  
 
8.2.3.1. GWAS SNPs and common MUTYH and XPC SNPs 
Of 36 GWAS SNPs, 14 SNPs were significantly associated with bladder cancer 
predisposition with P-values less than 0.05 (Table 26), of which the minor allele of 
three SNPs were associated with increased bladder cancer risk and the remaining 11 
being protective. The “SNP” with the strongest effect was on chromosome 2, 
rs17418689 A>G (Control MAF 0.002, age and gender adjusted OR 0.09 [95% CI 
0.01 - 0.78], Ptrend = 0.03), which interestingly was an uncommon SNP (MAF 0.06) 
with the minor allele being a risk allele (OR 1.17) in the original publication 
(Kiemeney et al. 2008) yet a protective allele and a rare variant in the LBCS and 
WTCC population. The most significant SNP was also on chromosome 2, 
rs11892031 A>C (age and gender adjusted OR 0.66 [0.52 - 0.84], Ptrend < 0.001), 
previously reported to be secondary to the tagging of the functional uncommon SNP 
rs17863783 G>T (Tang et al. 2012). On Bonferroni correction for 36 GWAS SNPs, 
only rs11892031 remained significant at a Bonferroni corrected P-value of 0.001. 
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Table 26: Genotyping results for GWAS SNPs with significant associations with bladder cancer susceptibility on univariate or multivariate logistic 
regression. The age and gender adjusted analysis was for the combined LBCS and WTCC populations while the multivariate analysis only 
included the LBCS study population. 
dbSNP rs number 
Chromosome 
(closest genes) 
MAF 
Case 
MAF 
Control 
No of 
alleles 
Case 
N (%) 
Control 
N (%) 
Age & gender adjusted  
OR (95% CI)a 
Ptrend
b Multivariate 
OR (95% CI)c 
Ptrend
b 
rs17418689 
A>G 
Chr 2 (THSD7B) 
0.001 0.002 0 843 (99.9) 1941 (99.5) 1  
0.03 
1  
0.04     1 1 (0.1) 9 (0.5) 0.09 (0.01 - 0.78) 0.10 (0.01 - 0.87) 
rs11892031 
A>C 
Chr 2 (UGT1A) 
0.07 0.10 0 730 (86.6) 1590 (81.6) 1  
<0.001 
1  
<0.001   1 107 (12.7) 342 (17.6) 0.62 (0.48 - 0.80) 0.56 (0.42 - 0.74) 
  2 6 (0.7) 16 (0.8) 0.88 (0.30 - 2.60) 1.27 (0.31 - 5.17) 
rs17863783 
G>T 
Chr 2 (UGT1A) 
0.01 0.02 0 821 (97.6) 1859 (95.2) 1  
<0.01 
1  
0.01   1 20 (2.4) 91 (4.7) 0.46 (0.27 - 0.79) 0.48 (0.27 - 0.85) 
    2 0 (0) 2 (0.1) Not seen in cases  Not seen in cases  
rs1495741 
G>A 
Chr 8 (NAT2) 
0.19 0.22 0 550 (66.3) 1185 (61) 1  
<0.01 
1  
<0.01   1 250 (30.2) 649 (33.4) 0.78 (0.64 - 0.96) 0.80 (0.64 - 1.01) 
  2 29 (3.5) 109 (5.6) 0.56 (0.35 - 0.89) 0.51 (0.31 - 0.86) 
rs9642880 
G>T 
Chr 8 (MYC) 
0.51 0.46 0 207 (25.1) 591 (31.4) 1  
<0.01 
1  
<0.01   1 401 (48.7) 868 (46.1) 1.38 (1.10 - 1.72) 1.41 (1.09 - 1.82) 
    2 216 (26.2) 424 (22.5) 1.50 (1.16 - 1.95) 1.50 (1.11 - 2.02) 
rs2294008 
C>T 
Chr 8 (PSCA) 
0.46 0.44 0 237 (28.2) 593 (30.6) 1  
0.05 
1  
0.06   1 430 (51.1) 982 (50.6) 1.10 (0.89 - 1.36) 1.00 (0.78 - 1.28) 
    2 174 (20.7) 366 (18.9) 1.31 (1.00 - 1.72) 1.41 (1.02 - 1.94) 
rs11615848 
G>T 
Chr 12 (UBA52P7) 
0.07 0.10 0 722 (86) 1610 (82.3) 1  
<0.01 
1  
<0.01   1 115 (13.7) 320 (16.4) 0.70 (0.54 - 0.91) 0.69 (0.52 - 0.92) 
    2 3 (0.4) 26 (1.3) 0.29 (0.08 - 1.02) 0.23 (0.06 - 0.86) 
rs233722 
G>A 
Chr 12 (PTPN11, 
MIR1302-1) 
0.40 0.40 0 306 (36.6) 701 (35.9) 1  
0.12 
1  
0.05 
  1 401 (47.9) 929 (47.7) 1.00 (0.81 - 1.22) 0.90 (0.71 - 1.14) 
  2 130 (15.5) 319 (16.4) 0.78 (0.59 - 1.02) 0.72 (0.53 - 0.99) 
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rs233716 
C>T 
Chr 12 (PTPN11, 
MIR1302-1) 
0.39 0.43 0 299 (36.9) 638 (34.2) 1  
0.04 
1  
0.07 
  1 386 (47.6) 857 (46) 0.97 (0.78 - 1.19) 0.85 (0.67 - 1.09) 
  2 126 (15.5) 370 (19.8) 0.72 (0.55 - 0.95) 0.75 (0.54 - 1.04) 
rs8102137 
T>C 
Chr 19 (CCNE1) 
0.37 0.33 0 330 (39.8) 857 (44.9) 1  
0.04 
1  
0.03   1 386 (46.5) 828 (43.4) 1.18 (0.97 - 1.44) 1.27 (1.01 - 1.60) 
  2 114 (13.7) 222 (11.6) 1.32 (0.98 - 1.78) 1.36 (0.96 - 1.91) 
rs12975781 
C>T 
Chr 19 (RASIP1, 
IZUMO1, FUT1, 
FGF21) 
0.38 0.39 0 329 (39.4) 709 (36.7) 1  
0.07 
1  
0.05 
  1 379 (45.4) 923 (47.8) 0.81 (0.66 - 0.99) 0.73 (0.58 - 0.93) 
    2 126 (15.1) 300 (15.5) 0.82 (0.62 - 1.08) 0.80 (0.58 - 1.11) 
rs1474680 
A>G 
Chr 20 (TGM6) 
0.33 0.35 0 392 (46.7) 828 (42.4) 1  
0.02 
1  
0.02   1 349 (41.6) 881 (45.1) 0.76 (0.62 - 0.92) 0.75 (0.60 - 0.94) 
    2 98 (11.7) 243 (12.4) 0.79 (0.58 - 1.07) 0.75 (0.53 - 1.06) 
rs6100488 
T>C 
Chr 20 (PHACTR3) 
0.18 0.18 0 564 (67.1) 1311 (67) 1  
0.54 
1  
0.05   1 249 (29.6) 575 (29.4) 0.97 (0.79 - 1.19) 0.84 (0.67 - 1.06) 
  2 28 (3.3) 70 (3.6) 0.85 (0.51 - 1.39) 0.66 (0.38 - 1.12) 
rs1014971 
C>T 
Chr 22 (APOBEC3, 
CBX6) 
0.35 0.37 0 345 (41.1) 764 (39.1) 1  
0.05 
1  
0.01 
  1 394 (47) 945 (48.3) 0.81 (0.66 - 0.98) 0.76 (0.60 - 0.96) 
    2 100 (11.9) 246 (12.6) 0.80 (0.59 - 1.09) 0.70 (0.50 - 0.99) 
a Logistic regression of the combined LBCS and WTCC populations adjusting for age and gender. 
b P-values less than 0.05 are in bold. 
c Multivariate logistic regression of only the LBCS study population adjusting for age, gender, ethnicity, family history, smoking history and 
occupational exposure. 
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On conditional analysis of all GWAS SNPs in the full study population, only seven 
SNPs continued to have an independent contribution to bladder cancer 
predisposition (Table 27). Interestingly, of the three chromosome 2 SNPs, only 
rs11892031 A>C remained significant but not rs17418689 A>G or rs17863783 G>T 
perhaps suggesting other functional variants being tagged by rs11892031 A>C not 
explained by rs17863783 G>T. 
Table 27: GWAS SNPs with an independent contribution to bladder cancer 
susceptibility on conditional analysis of the combined LBCS and WTCC study 
populations. 
dbSNP rs number OR (95% CI) P-value 
rs11892031 A>C 0.73 (0.55 - 0.97) 0.03 
rs1495741 G>A 0.81 (0.68 - 0.97) 0.02 
rs9642880 G>T 1.25 (1.08 - 1.43) 0.002 
rs233716 C>T 0.48 (0.26 - 0.91) 0.02 
rs11615848 G>T 0.58 (0.45 - 0.76) <0.001 
rs8102137 T>C 1.18 (1.01 - 1.36) 0.03 
rs1474680 A>G 0.82 (0.71 - 0.96) 0.01 
 
Among the MUTYH variants, there were two MUTYH variants, both obtained from the 
UCSC genome browser, with observed control MAFs greater than 0.05, rs3219484 
G>A (observed MAF 0.08) and rs74688071 G>T (observed MAF 0.17), with neither 
being associated with bladder cancer susceptibility (Ptrend = 0.46 and 0.52 
respectively). There were no XPC variants with a MAF greater than 0.05 in the study 
population, with common XPC SNP rs2228000 C>T (dbSNP MAF 0.24) 
unexpectedly having only an observed control MAF of 0.03. On univariate analysis, 
XPC SNP rs2228000 C>T had the most significant result of all variants genotyped 
(Ptrend = 3.31 x 10
-6). However, it was not associated with bladder cancer risk 
following age and gender adjustment or on full multivariate analysis (OR 1.24 [95%CI 
0.90 - 1.71], Ptrend = 0.13; and OR 1.37 [0.96 - 1.95], Ptrend = 0.54 respectively) which 
was surprising based on previous publications (Stern et al. 2009).  
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8.2.3.2.  Individual MUTYH and XPC uncommon SNPs and rare variants 
In the combined LBCS and WTCC population, 35.5% of the study population carried 
at least one minor allele of an uncommon SNP or RV (observed MAF < 0.05) in 
MUTYH or XPC (Table 28). 11.8% of the study population carried at least one minor 
rare variant allele (MAF < 0.01) in MUTYH or XPC. 
Table 28: The number of minor alleles of variants with a control MAF under 0.05 or 
under 0.01 carried by individuals in the combined LBCS and WTCC population. 
No of minor alleles 
carried 
Control MAF < 0.05 
N (%) 
Control MAF < 0.01 
N (%) 
0 1842 (64.5) 2522 (88.2) 
1 818 (28.6) 319 (11.2) 
2 167 (5.8) 15 (0.5) 
3 or more 31 (1.1) 2 (0.1) 
 
On single variant analyses, only two MUTYH and XPC variants were found to be 
associated with increased bladder cancer risk either on univariate or multivariate 
analyses (P < 0.05), the MUTYH rare variant rs36053993 G>A (G396D) and XPC 
uncommon SNP, rs3731078 A>G (Table 29). As earlier mentioned, the former 
variant MUTYH rs36053993 G>A (G396D) has been extensively investigated and 
linked with colorectal cancer risk (Theodoratou et al. 2010). XPC rs3731078 A>G 
remained significant even after adjusting for rs2228000 (P = 0.02). These results are 
tempered by the low statistical power of the study population size and issues of 
multiple testing. However, the application of the Bonferroni correction here may prove 
too conservative, as this presumes complete independence of all RVs within a gene. 
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Table 29: Genotyping results for MUTYH and XPC variants with significant associations with bladder cancer susceptibility. Age and gender 
adjusted, and multivariate logistic regression analysis results are displayed. 
Gene & dbSNP 
rs number 
MAF 
Case 
MAF 
Control 
No of 
alleles 
Case 
N (%) 
Control 
N (%) 
Age and gender 
adjusted 
OR (95% CI)a 
Ptrend
b Multivariate 
OR (95% CI)c 
Ptrend
b 
MUTYH 
rs36053993 G>A 
0.009 0.006 0 827 (98.2) 1927 (98.7) 1  
0.21 
1  
0.02 
  
1 15 (1.8) 25 (1.3) 
1.61 
(0.76 - 3.40) 
5.83 
(1.31 - 25.90) 
XPC 
rs3731078 A>G 
  
0.04 0.03 0 786 (92.9) 1861 (95.2) 1  
0.02 
1  
0.22   
1 59 (7.0) 92 (4.7) 
1.53 
(1.04 - 2.26) 
1.29 
(0.82 - 2.04) 
    2 1 (0.1) 2 (0.1) 
2.94 
(0.16 - 54.05) 
Insufficient samples 
to calculate 
a Logistic regression of the combined LBCS and WTCC populations adjusting for age and gender. 
b P-values less than 0.05 are in bold. 
c Multivariate logistic regression of only the LBCS study population adjusting for age, gender, ethnicity, family history, smoking history and 
occupational exposure. 
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8.2.3.3. MUTYH and XPC collapsed analyses 
This study undertook a simple single-direction collapsed variant analyses (performed 
by Dr J Nsengimana), as previously described (Barrett and Nsengimana 2011; Konig 
et al. 2011). In summary, this method collapses all uncommon SNPs (MAF < 0.05) 
and RVs (MAF < 0.01) within a gene (e.g. MUTYH or XPC) by generating a total 
count or gene score of all the minor alleles carried of these variants by an individual. 
It then tests for the association between this gene score with bladder cancer risk 
applying a Bonferroni-corrected significance level (P = 0.025 for two genes). For the 
multivariate analyses, among the GWAS SNPs, only rs11892031 was included being 
the only GWAS SNP that remained significant on Bonferroni correction. rs2228000 
was also corrected for, having the most significant result on univariate analyses. Age 
and gender, were adjusted for to account for the differences in case and control 
populations. No correction was performed for other population demographics as this 
would result in dropping the WTCC control population (which had no other 
demographic data available) and loss of statistical power. 
 
The collapsed XPC variants were significantly associated with increased bladder 
cancer susceptibility on univariate analyses (Per-RV allele OR 1.31 [95%CI 1.07 – 
1.60], P = 0.008) though they were just short of significance on multivariate analyses 
(1.29 [1.03 – 1.60], P = 0.026). Correction for all 36 GWAS SNPs and XPC 
rs2228000 revealed the collapsed XPC variants to be an independent genetic risk 
factor separate from these SNPs (P = 0.02). However, there was no significant 
association found for the collapsed MUTYH variants and bladder cancer risk on both 
univariate and multivariate analyses (0.94 [0.74 – 1.20], P = 0.62; and 0.92 [0.70 – 
1.21], P = 0.57 respectively).   
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With regards to validation of the Syzygy calls as part of the unindexed multiplexed 
NGS methods development, there was no association found with bladder cancer risk 
(1.01 [0.72 – 1.44], P = 0.93) on collapsed analyses of all MUTYH and XPC variants 
called by Syzygy to have a Chi2-value greater than two, unfortunately, invalidating the 
use of the Syzygy Chi2-value as a tool for selecting candidate RVs detected by 
unindexed multiplexed NGS for further investigation. The MUTYH rs34612342 
(Y179C) and rs36053993 (G396D) RVs have been extensively studied and 
implicated in colorectal cancer risk (Farrington et al. 2005; Tenesa et al. 2006; 
Theodoratou et al. 2010) and demonstrated to result in dysfunctional MUTYH activity 
(Ali et al. 2008; Kundu et al. 2009). It was hypothesised that these two functional RVs 
would affect bladder cancer risk. Preliminary Taqman genotyping was suggestive of 
an effect for these two RVs individually (Table 22, page 140) with collapsed analysis 
of these two RVS being significant (P=0.02, Table 23). In the complete Fluidigm 
genotyping of the LBCS and WTCC study populations, collapsed analysis of these 
two RVs did not reveal any association with bladder cancer predisposition (P = 0.37, 
Table 23). However, multivariate analyses in just the LBCS population adjusting for 
all covariates (age, gender, ethnicity, family history, smoking history and occupational 
exposure) and for GWAS SNP rs11892031 and XPC rs2228000, there was an 
observed increase in bladder cancer risk in carriers of these two RVs (P = 0.02). 
Table 30: Collapsed analyses of MUTYH rs34612342 and rs36053993 from the 
preliminary Taqman genotyping, and the Fluidigm genotyping for the combined LBCS 
and WTCC population and the LBCS population only. 
Collapsed analysis: 
rs34612342 + rs36053993 
Case Control OR 
(95%CI) 
P-
valueb VVa VWa WWa VVa VWa WWa 
Preliminary Taqman: 
LBCS sub-population 
0 15 728 0 4 699 
3.60 
(1.18-10.93) 
0.02 
Fluidigm genotyping:  
LBCS + WTCC population 
0 16 823 0 29 1909 
1.39 
(0.68-2.87) 
0.42c 
Fluidigm genotyping:  
LBCS population only 
0 16 823 0 6 759 
5.85 
(1.31-26.06) 
0.02d 
a
 VV – homozygote variant, VW – heterozygote variant, WW – homozygote wildtype.  
b
 Fisher's exact test P-value. Significant P-values (P < 0.05) in bold.  
c
 Adjusted for age, gender, GWAS SNP rs11892031 and XPC SNP rs2228000.  
d
 Adjusted for age, gender, ethnicity, family history, smoking history, occupational exposure, 
GWAS SNP rs11892031 and XPC SNP rs2228000. 
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8.2.3.4. Gene-gene and gene-environment interactions and gene-phenotype 
associations 
Tests for gene-gene interactions of collapsed MUTYH variants and collapsed XPC 
variants found no multiplicative effects of carrying variants in both genes on bladder 
cancer risk in the combined LBCS and WTCC populations (OR 1.64 [95% CI 0.89 – 
3.03], P = 0.12). There was also no evidence of interactions between either smoking 
or occupational exposure with collapsed variants in MUTYH (P = 0.40 and 0.97, 
respectively) and XPC (P = 0.30 and 0.77, respectively) on bladder cancer risk in the 
LBCS population. 
 
Among the bladder cases, variants were tested for correlations with bladder tumour 
phenotype (superficial tumours, Ta and T1, versus invasive tumours, Tis and T2+) 
and histological grade (low grade (G<2) versus high grade (G3)). Once again, no 
associations were found for the collapsed MUTYH and XPC variants with either 
tumour phenotype or histological grade (MUTYH: P = 0.72 and P = 0.57, 
respectively; XPC: P = 0.15 and P = 0.65, respectively). Of the GWAS SNPs, only 
four SNPs had associations with either bladder tumour phenotype or histological 
grade though none of these would have reached significance on Bonferroni 
correction (P = 0.001) (Table 30). 
Table 31: Associations between bladder tumour phenotype and histological grade with 
GWAS SNPs previously associated with bladder cancer susceptibility. 
  
Non-invasive versus 
invasive phenotype 
Low versus High 
Histological Grade 
GWAS SNP 
Per-allele OR  
(95% CI) P-valuea 
Per-allele OR  
(95% CI) P-valuea 
rs16982241 G>A 1.21 (0.88 - 1.65) 0.24 1.41 (1.05 - 1.60) 0.02 
rs17717312 G>A 0.65 (0.43 - 0.99) 0.05 0.80 (0.57 - 1.14) 0.22 
rs6610426 A>G 0.74 (0.56 - 0.97) 0.03 0.84 (0.68 - 1.05) 0.12 
rs6969519 T>C 1.69 (1.16 - 2.47) 0.006 1.32 (0.91 - 1.91) 0.15 
a P-values less than 0.05 are in bold. 
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8.2.4. Discussion 
8.2.4.1. CDRV hypothesis in bladder cancer susceptibility 
This is the first study exploring the CDRV hypothesis in bladder cancer genetic 
predisposition using an NGS RV discovery stage. This identified XPC variants to be 
associated with increased bladder cancer risk on univariate analysis though was not 
significant on multivariate analysis with a Bonferroni correction. This result partly 
supports previous work by Dr Kiltie’s group on RVs in bladder cancer (Qiao et al. 
2011), which found four XPC rare variants associated with increased bladder cancer 
risk. Multiple studies have found associations between common XPC coding SNPs 
and multiple cancer sites (Doherty et al. 2011; Jiao et al. 2011; Gil et al. 2012; Yang 
et al. 2012). Bladder cancer case-control SNP studies had predominantly 
investigated the rs2228000 (A499V variant) and rs2228001 (K939Q variant) (Sak et 
al. 2005; Sak et al. 2006; Fontana et al. 2008; Liu et al. 2012) but a pooled analysis 
found only rs2228000 weakly associated with bladder cancer risk (Stern et al. 
2009).The current study adds to this literature by demonstrating the independence of 
the effects of these XPC RVs from XPC rs2228000 and previously discovered GWAS 
SNPs based on the CDCV hypothesis. 
 
However, the risk effect observed was far smaller than predicted by the CDRV 
hypothesis with a combined OR of only about 1.30 observed, though this matches 
some of the observations by Rivas et al of RVs in inflammatory bowel disease with 
ORs of 1.40 to 1.60 (Rivas et al. 2011). These results, thus, could suggest that the 
relative contribution of the CDRV hypothesis to overall inherited disease susceptibility 
may not be as large as proposed. Looking at individual XPC markers, only XPC 
rs3731078 A>G was associated with an increased bladder cancer risk though on 
taking into account multiple testing, this could very well be a false positive result. 
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Validation and functional studies will be needed to clarify the relevance of this 
uncommon SNP on bladder cancer risk. 
 
In this study, no contribution was observed on collapsed analysis of MUTYH RVs to 
bladder cancer risk. Previous MUTYH RV studies have predominantly focused on the 
rs36053993 (G396D) and rs34612342 (Y179C) variants in MAP and colorectal 
cancer (Tenesa et al. 2006; Theodoratou et al. 2010), with reports of other solid 
cancers in MAP patients: duodenal, testicular germ cell, ovarian, bladder, skin, lung, 
and thyroid cancers (Vogt et al. 2009; Pervaiz et al. 2010; von der Thusen et al. 
2011; Castillejo et al. 2012). A breast cancer case-control study reported an 
increased breast cancer risk in heterozygote carriers of the G396D and Y179C 
variants (Rennert et al. 2012), while Win et al observed in heterozygote carriers of 12 
previously identified MUTYH missense and nonsense RVs an increased colorectal 
cancer (standardised incidence ratios (SIR) 2.04), gastric cancer (SIR 3.24), liver 
cancer (SIR 3.09) and endometrial cancer (SIR 2.33) compared to the general 
population (Win et al. 2011). The MUTYH G396D and Y179C protein variants have 
been demonstrated to have defective DNA binding and glycosylase functional 
activity. These studies highlighted the strong evidence for MUTYH RVs in population 
cancer susceptibility thus it was surprising for the lack of effect seen in the current 
study.  
 
The 1000 Genomes Exon Pilot Project undertook exome sequencing of 800 
individuals from seven populations identifying 12758 variants of which 73.7% had 
MAFs of under 1% with significantly low inter-population sharing of RVs (Marth et al. 
2011). They also reported that a significantly higher proportion of RVs (MAF<1%) 
resulted in missense or nonsense amino acid changes, and were predicted to have a 
functional impact (Figure 30). These findings were replicated by the NHLBI Exome 
Sequencing Project exome sequencing 2440 individuals with over 80% of all single 
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nucleotide variants (SNV) and 95.7% of putatively functional coding SNVs having a 
MAF under 0.5%, plus they also successfully modelled the growth of RVs with recent 
population growth, and the negative selection of coding RVs (Tennessen et al. 2012). 
They also demonstrated that, on average, each individual carried up to 580 putatively 
functional coding SNVs of which 35 were nonsense variants with each individual 
being homozygous for at least one of these nonsense variants. Nelson et al 
sequenced 202 candidate drug target genes in 14002 individuals, finding 95% of 
SNVs detected being rare, with over half of these RVs being predicted to be 
functionally deleterious (Nelson et al. 2012). These three studies, thus, underline the 
abundance and the potential pathogenicity of RVs in the general population. 
 
 
Figure 30: Distribution of variants identified by the 1000 Genomes Exon Pilot Project 
by allele frequency, amino acid change (left) and predicted functional effects by SIFT 
and PolyPhen-2 (right) (Marth et al. 2011). 
 
Over the last year, several studies have been published investigating predominantly 
coding RVs in common disease predisposition. These studies in inflammatory bowel 
disease (Rivas et al. 2011), asthma (Torgerson et al. 2012), deep vein thrombosis 
(Lotta et al. 2012), multiple sclerosis (Ramagopalan et al. 2011) and degenerative 
disorders (Raychaudhuri et al. 2011; Jin et al. 2012) identified RVs by conventional 
Sanger sequencing, multiplexed NGS or whole exome sequencing, with significant 
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moderate to large risk (individual rare variant OR 1.44 to greater than 10) or 
protective (individual rare variant OR 0.29 – 0.72) effects seen on genotyping. Some 
of these studies also proceeded to demonstrate the independence of significant RVs 
effects from known common GWAS disease variants or common haplotype risk 
groups (Raychaudhuri et al. 2011; Rivas et al. 2011), and the biological effects of 
these variants on gene or protein function (Rivas et al. 2011). Only one RV study by 
Heinzen et al on idiopathic generalised epilepsy has reported a negative result for 
individual RV association but this could be secondary to insufficient statistical power, 
the use of the over-conservative Bonferonni correction and not accounting for the 
overall effects of multiple RVs (Heinzen et al. 2012). 
 
In cancer, RV studies have focused on specific candidate genes or known candidate 
variants. Breast cancer studies have investigated DSB repair and HRR genes due to 
their relationship with the BRCA1/2 genes, identifying XRCC2 (Park et al. 2012), 
PALB2 (Tischkowitz et al. 2012) and potentially ATM (Goldgar et al. 2011) (not 
significant but study was underpowered) missense coding RVs associated with 
increased breast cancer risk. Lefevre et al examined 31 known RVs from candidate 
genes previously associated with colorectal, gastric, breast and prostate cancer for 
associations with multiple adenomatous polyposis and early-onset colorectal cancer, 
and found four individually significant risk RVs and pooled analysis of all RVs with 
MAF under 0.5% to be associated with increased disease risk (OR 3.14, P-value = 
0.02) (Lefevre et al. 2012). In melanoma, a rare missense coding variant (E318K; 
MAF 0.008) in the MITF transcription factor gene was confirmed as a susceptibility 
variant (overall OR 2.19) in two large case-control study populations, and was shown 
to be associated with a family history of melanoma, early disease onset and multiple 
melanomas, and found to increase the transcriptional activity of MITF target genes 
(Yokoyama et al. 2011). These studies thus highlight the role of the CDRV 
hypothesis in cancer genetic susceptibility. 
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8.2.4.2. Study limitations and future work 
This study suffers from several limitations inherent for most RV studies. The biggest 
limitation is the issue of achieving adequate statistical power to detect an association. 
Due to the rarity of RVs, single RV marker analysis would be severely underpowered 
using current case-control study sizes with reported powers under 5% for a sample 
size of 1000 cases and 1000 controls (Li and Leal 2008; Bansal et al. 2010; Witte 
2012), and clearly demonstrated for this study in Table 19. The CDRV hypothesis 
and the assumption for collapsed RV analysis is that, “in aggregate, (RVs) may be 
common enough to account for variation in common traits”, thus by collapsing these 
RVs together a greater power could be achieved (Ladouceur et al. 2012). As shown 
in Figure 31, over 100,000 samples would be needed to detect an RV with a MAF of 
0.001 (black line) for an OR of 2.0, but if 25 of such RVs were collapsed, this would 
in effect shift the sample size needed to the equivalent of a variant with MAF 0.025 
(blue line) reducing the study size by over ten-fold. 
 
Figure 31: The case-control study sample size needed to achieve 80% statistical power 
for a single variant with a MAF of 0.001 (black line), 0.025 (blue line) and 0.05 (red line) 
at different odds ratios of effect (adapted from (Bansal et al. 2010). 
 
Odds Ratio
S
a
m
p
le
 s
iz
e
 n
e
e
d
e
d
0
102
103
104
105
106
107
108
109
0 2 4 6 8 10
 159 
There are four main statistical approaches to collapsed RV analysis (Bansal et al. 
2010; Dering et al. 2011; Ladouceur et al. 2012): collapsing all RVs across a region/ 
gene (Li and Leal 2008), a priori weighted collapsing of RVs based on MAF or 
biological effects (Madsen and Browning 2009; Flanagan et al. 2010; Price et al. 
2010), RV variance distribution across cases and controls (Liu and Leal 2010; Ionita-
Laza et al. 2011; Wu et al. 2011), and data-adaptive summation (Han and Pan 2010). 
Comparisons of these different collapsing analytical approaches reported the 
greatest statistical power using the permutation-based variance distribution and data-
adaptive approaches, but even then the power remained low with maximum reported 
powers of just 30% for a study of 500 cases and 500 controls (Dering et al. 2011; 
Dering et al. 2011; Ladouceur et al. 2012). This study used the first approach, as for 
single gene analysis, this approach was simulated to have marginally higher 
statistical power compared to a similar approach to the data-adaptive summation 
method that accounts for the direction of effect on disease risk for each variant 
(Barrett and Nsengimana 2011; Konig et al. 2011). A permutation-based data-
adaptive sum test, as described by Han and Pan (Han and Pan 2010), was also 
tested producing similar results thus was not shown. In view of the low power even 
with these collapsing approaches, it is thus likely that the current study on MUTYH 
and XPC was not powered to detect all true causal RVs. The Genetic Analysis 
Workshop 17 has highlighted these issues with permutation-based approaches as 
well as issues of P-value estimation and the applicability of these methods to all 
scenarios, hence the need for further development of these statistical tools for RV 
association studies (Dering et al. 2011). 
 
On sub-analysis, an effect was observed for MUTYH rs36053993 (G396D) singly and 
for MUTYH rs36053993 (G396D) and MUTYH rs34612342 (Y179C) RVs combined 
in the preliminary genotyping results (Table 22) and in the final analysis on 
multivariate analysis, with both analyses involving only the LBCS cohort. This could 
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suggest that the WTCC cohort was not an adequately representative control group. 
This cohort was made up of blood donors recruited from the UK Blood Services (The 
Wellcome Trust Case Control Consortium 2007) thus would have no past history of 
cancer. However, they were markedly younger (Mean age: 41 years [Range: 15 – 65 
years]) than the LBCS cases (72.1 [21 – 99]) and LBCS controls (72.1 [27 – 98]). 
This age difference could be important as 80% of bladder cancer cases occurs over 
the age of 65 years (Cancer Research UK 2010), the maximum age in the WTCC 
cohort, making it probable that a sizeable proportion of individuals in the WTCC 
controls could go on to develop bladder cancer. It was presumed that statistically 
adjusting for age and gender would correct for these differences so it remains 
unclear how this population age difference could hide the influence of RVs in bladder 
cancer risk. 
 
For the NGS of MUTYH and XPC, the whole gene was not sequenced, being limited 
by feasibility of successful long PCR amplification, with 12 kb and 6 kb of intronic 
sequence not targeted during the unindexed and indexed NGS runs respectively. 
There are higher frequencies of SNVs in intronic regions (~70 variants per kilobase) 
compared to coding and UTR regions (~50 variants per kilobase) (Nelson et al. 
2012), which could be indicative of reduced negative selection of intronic variants but 
could also mean potentially missing any pathogenic RVs within these regions. This 
study also only focused on rare SNVs, but with some evidence of rare germline copy 
number variations also contributing to disease risk, potentially important genetic risk 
determinants could have been missed (Lalani et al. 2012; Pylkas et al. 2012).  
 
Selection of candidate RVs for genotyping was influenced by bioinformatics 
functional predictions of deleterious gene effects. Prediction tools for coding 
variations are based on the principles of biochemical categorisation of amino acids 
and evolutionary preservation (Ng and Henikoff 2006). These tools have been more 
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extensively developed and more readily available than prediction tools for non-coding 
variations especially intronic variants. Due to this, a higher proportion of candidate 
RVs selected for genotyping were coding variations (35 coding versus 25 non-
coding). However, there is reported to be only a 1% consensus between different 
bioinformatics prediction tools for non-synonymous coding variants (Tennessen et al. 
2012), while there are also potentially five times more evolutionarily conserved non-
coding positions in the human genome compared to coding positions, with previous 
identification of pathogenic non-coding RVs (Lettice et al. 2003; Cooper and 
Shendure 2011; Torgerson et al. 2012). The limited number of non-coding prediction 
tools, understanding of gene regulatory and splicing elements, and “benchmarking” 
of all coding and non-coding bioinformatics prediction tools with experimental and 
clinical data of true deleterious and benign sequence variations (Cooper and 
Shendure 2011; Mechanic et al. 2012), could thus result in truly deleterious variants 
being excluded from further investigation in this study. Alternatively, to overcome this 
limitation would require impartial genotyping of all identified RVs in the full bladder 
cancer case-control study but this approach at present remains highly costly. 
Hopefully, as NGS costs fall and high throughput library preparation protocols 
develop, a single stage indexed multiplexed NGS study combining both RV 
identification and genotyping would soon be feasible for large case-control studies. 
 
Significant RVs in this study will require validation in other bladder cancer case-
control populations of European descent. Due to the population specific origin of 
RVs, the XPC gene will need to be sequenced in other ethnic populations to 
determine if RVs in these candidate genes are involved in bladder cancer 
susceptibility across all populations (Mechanic et al. 2012). Though current studies 
on common SNP gene-gene and gene-environment interactions have only found 
moderate effects on complex disease risk (Milne et al. 2010; Ciampa et al. 2011), 
evaluation of RV gene-environment and gene- gene interactions have not yet been 
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assessed (Cordell 2009; Thomas 2010; Mechanic et al. 2012). However, in this 
study, no gene RV interactions were found with smoking and occupational exposure 
or between MUTYH and XPC RVs. However, these risk estimates are limited by the 
retrospective recall of participants of the degree of exposure or the use of arbitrary 
binary (ie. exposed/ not exposed) measures, and it is recognised that the collection 
of accurate measures of environmental carcinogen exposure can prove to be difficult 
(Mechanic et al. 2012). 
 
Functional studies on the biological effects of candidate RVs on gene/ protein 
function could aid statistical analysis by allowing a priori weighting, and exclusion of 
functionally neutral RVs to reduce multiple testing and potentially improve statistical 
power. Functional assays for XPC coding and 3’UTR variants have previously been 
developed by Dr Kiltie’s group (Qiao et al. 2011). Determining the functional effects 
of XPC rs3731078 A>G would be informative of the “truth” of its observed effect 
increasing bladder cancer risk. It is an intronic SNP with bioinformatics analysis 
indicating that it is located at a histone acetylation mark thus potentially affecting 
chromatin packing and gene transcriptional activity (Grunstein 1997). Experiments 
looking at the relative XPC expression between wildtypes and carriers of the 
rs3731078 G allele could thus be useful. 
 
As previously developed for XPC coding variants, attempts were made to develop an 
in vivo functional assay of RFP-tagged MUTYH recruitment to areas of oxidative 
laser DNA damage in RT112 bladder cancer cell lines. However, this assay proved 
insufficiently sensitive, requiring cell-cycle synchronisation and continuous live 
confocal imaging for several hours as the cells moved through DNA replication (S-
phase) when MUTYH would be active (data not shown). The functional effects of 
MUTYH Y179C and G396D protein variants on MUTYH DNA binding and mispaired 
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adenine removal have been previously reported using the in vitro DNA binding 
activity and MUTYH glycosylase assays (Ali et al. 2008; Kundu et al. 2009).  
 
In summary, this study investigated the CDRV hypothesis of rare variants in bladder 
cancer susceptibility specifically investigating two candidate genes, MUTYH  and 
XPC, demonstrating an increased bladder cancer risk with XPC variants only. This 
effect on bladder cancer risk was independent of SNPs previously identified in 
GWASs investigating the CDCV hypothesis. Though the effect observed was smaller 
than expected, these findings do support previous studies of the contribution of the 
CDRV hypothesis in complex diseases (Goldgar et al. 2011; Ramagopalan et al. 
2011; Raychaudhuri et al. 2011; Rivas et al. 2011; Stacey et al. 2011; Yokoyama et 
al. 2011; Jin et al. 2012; Lefevre et al. 2012; Lotta et al. 2012; Park et al. 2012; 
Tischkowitz et al. 2012; Torgerson et al. 2012), and will contribute to the greater 
understanding of bladder cancer genetic inheritability. These results will require 
further validation and integration with other bladder cancer “omics” studies to improve 
knowledge of biological mechanisms and future patient cancer phenotyping, risk-
stratisfication and treatment individualisation. 
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8.3. DNA repair gene microRNA-binding site SNPs in bladder 
cancer risk and radiotherapy outcomes 
 
In recent years, there has been increasing interest in the role of miRNAs on cancer 
risk and treatment outcomes. To test the hypothesis that germline SNPs in the 3’UTR 
of DNA repair genes could affect miRNA-mRNA binding and post-transcriptional 
regulation, thus influencing DNA repair capacity and bladder cancer risk and RT 
outcomes, SNPs residing in the 3’UTR of twenty candidate DNA repair genes were 
assessed for their effects on miRNA-binding in silico. Potentially functional SNPs 
were then assessed for their influence on bladder cancer susceptibility in a case-
control study of 752 bladder cancer cases and 704 controls, and for association with 
survival following radiotherapy treatment in 199 MIBC patients treated by RT. 
 
8.3.1. Bladder cancer case-control study of DNA repair gene miRNA-binding 
site SNPs  
8.3.1.1. Case-control study population demographics 
Germline DNAs for the bladder cancer case-control study were collected between 
2002 and 2006 at St James University Hospital as described earlier (7.2.2) and the 
demographics of this population is shown in Table 31. There were no significant 
differences in the matched traits of age, gender or ethnicity between the two groups. 
As previously reported (Choudhury et al. 2008), smoking history (ever versus never 
smoked) and the number of lifetime occupational carcinogen exposures were 
significantly associated with increased bladder cancer risk (OR 1.78 [95%CI 1.41-
2.26], P<0.001 and Per-exposure OR 1.26 [95%CI 1.05-1.52], Ptrend=0.02 
respectively). In the cases, 65.4% had superficial non-invasive tumours, 25.4% MIBC 
and 9.2% had unknown T-staging. 42.8% of cases had high pathological grade 
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disease. With 752 cases and 704 controls, this case-control study had a statistical 
power of at least 80% for detecting an OR of 1.50 for a MAF of 0.2 at a 1% 
significance level. 
Table 32: Case-control study population demographics and tumour characteristics. 
Characteristic 
Case 
(N) 
Control 
(N) 
OR 
(95% CI) 
P-value 
Age Mean 
(Range) 
73.2  
(30.1 - 100.7) 
73.4 
(28.1 - 99.7) 
 
0.71a 
Gender Male 528 467  
0.08b 
 Female 220 237  
Ethnicity Caucasian 740 689  
0.34b  Non-
Caucasian 
11 15  
Smoking 
History 
Never 161 226 1 
<0.001b Ever 586 461 1.78 
(1.41 - 2.26) 
Number of 
occupational 
exposures 
0 556 543 1  
1 160 123 
1.26 
(1.05 - 1.52)c 
0.02c 
2 23 14 
3 6 3 
4 0 1 
6 2 0 
Bladder tumour characteristics   
Tumour stage Ta 316    
CIS 14    
T1 162    
T2 128    
T3 59    
T4 4    
Tx 69    
Pathological 
grade 
G1 87    
G2 306    
G3 314    
Unrecorded 45    
NB. Missing data for gender in 4 patients, occupational history in 25 patients, 
smoking history in 22 patients and ethnicity data for 1 patient. 
a Two-tailed T-test 
b Pearson’s Chi-squared test 
c Per-occupational exposure OR and Chi-squared test for trend 
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8.3.1.2. Bioinformatics prediction for miRNA-binding sites 
Twenty DNA repair genes involved in the BER, NER, NHEJ, HR and DSB signalling 
pathways were selected for investigation (Table 32). Bio-informatics prediction of 
putative miRNA-binding sites were performed by collaborators (D Landi and S Landi) 
at the Dipartimento di Biologia, University of Pisa, Italy (see Methods chapter 7.5.2.2 
for full details). In July 2009, putative miRNA-binding sites within the 3’UTR genomic 
sequences for all 20 genes were predicted using several online bioinformatics 
algorithms. Common SNPs (MAF > 0.10 in Caucasians) within these putative 
miRNA-binding sites were identified and the Gibbs free energy (G) for both the 
wildtype and variant alleles for each identified SNP determined. The difference in G 
for the two alleles (Wildtype allele G – Variant allele G) was calculated as G. 
Therefore, negative G values indicate weaker miRNA-mRNA binding in the 
presence of the variant allele than the wildtype allele (ie. the wildtype allele G is 
more negative) while positive G values mean stronger binding in the presence of 
the variant allele (ie. the variant allele G is more negative). The sum of all |G|s 
greater than 3kJ/mol for each SNP (|Gtot|) was used to score the impact of that 
SNP on miRNA binding. The absolute value of G (|G|) was used to avoid 
positive and negative G values negating each other.  
 
 
 167 
Table 33: List of 20 candidate DNA repair genes investigated for putative miRNA-
binding site SNPs within the gene 3’UTR. 
Gene symbol Gene Name 
ATM Ataxia telangiectasia mutated 
ATRX (RAD54) Alpha thalassemia/mental retardation syndrome X-linked (RAD54 
homolog, S. cerevisiae) 
BRCA1 Breast cancer susceptibility protein 1 
BRCA2 Breast cancer susceptibility protein 2 
CETN2 Centrin 2 
FEN-1 Flap structure-specific endonuclease 1 
LIG1 DNA ligase I 
LIG3 DNA ligase III 
LIG4 DNA ligase IV 
MRE11 Meiotic recombination 11 homolog A (S. cerevisiae) 
NBS1 Nijmegen breakage syndrome protein 1 
PARP1 Poly (ADP-ribose) polymerase family, member 1 
PARP2 Poly (ADP-ribose) polymerase family, member 2 
PCNA Proliferating cell nuclear antigen 
DNA-PK DNA-dependent protein kinase catalytic subunit 
RAD23B (HR23B) RAD23 homolog B (S. cerevisiae) 
RAD50 RAD50 homolog (S. cerevisiae) 
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) 
XPC Xeroderma pigmentosum complementation group C 
XRCC1 X-ray repair complementing defective repair in Chinese hamster 
cells 1 (H. sapiens) 
 
Of the 20 genes, five genes, ATRX, CETN2, DNA-PK, RAD50 and XRCC1, had no 
SNPs located within their 3’UTR, while the 3’UTR SNPs in LIG1 and PCNA were not 
sited within a predicted miRNA-binding site. Of the remainder, there were 21 
common SNPs located within a predicted miRNA-binding site in 13 genes (Appendix 
D). Ten of these SNPs had a |Gtot| greater than 5 kJ/mol. Of these 10 SNPs, two 
had been previously genotyped in the bladder cancer case-control study, namely 
NBS1 rs1063054 (Choudhury et al. 2008) and XPC rs2229090 (Sak et al. 2006) and 
showed no association. XPC rs2229090 was also subsequently imputed from 
Hapmap phase 2 variants in the Nijmegen and Icelandic bladder cancer study 
populations (B Kiemeney, personal communication), with no association found with 
bladder cancer risk (combined OR 0.99 [95%CI 0.89-1.09], P=0.80) despite this 
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variant having the highest predicted |Gtot| of 113.27 for differential miRNA binding. 
The remaining eight candidate SNPs and corresponding predicted miRNA-binding 
sites with a |G| greater than 5 kJ/moL are listed in Table 33. 
 
8.3.1.3. Candidate SNP genotyping and bladder cancer risk 
Genomic DNA samples from the bladder cancer case-control series were sent for 
high-throughput Taqman genotyping to Gen-Probe Life Sciences in West Lothian, 
Scotland.  Blind duplicates from five percent of samples were included to ensure 
concordance of genotyping calls. Custom Taqman assays for ATM SNPs rs1137918 
and rs227091 failed genotyping and these SNPs were found to be located within Alu 
repeats. Capillary sequencing for ATM rs1137918 in 20 genomic control samples 
(undertaken by Dr C Taylor) failed to identify this common variant allele (dbSNP MAF 
= 0.22 reported by Sequenom in 92 individuals from a Caucasian population) making 
it very unlikely that this SNP truly exists. 
 
ATM rs227091 was successfully genotyped by Taqman genotyping of a nested PCR 
product for each sample (undertaken by Dr C Taylor), with full concordance in 
replicates and an assay failure rate of 6.25%. The remaining six candidate SNPs 
were genotyped with greater than 98% concordance in replicates and an assay 
failure rate of less than 5%. Non-concordant replicates were due to exhaustion of 
these DNA samples and so were dropped from analysis. Hardy-Weinberg equilibrium 
for all SNPs was maintained in the controls. 
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Table 34: Candidate DNA repair gene miRNA-binding site SNPs selected for 
genotyping in the bladder cancer case-control study population. Predicted miRNA-
binding with ∆∆G greater than 3 kJ/mol are listed. 
Gene, dbSNP ID & Allele 
Substitution 
MAF 
Predicted miRNA 
binding 
∆∆Ga |ΔΔGtot|
b 
LIG3 rs4796030 C>A 0.47 
miR-612 -5.36 
42.17 
miR-423-3p -5.23 
miR-346 -5.17 
miR-221 -4.49 
miR-888* -4.36 
miR-512-5p -3.90 
miR-615-3p -3.70 
miR-222 -3.44 
miR-525-3p -3.30 
miR-508-5p -3.22 
ATM rs227091 T>C 0.44 
miR-217 -5.41 
38.91 
miR-338-3p -5.37 
miR-199b-5p -4.79 
miR-199a-5p -4.70 
miR-24 -3.83 
miR-593* -3.49 
miR-134 -3.26 
miR-196a 3.34 
miR-939 4.72 
BRCA1 rs12516 C>T 0.36 
miR-874 -9.92 
25.76 miR-324-3p -8.83 
miR-623 -7.01 
BRCA1 rs8176318 G>T 0.35 
miR-328 -4.10 
21.82 
miR-565 -3.95 
miR-149 -3.71 
miR-146b-3p -3.49 
miR-345 -3.30 
miR-892b -3.27 
PARP1 rs8679 T>C 0.17 
miR-145 -5.71 
17.42 
miR-105 -4.91 
miR-630 -3.62 
miR-302a 3.18 
ATM rs1137918 A>G 0.22 
miR-615-5p -5.14 
12.80 miR-193a-5p -3.69 
miR-939 3.97 
NBN (NBS1) rs2735383 G>C 0.32 
miR-499 -4.36 
8.70 
miR-508-3p -4.34 
RAD51 rs7180135 A>G 0.47 miR-197 6.87 6.87 
aThe ∆∆G was calculated by deducting the variant ∆G  from the wildtype ∆G. A 
negative ∆∆G indicates decreased binding in the variant compared to the 
wildtype while a positive ∆∆G indicates increased binding in the variant. 
b|ΔΔGtot| is the total of the absolute values of ∆∆G (|∆∆G|). 
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Multivariate logistic regression of the seven SNPs for association with bladder cancer 
risk adjusting for gender, age, smoking status and occupational exposures showed 
that only PARP1 rs8679 (Ptrend = 0.05) was associated with increased bladder cancer 
risk (Table 34). Collaborators (L Vaslin, DG Cox and J Hall) at Institut Curie, Orsay, 
France, also genotyped PARP1 rs8679 in 257 breast cancer cases and 512 controls 
but did not identify an association with increased breast cancer risk (Ptrend = 0.45) 
though this population was underpowered (24% power at 5% significance level) to 
detect an equivalent effect size. However, CC homozygotes were noted to have a 
greater risk of developing breast cancer compared with TT (adjusted OR 1.90 [95% 
CI 1.05-3.43], P=0.03, data not shown).  
 
Visual inspection of Table 34 suggested that the dominant genotype association 
model may better describe the gene effects of PARP1 rs8679 rather than the additive 
genotype association model used here with the ORs for CC homozygotes and CT 
heterozygotes being similar. Under a dominant model, PARP1 rs8679 (CT + CC 
genotypes) as well as LIG3 rs4796030 (AC + AA genotypes) were associated with 
increased bladder cancer risk (OR 1.28 [95%CI 1.02-1.62], P=0.03 and OR 1.26 
[95%CI 1.00-1.58], P=0.05 respectively). The combined effects of LIG3 rs4796030 
and PARP1 rs8679 was assessed by collapsing unfavourable genotypes (AC + AA 
and CT + CC genotypes respectively) for analysis on bladder cancer risk (Table 35). 
This demonstrated an additive genotype-dose effect with the number of unfavourable 
SNP genotype groups carried (Ptrend=0.002). These results, however, have to be 
interpreted with care in view of the potential application of the incorrect genetic model 
and the use of multiple comparisons. 
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Table 35: Multivariate logistic regression analysis of candidate DNA repair gene 3’UTR 
SNPs on bladder cancer risk. 
Candidate 
SNP 
Observed 
MAF 
(Reported 
MAF) 
Genotype Case Control 
ORa 
(95% CI) 
Ptrend
b,c 
LIG3 
rs4796030 
C>A 
0.46 
(0.47) 
CC 204 226 1  
AC 369 321 1.28 (1.00 – 1.63) 
0.15 
AA 160 148 1.21 (0.90 – 1.64) 
AC + AA 529 469 1.26 (1.00 – 1.58) 0.05d 
ATM 
rs227091 
T>C 
0.45 
(0.44) 
TT 201 209 1  
CT 320 341 0.92 (0.69 – 1.21) 
0.70 
CC 146 148 0.93 (0.69 – 1.27) 
CT + CC 466 488 0.92 (0.71 – 1.23) 0.55d 
BRCA1 
rs12516 
C>T 
0.33 
(0.36) 
CC 342 292 1  
CT 297 318 0.80 (0.64 – 1.01) 
0.43 
TT 79 68 1.04 (0.72 – 1.50) 
CT + TT 376 386 0.84 (0.68 – 1.05) 0.12d 
PARP1 
rs8679 
T>C 
0.21 
(0.21) 
TT 412 424 1  
CT 266 214 1.29 (1.02 – 1.62) 
0.05 
CC 45 37 1.23 (0.77 – 1.95) 
CT + CC 311 251 1.28 (1.02 – 1.62) 0.03d 
BRCA1 
rs8176318 
G>T 
0.32 
(0.35) 
GG 349 296 1  
GT 303 321 0.80 (0.64 – 1.00) 
0.29 
TT 78 70 0.98 (0.68 – 1.41) 
GT + TT 381 391 0.83 (0.67 – 1.03) 0.09d 
NBS1 
rs2735383 
G>C 
0.32 
(0.32) 
GG 305 313 1  
CG 337 308 1.09 (0.87 – 1.36) 
0.27 
CC 69 59 1.22 (0.83 – 1.81) 
CG + CC 406 367 1.11 (0.89 – 1.38) 0.35d 
RAD51 
rs7180135 
A>G 
0.44 
(0.47) 
AA 224 237 1  
AG 369 327 1.06 (0.80 – 1.41) 
0.97 
GG 145 135 0.90 (0.66 – 1.21) 
AG + GG 514 462 0.99 (0.76 – 1.30) 0.97d 
a Adjusted for age, gender, smoking status and occupational exposure. 
b Statistically significant p-values (P ≤ 0.05) are in bold. 
c Additive model of genetic inheritance. 
d Dominant model of genetic inheritance. 
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Table 36: Multivariate logistic regression analysis of number of unfavourable LIG3 
rs4796030 and PARP1 rs8679 SNP genotypes on bladder cancer risk. 
No. of unfavourable 
genotypes carrieda 
Case Control 
ORb 
(95% CI) 
Ptrend
c 
0 115 145 1 
0.002 1 375 352 1.33 (0.99-1.78) 
2 220 169 1.65 (1.20-2.29) 
aUnfavourable genotypes defined as LIG3 rs4796030 AC + AA and PARP1 
rs8679 CT + CC. 
b Adjusted for age, gender, smoking status and occupational exposure. 
c Statistically significant p-values (P ≤ 0.05) are in bold. 
 
8.3.2. DNA repair gene miRNA-binding site SNPs and MIBC radiotherapy 
outcomes 
8.3.2.1. Radiotherapy cohort demographics 
The MIBC radiotherapy cohort consisted of 199 muscle-invasive bladder cancer 
cases treated with 3D-conformal external beam radiotherapy (52.5 – 55 Gy in 20 
fractions over four weeks) between August 2002 and October 2009 at Cookridge 
Hospital and St James Institute of Oncology, Leeds, UK. Median follow-up time was 
67.6 months (range: 20.0 – 97.1 months). For 100 cancer-specific events (assuming 
an overall 50% 5-year CSS, this study had a statistical power of 80% of detecting a 
hazard ratio (HR) of 2.00 in rare homozygotes and heterozygotes combined for a 
MAF of 0.2 at a 5% significance level. 
 
As shown in Table 36, MIBC patients treated by RT are predominantly male and tend 
to be an elderly population (median 78.5 years old), as would be expected in bladder 
cancer but also partly due to fit (hence, typically younger) patients being offered the 
option of radical cystectomy. Hydronephrosis rates in this population were much 
higher than those reported in recent published MIBC RT trials but this could be due 
to poor renal function being an exclusion criteria in these trials (Hoskin et al. 2010; 
James et al. 2012). However, these rates were similar to previous retrospective RT 
series (Scrimger et al. 2001; Tran et al. 2009). As neo-adjuvant chemotherapy has 
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only been introduced recently to standard guidelines, only a small proportion of the 
population received this treatment while concurrent chemotherapy or radiosensitisers 
were only used as part of clinical trials. Eleven percent of the cohort had local 
persistent disease or relapse requiring salvage cystectomy and the 5-year CSS for 
the whole population was 51.6%. Cox multivariate analysis of CSS identified only 
tumour (P=0.04) and nodal stage (P=0.05) as independent poor prognostic factors. 
Neo-adjuvant chemotherapy, concurrent chemotherapy or radiosensitiser use was 
associated with better 5-year CSS outcomes compared to without (60.6% vs 51.9% 
respectively, P=0.04).  
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Table 37: Radiotherapy cohort clinical characteristics and Cox multivariate survival 
analysis of the contribution of each variable to cancer-specific survival. 
Clinical 
Characteristics 
Study population  
No of patients (%) 
Cancer-specific Survival 
HR (95% CI) P-valuec 
Age (years)    
Median (range) 78.5 (51 – 92.5) 
1.02  
(0.98-1.05)d 
0.37 
Gender    
Female 53 (26.6) 1  
Male 146 (73.4) 1.22 (0.70-2.12) 0.49 
Tumour stage    
T2 112 (56.3) 1  
T3 76 (38.2) 
1.54 (1.02-2.35) 0.04 
T4 11 (5.5) 
Nodal stage    
N0 192 (96.5) 1  
N1 4 (2.0) 
2.23 (1.00-5.00) 0.05 
N2 2 (1.0) 
Nx 1 (0.5)   
Histological grade    
<G3 14 (7.0) 1  
G3 178 (89.5) 0.93 (0.61-1.41) 0.73 
Gx 7 (3.5)   
Hydronephrosis    
No 147 (73.9) 1  
Yes 52 (26.1) 1.22 (0.68-2.20) 0.51 
Neoadjuvant/ concurrent therapy 
None 168 (84.5) 1  
Neoadjuvant 
chemotherapy 
15 (7.5)a 
0.39  
(0.16-0.95)e 
0.04 e Concurrent 
chemotherapy/ 
radiosensitizer 
16 (8.0)b 
Salvage chemotherapy     
Not Received 189 (95.0)   
Received 10 (5.0)   
Salvage cystectomy    
Not Received 177 (88.9)   
Received 22 (11.1)   
a All received platinum based combination chemotherapy. 
b11 patients received concurrent gemcitabine (100 mg/m2 ) weekly ×4 and 5 
patients received concurrent carbogen and nicotinamide as part of a phase II 
clinical trial and as part of the BCON phase III clinical trial respectively. 
c Statistically significant p-values (P ≤ 0.05) are in bold. 
d Hazard ratio per-year increase in age. 
e Hazard ratio calculated for receiving any form of chemotherapy or 
radiosensitizer. 
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8.3.2.2. Candidate SNP genotyping and association with clinical outcomes 
Candidate DNA repair gene 3’UTR SNPs were genotyped in the RT cohort and 
correlated with RT clinical outcomes. Carriers of at least one RAD51 rs7180135 
minor allele (AG + GG) were found to have significantly better 5-year CSS rates 
compared to common homozygotes (AA) ((Figure 32), 56.2% vs 35.1% respectively, 
log-rank P=0.02). This remained true even after adjusting for covariates on 
multivariate analysis (HR 0.52 [95%CI 0.31-0.87], P=0.01) (Table 37). A dominant 
model was used, as like the case-control study, this model best described the genetic 
effects observed (AG: HR 0.51 [95%CI 0.29-0.89]; GG: HR 0.55 [95%CI 0.28-1.05]). 
There were no associations found with late radiotherapy bladder or bowel toxicity. 
 
Figure 32: Kaplan-Meier graph of cancer-specific survival in combined heterozygotes 
and rare homozygotes of RAD51 rs7180135 (AG+GG) versus wildtype (AA).
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Table 38: Cox multivariate analysis of cancer-specific survival and logistic regression for late radiation normal tissue toxicity following radical 
radiotherapy and associations with candidate SNPs using a dominant model. 
Candidate SNP Genotype 
 Cancer specific survival 
Late Bladder Toxicity 
(RTOG 2+) 
Late Bowel Toxicity 
(RTOG 2+) 
N HR (95% CI)a P-valueb OR (95%CI) P-valueb OR (95%CI) P-valueb 
LIG3 
rs4796030 C>A 
CC 56 1  1  1  
AC + AA 129 1.32 (0.77-2.26) 0.31 1.35 (0.68-2.70) 0.39 1.98 (0.64-6.15) 0.24 
ATM 
rs227091 T>C 
TT 52 1  1  1  
CT + CC 133 1.34 (0.71-2.54) 0.37 0.73 (0.35-1.54) 0.41 0.82 (0.28-2.38) 0.71 
BRCA1 
rs12516 C>T 
CC 85 1  1  1  
CT + TT 101 0.84 (0.53-1.34) 0.47 0.87 (0.47-1.60) 0.65 1.45 (0.58-3.63) 0.43 
PARP1 
rs8679 T>C 
TT 117 1  1  1  
CT + CC 71 1.14 (0.71-1.86) 0.57 0.54 (0.28-1.04) 0.06 0.74 (0.28-1.90) 0.53 
BRCA1 
rs8176318 G>T 
GG 87 1  1  1  
GT + TT 93 0.90 (0.56-1.44) 0.66 0.92 (0.50-1.70) 0.80 1.90 (0.74-4.91) 0.18 
NBS1 
rs2735383 G>C 
GG 81 1  1  1  
CG + CC 101 0.83 (0.52-1.34) 0.44 1.60 (0.84-3.00) 0.15 1.35 (0.54-3.39) 0.52 
RAD51 
rs7180135 A>G 
AA 50 1  1  1  
AG + GG 139 0.51 (0.30-0.86) 0.01 1.08 (0.50-2.30) 0.85 1.76 (0.49-6.28) 0.38 
a Adjusted for age, gender, tumour and nodal stage, tumour grade, hydronephrosis and neoadjuvant or concurrent chemotherapy or 
radiosensitiser. 
b Statistically significant p-values (P ≤ 0.05) are in bold.  
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8.3.3. Discussion 
8.3.3.1. DNA repair gene miRNA-binding site 3’UTR SNPs and bladder cancer 
susceptibility 
This was the first published study demonstrating an effect of DNA repair gene 3’UTR 
SNPs within putative miRNA-binding sites on bladder cancer susceptibility (Teo et al. 
2012). PARP1 rs8679 and possibly LIG3 rs4796030 were found to be associated 
with increased bladder cancer risk, with an additive effect seen with carriage of both 
SNP minor alleles. Further validation of these findings in an independent bladder 
cancer case-control population will be needed. 
 
LIG3 is a BER protein and is stabilised by XRCC1. It is recruited through interactions 
with PARP1 and XRCC1 to DNA SSBs and ligates the SSBs generated during short 
patch BER. It may also act as a “back-up” ligase for long-patch BER (Petermann et 
al. 2006). PARP1, another BER protein, carries out the poly(ADP-ribosyl)ation of 
histones, topoisomerases and DNA repair signalling proteins following DNA damage, 
resulting in chromatin unwinding and recruitment of DNA repair proteins (Megnin-
Chanet et al. 2010). PARP1 is also involved in the error-prone alternative NHEJ 
pathway, MMEJ, together with LIG3 and XRCC1 (Audebert et al. 2004). The Gs 
for the miRNAs predicted to bind to LIG3 rs4796030 and PARP1 rs8679 (Table 33) 
were predominantly negative, indicating decreased miRNA-mRNA binding in the 
variant alleles compared to the wildtype alleles. Thus, the variant allele would be 
expected to be associated with increased LIG3 and PARP1 expression. This result is 
counter-intuitive as it would be expected that higher levels of DNA repair enzymes 
would be associated with increased repair and reduced cancer risk. However, DNA 
repair enzyme over-expression in tumours may provide a selective advantage for 
tumour cell growth with over-expression having been associated with a greater risk of 
metastasis (Sarasin and Kauffmann 2008). The additive effect seen in our study of 
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carrying both LIG3 rs4796030 and PARP1 rs8679 on bladder cancer risk suggests 
that either an enhanced BER pathway or MMEJ repair pathway predisposes 
individuals to bladder cancer. PARP1 competes with Ku (classical NHEJ) for binding 
to DSB ends and initiating the MMEJ pathway (Wang et al. 2006). Increased PARP1 
and LIG3 expression due to LIG3 rs4796030 and PARP1 rs8679 could thus possibly 
promote DSB repair via the MMEJ over the classical NHEJ pathway resulting in more 
error-prone repair and mutagenesis, with the greatest influence seen in carriers of 
both SNPs.  
 
From the published literature of the miRNAs predicted to bind to LIG3 rs4796030, a 
pre-miRNA SNP of miR-423 has previously been associated with increased bladder 
cancer risk (Yang et al. 2008) while miR-221 has been reported to be upregulated in 
bladder cancer cell lines with miR-221 silencing leading to apoptosis (Lu et al. 2010). 
For the PARP1 rs8679 SNP, miR-145 binding was predicted to have the greatest 
G (-5.71kJ/mol) (Table 33), indicating decreased miR-145 binding to the variant 
PARP1 mRNA 3’UTR and thus increased PARP1 expression. Previous studies have 
reported down-regulation of miR-145 expression in bladder cancer (Catto et al. 2009; 
Dyrskjot et al. 2009), while transfection of miR-145 in bladder cancer cell lines had a 
tumour suppressor effect, reducing cell proliferation and inducing apoptotic pathways 
(Ostenfeld et al. 2010).  
 
Candidate gene association studies have identified cancer risk associations with 
3’UTR SNPs which were then investigated for possible miRNA-binding sites (Liang et 
al. 2010; Pharoah et al. 2011). In bladder cancer, DSB repair MRE11 rs2155209 
3’UTR SNP was previously found to increase bladder cancer risk (Choudhury et al. 
2008). This variant was predicted to be within the binding sites for miR-584 and miR-
744 but the minor allele is predicted to alter the G by less than 1 kJ/mol for both 
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miRNAs (Table 38 and Appendix D), thus the mechanism underlying this association 
remains to be determined.  
 
Table 39: Predicted miRNA bindings sites and predicted ∆G values for MRE11A 
rs2155209. 
 
Other studies also used in silico methods to try identify SNPs located within predicted 
miRNA-binding sites, then tested for associations with cancer susceptibility (Chin et 
al. 2008; Landi et al. 2008; Nicoloso et al. 2010). Using the same bioinformatics 
analysis methods, Landi et al reported an association between the CD86 3’UTR SNP 
rs17281995, predicted to affect the binding of four miRNAs, with increased colorectal 
cancer risk (Landi et al. 2008) while Naccarati et al identified two NER 3’UTR SNPs, 
GTF2H1 rs4596 and RPA2 rs7356, to be protective and to predispose to colorectal 
cancer respectively (Naccarati et al. 2012). Chin et al demonstrated that KRAS 
3’UTR SNP rs712 was sited within a let-7 binding site, resulted in increased 
luciferase activity compared to wild-type in a KRAS 3’UTR reporter assay, and was 
associated with increased lung cancer risk (Chin et al. 2008). Nicoloso et al identified 
two predicted miRNA-binding site SNPs within the coding regions of BRCA1 and 
TGFR1 that affected post-transcriptional miRNA regulation (Nicoloso et al. 2010), 
thus highlighting the possibility of miRNA-binding sites beyond the 3’UTR. 
 
Gene, dbSNP 
ID & Allele 
Substitution 
Minor 
Allele 
Frequency 
Predicted 
miRNA 
binding 
Wildtype 
Allele 
∆G 
Variant 
Allele 
∆G 
∆∆G |ΔΔG| 
MRE11A 
rs2155209 
A>G 
0.29 miR-744 -20.99 -20.02 -0.97 0.97 
miR-584 -18.6 -18.35 -0.25 0.25 
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8.3.3.2. DNA repair gene miRNA-binding site SNPs as markers of MIBC 
radiotherapy outcomes 
As ionising radiation from radiotherapy causes cancer cell death by inducing DNA 
damage, the candidate SNPs were also investigated as potential predictive markers 
of radiotherapy treatment outcomes in muscle invasive bladder cancer. Carriers of 
the RAD51 rs7180135 G minor allele were found to have an improved 5-year CSS 
with an absolute survival advantage at 5 years of 21.1% indicating a potential role as 
a predictive marker of RT treatment outcomes in MIBC.  
 
However, local recurrence would be a better measure for a local treatment such as 
radiotherapy. An accurate measure of local recurrence would be influenced by 
response at first check cystoscopy three months post-radiotherapy and frequency of 
follow-up cystoscopy. However, a high number of patients did not have their first 
cystoscopy performed or their findings documented, plus the frequency of follow-up 
cystoscopy was variable in the referring urology units in the region. Thus, analysis 
was performed on CSS instead but this measure would include deaths from 
metastatic disease. RAD51 rs7180135 could thus potentially be just a measure of a 
poorer prognostic phenotype and not a predictive marker of RT. This SNP will thus 
need to be validated in an independent RT treated as well as a surgically treated 
cohort to clarify its clinical value. 
 
It is hypothesised that miR-197 binds more strongly to the RAD51 rs7180135 G allele 
(G 6.87 kJ/mol) resulting in a reduction of RAD51 expression. RAD51 is involved 
in DSB homologous recombination repair, so in tumours, alteration of RAD51 
expression could potentiate tumour radiosensitisation. In breast cancer, low tumour 
RAD51 mRNA expression has been associated with lower local recurrence and 
improved survival following adjuvant chemotherapy and radiotherapy treatment (Le 
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Scodan et al. 2010). Differential expression of miR-197 has been reported in different 
cancer types with up-regulation seen in squamous cell carcinoma of the tongue and 
male breast carcinoma, and down-regulation in gastric cancer (Wong et al. 2008; 
Lehmann et al. 2010; Li et al. 2011). Plasma miR-197 levels have also been 
proposed as a potential diagnostic biomarker, being elevated in lung cancer (Zheng 
et al. 2011). In human colon cancer cell lines, miR-197 expression levels were found 
to be down-regulated following oxaliplatin and 5-fluorouracil treatment (Zhou et al. 
2010). In response to DNA damage, the effect of miR-197 down-regulation in cancer 
cells could thus be to increase DNA repair by increasing RAD51 expression. The 
current results suggest that the RAD51 rs7180135 genotype and its possible effects 
on miR-197-mRNA-binding may predict tumour radiosensitivity and radiotherapy 
outcomes in bladder cancer. If successfully validated, this might be used clinically as 
a predictive marker of radiotherapy outcome. 
 
8.3.3.3. Study strengths and limitations 
This was a large study able to detect moderate to large effects of the candidate 
common SNPs on bladder cancer risk and RT outcomes in MIBC. Further validation 
is needed in an independent bladder cancer case-control population and RT-treated 
MIBC population. This study may potentially have missed other miRNA-binding site 
SNPs within the candidate genes. The bioinformatics software used for predicting 
miRNA-binding sites were based purely on canonical “seed pairing rules” hence non-
canonical miRNA-binding sites would have been missed. Also by only examining 
SNPs within the 3’UTR, potential miRNA-binding sites within the 5’UTR or coding 
regions would not have been detected.  
 
This study examined seven polymorphisms for associations with risk of bladder 
cancer and cause-specific mortality following RT using multiple genetic models, thus 
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runs the risk of false positive results due to multiple comparisons. If a simple 
Bonferroni correction were applied for the number of SNPs genotyped, the 
significance threshold would be 0.007 thus none of the associations observed would 
remain statistically significant. However, with the complex correlations between these 
candidate genes, such as gene-gene interactions and linkage disequilibrium, 
influencing these multiple comparisons, it is difficult to determine the true number of 
tests carried out for simple Bonferroni correction. All the SNPs were chosen based 
on their prior probability of functional significance, due to their predicted influence on 
miRNA-binding. However, the magnitude of this prior probability would be difficult to 
estimate for use in correction methods such as the false positive reporting probability 
(FPRP) (Wacholder et al. 2004). Due to the subjectivity of the assumptions 
necessary, no formal multiple comparison corrections were used for the p-values 
reported, hence I acknowledge the possibility of false-positive discovery.  
 
In summary, this project examined the 3’UTR of 20 candidate DNA repair genes 
using in silico methods to identify SNPs that potentially affect miRNA-binding. 
Associations between PARP1 rs8679 with increased bladder cancer risk, and RAD51 
rs7180135 with improved cancer-specific survival following radiotherapy treatment in 
muscle-invasive bladder cancer were observed. Whilst the first of its kind in bladder 
cancer, this project also corroborates the findings seen in other cancer sites of the 
association of miRNA-binding site SNPs with cancer susceptibility (Chin et al. 2008; 
Landi et al. 2008; Liang et al. 2010; Nicoloso et al. 2010). These findings will need to 
be successfully validated in other bladder cancer series and the functional effects of 
these SNPs elicited. This will provide further insight into the biology of bladder 
carcinogenesis, potential predictive biomarker of RT outcomes, and potential novel 
targets for new cancer treatments. 
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8.4.  Germline MRE11A variants as a biomarker of 
radiotherapy outcomes in muscle-invasive bladder cancer 
 
In MIBC, Dr Kiltie’s group had previously shown tumour MRE11 protein expression to 
be predictive of survival following RT but not surgery (Choudhury et al. 2010), and 
that a common germline MRE11A SNP was associated with an increased risk of 
developing bladder cancer (Choudhury et al. 2008). MRE11A SNPs had also been 
shown to be associated with altered DSB repair response (Ricceri et al. 2011). As 
tumours initially inherit the host genotype (Stewart 2010), it was hypothesised that 
germline SNPs and rare variants in MRE11A may potentially be predictive of both 
tumour response and toxicity following radical radiotherapy in MIBC. To test this 
hypothesis, indexed multiplexed NGS was undertaken to identify germline MRE11A 
variants in MIBC patients treated by radical RT and to assess their association with 
survival and late radiation normal tissue toxicity. Validation studies were then 
undertaken in a surgically-treated MIBC cohort.  
 
8.4.1. Radiotherapy treated MIBC cohort demographics 
The characteristics and RT treatment details of the full MIBC radiotherapy cohort 
were described previously in Section 7.2.3.1. However, long PCR amplification failed 
in 15 samples so these patients were excluded with 70 cancer specific events in the 
remaining 186 patients. Patient clinical demographics of just the 186 included 
patients are displayed in Table 39. Therefore, this study was able to detect, with a 
statistical power of 80% at a 5% significance level, a HR of 2.20 for a MAF (or 
collapsed rare variant allele frequency) of 0.2, or a HR of 2.50 for a MAF of 0.1. 
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Table 40: Clinical demographics of patients from the MIBC radiotherapy cohort with 
successful long PCR amplification of MRE11A. 
Variable 
Study population (N=186)  
No of patients (%) 
Age (years)  
Median (range) 79 (55 - 93) 
Gender  
Male 139 (74.7) 
Female 47 (25.3) 
Tumour stage  
T2 118 (63.5) 
T3 51 (27.5) 
T4 9 (4.9) 
Tx 8 (4.4) 
Nodal stage  
N0 179 (96.3) 
N1 4 (2.2) 
N2 2 (1.1) 
Nx 1 (0.6) 
Histological Grade  
High grade 167 (89.8) 
Low grade 14 (7.6) 
Unknown 5 (2.7) 
Hydronephrosis  
No 135 (72.6) 
Yes 51 (27.5) 
Neoadjuvant/ concurrent therapy 
None 160 (86.0) 
Neoadjuvant chemotherapy 11 (5.9)a 
Concurrent chemotherapy/ radiosensitiser 15 (8.1)b 
Salvage chemotherapy 
Not Received 177 (95.2) 
Received 9 (4.9) 
Salvage Cystectomy  
Not Received 167 (89.8) 
Received 19 (10.3) 
 
a All received platinum based combination chemotherapy. 
b 10 patients received concurrent gemcitabine (100 mg/m2 ) weekly ×4 as part of a 
phase II clinical trial and 5 patients received concurrent carbogen and nicotinamide 
as part of the BCON phase III clinical trial. 
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8.4.2. Germline MRE11A variants from indexed multiplexed NGS 
A total of nine pools of 19 to 24 indexed samples per pool were sequenced on the 
Illumina GAII platform using 100bp single end reads. There was a median coverage 
of 2507x per sample (range 673 – 9891) and 95% of target candidate gene regions 
were sequenced at a coverage greater than 221x per sample. 
 
8.4.2.1. Variants identified 
In total, 121 variants were called. Alignment and coverage data were reviewed for 
variants in regions of poor coverage or with poor alignment consensus between 
forward and reverse strands (Figure 33), resulting in 85 variants being deemed high 
confidence calls and 36 variants low confidence calls.  
 
Figure 33: Illuminator alignment and coverage data demonstrating regions of poor 
confidence calling: A) a variant sited in a region with poor consensus between forward 
and reverse strands (red circle); B) a variant sited in a region of poor coverage (blue 
arrow). 
 
One variant carrier sample and one wildtype sample were conventionally Sanger 
sequenced for all variants to validate the NGS variant calls, with all high confidence 
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variants but just three low confidence variants confirmed. A summary of confirmed 
variants by MAF and gene region is shown in Table 40 with equal proportions of 
SNPs and rare variants identified. The full list of confirmed variants is in Appendix C. 
Thirty common SNPs were in linkage disequilibrium with R-squared values greater 
than 0.80 (Figure 35) with nine common SNP haplotype groups observed (Figure 
34). 
Table 41: Summary of confirmed MRE11A variants identified. Variants are divided by 
MAF, novel variants or variants within the dbSNP database and location within the 
gene. 
 
dbSNP New 
Variant type (MAF)  No of variants No of variants 
SNP (>0.01)  40 3 
Intronic  37 3 
3’-UTR  3 0 
Rare Variant (≤0.01)  14 31 
Intronic  10 25 
Coding  3 1 
3’-UTR  1 5 
 
 
Figure 34: MRE11A haplotypes in the study population with observed frequencies 
shown on the right. Each red square represents carriage of a corresponding SNP 
minor allele (Haploview ID at the top (see Figure 35)). The rs1805363 A minor allele is 
circled in green. 
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Figure 35: Linkage disequilibrium plot for all common MRE11A SNPs (MAF>0.01) generated using Haploview (http://www.broadinstitute.org/) – 
R-squared values are shown in each square while the heat map (see key) displays the D’-values. In blue are SNPs with a high D’ but low 
logarithm of odds (LOD) thus a low likelihood of a true linkage. Haploview ID and corresponding SNP details are at the top. 
 
High D’ (0.8-1.0)
Low D’ (0.0-0.2)
High D’/ 
Low LOD
D’ (0.6-0.8)
D’ (0.4-0.6)
D’ (0.2-0.4)
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8.4.2.2. Association with cancer-specific survival  
On multivariate Cox proportional hazards analysis, none of the covariates were 
significantly associated with CSS (Table 41). Individual variant analysis of all 
MRE11A variants detected identified only two common SNPs to be significantly 
associated with CSS with a Ptrend ≤ 0.05, rs1805363 (Ptrend = 0.001) and rs13447623 
(Ptrend = 0.05) (Table 41 and in Appendix C). However, the rs1805363 variant A allele 
was in linkage disequilibrium with the rs13447623 variant G allele (D’ = 1.00, r2 = 
0.38, SNP ID 41 in Figure 34). By adjusting for the rs1805363 genotype status, 
conditional analysis demonstrated that the contribution of rs13447623 on survival 
was completely dependent on the rs1805363 genotype status (Table 41). Several 
rare variants, with only one allele seen in the whole study population, attained P-
values less than 0.05 individually (Appendix C) but had very wide 95% confidence 
intervals, hence they were interpreted with caution and used only as part of the 
collapsed analyses discussed later. 
 
Figure 36: Kaplan Meier curve of cancer-specific survival for MRE11A rs1805363 
genotypes in the MIBC radiotherapy cohort. 
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The rs1805363 A minor allele was associated with worse CSS following radiotherapy 
treatment (Per-allele Hazard Ratio (HR) 2.10, 95% Confidence Interval (CI) 1.34 – 
3.28, Ptrend = 0.001) and a gene-dosage effect was seen with increasing number of A 
minor alleles carried with a 5-year CSS of 58.3% in wildtypes, 42.0% in 
heterozygotes and 0% in minor allele homozygotes (Figure 36). This suggests 
rs1805363 as a potential prognostic marker of bladder cancer survival following 
radical radiotherapy treatment. 
Table 42: Cox proportional hazards multivariate analysis of cancer specific survival in 
covariates, rs1805363, rs13447623 and 3’UTR rare variants. 
Covariates   HR (95% CI) P-valuea 
Age at Diagnosis   1.01 (0.98 - 1.04) 0.61 
Gender   0.72 (0.39 - 1.31) 0.28 
T Stage   1.50 (0.98 - 2.30) 0.06 
N Stage   1.96 (0.88 - 4.37) 0.10 
Histological Grade   1.12 (0.50 - 2.48) 0.79 
Hydronephrosis   1.21 (0.66 - 2.22) 0.53 
Neoadjuvant/ Concurrent Chemotherapy 0.52 (0.22 - 1.20) 0.12 
Variant (Observed MAF) Genotype N   
rs1805363 G>A (0.11) 
GG 152 1 
0.001 AG 28 1.49 (0.80 - 2.78) 
AA 6 8.00 (2.93 - 21.90) 
rs13447623 A>G (0.24) 
AA 110 1 
0.05 AG 62 0.86 (0.50 - 1.49) 
GG 14 3.68 (1.78 - 7.60) 
Conditional Analysis     
rs1805363 G>A   2.19 (1.12 - 4.30) 0.02 
rs13447623 A>G   0.95 (0.54 - 1.66) 0.86 
Rare Variants Collapsed Analysis   
No 3’UTR rare variants  179 1  
1+ 3’UTR rare variants  7 4.04 (1.42 - 11.51) 0.009 
a Significant p-values (<0.05) are In bold. 
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Collapsed analyses were performed by Dr J Nsengimana. Simple collapsed analysis 
of rare variants a uni-directional analyses looking at the presence or absence of rare 
variant carriage on survival revealed that carriage of at least one rare variant in the 
3’UTR of MRE11 was significantly associated with worse CSS (P = 0.009; Table 41) 
in carriers compared to non-carriers (5-year CSS: 42.9 vs 54.8% respectively; Figure 
37). However, using the data-adaptive sum test as described by Han and Pan (Han 
and Pan 2010), for a permutation-based collapsed analysis of the uncommon and 
rare variants (MAF<0.05) in this study taking into account the observed direction of 
effect for each different variant on survival, did not reveal any significant associations 
with CSS for all uncommon and rare variants (P = 0.45) or just uncommon and rare 
exonic variants (P = 0.59). Analysis of the nine common SNP haplotypes shown in 
Figure 34, did not reveal any haplotype groups associated with CSS (all P>0.05) 
unexplained by the rs1805363 A minor allele. 
 
 
Figure 37: Kaplan Meier curve of cancer-specific survival for carriers of at least one 
3’UTR MRE11A rare variant allele in the MIBC radiotherapy cohort. 
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8.4.2.3. Association with late radiation bladder and rectal toxicity 
Neither rs1805363 nor the 3’UTR rare variants were associated with developing late 
radiation bladder (P = 0.09 and 0.33 respectively) or rectal (P = 0.17 for rs1805363; 
no events for 3’UTR rare variants) toxicity. However, rs13447623 and the common 
3’UTR SNP rs2155209, previously found to be associated with increased bladder 
cancer risk (Choudhury et al. 2008), were associated with the likelihood of 
developing RTOG grade 2 or greater late bladder toxicity and rectal toxicity (Table 42 
and in Appendix C for full list). Collapsed analysis did not identify any associations of 
rare variants with bladder or rectal toxicity (P = 0.71 and P = 0.50 respectively) while 
there were no associations in the nine common SNP haplotypes unexplained by 
rs13447623 and rs2155209. 
 
Table 43: Ordered logistic regression of late radiation bladder and rectal toxicity with 
genotype of rs13447623 and rs2155209. 
   Late Bladder Toxicity Late Rectal Toxicity 
Variant 
(Observed MAF) 
Genotype N 
OR  
(95%CI) 
P-value 
OR  
(95%CI) 
P-value 
Rs13447623 A>G 
(0.24) 
AA 110 1 
0.003 
1 
0.04  AG 62 
3.15  
(1.61 - 6.18) 
2.42 
(0.94 - 6.22) 
 GG 14 
2.69 
(0.85 - 8.50) 
3.06 
(0.72 - 13.01) 
Rs2155209 A>G 
(0.38) 
AA 70 1 
0.02 
1 
0.04 
 
AG 90 
0.64 
(0.33 - 1.24) 
0.67 
(0.28 - 1.63) 
 
GG 26 
0.27 
(0.08 - 0.88) 
N/Aa 
a Insufficient events to calculate. 
 
8.4.2.4. Bioinformatics functional predictions 
Bioinformatics functional predictions for all MRE11A SNPs and variants identified are 
listed in Appendix C. Three intronic common SNPs including rs1805363 were 
postulated to have potential effects being sited within a predicted binding site or close 
proximity to a known splice site (Table 43). Of the four coding rare variants, three 
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were non-synonymous with only rs61749249 predicted to affect protein function. Two 
of the coding rare variants and one 3’UTR rare variant were predicted to be sited 
within a miRNA-binding site with a |ΔΔG| greater than 4kJ/mol. 
 
Table 44: MRE11A common SNPs and rare variants with predicted functional effects. 
Variant  
(Observed MAF) 
[Gene region] 
Coding 
Predicted 
miRNA binding 
Splicing/ 
Transcription 
factor binding 
site 
Protein 
Change 
Polyphen SIFT 
miRNA-
binding 
site 
ΔΔG 
(kJ/ 
mol) 
Common SNPs 
rs11020802 G>T  
(0.30) 
[5'-upstream] 
Non-coding Non-coding 
ELF/BRCA1 
transcription 
factor binding 
site 
rs1805363 G>A  
(0.11) 
[Intron 1 (Isoform 1) 
/ 5'UTR (Isoform 2)] 
Non-coding Nil 
5 bases 3' from 
Exon 1 GC 
donor splice site 
rs535801 G>A 
(0.27) 
[Intron 5] 
Non-coding Non-coding 
6 bases 5' from 
Exon 6 AG 
acceptor splice 
site 
Rare Variants 
rs3218740 C>T 
(0.003) 
[Exon 6] 
D142D (Synonymous) Nil Nil 
rs115244417 C>G 
(0.003) 
[Exon 9] 
S334R Benign Tolerated Nil Nil 
Chr 11: 94197302 
A>G 
(0.003) 
[Exon 11] 
H401R Benign Tolerated 
hsa-miR-
892a 
-4.4 Nil 
rs61749249 C>A 
(0.008) 
[Exon 13] 
A492D 
Probably 
damaging 
Affect 
protein 
function 
hsa-miR-
3659 
6.6 Nil 
rs104895004 G>T 
(0.003) 
[Exon 20 3'UTR] 
Non-coding 
hsa-miR-
338-5p 
4.4 Nil 
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8.4.3. Validation of rs1805363 
 
Figure 38: MRE11A isoform 1 and isoform 2 alternative splicing and the relative 
position of common SNP rs1805363. 
 
Rs1805363 is an intronic SNP in MRE11A isoform 1, five bases 3’ from the Exon 1 
AG donor splice site, or is located within the 5’UTR in MRE11A isoform 2 (Figure 38). 
It could thus potentially influence the splicing and/ or the expression of one isoform 
over the other. However, there were no predicted effects on exonic splice enhancer 
sites (Figure 39) or on miRNA-binding and post-transcriptional regulation (Table 43), 
but the accuracy of these prediction tools remains uncertain. 
 
Figure 39: Predicted exonic splice enhancer splice sites in the region surrounding 
rs1805363 (red arrows) using the ESEFinder 3.0 (http://rulai.cshl.edu/tools/ESE3/) 
prediction tool for the wildtype G allele and the variant A allele. 
MRE11A
Isoform 1
MRE11A
Isoform 2
Rs1805363 G>A
Exon 21
5’-UTR 5’-UTR
Codon 1
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8.4.3.1. MRE11A mRNA isoform profiling 
To investigate the influence of rs1805363 on isoform expression, Dr Kiltie’s group 
(performed by Mr C Buchwald) sequenced genomic DNA from eight bladder cancer 
and bladder-derived cell lines showing all were homozygous for the rs1805363 
wildtype G allele (Figure 40). 
 
Figure 40: Sequence data for genomic DNA from eight bladder cancer and bladder-
derived cell lines with all eight cell lines being wildtype for rs1805363 (red arrow). 
 
Of the 34 carriers of the rs1805363 minor A allele in the MIBC radiotherapy cohort, 
only one heterozygous individual had matched RNA already extracted from their 
bladder tumour (now referred to as tumour A) available (generously provided by Prof 
M Knowles). RNA was thus extracted from macro-dissected muscle-invasive regions 
from the FFPE bladder tumour blocks of another heterozygous individual (tumour B) 
and a homozygous minor A allele individual (tumour C), and cDNA generated by 
reverse transcription for all three tumours. cDNA for six of the above bladder cancer 
cell lines were provided by Prof M Knowles as wildtype controls. PCR primers sited in 
common sequence for both MRE11A isoforms and spanning exons 1 and 2 were 
used to produce two PCR products of different sizes corresponding to isoform 1 (139 
bp) and isoform 2 (246 bp) for cDNA from the six bladder cancer cell lines and 
tumours A to C. By gel electrophoresis, the band intensities of  isoform 1 and isoform 
2 relative to a housekeeper gene control, GAPDH, was measured for each sample 
and the relative expression of each isoform calculated (Figure 41A).  
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Figure 41: MRE11A isoform expression in bladder cancer cell lines and primary bladder tumours with different genotypes for rs1805363: A) Gel 
electrophoresis bands for MRE11A isoform 1 and 2, and GAPDH PCR amplified from cDNA from six bladder cancer cell lines (all wildtype GG 
genotype for rs1805363), primary bladder tumours A and B (heterozygote AG genotype for rs1805363), and primary bladder tumour C (homozygote 
variant AA genotype for rs1805363). B) Percentage expression of MRE11A for each isoform relative to overall MRE11A expression for each 
sample.  
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As shown in Figure 41B, the percentage of MRE11A isoform 1 relative to overall 
MRE11A (sum of isoforms 1 and 2) falls with each rs1805363 minor A allele carried. 
The average percentage of isoform 1 was 61.7% in wildtypes, 49.6% in 
heterozygotes and 30.3% in minor allele homozygotes. The two isoform gel bands 
were excised and sequenced to confirm they corresponded with isoforms 1 and 2 
(Figure 42). Overall MRE11A expression normalised to GAPDH expression varied 
between cell lines and tumours (Table 44). No obvious difference in overall MRE11A 
expression was observed between genotypes but more samples would need to be 
analysed for any firm conclusions to be made.  
 
Table 45: Overall MRE11A expression normalised to GAPDH expression in bladder 
cancer cell lines and primary bladder tumours A, B and C by MRE11A rs1805363 
genotype. 
Cell Line/ 
Tumour 
Overall MRE11A 
expression normalised 
to GAPDH expression 
GG genotype 
 
RT112 1.78 
HT2376 1.82 
VMCUB1 1.77 
5637 2.13 
253J 1.89 
CAL29 2.45 
Mean 1.97 
AG genotype   
Tumour A 3.91 
Tumour B 1.79 
Mean 2.50 
AA genotype   
Tumour C 2.46 
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Figure 42: Sequencing electropherograms for PCR products corresponding to isoform 
1 and isoform 2 for RT112 bladder cancer cell line, and primary bladder tumours A, B 
and C: A) Isoform 1/ 139 bp band, and B) isoform 2/ 246 bp band. 
  
(B)
(A)
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8.4.3.2. Radical cystectomy treated MIBC cohort 
To determine the prognostic versus predictive role of rs1805363, a cohort of 256 
MIBC patients treated by radical cystectomy from collaborators (Dr L Dyrskjøt and 
Prof T Ørntoft) at Aarhus University Hospital, Denmark, between 1992 and 2008 
were genotyped for rs1805363. The clinical demographics of this population are 
shown in Table 44. This cohort was notably younger which would be expected as 
younger (thus healthier) patients would be more likely to receive surgery (Choudhury 
et al. 2010). Treatment details of this cohort were previously described (Jensen et al. 
2011) but in summary, all patients had a radical cystectomy with two-thirds having a 
limited lymph node dissection to the obturator fossa and the remaining third of 
patients having an extended lymph node dissection to the level of the inferior 
mesenteric artery. None of these patients received neo-adjuvant or adjuvant 
chemotherapy. 
Table 46: Clinical demographics of patients from the MIBC cystectomy cohort. 
Variable 
Study population (N=256)  
No of patients (%) 
Age (years)  
Median (range) 65 (34 - 85) 
Gender  
Male 187 (73.0) 
Female 69 (27.0) 
Tumour stagea  
T2 94 (36.7) 
T3 112 (47.6) 
T4 40 (15.7) 
Nodal stagea  
N0 184 (71.9) 
N1 32 (12.5) 
N2 27 (10.5) 
N3 12 (4.7) 
Nx 1 (0.4) 
Histological Gradea  
High grade 251 (98.0) 
Low grade 5 (2.0) 
a Bladder cancer classification as per the seventh edition of the TNM classification 
(Sobin et al. 2010). 
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Survival data was obtained from the Danish Central Personal Registry with cancer-
specific deaths defined as deaths in patients with known bladder cancer recurrence 
following surgery. All other deaths were categorised as deaths from other causes. 
Median follow-up time was 63.7 months (range: 2.0 – 220.6 months) with 95 cancer-
specific events. Assuming the same MAF for rs1805363, this cohort had a statistical 
power of 80.5% at a 5% significance level for detecting a HR of 2.10. 
 
 
Figure 43: Kaplan Meier curve of cancer-specific survival for MRE11A rs1805363 
genotypes in the Aarhus MIBC cystectomy cohort. 
 
Genotyping for rs1805363 in this cohort found no association with CSS (Ptrend = 0.89) 
with a 5-year CSS of 59.7% in wildtypes, 54.0% in heterozygotes and 75.0% in minor 
allele homozygotes (Figure 43). Multivariate analysis, adjusting for age, gender, 
tumour stage, nodal stage and histological grade, did not reveal any significant 
associations of the rs1805363 genotypes with CSS (Table 45). 
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Table 47: Cox proportional hazards multivariate analysis of cancer specific survival for 
rs1805363 in the cystectomy treated cohort adjusting for age, gender, tumour stage, 
nodal stage and histological grade. 
Variant (Observed MAF) Genotype N HR (95% CI) P-value 
rs1805363 G>A (0.09) 
GG 216 1 
0.88 AG 36 1.21 (0.15 – 9.49) 
AA 4 0.96 (0.13 – 7.03) 
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8.4.4. Discussion 
The MRE11A gene has a key role in DSB detection and repair signalling, with the 
expression of tumour MRE11 protein previously associated with survival following 
radiotherapy in 180 MIBC patients (Choudhury et al. 2010). The MRE11A gene was 
thus investigated for potential underlying genetic variants associated with both 
tumour response and radiation toxicity. Previous candidate gene studies of common 
coding DNA repair SNPs have found associations with pathological response or 
survival in several cancer sites following radiotherapy treatment, predominantly in 
combination with chemotherapy (Parliament and Murray 2010; Yin et al. 2011; Yoon 
et al. 2011; Wibom et al. 2012). Although a candidate gene approach was also used 
here, the use of NGS technology allows the in depth investigation of all MRE11 
variants in the study population including novel rare ones, rather than studying only 
known variants or tag SNPs. 
 
In this pilot study, for the first time germline MRE11 SNPs and rare variants were 
found to be associated with survival and late radiation normal tissue toxicity following 
radical radiotherapy in MIBC. The common SNP rs1805363 and MRE11A 3’UTR rare 
variant carrier status were identified as markers of poor radiotherapy outcomes and 
rs13447623 and rs2155209 as potential markers for increased late radiation normal 
tissue toxicity, thus potentially identifying an MIBC patient population not best served 
by bladder conserving treatment. Investigation of rs1805363 in a cystectomy treated 
MIBC cohort findings did not reveal any association with prognosis supporting the 
hypothesis of rs1805363 as a predictive inherited genetic marker of radiotherapy 
outcomes in MIBC. 
 
Ricceri et al previously identified eight intronic MRE11A SNPs significantly 
associated with H2AX dephosphorylation at three hours, thus suggestive of 
increased completion of DSB repair (Taneja et al. 2004), following 2 Gy irradiation of 
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peripheral blood mononuclear cells from 118 healthy individuals (Ricceri et al. 2011). 
Though rs1805363 failed genotyping in their work, two of their significant MRE11A 
SNPs were detected by NGS in the MIBC radiotherapy cohort but were not 
associated with survival or toxicity.  However, from HapMap data 
(http://hapmap.ncbi.nlm.nih.gov/), rs1805363 and rs13447623 are in moderate to 
complete D’ linkage (D’ > 0.6) with the top three MRE11A SNPs in Ricceri et al’s 
work.  
 
There are two expressed isoforms of MRE11A transcripts: isoform 1 (4772 bases: 
shorter 5’UTR and exon 16 expressed) and isoform 2 (4668 bases: longer 5’UTR and 
exon 16 not expressed). However, there are no published data available on the 
relative expression or the functional differences of these two isoforms. As rs1805363 
was situated only five bases from the 3’ terminal of exon 1 in isoform 1 of MRE11A, it 
was postulated that this SNP may influence the MRE11A isoform expressed. PCR 
amplification of isoforms 1 and 2 in cDNA from wildtype bladder cancer cell lines and 
primary bladder tumours from heterozygote and minor allele homozygotes 
demonstrated a clear functional effect of rs1805363 on isoform expression with a 
reduction in isoform 1 expression with each minor allele carried. However, what 
remains unclear is why this relative change in isoform expression affects survival with 
several possible hypotheses raised: (1) Does isoform 2 result in more efficient DSB 
repair thus promoting cancer cell survival? (2) Alternatively, is isoform 1 the crucial 
factor for initiating the DSB repair cascade and cell death pathways thus reduction in 
isoform 1 results in the failure of cancer cells to initiate apoptosis after radiotherapy? 
(3) The MRN complex exists as a heterotetramer with two MRE11 molecules (Lavin 
2007). Are both isoforms 1 and 2 required in the MRN complex for complex stability 
or DSB detection with a critical balance needed in relative expression (hence the 
smaller effect on survival in heterozygotes)? These will require further investigation to 
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understand the role of these isoforms in DSB repair following radiotherapy treatment 
and to identify any potential therapeutic targets. 
 
This was the first study demonstrating an association of germline rare variants with 
radiotherapy outcomes. Borgmann et al previously sequenced the cDNA of several 
DSB repair genes for germline mutations associated with late normal tissue radiation 
toxicity in head and neck cancer but failed to identify any MRE11 coding variants 
(Borgmann et al. 2002). In contrast, we identified three known and one novel coding 
rare variants in our study, three of which are non-synonymous (Table 43). There are 
only nine MRE11A non-synonymous coding variants reported in the dbSNP database 
(http://www.ncbi.nlm.nih.gov/snp/), all with MAFs under 1%, indicating a high 
negative selection pressure against coding variants. Coding MRE11A mutations, 
after all, cause the rare Ataxia-Telangiectasia Like Disorder, associated with genomic 
instability and hypersensitivity to ionising radiation (Delia et al. 2004). Collapsed 
analysis of the coding rare variants in this study did not reveal any significant 
association with radiotherapy outcomes but this could be due to only five individuals 
carrying these rare variants. One known and five novel rare variants in the 3’UTR of 
MRE11A were also identified and were associated with survival following 
radiotherapy (Table 41). However, only one of these was predicted to affect miRNA 
binding (Table 43). If confirmed to affect miRNA binding, this would be in keeping 
with the previously demonstrated association with MIBC survival following RT 
treatment of another DNA repair gene 3’UTR SNP, RAD51 rs7180135, which was 
predicted to be within a miRNA binding site (Teo et al. 2012).  
 
This study demonstrated the first use of NGS technology for the in-depth 
investigation of germline common and rare variants within a candidate gene for 
potential biomarkers of radiotherapy outcomes. Currently, only three other studies, all 
investigating haematological malignancies, have applied NGS technology to 
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investigate for potential prognostic biomarkers specifically, leukaemic transformation 
in myelodysplasia (Jadersten et al. 2011) and chronic myelomonocytic leukemia 
(Kohlmann et al. 2010; Smith et al. 2010).  With rising read lengths, paired end 
sequencing technology and higher throughput sample preparation, it would be 
possible for larger targets and larger multiplexing sequencing reactions, hence, larger 
discovery studies  thus accelerating the discovery of new predictive and prognostic 
markers (Harakalova et al. 2011; Rivas et al. 2011). With diagnostic laboratories 
using this technology for clinical genetic testing (Morgan et al. 2010; Ozcelik et al. 
2012), the widespread use of next generation sequencing to aid clinical decision 
making is imminent (Human Genomics Strategy Group 2012). 
 
The main limitation of this study was the relatively small sample sizes and the 
inability to validate the findings in a separate RT treated MIBC study population. 
Muscle-invasive bladder cancer is an uncommon cancer, thus achieving the numbers 
seen in more common tumour sites is difficult, as demonstrated by two of the three 
most recent multi-centre phase III radiotherapy clinical trials on bladder cancer 
struggling to recruit and closing early (Huddart et al. 2010; James et al. 2012). 
However, there remains a need to validate if rs1805363 is a true predictive marker of 
radiotherapy response in a second independent radiotherapy treated MIBC cohort. 
Unfortunately, none of the recent or on-going phase III radiotherapy clinical trials on 
bladder cancer collected germline DNA samples for translational research (Huddart 
et al. 2009; Hoskin et al. 2010). As all cancers would be expected to mount a DNA 
repair response following radiotherapy, it was hypothesised that rs1805363, if a true 
predictive marker of radiotherapy response, would potentially be also predictive of 
survival in other radiotherapy treated cancers. 
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Wibom et al investigated 1458 DNA repair gene tag SNPs for associations with 
survival in a Swedish and Danish cohort of glioblastoma cases (Wibom et al. 2012). 
Rs1805363 was not genotyped in this study but of note, eight of the 11 MRE11A 
SNPs genotyped were significant in their predominantly radiotherapy treated test 
cohort. However, these findings were not validated in their validation cohort though 
no treatment details were available in this cohort. A collaboration has thus been set 
up with Professor Mellin’s group to validate rs1805363 as a marker of radiotherapy 
response in the radiotherapy treated GBM cases of the test cohort. The results of this 
collaboration are eagerly awaited. 
 
The low number of patients in the MIBC radiotherapy cohort receiving neo-adjuvant 
or concurrent chemotherapy allowed the specific assessment of the identified 
variants on RT response. However, whether the current standard of neo-adjuvant 
chemotherapy treatment and the likely introduction of concurrent chemotherapy and 
radiosensitisers would affect the predictive value of the identified MRE11A variants 
by involvement of other repair pathways thus bypassing the dependence on MRE11 
remains unclear.  
 
In summary, this study, using NGS technology, demonstrated germline MRE11A 
SNPs and rare variants as potential markers of radiotherapy outcomes and toxicity in 
muscle-invasive bladder cancer. Of note, carriage of the MRE11A rs1805363 minor 
A allele was found to be predictive of poor radiotherapy outcomes but not surgery in 
MIBC patients, and was shown to affect relative MRE11A  isoform expression. 
Further validation of rs1805363 is urgently needed for its translation into a clinical 
predictive tool for personalised medicine.  
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8.5. Tumour DNA repair protein expression as a marker of 
radiotherapy response 
 
Dr Kiltie’s group had previously studied MIBC tumour expression of several DNA 
repair proteins involved in BER and DSB repair for associations with bladder cancer 
specific survival following RT treatment demonstrating several associations with  
survival (Sak et al. 2005; Choudhury et al. 2010). The current study thus investigated 
several other candidate DNA repair proteins as potential markers of MIBC RT 
outcomes, specifically CtIP, MUTYH and XPC.  
 
These candidate DNA repair proteins were selected due to their potential direct or 
indirect influence on DSB repair. CtIP is closely involved with MRE11 in DSB end 
resection and processing (Sartori et al. 2007; Zha et al. 2009) and is associated with 
BRCA1 in regulating DSB repair pathway choice (Yu and Baer 2000; Yun and Hiom 
2009). Ionising radiation forms clusters of oxidative base damage surrounding SSBs 
or DSBs which slows DSB repair as well as potentially generating further DSBs 
during repair (Gulston et al. 2004; Harrison et al. 2006; Eccles et al. 2011). MUTYH 
was thus investigated due to its involvement in the repair of the most common 
oxidative base lesion, 8-oxoG. Besides its role in GGR-NER, XPC has also been 
indicated to modulate DSB repair (Despras et al. 2007; Zhang et al. 2009).  
 
8.5.1. Study population demographics 
The study population consisted of non-metastatic MIBC patients treated by radical 
RT between 2002 and 2005 in Leeds. Clinical FFPE tumour blocks taken at pre-
treatment TURBT were available for 88 individuals for CtIP. However, six blocks had 
too little tissue left, and so were dropped from further investigation for MUTYH and 
XPC. In the cohort of 88 individuals with 34 CSS events, assuming 75% of 
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individuals had high expression and 25% had low expression, this study had a power 
of 86.5% to detect a HR of 2.5 at the 5% significance level. For the reduced cohort 
size of 82 individuals with 33 CSS events, with the same division of protein 
expression and same significance level, the study had a power of 84.4% to detect a 
HR of 2.5. The study demographics are shown in Table 46. 
Table 48: Clinical demographics of bladder cancer patients treated by radical RT 
between 2002 and 2005 with available pre-treatment TURBT FFPE tumour blocks.  
Variable 
Study population (N=88) 
No of patients (%) 
Age (years) Median (range) 78.2 (55.7 - 89.9) 
Gender Male 67 (76.1) 
 Female 21 (23.9) 
Tumour stage T1 2 (2.3) 
 T2 48 (54.5) 
 T3 29 (33) 
 T4 9 (10.2) 
Nodal stage N0 84 (95.5) 
 N1 2 (2.3) 
 N2 2 (2.3) 
Histological 
grade 
G3 76 (86.4) 
<G3 9 (10.2) 
Gx 3 (3.4) 
Hydronephrosis No 58 (65.9) 
 Yes 30 (34.1) 
Neoadjuvant/ 
concurrent 
therapy 
None 73 (83) 
Neoadjuvant chemotherapy 8 (9.1)a 
Concurrent chemotherapy/ 
radiosensitiser 
7 (8)b 
Salvage 
chemotherapy 
Not received 83 (94.3) 
Received 5 (5.7) 
Salvage 
cystectomy 
Not received 83 (94.3) 
Received 5 (5.7) 
a All received platinum based combination chemotherapy. 
b 6 patients received concurrent gemcitabine (100 mg/m2 ) weekly ×4 as part of a 
phase II clinical trial and one patient received concurrent carbogen and nicotinamide 
as part of the BCON phase III clinical trial. 
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8.5.2. Antibody specificity validation and optimisation 
Antibody specificity was validated using cell line extracts by Western blotting (Figure 
44). Corresponding FFPE cell line pellets were then made and used as positive 
controls and IHC protocols optimised using these positive controls (see Methods 
section 7.3). 
 
Figure 44: Western blots of cell line extracts for MUTYH (top left, blue), CtIP (top right, 
white) and XPC (bottom, red). Non-specific band (green) noted with anti-XPC antibody. 
XPC western blot was performed by Dr J Bentley and Ms M McCarthy. 
 
As shown in Figure 44, the anti-XPC antibody had a second unspecified band on 
Western blotting so a cell pellet of the known null-XPC expressing GM15983 cell line 
was used as a separate negative control tissue for IHC protocol optimisation. Stained 
positive control cell pellets with the respective antibodies are shown in Figure 45. 
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Figure 45: Stained positive control (and negative control in the case of GM15983) cell 
line pellets for MUTYH, CtIP and XPC. 
 
8.5.3. Bladder tumour CtIP, MUTYH and XPC expression 
Tumour DNA repair protein expression was graded using a multiplicative SQS (see 
Methods chapter 7.3.7). Nuclear CtIP expression varied across the cohort with a 
median SQS of 3 (range: 0 – 12). Of interest, among CtIP expressing malignant cells 
within the same bladder tumour, some bladder cancer cells had distinct nuclear foci 
of CtIP (Figure 46A) while others had a diffuse expression throughout the nucleus 
(Figure 46B). The significance of these foci are unclear but previous associations 
have been reported of nuclear CtIP foci with S-phase replication forks (Gu and Chen 
2009) and Akt signalling (Xu et al. 2007). In contrast, most tumours had low nuclear 
MUTYH expression with 74.4% of tumours having an SQS of 0 or 1 (range: 0 – 10.5) 
but just over half (51.2%) of tumours had cytoplasmic MUTYH expression (Figure 
46C and D). Tumour nuclear XPC expression was relatively evenly spread with a 
median SQS of 6 (range: 1 – 12). No associations were found between CtIP, MUTYH 
and XPC expression levels with tumour stage or histological grade (P = 0.54 and 
0.22; 0.13 and 0.67; and 0.89 and 0.86 respectively). 
MUTYH CtIP XPC
HeLa Daudi GM15983 Daudi
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Figure 46: Representative images of variation in nuclear CtIP staining and MUTYH 
cytoplasmic staining: A) Bladder tumour nuclear CtIP expression with the presence of 
distinct foci (white arrow), B) Diffuse nuclear CtIP expression in malignant cells from 
the same bladder tumour, C) Absent MUTYH cytoplasmic expression, and (D) Positive 
MUTYH cytoplasmic expression. 
A)
D)
B)
C)
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8.5.4. Association with cancer-specific survival 
 
Figure 47: Kaplan-Meier survival curves of CSS for CtIP, XPC and MUTYH: A) SQS 
quartiles of CtIP expression, B) SQS quartiles of XPC expression, C) SQS of one or 
less versus greater than one for nuclear MUTYH expression, and D) absent versus 
present cytoplasmic MUTYH expression. 
 
Nuclear CtIP and XPC expression SQS were divided into quartiles and analysed for 
any trend of increasing protein expression with CSS (Figure 47A and B) but no 
significant associations were found (P = 0.43 and 0.84 respectively). For nuclear 
MUTYH expression, “low” expressing tumours with SQS of less than or equal to one, 
were compared with “high expressing” tumours with SQS greater than one. Once 
again, no significant associations were found with CSS (P = 0.85, Figure 47C) nor 
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were there any associations with the presence or absence of cytoplasmic expression 
(P = 0.94, Figure 47D).  
 
8.5.5. Discussion 
This study investigating three candidate DNA repair proteins involved in DSB repair, 
BER and NER found no significant associations between the three candidate 
proteins, CtIP, MUTYH and XPC, with cancer-specific survival following radical 
radiotherapy treatment for MIBC.  
 
CtIP’s involvement in DSB end resection and processing with MRE11, previously 
shown to be predictive of CSS in MIBC following RT (Choudhury et al. 2010; 
Laurberg et al. 2012) highlighted CtIP as a potential candidate for investigation. On 
top of this, CtIP’s also regulates DSB repair HRR or NHEJ pathway choice (Yu and 
Baer 2000; Yun and Hiom 2009), and maintains S-phase/ G2-phase cell cycle 
checkpoints following DNA damage (Kousholt et al. 2012).  This negative result may 
indicate that MRE11’s position upstream of CtIP in the DSB repair pathway and its 
regulation of CtIP phosphorylation by CDK2 (Buis et al. 2012), supersedes any 
influence CtIP levels have on DSB repair and cancer cell survival. Only one study 
has looked at CtIP expression in primary human tumours with clinical outcomes, 
observing an association with response to endocrine treatment in breast cancer (Wu 
et al. 2007). However, in that study, CtiP expression levels were based on 
cytoplasmic staining of CtIP which is peculiar as CtIP is supposed to be only 
localised within the nucleus (Yu and Baer 2000).  
 
What remains unclear is the significance of the observed diffuse CtIP nuclear 
staining versus CtIP nuclear foci. The CtIP SQS scoring used did not differentiate 
between the two forms of staining in scoring if a malignant cell was positive or 
negative for CtIP expression. The formation of CtIP foci following ionising radiation in 
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cancer cell lines could suggest that scoring of these foci, either by the number of foci 
per cell or cells with CtIP foci, could potentially be a better measure of CtIP activity 
(Yuan and Chen 2009). 
   
MUTYH, as previously mentioned, is involved in maintaining genomic stability by 
detecting 8-oxoG following oxidative damage and excising any mispaired A during 
replication which results in an abasic site. The repair of this abasic site results in the 
formation of a SSB (David et al. 2007; Hegde et al. 2008), which in regions of 
clustered DNA damage as in following IR, the presence of a SSB on the sister strand 
could result in the formation of additional lethal DSBs (Gulston et al. 2004; Harrison 
et al. 2006; Eccles et al. 2011). Expression of both nuclear and mitochondrial 
MUTYH was assessed in this study. High nuclear MUTYH expression has previously 
been associated with better prognosis in gastric cancer (Shinmura et al. 2011). 
Mitochondrial MUTYH in cancer prognosis has not been previously researched but 
mitochondrial genetic instability has been linked with improved survival in Duke’s C 
colorectal cancer (Tsai et al. 2009). Mitochondrial dysfunction, secondary to 
mitochondrial genetic instability, results in impaired p53 function and IR-induced cell 
death (Kim et al. 2006; Compton et al. 2011).  
 
However, this report did not find any correlation of nuclear or mitochondrial MUTYH 
with radiotherapy outcomes in MIBC. MUTYH would only be active during DNA 
replication (ie. S-phase) thus any additional DSBs formed could be compensated by 
the activity of HRR. Also studies in Escherichia coli found that clustered 8-oxoG 
lesions with or without uracil mispairing did not result in the formation of DSBs 
(Malyarchuk et al. 2004), which could account for the result seen in this study. 
 
Besides its activity in NER, XPC has been implicated in the repair of DSBs and 
oxidative base damage (D'Errico et al. 2006; Despras et al. 2007; Zhang et al. 2009). 
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Despite this, no association was found in this study with prognosis following RT 
treatment. Several other studies have examined XPC expression in cancer outcomes 
though not in relation to radiotherapy. Yang et al in a study of 66 bladder tumours, 
with over a third being superficial non-invasive disease, reported associations of null 
XPC expression with worse bladder cancer pathological grade and prognosis (Yang 
et al. 2010). However, the XPC expression seen in the MIBC RT cohort 
(predominantly high grade disease) did not correlate with Yang et al’s findings with 
only four tumours having less than 10% of malignant cells expressing XPC. In breast 
cancer, one study reported lower XPC expression in malignant cells compared to 
normal breast tissue, but no correlation was seen with survival on multivariate 
analysis (Bai et al. 2012).  
 
Studies investigating XPC and chemosensitivity (predominantly platinum-based 
chemotherapy) have been more fruitful with several SNP studies reporting 
associations with survival in breast, ovarian and lung cancer (Dong et al. 2012; 
Fleming et al. 2012; Yang et al. 2012). Lai et al reported decreased cisplatin 
chemotherapy response and survival in lung adenocarcinomas with high tumour XPC 
expression (Lai et al. 2011). Only 8 individuals in the MIBC RT cohort received 
platinum-based chemotherapy but with current practice recommending neoadjuvant 
cisplatin-based chemotherapy (Vale and ABC Meta-analysis Group 2005) and 
interest in the use of concurrent cisplatin chemoradiotherapy (Efstathiou et al. 2012), 
XPC expression as a possible prognostic/ predictive marker of the added benefit of 
chemotherapy in these groups may be of future clinical significance. 
 
Studies of tumour expression of multiple DNA repair proteins have been investigated 
for markers of radiotherapy or chemoradiotherapy outcomes in cervical carcinoma, 
glioblastoma, oesophageal cancer and squamous cell carcinomas of the head and 
neck, with associations seen with DNA-PK, ERCC1, ERCC4, Ku80 and PARP1 
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(Kase et al. 2011; Liang et al. 2011; Moeller et al. 2011; Sun et al. 2011; Vaezi et al. 
2011; Alexander et al. 2012). In MIBC, as previously mentioned, Dr Kiltie’s group had 
initially found that tumours with a “high” percentage of positive nuclear staining 
malignant cells for APE1 and XRCC1 was associated with CSS following RT (Sak et 
al. 2005). High MRE11 expression was then identified and validated as a predictive 
biomarker of better CSS following RT in two radiotherapy cohorts but not following 
cystectomy treatment (Choudhury et al. 2010). This finding was further validated by 
an independent group who also identified high expression of TIP60 acetyltransferase, 
which is involved in multiple signalling pathways including DSB repair, histone 
acetylation and chromatin modelling, as predictive of improved CSS following 
cystectomy but not following RT (Sun et al. 2010; Laurberg et al. 2012). These 
biomarkers are currently under development.  
 
One of the strengths of this study was that immunohistochemistry protocols and 
scoring methods are widely used clinically and in research thus are well validated. 
However, one of the main limitations was the difficulties in identifying adequately 
robust antibodies for immunohistochemistry. Immunohistochemistry antibody choice 
was based, as recommended, on the specificity seen on Western blotting on a 
complex protein sample such as cell line lysates, with minimal non-specific cross-
reaction bands seen (Kurien et al. 2011; Signore and Reeder 2012). However, 
antibodies for Western blotting are designed to target short linear amino acid 
sequences under reducing conditions. These antibodies may thus not bind to protein 
in its tertiary conformation as in during immunohistochemistry. In turn, antibodies with 
non-specific binding on Western blotting may have specific binding to only the target 
protein on immunohistochemistry. For this study, what was thus unclear, for example, 
was whether the weak MUTYH staining throughout the cohort truly representative of 
low MUTYH expression or just representative of differences in antibody activity 
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between application types. Without fully profiled control FFPE tissue, it was very 
difficult to be confident of the specificity of an antibody for immunohistochemistry.  
 
Another difficulty encountered was the reliability of manufacturer datasheets for the 
selection of suitable antibodies for validation. During preliminary validation for an 
OGG1 antibody, the most cited anti-OGG1 antibody used for immunohistochemistry 
(Li et al. 2001; Fukae et al. 2005; Sheehan et al. 2005) was tested by Western 
blotting using the manufacturer recommended positive control cell lysate.  This 
revealed a very weak target band and two much stronger non-specific bands (Figure 
48, Lane A) not seen on the manufacturer’s datasheet (Figure 48, Lane B) yet 
present on the supplier’s internal quality assurance blot (Figure 48, Lane C). The 
significance of these non-specific bands on immunohistochemistry was unknown but 
raised questions on the reliability of previously published work plus highlights the 
costs and time required to identify and validate viable antibodies for a project with in 
this case, OGG1 being dropped from further investigation. 
 
Figure 48: Western blots using rabbit polyclonal anti-OGG1 antibody on manufacturer 
recommended cell line lysate. Lane A: Experimental western blot; Lane B: 
Manufacturer’s supplied datasheet western blot image; Lane C: Supplier’s internal 
quality assurance western blot image on request. 
 
A B C
OGG1
Non-specific
bands
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It is likely that the majority of clinically relevant predictive tools will consist of a panel 
of biomarkers, each with moderate predictive power, rather than a single biomarker 
with strong predictive power (Shariat et al. 2010). However, this study investigated 
only three candidate proteins in a small study size with power to detect only 
biomarkers with relatively large effects. It is thus possible that smaller yet clinically 
relevant effects could have been missed. Pathway-based strategies or larger panels 
could thus potentially yield greater success (Choudhury et al. 2010; Moeller et al. 
2011; Alexander et al. 2012). Due to the heterogeneity inherent within bladder 
tumours (Jones et al. 2005), the high-throughput advantages of using tissue 
microarrays for MIBC is limited as selected tumour cores may not be representative 
of the whole tumour hence the use of tissue sections in this study. This potentially 
limits the project’s sample size, statistical power and number of candidate markers 
studied based on available time and resources. Due to the subjective nature of 
differentiating malignant cells from surrounding stroma, inflammatory or immune 
cells, the use of current automated scoring software was also not feasible to help 
boost throughput and study power. 
 
In summary, MIBC tumour expression of three candidate DNA repair proteins, CtIP, 
MUTYH and XPC were investigated for potential markers of CSS following RT 
treatment with no significant associations found. Further research potentially studying 
larger target protein panels and sample sizes would be useful for the identification of 
new potential biomarkers.   
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9. General discussion and future work 
Genetic instability is one of the ten hallmarks of cancer and is probably the most 
important (Hanahan and Weinberg 2011). It triggers the mutational changes required 
for the acquisition and progression of the other nine hallmarks. Cytotoxic agents and 
radiotherapy treatment work in the therapeutic window created by the differential 
capability to repair DNA damage generated by these treatment modalities in 
genetically unstable cancer cells compared to genetically stable normal cells, thus 
balancing cancer cell kill versus damage to normal tissues. The maintenance of 
genomic stability by the DNA repair pathways is thus integral to prevention of 
carcinogenesis (Hoeijmakers 2001; Bristow and Harrington 2005) as well as 
determining treatment response to radiotherapy (Steel 2002; Hall and Giaccia 2006). 
This thesis investigated the role of germline genetic variants in DNA repair genes on 
bladder cancer inherited risk, and DNA repair germline genetic variants and tumour 
protein expression in bladder cancer survival following RT treatment.  
 
The CDCV hypothesis had been the premise of all GWAS studies on the genetic 
inheritability of bladder cancer (Kiemeney et al. 2008; Wu et al. 2009; Kiemeney et al. 
2010; Rothman et al. 2010; Garcia-Closas et al. 2011; Rafnar et al. 2011), while 
common DNA repair gene SNPs had been implicated in bladder cancer risk (Stern et 
al. 2009). However, the contribution of rare variants and the CDRV hypothesis had 
not been explored in bladder cancer but is now feasible with NGS technology. The 
NGS methods development study demonstrated the capability of what is already 
becoming out-dated technology for the cost-effective multiplexed sequencing of 
candidate genes for RVs, showing two approaches involving unindexed pooling or 
bar-coding technology, with the choice of approach based on balancing between 
costs and manual laboratory time versus accuracy and the need for genotype data 
respectively. However, unexpectedly the issue discovered was not one of detecting 
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RVs but of how to prioritise candidate RVs for further investigation from the hundreds 
detected. With non-coding variants being the most frequent RVs encountered, the 
limited bioinformatics functional prediction tools available made prioritisation of these 
variants very arbitrary. Unfortunately, the Syzygy software generated Chi2-value for 
detected RVs proved not to be an effective predictor of disease susceptibility RVs. 
Other equivalent NGS studies of common diseases, have either just described the 
discovered RVs (Kelleher et al. 2012; Lotta et al. 2012), gone on to genotype just 
novel variants (Doyle et al. 2012), or to pay the costs to perform large-scale 
genotyping of most/ all detected RVs with mixed results (Rivas et al. 2011; Heinzen 
et al. 2012).  
 
What also remains unclear is whether the current recommended two-stage design of 
RV, namely RV discovery followed by genotyping in a large case-control study, 
represents the best approach for future disease risk RV discovery. This protocol has 
been based on trying to maximise cost-efficacy for NGS use (Kang et al. 2012) and 
statistical power (Yang and Thomas 2011). With the rapid development in newer, 
higher throughput and automated technology, such as “third” generation sequencing 
platforms (Pareek et al. 2011), larger scale target-enrichment methods (Mamanova 
et al. 2010) and automated library preparation protocols, undertaking a large scale 
whole genome sequencing studies does not seem far away. This technological surge 
will require the development of newer protocols, study designs and analytical tools 
for the handling and filtering of the immense data load for what is clinically relevant. 
With falling sequencing costs, a two stage sequencing study could soon be feasible 
with whole genome sequencing of an enriched population followed by multiplexed 
sequencing of candidate genes with an over-/under-representation of RVs in the 
enriched population in a larger case-control study. 
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Investigation of the CDRV hypothesis in bladder cancer genetic susceptibility 
specifically looking at two DNA repair genes, MUTYH and XPC, yielded mixed 
results. Collapsed analysis of XPC RVs found an association with increased bladder 
cancer risk as previously found by the group (Qiao et al. 2011), but the effect seen 
was far smaller than predicted by the CDRV hypothesis. However, this effect size 
emulated some of the results found in other RV studies (Rivas et al. 2011). 
Surprisingly, MUTYH was not associated with bladder cancer risk despite multiple 
associations of MUTYH RVs with colorectal cancer and other cancer types (Vogt et 
al. 2009; Pervaiz et al. 2010; Theodoratou et al. 2010; Win et al. 2011; Castillejo et 
al. 2012; Rennert et al. 2012). Like all RV association studies, this study was 
severely limited by having insufficient samples to achieve statistical power with a 
power of only 69% for an OR of 2.0 at a RV MAF of 0.01, thus the negative result 
does not exclude the involvement of MUTYH RVs in bladder cancer risk. 
 
miRNAs mediate post-transcriptional regulation and are observed to be dysregulated 
in bladder cancer (Catto et al. 2009; Catto et al. 2011) with SNPs in miRNA-related 
and biogenesis genes increasing bladder cancer risk (Yang et al. 2008). What had 
not yet been investigated was how SNPs in DNA repair gene miRNA-binding sites 
could affect bladder cancer susceptibility by altering miRNA-binding and DNA repair 
gene expression. Examination of putatively functional 3’UTR SNPs in DNA repair 
genes found the BER genes, PARP1 rs8679 and LIG3 rs4796030, to be associated 
with increased bladder cancer risk, with an additive effect seen with carriage of both 
SNPs. However, functional predictions of miRNA binding propose an increase in 
expression of these two genes in carriers of these SNPs which would be expected to 
increase DNA repair thus reduce mutation and cancer risk, the reverse effect on 
bladder cancer risk to what was seen. It was thus hypothesised that increased 
PARP1 and LIG3 expression due to LIG3 rs4796030 and PARP1 rs8679 could 
possibly promote DSB repair via the MMEJ over the classical NHEJ pathway 
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resulting in more error-prone repair and mutagenesis. Overexpression of PARP1 had 
been shown to promote MMEJ over classical NHEJ (Wang et al. 2006), while 
increased MMEJ repair in peripheral blood lymphocytes had been observed in 
women with breast cancer or with a familial risk of bladder cancer potentially 
implicating MMEJ repair in cancer susceptibility (Keimling et al. 2012). Since this 
study, SNPs in miRNA-binding sites in NER genes have been implicated in colorectal 
cancer risk (Naccarati et al. 2012) thus emphasising the influence of miRNAs on 
DNA repair gene activity and overall cancer risk. 
 
These case-control studies reinforce the contribution of DNA repair gene variants in 
bladder cancer risk despite none being detected by the bladder cancer GWAS 
studies.  However, further work is needed to validate the results reported here. Due 
to the population specific nature of RVs, validation of RVs in other ethnically similar 
cohorts would be required. To this purpose, preliminary results of this study were 
recently presented at the International Bladder Cancer Consortium meeting. 
Experimental studies assessing the functional consequences of RVs would be highly 
useful not just to corroborate significant associations but as a method to prioritise 
candidate variants for genotyping and to provide an a priori weighting in statistical 
analyses thus potentially boosting statistical power (Cooper and Shendure 2011; Zhu 
et al. 2011). In a similar way, functional assays will be needed to assess the effects 
of rs8679 and rs4796030 on PARP1 and LIG3 expression respectively, as well as 
any influence on choice of MMEJ over NHEJ repair of DSBs. 
 
DNA repair is one of the 5 R’s of radiobiology for determining cancer response to 
radiotherapy (Steel 2002). In MIBC, with there being no clear evidence of superiority 
of cystectomy over radiotherapy or vice-versa, predictive biomarkers of radiotherapy 
responders are needed to aid clinicians in personalising treatment for each patient, 
thus reducing morbidity of ineffective or over-invasive treatment and decreasing 
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delay (and risk of metastasis) to receiving optimum treatment. The study of putatively 
functional DNA repair gene 3’UTR SNPs identified RAD51 rs7180135 as a marker of 
good prognosis following radiotherapy treatment with functional predictions of this 
SNP resulting in stronger miR-197 binding thus decreased RAD51 expression. This 
would fit with other studies demonstrating increased radiosensitivity of tumour cell 
lines following RAD51 knockdown (Short et al. 2011) but also highlighted miR-197 as 
a possible therapeutic target for radiosensitisation. 
 
Following the success in identifying tumour MRE11 protein expression (Choudhury et 
al. 2010) and previously unpublished work on MRE11A SNPs as predictive markers 
of RT outcomes by Dr Kiltie’s group, multiplexed NGS of MRE11A was undertaken to 
interrogate this candidate gene in detail for SNPs and RVs associated with RT 
outcomes. This proved to be a successful endeavour identifying MRE11A rs1805363 
G>A as being predictive of CSS following RT but not cystectomy, and functional 
studies went on to demonstrate its effect on MRE11A mRNA isoform expression. 
These results support the small number of studies demonstrating associations of 
inherited DNA repair gene SNPs with treatment response (Parliament and Murray 
2010) thus highlighting the potential of developing a panel of genetic markers for the 
prediction of radiotherapy response in the future. 
  
Unfortunately, investigation of the tumour protein expression of three DNA repair 
proteins, CtIP, MUTYH and XPC, did not reveal any correlation of tumour protein 
expression with radiotherapy outcomes unlike previous work by Dr Kiltie’s group in 
this area (Sak et al. 2005; Choudhury et al. 2010). These proteins have never been 
investigated before for associations with radiotherapy outcomes in any cancer. 
Though not predictive of radiotherapy outcomes, XPC expression was previously 
associated with increased cisplatin chemotherapy resistance in adenocarcinomas of 
the lung (Lai et al. 2011). It could thus still have a role in determining patients who 
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would benefit from cisplatin as part of neo-adjuvant chemotherapy or concurrent 
chemo-radiotherapy regimes. 
 
Future work is needed to validate MRE11A rs1805363 and RAD51 rs7180135 as 
markers of radiotherapy outcomes. Due to the unavailability of other cohorts of 
radiotherapy treated MIBC, collaborations are under way exploring the role of the 
MRE11A SNP rs18053636 as a potential universal marker of radiotherapy response 
due to the central role of MRE11 in DSB repair. Ultimately, this SNP will need to be 
validated as part of a prospective clinical trial to assess its true applicability in the 
clinical environment. 
 
A greater understanding of the inherited risk determinants of bladder cancer will allow 
the risk stratification of individuals for the targeted screening of high risk sub-
populations for earlier diagnosis or the monitoring of only patients at high risk of 
recurrence thus reducing the morbidity of repeated invasive cystosopic procedures 
with the associated high costs to stretched healthcare budgets. Improved prediction 
of RT treatment outcomes in MIBC could spare individuals from either having to 
endure the morbidity of four or more weeks of ineffective RT treatment, or the 
morbidity of having a urostomy following a cystectomy when bladder function could 
have been preserved by RT treatment. This individualisation of MIBC treatment could 
also result in an overall improvement in bladder cancer survival. This study has 
shown the genetic contributions of DNA repair gene SNPs that influence post-
transcriptional regulation and RVs on bladder cancer risk as well as identifying 
potentially new clinical genetic markers for predicting RT outcomes in MIBC.  
 224 
10. References 
Aben, K. K., J. A. Witjes, M. P. Schoenberg, C. Hulsbergen-van de Kaa, A. L. 
Verbeek and L. A. Kiemeney (2002). "Familial aggregation of urothelial cell 
carcinoma." Int J Cancer 98(2): 274-278. 
Al-Tassan, N., N. H. Chmiel, J. Maynard, N. Fleming, A. L. Livingston, G. T. Williams, 
et al. (2002). "Inherited variants of MYH associated with somatic G:C-->T:A 
mutations in colorectal tumors." Nat Genet 30(2): 227-232. 
Alexander, B. M., X. Z. Wang, A. Niemierko, D. T. Weaver, R. H. Mak, K. S. Roof, et 
al. (2012). "DNA repair biomarkers predict response to neoadjuvant 
chemoradiotherapy in esophageal cancer." Int J Radiat Oncol Biol Phys 
83(1): 164-171. 
Ali, M., H. Kim, S. Cleary, C. Cupples, S. Gallinger and R. Bristow (2008). 
"Characterization of mutant MUTYH proteins associated with familial 
colorectal cancer." Gastroenterology 135(2): 499-507. 
Alsner, J., C. N. Andreassen and J. Overgaard (2008). "Genetic markers for 
prediction of normal tissue toxicity after radiotherapy." Semin Radiat Oncol 
18(2): 126-135. 
Amstutz, U., G. Andrey-Zurcher, D. Suciu, R. Jaggi, J. Haberle and C. R. Largiader 
(2011). "Sequence capture and next-generation resequencing of multiple 
tagged nucleic acid samples for mutation screening of urea cycle disorders." 
Clin Chem 57(1): 102-111. 
Audebert, M., B. Salles and P. Calsou (2004). "Involvement of poly(ADP-ribose) 
polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA 
double-strand breaks rejoining." J Biol Chem 279(53): 55117-55126. 
Babjuk, M., W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou and M. 
Rouprêt (2011). Guidelines on non-muscle invasive bladder cancer (TaT1 
and CIS), European Association of Urology. 
Bai, X., F. Jin, Y. Fu, Z. Yu, L. Zhao, J. Ren, et al. (2012). "Clinicopathological 
significance and prognostic value of Xeroderma pigmentosum complementary 
group C (XPC) expression in sporadic breast cancer patients." Med Oncol 
29(3): 1543-1553. 
Bakkar, A. A., H. Wallerand, F. Radvanyi, J. B. Lahaye, S. Pissard, L. Lecerf, et al. 
(2003). "FGFR3 and TP53 gene mutations define two distinct pathways in 
urothelial cell carcinoma of the bladder." Cancer Res 63(23): 8108-8112. 
Bansal, V., O. Libiger, A. Torkamani and N. J. Schork (2010). "Statistical analysis 
strategies for association studies involving rare variants." Nat Rev Genet 
11(11): 773-785. 
Barnett, G. C., C. E. Coles, R. M. Elliott, C. Baynes, C. Luccarini, D. Conroy, et al. 
(2012). "Independent validation of genes and polymorphisms reported to be 
associated with radiation toxicity: a prospective analysis study." Lancet Oncol 
13(1): 65-77. 
Barrett, J. H. and J. Nsengimana (2011). "Two-stage analyses of sequence variants 
in association with quantitative traits." BMC Proc 5 Suppl 9: S53. 
Barrett, J. H., G. Smith, R. Waxman, N. Gooderham, T. Lightfoot, R. C. Garner, et al. 
(2003). "Investigation of interaction between N-acetyltransferase 2 and 
heterocyclic amines as potential risk factors for colorectal cancer." 
Carcinogenesis 24(2): 275-282. 
Begg, A. C. (2012). "Predicting recurrence after radiotherapy in head and neck 
cancer." Semin Radiat Oncol 22(2): 108-118. 
Bentley, J., C. P. Diggle, P. Harnden, M. A. Knowles and A. E. Kiltie (2004). "DNA 
double strand break repair in human bladder cancer is error prone and 
involves microhomology-associated end-joining." Nucleic Acids Res 32(17): 
5249-5259. 
 225 
Bentley, J., C. L'Hote, F. Platt, C. D. Hurst, J. Lowery, C. Taylor, et al. (2009). 
"Papillary and muscle invasive bladder tumors with distinct genomic stability 
profiles have different DNA repair fidelity and KU DNA-binding activities." 
Genes Chromosomes Cancer 48(4): 310-321. 
Bergink, S., W. Toussaint, M. S. Luijsterburg, C. Dinant, S. Alekseev, J. H. 
Hoeijmakers, et al. (2012). "Recognition of DNA damage by XPC coincides 
with disruption of the XPC-RAD23 complex." J Cell Biol 196(6): 681-688. 
Bertagnolli, M. M., D. Niedzwiecki, C. C. Compton, H. P. Hahn, M. Hall, B. Damas, et 
al. (2009). "Microsatellite instability predicts improved response to adjuvant 
therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: 
Cancer and Leukemia Group B Protocol 89803." J Clin Oncol 27(11): 1814-
1821. 
Berwick, M. and P. Vineis (2000). "Markers of DNA repair and susceptibility to cancer 
in humans: an epidemiologic review." J Natl Cancer Inst 92(11): 874-897. 
Biomarker Definitions Working Group (2001). "Biomarkers and surrogate endpoints: 
preferred definitions and conceptual framework." Clin Pharmacol Ther 69(3): 
89-95. 
Blandy, J. (1998). Bladder Cancer. Lecture Notes on Urology. Oxford, Blackwell 
Publishing: 161-175. 
Bodmer, W. and C. Bonilla (2008). "Common and rare variants in multifactorial 
susceptibility to common diseases." Nat Genet 40(6): 695-701. 
Bodmer, W. and I. Tomlinson (2010). "Rare genetic variants and the risk of cancer." 
Curr Opin Genet Dev 20(3): 262-267. 
Bonilla, C., J. H. Lefevre, B. Winney, E. Johnstone, S. Tonks, C. Colas, et al. (2011). 
"Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal 
cancer patients." J Hum Genet 56(1): 58-63. 
Borgmann, K., B. Roper, R. El-Awady, S. Brackrock, M. Bigalke, T. Dork, et al. 
(2002). "Indicators of late normal tissue response after radiotherapy for head 
and neck cancer: fibroblasts, lymphocytes, genetics, DNA repair, and 
chromosome aberrations." Radiother Oncol 64(2): 141-152. 
Botteman, M. F., C. L. Pashos, A. Redaelli, B. Laskin and R. Hauser (2003). "The 
health economics of bladder cancer: a comprehensive review of the published 
literature." Pharmacoeconomics 21(18): 1315-1330. 
Brennecke, J., A. Stark, R. B. Russell and S. M. Cohen (2005). "Principles of 
microRNA-target recognition." PLoS Biol 3(3): e85. 
Bristow, R. and L. Harrington (2005). Genomic Stability and DNA Repair. The Basic 
Science of Oncology. I. F. Tannock, R. P. Hill, R. Bristow and L. Harrington. 
Toronto, McGraw-Hill Medical Publishing: 77-99. 
British Association of Urological Surgeons and British Uro-oncology Group (2007). 
"MDT (Multi-disciplinary Team) Guidance for Managing Bladder Cancer." 
Brown, T., R. Slack and L. Rushton (2012). "Occupational cancer in Britain." British 
journal of cancer 107 Suppl 1: S76-84. 
Buis, J., T. Stoneham, E. Spehalski and D. O. Ferguson (2012). "Mre11 regulates 
CtIP-dependent double-strand break repair by interaction with CDK2." Nat 
Struct Mol Biol 19(2): 246-252. 
Burnet, N. G., R. M. Elliott, A. Dunning and C. M. West (2006). "Radiosensitivity, 
radiogenomics and RAPPER." Clin Oncol 18(7): 525-528. 
Calabro, F. and C. N. Sternberg (2009). "Neoadjuvant and adjuvant chemotherapy in 
muscle-invasive bladder cancer." Eur Urol 55(2): 348-358. 
Camenisch, U., D. Trautlein, F. C. Clement, J. Fei, A. Leitenstorfer, E. Ferrando-May 
and H. Naegeli (2009). "Two-stage dynamic DNA quality check by xeroderma 
pigmentosum group C protein." Embo J 28(16): 2387-2399. 
Cancer Research UK (2010). "Bladder cancer statistics - Key Facts." 
 226 
Capanu, M., P. Concannon, R. W. Haile, L. Bernstein, K. E. Malone, C. F. Lynch, et 
al. (2011). "Assessment of rare BRCA1 and BRCA2 variants of unknown 
significance using hierarchical modeling." Genet Epidemiol 35(5): 389-397. 
Carr, I. M., J. E. Morgan, C. P. Diggle, E. Sheridan, A. F. Markham, C. V. Logan, et 
al. (2011). "Illuminator, a desktop program for mutation detection using short-
read clonal sequencing." Genomics 98(4): 302-309. 
Cartwright, R. A., R. W. Glashan, H. J. Rogers, R. A. Ahmad, D. Barham-Hall, E. 
Higgins and M. A. Kahn (1982). "Role of N-acetyltransferase phenotypes in 
bladder carcinogenesis: a pharmacogenetic epidemiological approach to 
bladder cancer." Lancet 2(8303): 842-845. 
Carvajal-Carmona, L. G. (2010). "Challenges in the identification and use of rare 
disease-associated predisposition variants." Curr Opin Genet Dev. 
Castillejo, A., A. B. Sanchez-Heras, R. Jover, M. I. Castillejo, C. Guarinos, S. Oltra, 
et al. (2012). "Recurrent Testicular Germ Cell Tumors in a Family With MYH-
Associated Polyposis." J Clin Oncol 30(23): e216-217. 
Castillo-Martin, M., J. Domingo-Domenech, O. Karni-Schmidt, T. Matos and C. 
Cordon-Cardo (2010). "Molecular pathways of urothelial development and 
bladder tumorigenesis." Urol Oncol 28(4): 401-408. 
Catto, J. W., A. Alcaraz, A. S. Bjartell, R. De Vere White, C. P. Evans, S. Fussel, et 
al. (2011). "MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic 
Review." Eur Urol. 
Catto, J. W., S. Miah, H. C. Owen, H. Bryant, K. Myers, E. Dudziec, et al. (2009). 
"Distinct microRNA alterations characterize high- and low-grade bladder 
cancer." Cancer Res 69(21): 8472-8481. 
Chaplin, D. J., C. E. Peters, M. R. Horsman and M. J. Trotter (1991). "Drug induced 
perturbations in tumor blood flow: therapeutic potential and possible 
limitations." Radiother Oncol 20 Suppl 1: 93-101. 
Cheng, Q., N. Barboule, P. Frit, D. Gomez, O. Bombarde, B. Couderc, et al. (2011). 
"Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with 
DNA double-strand breaks." Nucleic Acids Res 39(22): 9605-9619. 
Chi, S. W., G. J. Hannon and R. B. Darnell (2012). "An alternative mode of microRNA 
target recognition." Nat Struct Mol Biol 19(3): 321-327. 
Chin, L. J., E. Ratner, S. Leng, R. Zhai, S. Nallur, I. Babar, et al. (2008). "A SNP in a 
let-7 microRNA complementary site in the KRAS 3' untranslated region 
increases non-small cell lung cancer risk." Cancer Res 68(20): 8535-8540. 
Choudhury, A., F. Elliott, M. M. Iles, M. Churchman, R. G. Bristow, D. T. Bishop and 
A. E. Kiltie (2008). "Analysis of variants in DNA damage signalling genes in 
bladder cancer." BMC Med Genet 9: 69. 
Choudhury, A., L. D. Nelson, M. T. Teo, S. Chilka, S. Bhattarai, C. F. Johnston, et al. 
(2010). "MRE11 expression is predictive of cause-specific survival following 
radical radiotherapy for muscle-invasive bladder cancer." Cancer Res 70(18): 
7017-7026. 
Choudhury, A., L. D. Nelson, M. T. Teo, S. Chilka, S. Bhattarai, C. F. Johnston, et al. 
(2010). "MRE11 expression is predictive of cause-specific survival following 
radical radiotherapy for muscle-invasive bladder cancer." Cancer Res 70(18): 
7017-7026. 
Choudhury, A., R. Swindell, J. P. Logue, P. A. Elliott, J. E. Livsey, M. Wise, et al. 
(2011). "Phase II Study of Conformal Hypofractionated Radiotherapy With 
Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer." J Clin Oncol 
29(6): 733-738. 
Ciampa, J., M. Yeager, L. Amundadottir, K. Jacobs, P. Kraft, C. Chung, et al. (2011). 
"Large-scale exploration of gene-gene interactions in prostate cancer using a 
multistage genome-wide association study." Cancer Res 71(9): 3287-3295. 
 227 
Cirulli, E. T. and D. B. Goldstein (2010). "Uncovering the roles of rare variants in 
common disease through whole-genome sequencing." Nat Rev Genet 11(6): 
415-425. 
Compton, S., C. Kim, N. B. Griner, P. Potluri, I. E. Scheffler, S. Sen, et al. (2011). 
"Mitochondrial dysfunction impairs tumor suppressor p53 
expression/function." J Biol Chem 286(23): 20297-20312. 
Cooper, G. M. and J. Shendure (2011). "Needles in stacks of needles: finding 
disease-causal variants in a wealth of genomic data." Nat Rev Genet 12(9): 
628-640. 
Coppin, C. M., M. K. Gospodarowicz, K. James, I. F. Tannock, B. Zee, J. Carson, et 
al. (1996). "Improved local control of invasive bladder cancer by concurrent 
cisplatin and preoperative or definitive radiation. The National Cancer Institute 
of Canada Clinical Trials Group." J Clin Oncol 14(11): 2901-2907. 
Cordell, H. J. (2009). "Detecting gene-gene interactions that underlie human 
diseases." Nat Rev Genet 10(6): 392-404. 
Coventry, A., L. M. Bull-Otterson, X. Liu, A. G. Clark, T. J. Maxwell, J. Crosby, et al. 
(2010). "Deep resequencing reveals excess rare recent variants consistent 
with explosive population growth." Nat Commun 1: 131. 
Cox, J. D., J. Stetz and T. F. Pajak (1995). "Toxicity criteria of the Radiation Therapy 
Oncology Group (RTOG) and the European Organization for Research and 
Treatment of Cancer (EORTC)." Int J Radiat Oncol Biol Phys 31(5): 1341-
1346. 
Craig, D. W., J. V. Pearson, S. Szelinger, A. Sekar, M. Redman, J. J. Corneveaux, et 
al. (2008). "Identification of genetic variants using bar-coded multiplexed 
sequencing." Nat Methods 5(10): 887-893. 
D'Errico, M., E. Parlanti, M. Teson, B. M. de Jesus, P. Degan, A. Calcagnile, et al. 
(2006). "New functions of XPC in the protection of human skin cells from 
oxidative damage." Embo J 25(18): 4305-4315. 
David, S. S., V. L. O'Shea and S. Kundu (2007). "Base-excision repair of oxidative 
DNA damage." Nature 447(7147): 941-950. 
Delia, D., M. Piane, G. Buscemi, C. Savio, S. Palmeri, P. Lulli, et al. (2004). "MRE11 
mutations and impaired ATM-dependent responses in an Italian family with 
ataxia-telangiectasia-like disorder." Hum Mol Genet 13(18): 2155-2163. 
Della-Maria, J., Y. Zhou, M. S. Tsai, J. Kuhnlein, J. P. Carney, T. T. Paull and A. E. 
Tomkinson (2011). "Human Mre11/human Rad50/Nbs1 and DNA ligase 
IIIalpha/XRCC1 protein complexes act together in an alternative 
nonhomologous end joining pathway." J Biol Chem 286(39): 33845-33853. 
Dering, C., C. Hemmelmann, E. Pugh and A. Ziegler (2011). "Statistical analysis of 
rare sequence variants: an overview of collapsing methods." Genet Epidemiol 
35 Suppl 1: S12-17. 
Dering, C., A. Ziegler, I. R. Konig and C. Hemmelmann (2011). "Comparison of 
collapsing methods for the statistical analysis of rare variants." BMC Proc 5 
Suppl 9: S115. 
Despras, E., P. Pfeiffer, B. Salles, P. Calsou, S. Kuhfittig-Kulle, J. F. Angulo and D. 
S. Biard (2007). "Long-term XPC silencing reduces DNA double-strand break 
repair." Cancer Res 67(6): 2526-2534. 
Detre, S., G. Saclani Jotti and M. Dowsett (1995). "A "quickscore" method for 
immunohistochemical semiquantitation: validation for oestrogen receptor in 
breast carcinomas." J Clin Pathol 48(9): 876-878. 
Dickson, S. P., K. Wang, I. Krantz, H. Hakonarson and D. B. Goldstein (2010). "Rare 
variants create synthetic genome-wide associations." PLoS Biol 8(1): 
e1000294. 
Ding, L., M. C. Wendl, D. C. Koboldt and E. R. Mardis (2010). "Analysis of next-
generation genomic data in cancer: accomplishments and challenges." Hum 
Mol Genet 19(R2): R188-196. 
 228 
Doherty, J. A., N. S. Weiss, S. Fish, W. Fan, M. M. Loomis, L. C. Sakoda, et al. 
(2011). "Polymorphisms in nucleotide excision repair genes and endometrial 
cancer risk." Cancer Epidemiol Biomarkers Prev 20(9): 1873-1882. 
Dong, J., Z. Hu, Y. Shu, S. Pan, W. Chen, Y. Wang, et al. (2012). "Potentially 
functional polymorphisms in DNA repair genes and non-small-cell lung cancer 
survival: a pathway-based analysis." Mol Carcinog 51(7): 546-552. 
Doyle, G. A., A. T. Lai, A. D. Chou, M. J. Wang, X. Gai, E. F. Rappaport and W. H. 
Berrettini (2012). "Re-sequencing of ankyrin 3 exon 48 and case-control 
association analysis of rare variants in bipolar disorder type I." Bipolar Disord. 
Dyrskjot, L., M. S. Ostenfeld, J. B. Bramsen, A. N. Silahtaroglu, P. Lamy, R. 
Ramanathan, et al. (2009). "Genomic profiling of microRNAs in bladder 
cancer: miR-129 is associated with poor outcome and promotes cell death in 
vitro." Cancer Res 69(11): 4851-4860. 
Easton, D. F., A. M. Deffenbaugh, D. Pruss, C. Frye, R. J. Wenstrup, K. Allen-Brady, 
et al. (2007). "A systematic genetic assessment of 1,433 sequence variants of 
unknown clinical significance in the BRCA1 and BRCA2 breast cancer-
predisposition genes." Am J Hum Genet 81(5): 873-883. 
Eccles, L. J., P. O'Neill and M. E. Lomax (2011). "Delayed repair of radiation induced 
clustered DNA damage: friend or foe?" Mutat Res 711(1-2): 134-141. 
Edge, S. B., D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene and A. E. Trotti 
(2010). "Urinary bladder." AJCC Cancer Staging Manual 7th edition: 497-505. 
Efstathiou, J. A., D. Y. Spiegel, W. U. Shipley, N. M. Heney, D. S. Kaufman, A. 
Niemierko, et al. (2012). "Long-Term Outcomes of Selective Bladder 
Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: 
The MGH Experience." Eur Urol 61(4): 705-711. 
Eid, W., M. Steger, M. El-Shemerly, L. P. Ferretti, J. Pena-Diaz, C. Konig, et al. 
(2010). "DNA end resection by CtIP and exonuclease 1 prevents genomic 
instability." EMBO Rep 11(12): 962-968. 
Esquela-Kerscher, A. and F. J. Slack (2006). "Oncomirs - microRNAs with a role in 
cancer." Nat Rev Cancer 6(4): 259-269. 
Esteller, M. (2011). "Non-coding RNAs in human disease." Nat Rev Genet 12(12): 
861-874. 
Eswara, J. R., J. A. Efstathiou, N. M. Heney, J. Paly, D. S. Kaufman, W. S. 
McDougal, et al. (2012). "Complications and long-term results of salvage 
cystectomy after failed bladder sparing therapy for muscle invasive bladder 
cancer." J Urol 187(2): 463-468. 
Evans, A. R., M. Limp-Foster and M. R. Kelley (2000). "Going APE over ref-1." Mutat 
Res 461(2): 83-108. 
Evans, D. A. and T. A. White (1964). "Human Acetylation Polymorphism." J Lab Clin 
Med 63: 394-403. 
Farrington, S. M., A. Tenesa, R. Barnetson, A. Wiltshire, J. Prendergast, M. 
Porteous, et al. (2005). "Germline susceptibility to colorectal cancer due to 
base-excision repair gene defects." Am J Hum Genet 77(1): 112-119. 
Fattah, F., E. H. Lee, N. Weisensel, Y. Wang, N. Lichter and E. A. Hendrickson 
(2010). "Ku regulates the non-homologous end joining pathway choice of 
DNA double-strand break repair in human somatic cells." PLoS Genet 6(2): 
e1000855. 
Fearnhead, N. S., J. L. Wilding, B. Winney, S. Tonks, S. Bartlett, D. C. Bicknell, et al. 
(2004). "Multiple rare variants in different genes account for multifactorial 
inherited susceptibility to colorectal adenomas." Proc Natl Acad Sci U S A 
101(45): 15992-15997. 
Figueroa, J. D., N. Malats, F. X. Real, D. Silverman, M. Kogevinas, S. Chanock, et al. 
(2007). "Genetic variation in the base excision repair pathway and bladder 
cancer risk." Hum Genet 121(2): 233-242. 
 229 
Figueroa, J. D., N. Malats, N. Rothman, F. X. Real, D. Silverman, M. Kogevinas, et 
al. (2007). "Evaluation of genetic variation in the double-strand break repair 
pathway and bladder cancer risk." Carcinogenesis 28(8): 1788-1793. 
Flanagan, S. E., A. M. Patch and S. Ellard (2010). "Using SIFT and PolyPhen to 
predict loss-of-function and gain-of-function mutations." Genet Test Mol 
Biomarkers 14(4): 533-537. 
Fleischmann, C., J. Peto, J. Cheadle, B. Shah, J. Sampson and R. S. Houlston 
(2004). "Comprehensive analysis of the contribution of germline MYH 
variation to early-onset colorectal cancer." Int J Cancer 109(4): 554-558. 
Fleming, N. D., H. Agadjanian, H. Nassanian, C. W. Miller, S. Orsulic, B. Y. Karlan 
and C. S. Walsh (2012). "Xeroderma pigmentosum complementation group C 
single-nucleotide polymorphisms in the nucleotide excision repair pathway 
correlate with prolonged progression-free survival in advanced ovarian 
cancer." Cancer 118(3): 689-697. 
Fokdal, L., M. Hoyer, P. Meldgaard and H. von der Maase (2004). "Long-term 
bladder, colorectal, and sexual functions after radical radiotherapy for urinary 
bladder cancer." Radiother Oncol 72(2): 139-145. 
Fontana, L., R. Bosviel, L. Delort, L. Guy, N. Chalabi, F. Kwiatkowski, et al. (2008). 
"DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and 
associations with bladder cancer risk in a French cohort." Anticancer Res 
28(3B): 1853-1856. 
Freedman, N. D., D. T. Silverman, A. R. Hollenbeck, A. Schatzkin and C. C. Abnet 
(2011). "Association Between Smoking and Risk of Bladder Cancer Among 
Men and Women." JAMA 306(7): 737-745. 
Friedman, R. C., K. K. Farh, C. B. Burge and D. P. Bartel (2009). "Most mammalian 
mRNAs are conserved targets of microRNAs." Genome Res 19(1): 92-105. 
Fu, Y. P., I. Kohaar, N. Rothman, J. Earl, J. D. Figueroa, Y. Ye, et al. (2012). 
"Common genetic variants in the PSCA gene influence gene expression and 
bladder cancer risk." Proc Natl Acad Sci U S A. 
Fukae, J., M. Takanashi, S. Kubo, K. Nishioka, Y. Nakabeppu, H. Mori, et al. (2005). 
"Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's 
disease and related neurodegenerative disorders." Acta Neuropathol 109(3): 
256-262. 
Gao, D., C. Wei, L. Chen, J. Huang, S. Yang and A. M. Diehl (2004). "Oxidative DNA 
damage and DNA repair enzyme expression are inversely related in murine 
models of fatty liver disease." Am J Physiol Gastrointest Liver Physiol 287(5): 
G1070-1077. 
Garcia-Closas, M., N. Malats, F. X. Real, R. Welch, M. Kogevinas, N. Chatterjee, et 
al. (2006). "Genetic variation in the nucleotide excision repair pathway and 
bladder cancer risk." Cancer Epidemiol Biomarkers Prev 15(3): 536-542. 
Garcia-Closas, M., N. Malats, D. Silverman, M. Dosemeci, M. Kogevinas, D. W. Hein, 
et al. (2005). "NAT2 slow acetylation, GSTM1 null genotype, and risk of 
bladder cancer: results from the Spanish Bladder Cancer Study and meta-
analyses." Lancet 366(9486): 649-659. 
Garcia-Closas, M., Y. Ye, N. Rothman, J. D. Figueroa, N. Malats, C. P. Dinney, et al. 
(2011). "A genome-wide association study of bladder cancer identifies a new 
susceptibility locus within SLC14A1, a urea transporter gene on chromosome 
18q12.3." Hum Mol Genet 20(21): 4282-4289. 
Gibson, G. (2011). "Rare and common variants: twenty arguments." Nat Rev Genet 
13(2): 135-145. 
Gil, J., D. Ramsey, A. Stembalska, P. Karpinski, K. A. Pesz, I. Laczmanska, et al. 
(2012). "The C/A polymorphism in intron 11 of the XPC gene plays a crucial 
role in the modulation of an individual's susceptibility to sporadic colorectal 
cancer." Mol Biol Rep 39(1): 527-534. 
 230 
Glashan, R. W. and R. A. Cartwright (1981). "Occupational bladder cancer and 
cigarette smoking in West Yorkshire." Br J Urol 53(6): 602-604. 
Goebell, P. J., S. G. Groshen and B. J. Schmitz-Drager (2010). "p53 
immunohistochemistry in bladder cancer--a new approach to an old question." 
Urol Oncol 28(4): 377-388. 
Goebell, P. J. and M. A. Knowles (2010). "Bladder cancer or bladder cancers? 
Genetically distinct malignant conditions of the urothelium." Urol Oncol 28(4): 
409-428. 
Goldgar, D. E., S. Healey, J. G. Dowty, L. Da Silva, X. Chen, A. B. Spurdle, et al. 
(2011). "Rare variants in the ATM gene and risk of breast cancer." Breast 
Cancer Res 13(4): R73. 
Goode, E. L., C. M. Ulrich and J. D. Potter (2002). "Polymorphisms in DNA repair 
genes and associations with cancer risk." Cancer Epidemiol Biomarkers Prev 
11(12): 1513-1530. 
Gorlov, I., O. Gorlova, M. Frazier, M. Spitz and C. Amos (2011). "Evolutionary 
evidence of the effect of rare variants on disease etiology." Clin Genet 79(3): 
199-206. 
Griffiths-Jones, S., R. J. Grocock, S. van Dongen, A. Bateman and A. J. Enright 
(2006). "miRBase: microRNA sequences, targets and gene nomenclature." 
Nucleic Acids Res 34(Database issue): D140-144. 
Grignon, D. J. (2009). "The current classification of urothelial neoplasms." Mod 
Pathol 22 Suppl 2: S60-69. 
Grunstein, M. (1997). "Histone acetylation in chromatin structure and transcription." 
Nature 389(6649): 349-352. 
Gu, B. and P. L. Chen (2009). "Expression of PCNA-binding domain of CtIP, a motif 
required for CtIP localization at DNA replication foci, causes DNA damage 
and activation of DNA damage checkpoint." Cell Cycle 8(9): 1409-1420. 
Gulston, M., C. de Lara, T. Jenner, E. Davis and P. O'Neill (2004). "Processing of 
clustered DNA damage generates additional double-strand breaks in 
mammalian cells post-irradiation." Nucleic Acids Res 32(4): 1602-1609. 
Haince, J. F., D. McDonald, A. Rodrigue, U. Dery, J. Y. Masson, M. J. Hendzel and 
G. G. Poirier (2008). "PARP1-dependent kinetics of recruitment of MRE11 
and NBS1 proteins to multiple DNA damage sites." J Biol Chem 283(2): 1197-
1208. 
Hall, E. J. and A. J. Giaccia (2006). Repair of Radiation Damage and the Dose-Rate 
Effect. Radiobiology for the Radiologist. Philadelphia, Lippincott Williams & 
Wilkins: 60-64. 
Hammond, S. M. (2007). "MicroRNAs as tumor suppressors." Nat Genet 39(5): 582-
583. 
Han, F. and W. Pan (2010). "A data-adaptive sum test for disease association with 
multiple common or rare variants." Hum Hered 70(1): 42-54. 
Hanahan, D. and R. A. Weinberg (2011). "Hallmarks of cancer: the next generation." 
Cell 144(5): 646-674. 
Harakalova, M., I. J. Nijman, J. Medic, M. Mokry, I. Renkens, J. D. Blankensteijn, et 
al. (2011). "Genomic DNA Pooling Strategy for Next-Generation Sequencing-
Based Rare Variant Discovery in Abdominal Aortic Aneurysm Regions of 
Interest-Challenges and Limitations." J Cardiovasc Transl Res 4(3): 271-280. 
Harismendy, O., P. C. Ng, R. L. Strausberg, X. Wang, T. B. Stockwell, K. Y. Beeson, 
et al. (2009). "Evaluation of next generation sequencing platforms for 
population targeted sequencing studies." Genome Biol 10(3): R32. 
Harris, A. L. and D. E. Neal (1992). "Bladder cancer--field versus clonal origin." N 
Engl J Med 326(11): 759-761. 
Harris, J. K., J. W. Sahl, T. A. Castoe, B. D. Wagner, D. D. Pollock and J. R. Spear 
(2010). "Comparison of normalization methods for construction of large, 
 231 
multiplex amplicon pools for next-generation sequencing." Appl Environ 
Microbiol 76(12): 3863-3868. 
Harris, R. E., J. Y. Chen-Backlund and E. L. Wynder (1990). "Cancer of the urinary 
bladder in blacks and whites. A case-control study." Cancer 66(12): 2673-
2680. 
Harrison, L., K. L. Brame, L. E. Geltz and A. M. Landry (2006). "Closely opposed 
apurinic/apyrimidinic sites are converted to double strand breaks in 
Escherichia coli even in the absence of exonuclease III, endonuclease IV, 
nucleotide excision repair and AP lyase cleavage." DNA repair 5(3): 324-335. 
Hegde, M. L., T. K. Hazra and S. Mitra (2008). "Early steps in the DNA base 
excision/single-strand interruption repair pathway in mammalian cells." Cell 
Res 18(1): 27-47. 
Heinzen, E. L., C. Depondt, G. L. Cavalleri, E. K. Ruzzo, N. M. Walley, A. C. Need, et 
al. (2012). "Exome sequencing followed by large-scale genotyping fails to 
identify single rare variants of large effect in idiopathic generalized epilepsy." 
Am J Hum Genet 91(2): 293-302. 
Hernandez, S., E. Lopez-Knowles, J. Lloreta, M. Kogevinas, A. Amoros, A. Tardon, 
et al. (2006). "Prospective study of FGFR3 mutations as a prognostic factor in 
nonmuscle invasive urothelial bladder carcinomas." J Clin Oncol 24(22): 
3664-3671. 
Hindorff, L. A., E. M. Gillanders and T. A. Manolio (2011). "Genetic architecture of 
cancer and other complex diseases: lessons learned and future directions." 
Carcinogenesis 32(7): 945-954. 
Hindson, B. R., S. L. Turner, J. L. Millar, F. Foroudi, N. K. Gogna, M. Skala, et al. 
(2012). "Australian & New Zealand Faculty of Radiation Oncology Genito-
Urinary Group: 2011 consensus guidelines for curative radiotherapy for 
urothelial carcinoma of the bladder." J Med Imaging Radiat Oncol 56(1): 18-
30. 
Hoeijmakers, J. H. (2001). "Genome maintenance mechanisms for preventing 
cancer." Nature 411(6835): 366-374. 
Horikawa, Y., C. G. Wood, H. Yang, H. Zhao, Y. Ye, J. Gu, et al. (2008). "Single 
nucleotide polymorphisms of microRNA machinery genes modify the risk of 
renal cell carcinoma." Clin Cancer Res 14(23): 7956-7962. 
Hoskin, P. J., A. M. Rojas, S. M. Bentzen and M. I. Saunders (2010). "Radiotherapy 
with concurrent carbogen and nicotinamide in bladder carcinoma." J Clin 
Oncol 28(33): 4912-4918. 
Hoskin, P. J., A. M. Rojas, S. M. Bentzen and M. I. Saunders (2010). "Radiotherapy 
with concurrent carbogen and nicotinamide in bladder carcinoma." J Clin 
Oncol 28(33): 4912-4918. 
Huang, L., J. Luo, Q. Cai, Q. Pan, H. Zeng, Z. Guo, et al. (2011). "MicroRNA-125b 
suppresses the development of bladder cancer by targeting E2F3." Int J 
Cancer 128(8): 1758-1769. 
Huddart, R., E. Hall, R. Lewis, A. Birtle and SPARE Trial Management Group (2010). 
"Life and death of spare (selective bladder preservation against radical 
excision): reflections on why the spare trial closed." BJU Int 106(6): 753-755. 
Huddart, R. A., N. D. James, F. Adab, I. Syndikus, P. Jenkins, C. Rawlings, et al. 
(2009). "BC2001: A multicenter phase III randomized trial of standard versus 
reduced volume radiotherapy for muscle invasive bladder cancer 
(ISCRTN:68324339)." J Clin Oncol 27(15s (suppl; abstr 5022) ). 
Human Genomics Strategy Group (2012). Building on our inheritance. 
Genomic technology in healthcare. D. o. Health. United Kingdom. 
Hung, R. J., J. Hall, P. Brennan and P. Boffetta (2005). "Genetic polymorphisms in 
the base excision repair pathway and cancer risk: a HuGE review." Am J 
Epidemiol 162(10): 925-942. 
 232 
Ichimi, T., H. Enokida, Y. Okuno, R. Kunimoto, T. Chiyomaru, K. Kawamoto, et al. 
(2009). "Identification of novel microRNA targets based on microRNA 
signatures in bladder cancer." Int J Cancer 125(2): 345-352. 
Iijima, K., M. Ohara, R. Seki and H. Tauchi (2008). "Dancing on damaged chromatin: 
functions of ATM and the RAD50/MRE11/NBS1 complex in cellular 
responses to DNA damage." J Radiat Res (Tokyo) 49(5): 451-464. 
Iles, M. M. (2008). "What can genome-wide association studies tell us about the 
genetics of common disease?" PLoS Genet 4(2): e33. 
Ionita-Laza, I., J. D. Buxbaum, N. M. Laird and C. Lange (2011). "A new testing 
strategy to identify rare variants with either risk or protective effect on 
disease." PLoS Genet 7(2): e1001289. 
Jadersten, M., L. Saft, A. Smith, A. Kulasekararaj, S. Pomplun, G. Gohring, et al. 
(2011). "TP53 mutations in low-risk myelodysplastic syndromes with del(5q) 
predict disease progression." J Clin Oncol 29(15): 1971-1979. 
Jalal, S., J. N. Earley and J. J. Turchi (2011). "DNA repair: from genome 
maintenance to biomarker and therapeutic target." Clin Cancer Res 17(22): 
6973-6984. 
James, N. and S. A. Hussain (2005). "Management of muscle invasive bladder 
cancer--British approaches to organ conservation." Semin Radiat Oncol 
15(1): 19-27. 
James, N. and A. Zarkar (2006). Bladder cancer. Radiotherapy in Practice: External 
Beam Therapy. P. J. Hoskin. Oxford, Oxford University Press: 213-221. 
James, N. D., S. A. Hussain, E. Hall, P. Jenkins, J. Tremlett, C. Rawlings, et al. 
(2012). "Radiotherapy with or without chemotherapy in muscle-invasive 
bladder cancer." N Engl J Med 366(16): 1477-1488. 
Jebar, A. H., C. D. Hurst, D. C. Tomlinson, C. Johnston, C. F. Taylor and M. A. 
Knowles (2005). "FGFR3 and Ras gene mutations are mutually exclusive 
genetic events in urothelial cell carcinoma." Oncogene 24(33): 5218-5225. 
Jensen, J. B., P. P. Munksgaard, C. M. Sorensen, N. Fristrup, K. Birkenkamp-
Demtroder, B. P. Ulhoi, et al. (2011). "High expression of karyopherin-alpha2 
defines poor prognosis in non-muscle-invasive bladder cancer and in patients 
with invasive bladder cancer undergoing radical cystectomy." Eur Urol 59(5): 
841-848. 
Jiao, X., J. Ren, H. Chen, J. Ma, S. Rao, K. Huang, et al. (2011). "Ala499Val (C>T) 
and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with 
the risk of primary gallbladder adenocarcinoma--a case-control study in 
China." Carcinogenesis 32(4): 496-501. 
Jin, S. C., P. Pastor, B. Cooper, S. Cervantes, B. A. Benitez, C. Razquin, et al. 
(2012). "Pooled-DNA sequencing identifies novel causative variants in 
PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's 
disease Ibero-American cohort." Alzheimers Res Ther 4(4): 34. 
Johansen, C. T., J. Wang, M. B. Lanktree, H. Cao, A. D. McIntyre, M. R. Ban, et al. 
(2010). "Excess of rare variants in genes identified by genome-wide 
association study of hypertriglyceridemia." Nat Genet 42(8): 684-687. 
John, B., A. J. Enright, A. Aravin, T. Tuschl, C. Sander and D. S. Marks (2004). 
"Human MicroRNA targets." PLoS Biol 2(11): e363. 
Jones, T. D., M. Wang, J. N. Eble, G. T. MacLennan, A. Lopez-Beltran, S. Zhang, et 
al. (2005). "Molecular evidence supporting field effect in urothelial 
carcinogenesis." Clin Cancer Res 11(18): 6512-6519. 
Ju, Y. S., J. I. Kim, S. Kim, D. Hong, H. Park, J. Y. Shin, et al. (2011). "Extensive 
genomic and transcriptional diversity identified through massively parallel 
DNA and RNA sequencing of eighteen Korean individuals." Nat Genet 43(8): 
745-752. 
 233 
Kang, G., D. Lin, H. Hakonarson and J. Chen (2012). "Two-stage extreme phenotype 
sequencing design for discovering and testing common and rare genetic 
variants: efficiency and power." Hum Hered 73(3): 139-147. 
Kantor, A. F., P. Hartge, R. N. Hoover and J. F. Fraumeni, Jr. (1985). "Familial and 
environmental interactions in bladder cancer risk." Int J Cancer 35(6): 703-
706. 
Karakiewicz, P. I., S. F. Shariat, G. S. Palapattu, A. E. Gilad, Y. Lotan, C. G. Rogers, 
et al. (2006). "Nomogram for predicting disease recurrence after radical 
cystectomy for transitional cell carcinoma of the bladder." J Urol 176(4 Pt 1): 
1354-1361; discussion 1361-1352. 
Kase, M., M. Vardja, A. Lipping, T. Asser and J. Jaal (2011). "Impact of PARP-1 and 
DNA-PK expression on survival in patients with glioblastoma multiforme." 
Radiother Oncol 101(1): 127-131. 
Kass, E. M. and M. Jasin (2010). "Collaboration and competition between DNA 
double-strand break repair pathways." FEBS Lett 584(17): 3703-3708. 
Kawashima, A., M. Nakayama, Y. Kakuta, T. Abe, K. Hatano, M. Mukai, et al. (2011). 
"Excision repair cross-complementing group 1 may predict the efficacy of 
chemoradiation therapy for muscle-invasive bladder cancer." Clin Cancer Res 
17(8): 2561-2569. 
Keimling, M., M. Deniz, D. Varga, A. Stahl, H. Schrezenmeier, R. Kreienberg, et al. 
(2012). "The power of DNA double-strand break (DSB) repair testing to 
predict breast cancer susceptibility." Faseb J 26(5): 2094-2104. 
Kelleher, R. J., 3rd, U. Geigenmuller, H. Hovhannisyan, E. Trautman, R. Pinard, B. 
Rathmell, et al. (2012). "High-throughput sequencing of mGluR signaling 
pathway genes reveals enrichment of rare variants in autism." PLoS One 
7(4): e35003. 
Kenny, E. M., P. Cormican, W. P. Gilks, A. S. Gates, C. T. O'Dushlaine, C. Pinto, et 
al. (2010). "Multiplex Target Enrichment Using DNA Indexing for Ultra-High 
Throughput SNP Detection." DNA Res 18(1): 31-38. 
Kiemeney, L. A., P. Sulem, S. Besenbacher, S. H. Vermeulen, A. Sigurdsson, G. 
Thorleifsson, et al. (2010). "A sequence variant at 4p16.3 confers 
susceptibility to urinary bladder cancer." Nat Genet 42(5): 415-419. 
Kiemeney, L. A., S. Thorlacius, P. Sulem, F. Geller, K. K. Aben, S. N. Stacey, et al. 
(2008). "Sequence variant on 8q24 confers susceptibility to urinary bladder 
cancer." Nat Genet 40(11): 1307-1312. 
Kiltie, A. E. (2009). "Molecular epidemiology of DNA repair genes in bladder cancer." 
Methods Mol Biol 472: 281-306. 
Kiltie, A. E. (2010). "Common predisposition alleles for moderately common cancers: 
bladder cancer." Curr Opin Genet Dev 20(3): 218-224. 
Kim, G. J., K. Chandrasekaran and W. F. Morgan (2006). "Mitochondrial dysfunction, 
persistently elevated levels of reactive oxygen species and radiation-induced 
genomic instability: a review." Mutagenesis 21(6): 361-367. 
Kim, S. Y., Y. Li, Y. Guo, R. Li, J. Holmkvist, T. Hansen, et al. (2010). "Design of 
association studies with pooled or un-pooled next-generation sequencing 
data." Genet Epidemiol 34(5): 479-491. 
Kiriakidou, M., P. T. Nelson, A. Kouranov, P. Fitziev, C. Bouyioukos, Z. Mourelatos 
and A. Hatzigeorgiou (2004). "A combined computational-experimental 
approach predicts human microRNA targets." Genes Dev 18(10): 1165-1178. 
Klopp, A. H. and P. J. Eifel (2012). "Biological predictors of cervical cancer response 
to radiation therapy." Semin Radiat Oncol 22(2): 143-150. 
Knowles, M. A. (2006). "Molecular subtypes of bladder cancer: Jekyll and Hyde or 
chalk and cheese?" Carcinogenesis 27(3): 361-373. 
Kogevinas, M., M. Sala, P. Boffetta, N. Kazerouni, H. Kromhout and S. Hoar-Zahm 
(1998). "Cancer risk in the rubber industry: a review of the recent 
epidemiological evidence." Occup Environ Med 55(1): 1-12. 
 234 
Kohlmann, A., V. Grossmann, H. U. Klein, S. Schindela, T. Weiss, B. Kazak, et al. 
(2010). "Next-generation sequencing technology reveals a characteristic 
pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia 
by detecting frequent alterations in TET2, CBL, RAS, and RUNX1." J Clin 
Oncol 28(24): 3858-3865. 
Konig, I. R., J. Nsengimana, C. Papachristou, M. A. Simonson, K. Wang and J. A. 
Weisburd (2011). "Multiple testing in high-throughput sequence data: 
experiences from Group 8 of Genetic Analysis Workshop 17." Genet 
Epidemiol 35 Suppl 1: S61-66. 
Kotwal, S., A. Choudhury, C. Johnston, A. B. Paul, P. Whelan and A. E. Kiltie (2008). 
"Similar treatment outcomes for radical cystectomy and radical radiotherapy 
in invasive bladder cancer treated at a United Kingdom specialist treatment 
center." Int J Radiat Oncol Biol Phys 70(2): 456-463. 
Kousholt, A. N., K. Fugger, S. Hoffmann, B. D. Larsen, T. Menzel, A. A. Sartori and 
C. S. Sorensen (2012). "CtIP-dependent DNA resection is required for DNA 
damage checkpoint maintenance but not initiation." J Cell Biol 197(7): 869-
876. 
Kozak, K. R., M. Hamidi, M. Manning and J. S. Moody (2012). "Bladder Preservation 
for Localized Muscle-Invasive Bladder Cancer: The Survival Impact of Local 
Utilization Rates of Definitive Radiotherapy." Int J Radiat Oncol Biol Phys. 
Krek, A., D. Grun, M. N. Poy, R. Wolf, L. Rosenberg, E. J. Epstein, et al. (2005). 
"Combinatorial microRNA target predictions." Nat Genet 37(5): 495-500. 
Krol, J., I. Loedige and W. Filipowicz (2010). "The widespread regulation of 
microRNA biogenesis, function and decay." Nat Rev Genet 11(9): 597-610. 
Kruger, J. and M. Rehmsmeier (2006). "RNAhybrid: microRNA target prediction easy, 
fast and flexible." Nucleic Acids Res 34(Web Server issue): W451-454. 
Kundu, S., M. K. Brinkmeyer, A. L. Livingston and S. S. David (2009). "Adenine 
removal activity and bacterial complementation with the human MutY 
homologue (MUTYH) and Y165C, G382D, P391L and Q324R variants 
associated with colorectal cancer." DNA Repair (Amst) 8(12): 1400-1410. 
Kurien, B. T., Y. Dorri, S. Dillon, A. Dsouza and R. H. Scofield (2011). "An overview 
of Western blotting for determining antibody specificities for 
immunohistochemistry." Methods Mol Biol 717: 55-67. 
La Thangue, N. B. and D. J. Kerr (2011). "Predictive biomarkers: a paradigm shift 
towards personalized cancer medicine." Nat Rev Clin Oncol 8(10): 587-596. 
Ladouceur, M., Z. Dastani, Y. S. Aulchenko, C. M. Greenwood and J. B. Richards 
(2012). "The empirical power of rare variant association methods: results from 
sanger sequencing in 1,998 individuals." PLoS Genet 8(2): e1002496. 
Lai, T. C., K. C. Chow, H. Y. Fang, H. C. Cho, C. Y. Chen, T. Y. Lin, et al. (2011). 
"Expression of xeroderma pigmentosum complementation group C protein 
predicts cisplatin resistance in lung adenocarcinoma patients." Oncol Rep 
25(5): 1243-1251. 
Lal, A., F. Navarro, C. A. Maher, L. E. Maliszewski, N. Yan, E. O'Day, et al. (2009). 
"miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle 
genes via binding to "seedless" 3'UTR microRNA recognition elements." Mol 
Cell 35(5): 610-625. 
Lalani, S. R., C. Shaw, X. Wang, A. Patel, L. W. Patterson, K. Kolodziejska, et al. 
(2012). "Rare DNA copy number variants in cardiovascular malformations 
with extracardiac abnormalities." Eur J Hum Genet. 
Lalondrelle, S., R. Huddart, K. Warren-Oseni, V. N. Hansen, H. McNair, K. Thomas, 
et al. (2011). "Adaptive-predictive organ localization using cone-beam 
computed tomography for improved accuracy in external beam radiotherapy 
for bladder cancer." Int J Radiat Oncol Biol Phys 79(3): 705-712. 
Lamm, D. L., B. A. Blumenstein, J. D. Crissman, J. E. Montie, J. E. Gottesman, B. A. 
Lowe, et al. (2000). "Maintenance bacillus Calmette-Guerin immunotherapy 
 235 
for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the 
bladder: a randomized Southwest Oncology Group Study." J Urol 163(4): 
1124-1129. 
Landi, D., F. Gemignani, A. Naccarati, B. Pardini, P. Vodicka, L. Vodickova, et al. 
(2008). "Polymorphisms within micro-RNA-binding sites and risk of sporadic 
colorectal cancer." Carcinogenesis 29(3): 579-584. 
Landi, S., F. Gemignani, F. Canzian, V. Gaborieau, R. Barale, D. Landi, et al. (2006). 
"DNA repair and cell cycle control genes and the risk of young-onset lung 
cancer." Cancer Res 66(22): 11062-11069. 
Laurberg, J. R., A. S. Brems-Eskildsen, I. Nordentoft, N. Fristrup, T. Schepeler, B. P. 
Ulhoi, et al. (2012). "Expression of TIP60 (tat-interactive protein) and MRE11 
(meiotic recombination 11 homolog) predict treatment-specific outcome of 
localised invasive bladder cancer." BJU Int [E-publication ahead of print]. 
Laurberg, J. R., A. S. Brems-Eskildsen, I. Nordentoft, N. Fristrup, T. Schepeler, B. P. 
Ulhoi, et al. (2012). "Expression of TIP60 (tat-interactive protein) and MRE11 
(meiotic recombination 11 homolog) predict treatment-specific outcome of 
localised invasive bladder cancer." BJU Int. 
Lavin, M. F. (2007). "ATM and the Mre11 complex combine to recognize and signal 
DNA double-strand breaks." Oncogene 26(56): 7749-7758. 
Le May, N., D. Mota-Fernandes, R. Velez-Cruz, I. Iltis, D. Biard and J. M. Egly 
(2010). "NER factors are recruited to active promoters and facilitate chromatin 
modification for transcription in the absence of exogenous genotoxic attack." 
Mol Cell 38(1): 54-66. 
Le Scodan, R., G. Cizeron-Clairac, E. Fourme, D. Meseure, S. Vacher, F. Spyratos, 
et al. (2010). "DNA repair gene expression and risk of locoregional relapse in 
breast cancer patients." Int J Radiat Oncol Biol Phys 78(2): 328-336. 
Lee, J. S., M. Choi, X. Yan, R. P. Lifton and H. Zhao (2011). "On optimal pooling 
designs to identify rare variants through massive resequencing." Genet 
Epidemiol. 
Lefevre, J. H., C. Bonilla, C. Colas, B. Winney, E. Johnstone, S. Tonks, et al. (2012). 
"Role of rare variants in undetermined multiple adenomatous polyposis and 
early-onset colorectal cancer." J Hum Genet. 
Lehmann, U., T. Streichert, B. Otto, C. Albat, B. Hasemeier, H. Christgen, et al. 
(2010). "Identification of differentially expressed microRNAs in human male 
breast cancer." BMC Cancer 10: 109. 
Lettice, L. A., S. J. Heaney, L. A. Purdie, L. Li, P. de Beer, B. A. Oostra, et al. (2003). 
"A long-range Shh enhancer regulates expression in the developing limb and 
fin and is associated with preaxial polydactyly." Hum Mol Genet 12(14): 1725-
1735. 
Lewis, B. P., I. H. Shih, M. W. Jones-Rhoades, D. P. Bartel and C. B. Burge (2003). 
"Prediction of mammalian microRNA targets." Cell 115(7): 787-798. 
Li, B. and S. M. Leal (2008). "Methods for detecting associations with rare variants 
for common diseases: application to analysis of sequence data." Am J Hum 
Genet 83(3): 311-321. 
Li, D., W. Zhang, J. Zhu, P. Chang, A. Sahin, E. Singletary, et al. (2001). "Oxidative 
DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic 
lyase in human breast cancer." Mol Carcinog 31(4): 214-223. 
Li, Q., G. Zheng, X. Liang and K. Yu (2009). "Robust tests for single-marker analysis 
in case-control genetic association studies." Ann Hum Genet 73(2): 245-252. 
Li, X., Y. Zhang, H. Zhang, X. Liu, T. Gong, M. Li, et al. (2011). "miRNA-223 
promotes gastric cancer invasion and metastasis by targeting tumor 
suppressor EPB41L3." Mol Cancer Res 9(7): 824-833. 
Liang, D., L. Meyer, D. W. Chang, J. Lin, X. Pu, Y. Ye, et al. (2010). "Genetic variants 
in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer 
risk, survival, and treatment response." Cancer Res 70(23): 9765-9776. 
 236 
Liang, Z. L., E. K. Song, Y. B. Ko, N. R. Lee, H. Y. Yhim, H. T. Noh, et al. (2011). 
"Excision repair cross-complementation group 1 expression predicts response 
and survival in locally advanced cervical carcinoma patients treated with 
concurrent chemoradiotherapy." Histopathology 59(3): 564-567. 
Lipton, L., S. E. Halford, V. Johnson, M. R. Novelli, A. Jones, C. Cummings, et al. 
(2003). "Carcinogenesis in MYH-associated polyposis follows a distinct 
genetic pathway." Cancer Res 63(22): 7595-7599. 
Liu, D. J. and S. M. Leal (2010). "A novel adaptive method for the analysis of next-
generation sequencing data to detect complex trait associations with rare 
variants due to gene main effects and interactions." PLoS Genet 6(10): 
e1001156. 
Liu, Y., H. Wang, T. Lin, Q. Wei, Y. Zhi, F. Yuan, et al. (2012). "Interactions between 
cigarette smoking and XPC-PAT genetic polymorphism enhance bladder 
cancer risk." Oncol Rep 28(1): 337-345. 
Liu, Z., G. Li, S. Wei, J. Niu, A. K. El-Naggar, E. M. Sturgis and Q. Wei (2010). 
"Genetic variants in selected pre-microRNA genes and the risk of squamous 
cell carcinoma of the head and neck." Cancer 116(20): 4753-4760. 
Liu, Z., A. Sall and D. Yang (2008). "MicroRNA: An emerging therapeutic target and 
intervention tool." Int J Mol Sci 9(6): 978-999. 
Lohmueller, K. E., C. L. Pearce, M. Pike, E. S. Lander and J. N. Hirschhorn (2003). 
"Meta-analysis of genetic association studies supports a contribution of 
common variants to susceptibility to common disease." Nat Genet 33(2): 177-
182. 
Lopez-Beltran, A., G. Sauter, T. Gasser, A. Hartmann, B. J. Schmitz-Dräger, B. 
Helpap, et al. (2004). Pathology and Genetics of Tumours of the Urinary 
System and Male Genital Organs. Pathology and Genetics of Tumours of the 
Urinary System and Male Genital Organs. J. N. Ebele, G. Sauter, J. I. Epstein 
and I. A. Sesterhenn. Lyon, IARCC Press: 29-34. 
Lotta, L. A., M. Wang, J. Yu, I. Martinelli, F. Yu, S. M. Passamonti, et al. (2012). 
"Identification of genetic risk variants for deep vein thrombosis by multiplexed 
next-generation sequencing of 186 hemostatic/pro-inflammatory genes." BMC 
Med Genomics 5: 7. 
Lu, Q., C. Lu, G. P. Zhou, W. Zhang, H. Xiao and X. R. Wang (2010). "MicroRNA-221 
silencing predisposed human bladder cancer cells to undergo apoptosis 
induced by TRAIL." Urol Oncol 28(6): 635-641. 
Lupton, M. K., P. Proitsi, M. Danillidou, M. Tsolaki, G. Hamilton, R. Wroe, et al. 
(2011). "Deep sequencing of the nicastrin gene in pooled DNA, the 
identification of genetic variants that affect risk of Alzheimer's disease." PLoS 
One 6(2): e17298. 
Madsen, B. E. and S. R. Browning (2009). "A groupwise association test for rare 
mutations using a weighted sum statistic." PLoS Genet 5(2): e1000384. 
Majewski, W. and R. Tarnawski (2009). "Acute and late toxicity in radical 
radiotherapy for bladder cancer." Clin Oncol 21(8): 598-609. 
Malyarchuk, S., K. L. Brame, R. Youngblood, R. Shi and L. Harrison (2004). "Two 
clustered 8-oxo-7,8-dihydroguanine (8-oxodG) lesions increase the point 
mutation frequency of 8-oxodG, but do not result in double strand breaks or 
deletions in Escherichia coli." Nucleic Acids Res 32(19): 5721-5731. 
Mamanova, L., A. J. Coffey, C. E. Scott, I. Kozarewa, E. H. Turner, A. Kumar, et al. 
(2010). "Target-enrichment strategies for next-generation sequencing." Nat 
Methods 7(2): 111-118. 
Manolio, T. A., F. S. Collins, N. J. Cox, D. B. Goldstein, L. A. Hindorff, D. J. Hunter, et 
al. (2009). "Finding the missing heritability of complex diseases." Nature 
461(7265): 747-753. 
Margulis, V., Y. Lotan, P. I. Karakiewicz, Y. Fradet, R. Ashfaq, U. Capitanio, et al. 
(2009). "Multi-institutional validation of the predictive value of Ki-67 labeling 
 237 
index in patients with urinary bladder cancer." J Natl Cancer Inst 101(2): 114-
119. 
Mariappan, P., A. Zachou and K. M. Grigor (2010). "Detrusor muscle in the first, 
apparently complete transurethral resection of bladder tumour specimen is a 
surrogate marker of resection quality, predicts risk of early recurrence, and is 
dependent on operator experience." Eur Urol 57(5): 843-849. 
Marth, G. T., F. Yu, A. R. Indap, K. Garimella, S. Gravel, W. F. Leong, et al. (2011). 
"The functional spectrum of low-frequency coding variation." Genome Biol 
12(9): R84. 
Martin, E. A. (1998). Oxford Concise Colour Medical Dictionary. Oxford, Oxford 
University Press: 101. 
Matsushita, K., E. K. Cha, K. Matsumoto, S. Baba, T. F. Chromecki, H. Fajkovic, et 
al. (2011). "Immunohistochemical biomarkers for bladder cancer prognosis." 
Int J Urol 18(9): 616-629. 
McConkey, D. J., S. Lee, W. Choi, M. Tran, T. Majewski, A. Siefker-Radtke, et al. 
(2010). "Molecular genetics of bladder cancer: Emerging mechanisms of 
tumor initiation and progression." Urol Oncol 28(4): 429-440. 
Mechanic, L. E., H. S. Chen, C. I. Amos, N. Chatterjee, N. J. Cox, R. L. Divi, et al. 
(2012). "Next generation analytic tools for large scale genetic epidemiology 
studies of complex diseases." Genet Epidemiol 36(1): 22-35. 
Megnin-Chanet, F., M. A. Bollet and J. Hall (2010). "Targeting poly(ADP-ribose) 
polymerase activity for cancer therapy." Cell Mol Life Sci 67(21): 3649-3662. 
Menashe, I., J. D. Figueroa, M. Garcia-Closas, N. Chatterjee, N. Malats, A. Picornell, 
et al. (2012). "Large-scale pathway-based analysis of bladder cancer 
genome-wide association data from five studies of European background." 
PLoS One 7(1): e29396. 
Mhawech-Fauceglia, P., R. T. Cheney, G. Fischer, A. Beck and F. R. Herrmann 
(2006). "FGFR3 and p53 protein expressions in patients with pTa and pT1 
urothelial bladder cancer." Eur J Surg Oncol 32(2): 231-237. 
Mignone, F., G. Grillo, F. Licciulli, M. Iacono, S. Liuni, P. J. Kersey, et al. (2005). 
"UTRdb and UTRsite: a collection of sequences and regulatory motifs of the 
untranslated regions of eukaryotic mRNAs." Nucleic Acids Res 33(Database 
issue): D141-146. 
Millan-Rodriguez, F., G. Chechile-Toniolo, J. Salvador-Bayarri, J. Palou, F. Algaba 
and J. Vicente-Rodriguez (2000). "Primary superficial bladder cancer risk 
groups according to progression, mortality and recurrence." J Urol 164(3 Pt 
1): 680-684. 
Milne, R. L., M. M. Gaudet, A. B. Spurdle, P. A. Fasching, F. J. Couch, J. Benitez, et 
al. (2010). "Assessing interactions between the associations of common 
genetic susceptibility variants, reproductive history and body mass index with 
breast cancer risk in the breast cancer association consortium: a combined 
case-control study." Breast Cancer Res 12(6): R110. 
Mirnezami, R., J. Nicholson and A. Darzi (2011). "Preparing for Precision Medicine." 
N Engl J Med 366(6): 489-491. 
Moeller, B. J., J. S. Yordy, M. D. Williams, U. Giri, U. Raju, D. P. Molkentine, et al. 
(2011). "DNA repair biomarker profiling of head and neck cancer: Ku80 
expression predicts locoregional failure and death following radiotherapy." 
Clin Cancer Res 17(7): 2035-2043. 
Morgan, J. E., I. M. Carr, E. Sheridan, C. E. Chu, B. Hayward, N. Camm, et al. 
(2010). "Genetic diagnosis of familial breast cancer using clonal sequencing." 
Hum Mutat 31(4): 484-491. 
Morgan, J. E., I. M. Carr, E. Sheridan, C. E. Chu, B. Hayward, N. Camm, et al. 
(2010). "Genetic diagnosis of familial breast cancer using clonal sequencing." 
Hum Mutat 31(4): 484-491. 
 238 
Morrison, A. S., J. E. Buring, W. G. Verhoek, K. Aoki, I. Leck, Y. Ohno and K. Obata 
(1984). "An international study of smoking and bladder cancer." J Urol 131(4): 
650-654. 
Mostafa, M. H., S. A. Sheweita and P. J. O'Connor (1999). "Relationship between 
schistosomiasis and bladder cancer." Clin Microbiol Rev 12(1): 97-111. 
Mukherjee, B., H. Choy, C. Nirodi and S. Burma (2010). "Targeting nonhomologous 
end-joining through epidermal growth factor receptor inhibition: rationale and 
strategies for radiosensitization." Semin Radiat Oncol 20(4): 250-257. 
Murta-Nascimento, C., D. T. Silverman, M. Kogevinas, M. Garcia-Closas, N. 
Rothman, A. Tardon, et al. (2007). "Risk of bladder cancer associated with 
family history of cancer: do low-penetrance polymorphisms account for the 
increase in risk?" Cancer Epidemiol Biomarkers Prev 16(8): 1595-1600. 
Naccarati, A., B. Pardini, S. Landi, D. Landi, J. Slyskova, J. Novotny, et al. (2012). 
"Polymorphisms in miRNA binding sites of nucleotide excision repair genes 
and colorectal cancer risk." Carcinogenesis. 
Naccarati, A., B. Pardini, L. Stefano, D. Landi, J. Slyskova, J. Novotny, et al. (2012). 
"Polymorphisms in miRNA-binding sites of nucleotide excision repair genes 
and colorectal cancer risk." Carcinogenesis 33(7): 1346-1351. 
Nelson, M. R., D. Wegmann, M. G. Ehm, D. Kessner, P. St Jean, C. Verzilli, et al. 
(2012). "An abundance of rare functional variants in 202 drug target genes 
sequenced in 14,002 people." Science 337(6090): 100-104. 
Ng, P. C. and S. Henikoff (2006). "Predicting the effects of amino acid substitutions 
on protein function." Annu Rev Genomics Hum Genet 7: 61-80. 
Nicoloso, M. S., H. Sun, R. Spizzo, H. Kim, P. Wickramasinghe, M. Shimizu, et al. 
(2010). "Single-nucleotide polymorphisms inside microRNA target sites 
influence tumor susceptibility." Cancer Res 70(7): 2789-2798. 
Nijman, I. J., M. Mokry, R. van Boxtel, P. Toonen, E. de Bruijn and E. Cuppen (2010). 
"Mutation discovery by targeted genomic enrichment of multiplexed barcoded 
samples." Nat Methods 7(11): 913-915. 
Nishiyama, H., J. Watanabe and O. Ogawa (2008). "p53 and chemosensitivity in 
bladder cancer." Int J Clin Oncol 13(4): 282-286. 
Nuhn, P., M. May, M. Sun, H. M. Fritsche, S. Brookman-May, A. Buchner, et al. 
(2012). "External validation of postoperative nomograms for prediction of all-
cause mortality, cancer-specific mortality, and recurrence in patients with 
urothelial carcinoma of the bladder." Eur Urol 61(1): 58-64. 
Ohtsubo, T., K. Nishioka, Y. Imaiso, S. Iwai, H. Shimokawa, H. Oda, et al. (2000). 
"Identification of human MutY homolog (hMYH) as a repair enzyme for 2-
hydroxyadenine in DNA and detection of multiple forms of hMYH located in 
nuclei and mitochondria." Nucleic Acids Res 28(6): 1355-1364. 
Okey, A., P. A. Harper, D. M. Grant and R. P. Hill (2005). Chemical and Radiation 
Carcinogenesis. The Basic Science of Oncology. I. F. Tannock, R. P. Hill, R. 
Bristow and L. Harrington. Toronto, McGraw-Hill Medical Publishing: 25-48. 
Ostenfeld, M. S., J. B. Bramsen, P. Lamy, S. B. Villadsen, N. Fristrup, K. D. 
Sorensen, et al. (2010). "miR-145 induces caspase-dependent and -
independent cell death in urothelial cancer cell lines with targeting of an 
expression signature present in Ta bladder tumors." Oncogene 29(7): 1073-
1084. 
Ott, O. J., C. Rodel, C. Weiss, M. Wittlinger, F. St Krause, J. Dunst, et al. (2009). 
"Radiochemotherapy for bladder cancer." Clin Oncol 21(7): 557-565. 
Out, A. A., I. J. van Minderhout, J. J. Goeman, Y. Ariyurek, S. Ossowski, K. 
Schneeberger, et al. (2009). "Deep sequencing to reveal new variants in 
pooled DNA samples." Hum Mutat 30(12): 1703-1712. 
Ozcelik, H., X. Shi, M. C. Chang, E. Tram, M. Vlasschaert, N. Di Nicola, et al. (2012). 
"Long-Range PCR and Next-Generation Sequencing of BRCA1 and BRCA2 
in Breast Cancer." J Mol Diagn [Epub ahead of print]. 
 239 
Pareek, C. S., R. Smoczynski and A. Tretyn (2011). "Sequencing technologies and 
genome sequencing." J Appl Genet 52(4): 413-435. 
Park, D. J., F. Lesueur, T. Nguyen-Dumont, M. Pertesi, F. Odefrey, F. Hammet, et al. 
(2012). "Rare mutations in XRCC2 increase the risk of breast cancer." Am J 
Hum Genet 90(4): 734-739. 
Parliament, M. B. and D. Murray (2010). "Single nucleotide polymorphisms of DNA 
repair genes as predictors of radioresponse." Semin Radiat Oncol 20(4): 232-
240. 
Pasquinelli, A. E. (2012). "MicroRNAs and their targets: recognition, regulation and 
an emerging reciprocal relationship." Nat Rev Genet 13(4): 271-282. 
Pervaiz, M. A., A. Eppolito and K. Schmidt (2010). "Papillary thyroid cancer in a 
patient with MUTYH-associated polyposis (MAP)." Fam Cancer 9(4): 595-
597. 
Petermann, E., C. Keil and S. L. Oei (2006). "Roles of DNA ligase III and XRCC1 in 
regulating the switch between short patch and long patch BER." DNA Repair 
(Amst) 5(5): 544-555. 
Pharoah, P. D., R. T. Palmieri, S. J. Ramus, S. A. Gayther, I. L. Andrulis, H. Anton-
Culver, et al. (2011). "The role of KRAS rs61764370 in invasive epithelial 
ovarian cancer: implications for clinical testing." Clin Cancer Res 17(11): 
3742-3750. 
Plna, K. and K. Hemminki (2001). "Familial bladder cancer in the National Swedish 
Family Cancer Database." J Urol 166(6): 2129-2133. 
Plotz, G., M. Casper, J. Raedle, I. Hinrichsen, V. Heckel, A. Brieger, et al. (2012). 
"MUTYH gene expression and alternative splicing in controls and polyposis 
patients." Human mutation 33(7): 1067-1074. 
Pos, F. and P. Remeijer (2010). "Adaptive management of bladder cancer 
radiotherapy." Semin Radiat Oncol 20(2): 116-120. 
Price, A. L., G. V. Kryukov, P. I. de Bakker, S. M. Purcell, J. Staples, L. J. Wei and S. 
R. Sunyaev (2010). "Pooled association tests for rare variants in exon-
resequencing studies." Am J Hum Genet 86(6): 832-838. 
Pritchard, C. C., C. Smith, S. J. Salipante, M. K. Lee, A. M. Thornton, A. S. Nord, et 
al. (2012). "ColoSeq Provides Comprehensive Lynch and Polyposis 
Syndrome Mutational Analysis Using Massively Parallel Sequencing." J Mol 
Diagn 14(4): 357-366. 
Proctor, I., K. Stoeber and G. H. Williams (2010). "Biomarkers in bladder cancer." 
Histopathology 57(1): 1-13. 
Pugh, T. J., M. Keyes, L. Barclay, A. Delaney, M. Krzywinski, D. Thomas, et al. 
(2009). "Sequence variant discovery in DNA repair genes from radiosensitive 
and radiotolerant prostate brachytherapy patients." Clin Cancer Res 15(15): 
5008-5016. 
Pylkas, K., M. Vuorela, M. Otsukka, A. Kallioniemi, A. Jukkola-Vuorinen and R. 
Winqvist (2012). "Rare Copy Number Variants Observed in Hereditary Breast 
Cancer Cases Disrupt Genes in Estrogen Signaling and TP53 Tumor 
Suppression Network." PLoS Genet 8(6): e1002734. 
Qiao, B., A. H. Ansari, G. B. Scott, S. C. Sak, P. A. Chambers, F. Elliott, et al. (2011). 
"In vitro functional effects of XPC gene rare variants from bladder cancer 
patients." Carcinogenesis 32(4): 516-521. 
Qiao, B., A. H. Ansari, G. B. Scott, S. C. Sak, P. A. Chambers, F. Elliott, et al. (2011). 
"In vitro functional effects of XPC gene rare variants from bladder cancer 
patients." Carcinogenesis 32(4): 516-521. 
Rafnar, T., S. H. Vermeulen, P. Sulem, G. Thorleifsson, K. K. Aben, J. A. Witjes, et 
al. (2011). "European genome-wide association study identifies SLC14A1 as 
a new urinary bladder cancer susceptibility gene." Hum Mol Genet 20(21): 
4268-4281. 
 240 
Ramagopalan, S. V., D. A. Dyment, M. Z. Cader, K. M. Morrison, G. Disanto, J. M. 
Morahan, et al. (2011). "Rare variants in the CYP27B1 gene are associated 
with multiple sclerosis." Ann Neurol 70(6): 881-886. 
Raychaudhuri, S., O. Iartchouk, K. Chin, P. L. Tan, A. K. Tai, S. Ripke, et al. (2011). 
"A rare penetrant mutation in CFH confers high risk of age-related macular 
degeneration." Nat Genet 43(12): 1232-1236. 
Reich, D. E. and E. S. Lander (2001). "On the allelic spectrum of human disease." 
Trends Genet 17(9): 502-510. 
Reiner, A., B. Neumeister, J. Spona, G. Reiner, M. Schemper and R. Jakesz (1990). 
"Immunocytochemical localization of estrogen and progesterone receptor and 
prognosis in human primary breast cancer." Cancer Res 50(21): 7057-7061. 
Rennert, G., F. Lejbkowicz, I. Cohen, M. Pinchev, H. S. Rennert and O. Barnett-
Griness (2012). "MutYH mutation carriers have increased breast cancer risk." 
Cancer 118(8): 1989-1993. 
Rhee, J. G., D. Li, M. Suntharalingam, C. Guo, B. W. O'Malley, Jr. and J. P. Carney 
(2007). "Radiosensitization of head/neck squamous cell carcinoma by 
adenovirus-mediated expression of the Nbs1 protein." Int J Radiat Oncol Biol 
Phys 67(1): 273-278. 
Ribic, C. M., D. J. Sargent, M. J. Moore, S. N. Thibodeau, A. J. French, R. M. 
Goldberg, et al. (2003). "Tumor microsatellite-instability status as a predictor 
of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer." N 
Engl J Med 349(3): 247-257. 
Ricceri, F., G. Matullo and P. Vineis (2011). "Is there evidence of involvement of DNA 
repair polymorphisms in human cancer?" Mutat Res. 
Ricceri, F., P. Porcedda, A. Allione, V. Turinetto, S. Polidoro, S. Guarrera, et al. 
(2011). "Involvement of MRE11A and XPA gene polymorphisms in the 
modulation of DNA double-strand break repair activity: a genotype-phenotype 
correlation study." DNA Repair (Amst) 10(10): 1044-1050. 
Riester, M., J. M. Taylor, A. Feifer, T. Koppie, J. E. Rosenberg, R. J. Downey, et al. 
(2012). "Combination of a novel gene expression signature with a clinical 
nomogram improves the prediction of survival in high-risk bladder cancer." 
Clin Cancer Res 18(5): 1323-1333. 
Rivas, M. A., M. Beaudoin, A. Gardet, C. Stevens, Y. Sharma, C. K. Zhang, et al. 
(2011). "Deep resequencing of GWAS loci identifies independent rare 
variants associated with inflammatory bowel disease." Nat Genet 43(11): 
1066-1073. 
Rodel, C., C. Weiss and R. Sauer (2005). "Organ preservation by combined modality 
treatment in bladder cancer: the European perspective." Semin Radiat Oncol 
15(1): 28-35. 
Rossetti, S., K. Hopp, R. A. Sikkink, J. L. Sundsbak, Y. K. Lee, V. Kubly, et al. 
(2012). "Identification of gene mutations in autosomal dominant polycystic 
kidney disease through targeted resequencing." J Am Soc Nephrol 23(5): 
915-933. 
Rothman, N., M. Garcia-Closas, N. Chatterjee, N. Malats, X. Wu, J. D. Figueroa, et 
al. (2010). "A multi-stage genome-wide association study of bladder cancer 
identifies multiple susceptibility loci." Nat Genet 42(11): 978-984. 
Rusinov, V., V. Baev, I. N. Minkov and M. Tabler (2005). "MicroInspector: a web tool 
for detection of miRNA binding sites in an RNA sequence." Nucleic Acids Res 
33(Web Server issue): W696-700. 
Sak, A. and M. Stuschke (2010). "Use of gammaH2AX and other biomarkers of 
double-strand breaks during radiotherapy." Semin Radiat Oncol 20(4): 223-
231. 
Sak, S. C., J. H. Barrett, A. B. Paul, D. T. Bishop and A. E. Kiltie (2005). "The polyAT, 
intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with 
transitional cell carcinoma of the bladder." Br J Cancer 92(12): 2262-2265. 
 241 
Sak, S. C., J. H. Barrett, A. B. Paul, D. T. Bishop and A. E. Kiltie (2006). 
"Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk." 
Cancer Epidemiol Biomarkers Prev 15(12): 2537-2541. 
Sak, S. C., P. Harnden, C. F. Johnston, A. B. Paul and A. E. Kiltie (2005). "APE1 and 
XRCC1 protein expression levels predict cancer-specific survival following 
radical radiotherapy in bladder cancer." Clin Cancer Res 11(17): 6205-6211. 
Sakano, S., T. Wada, H. Matsumoto, S. Sugiyama, R. Inoue, S. Eguchi, et al. (2006). 
"Single nucleotide polymorphisms in DNA repair genes might be prognostic 
factors in muscle-invasive bladder cancer patients treated with 
chemoradiotherapy." Br J Cancer 95(5): 561-570. 
Sarasin, A. and A. Kauffmann (2008). "Overexpression of DNA repair genes is 
associated with metastasis: a new hypothesis." Mutat Res 659(1-2): 49-55. 
Sartori, A. A., C. Lukas, J. Coates, M. Mistrik, S. Fu, J. Bartek, et al. (2007). "Human 
CtIP promotes DNA end resection." Nature 450(7169): 509-514. 
Schairer, C., P. Hartge, R. N. Hoover and D. T. Silverman (1988). "Racial differences 
in bladder cancer risk: a case-control study." Am J Epidemiol 128(5): 1027-
1037. 
Schneider, A. C., L. C. Heukamp, S. Rogenhofer, G. Fechner, P. J. Bastian, A. von 
Ruecker, et al. (2011). "Global histone H4K20 trimethylation predicts cancer-
specific survival in patients with muscle-invasive bladder cancer." BJU Int 
108(8 Pt 2): E290-296. 
Schork, N. J., S. S. Murray, K. A. Frazer and E. J. Topol (2009). "Common vs. rare 
allele hypotheses for complex diseases." Curr Opin Genet Dev 19(3): 212-
219. 
Scrimger, R. A., A. D. Murtha, M. B. Parliament, P. M. Venner, J. Hanson, G. Houle 
and M. Chetner (2001). "Muscle-invasive transitional cell carcinoma of the 
urinary bladder: a population-based study of patterns of care and prognostic 
factors." Int J Radiat Oncol Biol Phys 51(1): 23-30. 
Sengelov, L. and H. von der Maase (1999). "Radiotherapy in bladder cancer." 
Radiother Oncol 52(1): 1-14. 
Shariat, S. F., P. I. Karakiewicz, G. S. Palapattu, G. E. Amiel, Y. Lotan, C. G. Rogers, 
et al. (2006). "Nomograms provide improved accuracy for predicting survival 
after radical cystectomy." Clin Cancer Res 12(22): 6663-6676. 
Shariat, S. F., Y. Lotan, A. Vickers, P. I. Karakiewicz, B. J. Schmitz-Drager, P. J. 
Goebell and N. Malats (2010). "Statistical consideration for clinical biomarker 
research in bladder cancer." Urol Oncol 28(4): 389-400. 
Sheehan, A. M., D. K. McGregor, A. Patel, V. Shidham, C. Y. Fan and C. C. Chang 
(2005). "Expression of human 8-oxoguanine DNA glycosylase (hOGG1) in 
follicular lymphoma." Mod Pathol 18(11): 1512-1518. 
Shelley, M., J. Barber, T. Wilt and M. Mason (2008). "Surgery versus radiotherapy for 
muscle invasive bladder cancer (Review)." Cochrane Database Syst Rev(4). 
Shen, M., I. Menashe, L. M. Morton, Y. Zhang, B. Armstrong, S. S. Wang, et al. 
(2010). "Polymorphisms in DNA repair genes and risk of non-Hodgkin 
lymphoma in a pooled analysis of three studies." Br J Haematol 151(3): 239-
244. 
Shendure, J. and H. Ji (2008). "Next-generation DNA sequencing." Nat Biotechnol 
26(10): 1135-1145. 
Shin, C., J. W. Nam, K. K. Farh, H. R. Chiang, A. Shkumatava and D. P. Bartel 
(2010). "Expanding the microRNA targeting code: functional sites with 
centered pairing." Mol Cell 38(6): 789-802. 
Shinmura, K., M. Goto, M. Suzuki, H. Tao, H. Yamada, H. Igarashi, et al. (2011). 
"Reduced expression of MUTYH with suppressive activity against mutations 
caused by 8-hydroxyguanine is a novel predictor of a poor prognosis in 
human gastric cancer." J Pathol 225(3): 414-423. 
 242 
Short, S. C., S. Giampieri, M. Worku, M. Alcaide-German, G. Sioftanos, S. Bourne, et 
al. (2011). "Rad51 inhibition is an effective means of targeting DNA repair in 
glioma models and CD133+ tumor-derived cells." Neuro Oncol 13(5): 487-
499. 
Signore, M. and K. A. Reeder (2012). "Antibody validation by Western blotting." 
Methods Mol Biol 823: 139-155. 
Smith, A. E., A. M. Mohamedali, A. Kulasekararaj, Z. Lim, J. Gaken, N. C. Lea, 
et al. (2010). "Next-generation sequencing of the TET2 gene in 355 
MDS and CMML patients reveals low-abundance mutant clones with 
early origins, but indicates no definite prognostic value." Blood 116(19): 
3923-3932. 
Sobin, L. H., M. K. Gospodarowicz and C. Wittekind (2010). TNM Classification of 
Malignant Tumours, 7th Edition. New York, Wiley-Blackwell. 
Soderlund, K., O. Stal, L. Skoog, L. E. Rutqvist, B. Nordenskjold and M. S. Askmalm 
(2007). "Intact Mre11/Rad50/Nbs1 complex predicts good response to 
radiotherapy in early breast cancer." Int J Radiat Oncol Biol Phys 68(1): 50-
58. 
Spruck, C. H., 3rd, P. F. Ohneseit, M. Gonzalez-Zulueta, D. Esrig, N. Miyao, Y. C. 
Tsai, et al. (1994). "Two molecular pathways to transitional cell carcinoma of 
the bladder." Cancer Res 54(3): 784-788. 
Stacey, S. N., P. Sulem, A. Jonasdottir, G. Masson, J. Gudmundsson, D. F. 
Gudbjartsson, et al. (2011). "A germline variant in the TP53 polyadenylation 
signal confers cancer susceptibility." Nat Genet 43(11): 1098-1103. 
Stadler, W. M., S. P. Lerner, S. Groshen, J. P. Stein, S. R. Shi, D. Raghavan, et al. 
(2011). "Phase III study of molecularly targeted adjuvant therapy in locally 
advanced urothelial cancer of the bladder based on p53 status." J Clin Oncol 
29(25): 3443-3449. 
Steel, G. (2002). "Chapter 8: DNA damage and cell killing." Basic Clinical 
Radiobiology 3rd Edition. 
Stenzl, A., N. C. Cowan, M. De Santis, M. A. Kuczyk, A. S. Merseburger, M. J. Ribal, 
et al. (2011). "Treatment of muscle-invasive and metastatic bladder cancer: 
update of the EAU guidelines." Eur Urol 59(6): 1009-1018. 
Stern, M. C., J. Lin, J. D. Figueroa, K. T. Kelsey, A. E. Kiltie, J. M. Yuan, et al. (2009). 
"Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: 
findings from the international consortium of bladder cancer." Cancer Res 
69(17): 6857-6864. 
Stevens, A. and J. Lowe (1995). Tumours of the Lower Urinary Tract. Pathology, 
Mosby: 346-347. 
Stewart, D. J. (2010). "Tumor and host factors that may limit efficacy of 
chemotherapy in non-small cell and small cell lung cancer." Crit Rev Oncol 
Hematol 75(3): 173-234. 
Sugasawa, K. (2008). "Xeroderma pigmentosum genes: functions inside and outside 
DNA repair." Carcinogenesis 29(3): 455-465. 
Sugasawa, K. (2010). "Regulation of damage recognition in mammalian global 
genomic nucleotide excision repair." Mutat Res 685(1-2): 29-37. 
Sun, J. M., M. J. Ahn, M. J. Park, H. Y. Lee, J. S. Ahn, S. Lee, et al. (2011). 
"Expression of excision repair cross-complementation group 1 as predictive 
marker for nasopharyngeal cancer treated with concurrent 
chemoradiotherapy." Int J Radiat Oncol Biol Phys 80(3): 655-660. 
Sun, Y., X. Jiang and B. D. Price (2010). "Tip60: connecting chromatin to DNA 
damage signaling." Cell Cycle 9(5): 930-936. 
Suzuki, S., N. Ono, C. Furusawa, B. W. Ying and T. Yomo (2011). "Comparison of 
sequence reads obtained from three next-generation sequencing platforms." 
PLoS One 6(5): e19534. 
 243 
Sylvester, R. J., A. P. van der Meijden, W. Oosterlinck, J. A. Witjes, C. Bouffioux, L. 
Denis, et al. (2006). "Predicting recurrence and progression in individual 
patients with stage Ta T1 bladder cancer using EORTC risk tables: a 
combined analysis of 2596 patients from seven EORTC trials." Eur Urol 49(3): 
466-465; discussion 475-467. 
Taneja, N., M. Davis, J. S. Choy, M. A. Beckett, R. Singh, S. J. Kron and R. R. 
Weichselbaum (2004). "Histone H2AX phosphorylation as a predictor of 
radiosensitivity and target for radiotherapy." J Biol Chem 279(3): 2273-2280. 
Tang, W., Y. P. Fu, J. D. Figueroa, N. Malats, M. Garcia-Closas, N. Chatterjee, et al. 
(2012). "Mapping of the UGT1A locus identifies an uncommon coding variant 
that affects mRNA expression and protects from bladder cancer." Hum Mol 
Genet 21(8): 1918-1930. 
Taylor, C. F. (2009). "Mutation scanning using high-resolution melting." Biochem Soc 
Trans 37(Pt 2): 433-437. 
Tenesa, A., H. Campbell, R. Barnetson, M. Porteous, M. Dunlop and S. M. Farrington 
(2006). "Association of MUTYH and colorectal cancer." Br J Cancer 95(2): 
239-242. 
Tennessen, J. A., A. W. Bigham, T. D. O'Connor, W. Fu, E. E. Kenny, S. Gravel, et 
al. (2012). "Evolution and functional impact of rare coding variation from deep 
sequencing of human exomes." Science 337(6090): 64-69. 
Teo, M. T., D. Landi, C. F. Taylor, F. Elliott, L. Vaslin, D. G. Cox, et al. (2012). "The 
role of microRNA-binding site polymorphisms in DNA repair genes as risk 
factors for bladder cancer and breast cancer and their impact on radiotherapy 
outcomes." Carcinogenesis 33(3): 581-586. 
Thariat, J., S. Aluwini, Q. Pan, M. Caullery, P. Y. Marcy, M. Housset and J. L. 
Lagrange (2012). "Image-guided radiation therapy for muscle-invasive 
bladder cancer." Nat Rev Urol 9(1): 23-29. 
The 1000 Genomes Project Consortium (2010). "A map of human genome variation 
from population-scale sequencing." Nature 467(7319): 1061-1073. 
The Wellcome Trust Case Control Consortium (2007). "Genome-wide association 
study of 14,000 cases of seven common diseases and 3,000 shared 
controls." Nature 447(7145): 661-678. 
Theodoratou, E., H. Campbell, A. Tenesa, R. Houlston, E. Webb, S. Lubbe, et al. 
(2010). "A large-scale meta-analysis to refine colorectal cancer risk estimates 
associated with MUTYH variants." Br J Cancer 103(12): 1875-1884. 
Thomas, D. (2010). "Gene--environment-wide association studies: emerging 
approaches." Nat Rev Genet 11(4): 259-272. 
Tischkowitz, M., M. Capanu, N. Sabbaghian, L. Li, X. Liang, M. P. Vallee, et al. 
(2012). "Rare germline mutations in PALB2 and breast cancer risk: a 
population-based study." Human mutation 33(4): 674-680. 
Torgerson, D. G., D. Capurso, R. A. Mathias, P. E. Graves, R. D. Hernandez, T. H. 
Beaty, et al. (2012). "Resequencing candidate genes implicates rare variants 
in asthma susceptibility." Am J Hum Genet 90(2): 273-281. 
Toustrup, K., B. S. Sorensen, J. Alsner and J. Overgaard (2012). "Hypoxia gene 
expression signatures as prognostic and predictive markers in head and neck 
radiotherapy." Semin Radiat Oncol 22(2): 119-127. 
Tran, E., L. Souhami, S. Tanguay and R. Rajan (2009). "Bladder conservation 
treatment in the elderly population: results and prognostic factors of muscle-
invasive bladder cancer." Am J Clin Oncol 32(4): 333-337. 
Tsai, M. H., W. H. Fang, S. W. Lin, S. J. Yen, S. J. Chou and Y. C. Yang (2009). 
"Mitochondrial genomic instability in colorectal cancer: no correlation to 
nuclear microsatellite instability and allelic deletion of hMSH2, hMLH1, and 
p53 genes, but prediction of better survival for Dukes' stage C disease." Ann 
Surg Oncol 16(10): 2918-2925. 
 244 
Tucker, T., M. Marra and J. M. Friedman (2009). "Massively parallel sequencing: the 
next big thing in genetic medicine." Am J Hum Genet 85(2): 142-154. 
Vaezi, A., X. Wang, S. Buch, W. Gooding, L. Wang, R. R. Seethala, et al. (2011). 
"XPF expression correlates with clinical outcome in squamous cell carcinoma 
of the head and neck." Clin Cancer Res 17(16): 5513-5522. 
Vale, C. and ABC Meta-analysis Group (2005). "Adjuvant chemotherapy in invasive 
bladder cancer: a systematic review and meta-analysis of individual patient 
data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration." Eur Urol 
48(2): 189-199; discussion 199-201. 
Vale, C. and ABC Meta-analysis Group (2005). "Neoadjuvant chemotherapy in 
invasive bladder cancer: update of a systematic review and meta-analysis of 
individual patient data advanced bladder cancer (ABC) meta-analysis 
collaboration." Eur Urol 48(2): 202-205; discussion 205-206. 
Vale, C. and Advanced Bladder Cancer Meta-analysis Collaboration (2004). 
"Neoadjuvant chemotherapy for invasive bladder cancer." Cochrane 
Database Syst Rev(1). 
van Rhijn, B. W., L. Liu, A. N. Vis, P. J. Bostrom, T. C. Zuiverloon, N. E. Fleshner, et 
al. (2012). "Prognostic value of molecular markers, sub-stage and European 
Organisation for the Research and Treatment of Cancer risk scores in primary 
T1 bladder cancer." BJU Int. 
Vogt, S., N. Jones, D. Christian, C. Engel, M. Nielsen, A. Kaufmann, et al. (2009). 
"Expanded extracolonic tumor spectrum in MUTYH-associated polyposis." 
Gastroenterology 137(6): 1976-1985 e1971-1910. 
von der Thusen, J. H., M. D. van de Wetering, A. M. Westermann, D. A. Heideman 
and E. Thunnissen (2011). "Bronchioloalveolar adenocarcinoma and 
pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated 
polyposis." J Clin Oncol 29(8): e188-190. 
Wacholder, S., S. Chanock, M. Garcia-Closas, L. El ghormli and N. Rothman (2004). 
"Assessing the Probability That a Positive Report is False: An Approach for 
Molecular Epidemiology Studies." J Natl Cancer Inst 96(6): 434-442. 
Wang, M., W. Wu, B. Rosidi, L. Zhang, H. Wang and G. Iliakis (2006). "PARP-1 and 
Ku compete for repair of DNA double strand breaks by distinct NHEJ 
pathways." Nucleic Acids Res 34(21): 6170-6182. 
Wang, Q. E., C. Han, B. Zhang, K. Sabapathy and A. A. Wani (2012). "Nucleotide 
excision repair factor XPC enhances DNA damage-induced apoptosis by 
downregulating the antiapoptotic short isoform of caspase-2." Cancer Res 
72(3): 666-675. 
Weedon, M. N. and T. M. Frayling (2007). "Insights on pathogenesis of type 2 
diabetes from MODY genetics." Curr Diab Rep 7(2): 131-138. 
Wibom, C., S. Sjostrom, R. Henriksson, T. Brannstrom, H. Broholm, P. Ryden, et al. 
(2012). "DNA-repair gene variants are associated with glioblastoma survival." 
Acta Oncol 51(3): 325-332. 
Williams, R. S., J. S. Williams and J. A. Tainer (2007). "Mre11-Rad50-Nbs1 is a 
keystone complex connecting DNA repair machinery, double-strand break 
signaling, and the chromatin template." Biochem Cell Biol 85(4): 509-520. 
Win, A. K., S. P. Cleary, J. G. Dowty, J. A. Baron, J. P. Young, D. D. Buchanan, et al. 
(2011). "Cancer risks for monoallelic MUTYH mutation carriers with a family 
history of colorectal cancer." Int J Cancer 129(9): 2256-2262. 
Witte, J. S. (2012). "Rare genetic variants and treatment response: sample size and 
analysis issues." Stat Med (Epub ahead of print). 
Wong, T. S., X. B. Liu, B. Y. Wong, R. W. Ng, A. P. Yuen and W. I. Wei (2008). 
"Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell 
Carcinoma of Tongue." Clin Cancer Res 14(9): 2588-2592. 
 245 
Wu, M., D. R. Soler, M. C. Abba, M. I. Nunez, R. Baer, C. Hatzis, et al. (2007). "CtIP 
silencing as a novel mechanism of tamoxifen resistance in breast cancer." 
Mol Cancer Res 5(12): 1285-1295. 
Wu, M. C., S. Lee, T. Cai, Y. Li, M. Boehnke and X. Lin (2011). "Rare-variant 
association testing for sequencing data with the sequence kernel association 
test." Am J Hum Genet 89(1): 82-93. 
Wu, X., J. Gu, H. B. Grossman, C. I. Amos, C. Etzel, M. Huang, et al. (2006). 
"Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-
cycle-control genes." Am J Hum Genet 78(3): 464-479. 
Wu, X., Y. Ye, L. A. Kiemeney, P. Sulem, T. Rafnar, G. Matullo, et al. (2009). 
"Genetic variation in the prostate stem cell antigen gene PSCA confers 
susceptibility to urinary bladder cancer." Nat Genet 41(9): 991-995. 
Xing, J., C. P. Dinney, S. Shete, M. Huang, M. A. Hildebrandt, Z. Chen and J. Gu 
(2012). "Comprehensive pathway-based interrogation of genetic variations in 
the nucleotide excision DNA repair pathway and risk of bladder cancer." 
Cancer 118(1): 205-215. 
Xu, J., S. Lv, Y. Qin, F. Shu, Y. Xu, J. Chen, et al. (2007). "TRB3 interacts with CtIP 
and is overexpressed in certain cancers." Biochim Biophys Acta 1770(2): 273-
278. 
Yang, F. and D. C. Thomas (2011). "Two-stage design of sequencing studies for 
testing association with rare variants." Hum Hered 71(4): 209-220. 
Yang, H., C. P. Dinney, Y. Ye, Y. Zhu, H. B. Grossman and X. Wu (2008). 
"Evaluation of genetic variants in microRNA-related genes and risk of bladder 
cancer." Cancer Res 68(7): 2530-2537. 
Yang, J., Z. Xu, J. Li, R. Zhang, G. Zhang, H. Ji, et al. (2010). "XPC epigenetic 
silence coupled with p53 alteration has a significant impact on bladder cancer 
outcome." J Urol 184(1): 336-343. 
Yang, R., B. Schlehe, K. Hemminki, C. Sutter, P. Bugert, B. Wappenschmidt, et al. 
(2010). "A genetic variant in the pre-miR-27a oncogene is associated with a 
reduced familial breast cancer risk." Breast Cancer Res Treat 121(3): 693-
702. 
Yang, X., D. Liu, H. Wu, H. Kang, H. Pang, D. Huang, et al. (2012). "Association of 
XPC polymorphisms with susceptibility and clinical outcome to chemotherapy 
in breast cancer patients." Cancer Sci [E-publication ahead of print]. 
Yin, M., Z. Liao, Y. J. Huang, Z. Liu, X. Yuan, D. Gomez, et al. (2011). 
"Polymorphisms of homologous recombination genes and clinical outcomes 
of non-small cell lung cancer patients treated with definitive radiotherapy." 
PLoS One 6(5): e20055. 
Yokoyama, S., S. L. Woods, G. M. Boyle, L. G. Aoude, S. MacGregor, V. Zismann, et 
al. (2011). "A novel recurrent mutation in MITF predisposes to familial and 
sporadic melanoma." Nature 480(7375): 99-103. 
Yoon, H. H., P. J. Catalano, K. M. Murphy, T. C. Skaar, S. Philips, M. Powell, et al. 
(2011). "Genetic variation in DNA-repair pathways and response to 
radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort 
study of the Eastern Cooperative Oncology Group." BMC Cancer 11(1): 176. 
Yu, H., H. Zhao, L. E. Wang, Y. Han, W. V. Chen, C. I. Amos, et al. (2011). "An 
analysis of single nucleotide polymorphisms of 125 DNA repair genes in the 
Texas genome-wide association study of lung cancer with a replication for the 
XRCC4 SNPs." DNA Repair (Amst) 10(4): 398-407. 
Yu, X. and R. Baer (2000). "Nuclear localization and cell cycle-specific expression of 
CtIP, a protein that associates with the BRCA1 tumor suppressor." J Biol 
Chem 275(24): 18541-18549. 
Yu, Z., Z. Li, N. Jolicoeur, L. Zhang, Y. Fortin, E. Wang, et al. (2007). "Aberrant allele 
frequencies of the SNPs located in microRNA target sites are potentially 
associated with human cancers." Nucleic Acids Res 35(13): 4535-4541. 
 246 
Yuan, J. and J. Chen (2009). "N terminus of CtIP is critical for homologous 
recombination-mediated double-strand break repair." J Biol Chem 284(46): 
31746-31752. 
Yun, M. H. and K. Hiom (2009). "CtIP-BRCA1 modulates the choice of DNA double-
strand-break repair pathway throughout the cell cycle." Nature 459(7245): 
460-463. 
Zeng, Y., R. Yi and B. R. Cullen (2003). "MicroRNAs and small interfering RNAs can 
inhibit mRNA expression by similar mechanisms." Proc Natl Acad Sci U S A 
100(17): 9779-9784. 
Zha, S., C. Boboila and F. W. Alt (2009). "Mre11: roles in DNA repair beyond 
homologous recombination." Nat Struct Mol Biol 16(8): 798-800. 
Zhang, L., J. Huang, N. Yang, J. Greshock, M. S. Megraw, A. Giannakakis, et al. 
(2006). "microRNAs exhibit high frequency genomic alterations in human 
cancer." Proc Natl Acad Sci U S A 103(24): 9136-9141. 
Zhang, Y., L. H. Rohde and H. Wu (2009). "Involvement of nucleotide excision and 
mismatch repair mechanisms in double strand break repair." Current 
Genomics 10(4): 250-258. 
Zheng, D., S. Haddadin, Y. Wang, L. Q. Gu, M. C. Perry, C. E. Freter and M. X. 
Wang (2011). "Plasma microRNAs as novel biomarkers for early detection of 
lung cancer." Int J Clin Exp Pathol 4(6): 575-586. 
Zhou, J., Y. Zhou, B. Yin, W. Hao, L. Zhao, W. Ju and C. Bai (2010). "5-Fluorouracil 
and oxaliplatin modify the expression profiles of microRNAs in human colon 
cancer cells in vitro." Oncol Rep 23(1): 121-128. 
Zhu, C., X. Li and J. Yu (2011). "Integrating Rare-Variant Testing, Function 
Prediction, and Gene Network in Composite Resequencing-Based Genome-
Wide Association Studies (CR-GWAS)." G3 (Bethesda) 1(3): 233-243. 
 
  
 247 
 
 
 
11. APPENDICES 
 248 
11.1. Appendix A 
 
11.1.1. Reagents 
Compound Supplier/ Manufacturer 
2-mercaptoethanol Sigma-Aldrich, UK 
Absolute ethanol Sigma-Aldrich, UK 
Ammonium persulphate Sigma-Aldrich, UK 
Bovine serum albumin  Sigma-Aldrich, UK 
Bradford solution  Sigma-Aldrich, UK 
Citric acid Sigma-Aldrich, UK 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK 
DPX mountant  Sigma-Aldrich, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, UK 
Eosin Sigma-Aldrich, UK 
Ethidium bromide Sigma-Aldrich, UK 
Formalin Sigma-Aldrich, UK 
Hi-Di formamide  Life Technologies, UK 
Hydrochloric acid, concentrated (38.5 – 38.0%) Sigma-Aldrich, UK 
Hydrogen peroxide  Sigma-Aldrich, UK 
L-glutamine  Sigma-Aldrich, UK 
Meyers Haematoxylin Sigma-Aldrich, UK 
Molecular grade agarose Promega, USA 
Paraformaldehyde Sigma-Aldrich, UK 
Phosphate buffered saline, tablets Sigma-Aldrich, UK 
Phosphatase inhibitor  Roche, Switzerland 
Ponceau red  Sigma-Aldrich, UK 
Proteinase inhibitor  Roche, Switzerland 
Protogel National Diagnostics, UK 
RIPA buffer  Sigma-Aldrich, UK 
Scott’s tap water  Sigma-Aldrich, UK 
Sodium chloride Sigma-Aldrich, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, UK 
Sodium hydroxide Sigma-Aldrich, UK 
TEMED Sigma-Aldrich, UK 
Tris base Sigma-Aldrich, UK 
 249 
Compound Supplier/ Manufacturer 
Tris/Borate/EDTA (TBE) buffer, 10 x solution 
 (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 
8.3) 
Bio-Rad Laboratories, UK 
Tris-Chloride buffer (Buffer EB) 
(10 mM Tris-Cl pH 8.5) 
Qiagen, UK 
Tris-EDTA buffer, molecular grade 
(10 mM Tris pH 8, 1 mM EDTA) 
Sigma-Aldrich, UK 
Tris-Glycine transfer buffer, 10 x solution 
(25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) 
Bio-Rad Laboratories, UK 
Triton-X-100 Sigma-Aldrich, UK 
Trypsin 0.25% - EDTA solution, sterile Sigma-Aldrich, UK 
Tween 20  Sigma-Aldrich, UK 
Xylene Sigma-Aldrich, UK 
 
11.1.2. Buffers 
Citric acid antigen retrieval buffer, 1 x solution: 
 4.2 g Citric acid 
 Made up to 2 l with water 
 Adjusted to pH 6 with sodium hydroxide 
 
Phosphate buffered saline, 1 x solution: 
 5 PBS tablets made up to 1 l with water 
 
Tris-buffered saline (TBS) pH 7.5, 10 x solution: 
 12.11 g Tris-base 
 87.66 g Sodium chloride 
 Made up to 1 l with water 
 Adjusted to pH 7.5 with concentrated hydrochloric acid 
 
Tris-EDTA + 0.05% Triton-X-100 antigen retrieval buffer, 1 x solution: 
 2.42 g Tris-base 
 0.74 g EDTA 
 1 ml Tween 20 
 1 ml Triton-X-100 
 Made up to 2 l with water 
 Adjusted to pH 8 with concentrated hydrochloric acid 
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Tris-Glycine-SDS running buffer, 5 x solution: 
 15.1 g Tris base 
 94 g Glycine 
 50 ml 10% SDS 
 Made up to 1 l with sterile water 
 
11.1.3. Cell Culture Media 
RPMI-1640 medium Catalogue No R0883 (Sigma-Aldrich, UK) 
Minimum Essential Medium Eagle medium Catalogue No M2279 (Sigma-Aldrich, UK) 
Media were supplemented with 10% fetal bovine serum (Sigma-Aldrich, UK) and 1% 
L-glutamine (Sigma-Aldrich, UK). 
 
 
11.1.4. PCR Kits 
PCR kit Supplier/ 
Manufacturer 
Contents 
ABgene Extensor Long PCR 
Master Mix  
Cat No: AB-0792 
ThermoFisher 
Scientific, UK 
2 x Extensor Long PCR master mix, 
Buffer 1/2 
Bio-X-act  
Cat No: BIO-25024 
BioLine, UK 2 x Bio-X-Act Long mix 
50 mM MgCl2 solution 
Fermentas Phusion Flash 
High-Fidelity PCR Master Mix 
Cat No: F-548 
ThermoFisher 
Scientific, UK 
2 x Phusion Flash PCR master mix 
Fermentas Phusion High 
Fidelity Master Mix  
Cat No: F-530 
ThermoFisher 
Scientific, UK 
Phusion DNA Polymerase (100 U) 
5 x Phusion HF Buffer 
5 x Phusion GC Buffer 
50 mM MgCl2 solution 
HotShot Diamond PCR 
Master Mix  
Cat No: HS002 
Clent Life 
Science, UK 
2 x HotShot Diamond PCR master mix  
HotStarTaq Master Mix kit  
Cat No: 203443 
Qiagen, UK 2 x HotStarTaq master mix 
Distilled water 
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PCR kit Supplier/ 
Manufacturer 
Contents 
Invitrogen SequelPrep Long 
PCR Kit 
Cat No: A10498 
Life 
Technologies, 
UK 
Sequel Prep Long Polymerase 5 U / μl 
Sequel Prep 10 x Reaction Buffer 
Sequel Prep 10 x Enhancer A 
Sequel Prep 10 x Enhancer B 
DMSO 
LCGreen Plus+ Dye  
Cat No: BCHM-ASY-0005 
Idaho 
Technology, 
USA 
LCGreen dye 
Qiagen Muliplex PCR Master 
Mix 
Cat No: 206143 
Qiagen, UK 2x Muliplex PCR Master Mix 
Q Solution Buffer 
Distilled water 
Biotium Fast Probe Master 
Mix 
Cat No: 31005 
Biotium, USA 2x Fast Probe Master Mix 
 
  
11.1.4.1. Miscellaneous kits 
Item Name 
Supplier/ 
Manufacturer 
Cat No 
QIAquick PCR Purification Kit  Qiagen, UK 28106 
Dako REA Detection System, 
Peroxidase DAB+, Rabbit/ Mouse  
Dakocytomation, 
Denmark 
K500111 
MenaPath X-Cell Plus HRP-Polymer 
Detection Kit  
Menarini Diagnostics, 
UK 
MP-XCP-U100 
Invitrogen Quant-IT BR PicoGreen Kit  Life Technologies, UK P7589 
BigDye® Terminator v1.1 Cycle 
Sequencing Kit  
Applied Biosystems, 
UK 
4337449 
MinElute PCR Purification Kit  Qiagen, UK 28006 
DNA 1000 Kit  
Agilent Technologies, 
USA 
5067-1504 
End-It DNA End Repair kit  EpiCentre, USA ER81050 
DNA Polymerase I Large (Klenow) 
Fragment Exonuclease Minus  
Promega, USA M2181 
LigaFast Rapid DNA Ligation System Promega, USA M8225 
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Item Name 
Supplier/ 
Manufacturer 
Cat No 
AllPrep DNA/RNA FFPE Kit Qiagen, UK 80234 
High Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, 
UK 
4374966 
Taqman GAPDH Control Reagents 
(Human) 
Applied Biosystems, 
UK 
402869 
Invitrogen ROX Reference Dye Life Technologies, UK 12223-012 
QIAquick Gel Extraction Kit Qiagen, UK 28704 
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11.1.5. Primers & PCR conditions 
DNA oligonucleotides were purchased from Eurogentec, Belgium dissolved in molecular grade water at 100 µM concentration and stored at 
4°C. 
 
11.1.5.1. Long PCR 
Table 49: MUTYH long PCR primers and conditions for the pilot multiplexed NGS study. 
Gene Amplicon Exons Forward Primer Reverse Primer 
Amplicon 
Size (bp) 
Long PCR 
Kit 
Annealing 
Temp (°C) 
Extension 
Time 
(min) 
Total 
no of 
cycles 
MUTYH 
1 1 - 4 
GTATGAGCCTGG
GTAAATTACTTCC 
TTCAGTAAATAAAA
CATCAAAAGTTCC 
3049 
 SequelPrep 
Enhancer B 
65 3 35 
2 5 - 9 
TAACAGTTAGGGA
GCAGTGAAAATC 
ATTAGAGCTGACC
TGAGACGTAAAC 
6583 
 SequelPrep 
Enhancer B 
68 8 40 
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Table 50: XPC long PCR primers and conditions for the pilot multiplexed NGS study. 
Gene Amplicon Exons Forward Primer Reverse Primer 
Amplicon 
Size (bp) 
Long PCR 
Kit 
Annealing 
Temp (°C) 
Extension 
Time 
(min) 
Total 
no of 
cycles 
XPC 
1 1 
TGAATAAATAATTG
TTGCGCTCAC 
GGAGGAAAGCATA
GATTTAAAGAGG 
1265 
 Extensor 
Long PCR 
Master Mix 2 
54 4 35 
2 2 - 3 
GAGGTTAGCTGAC
ATTTAAGATCTGG 
TACTCACTCACAC
TGCCACCTAAG 
3261 
 Extensor 
Long PCR 
Master Mix 2 
56 4 35 
3.1 4 - 5.1 
TCTAAAGACTGTC
TGGGTTGTGTG 
TCTAATCCTTTCC
CCTACATAAAGC 
1994  Bio-X-act  61 4 35 
3.2 5.2 - 6 
AAGCAATTTGTATT
TTGAAGCTTTG 
TAGCACATCTGAC
CAAAAACTACG 
1316 
 Extensor 
Long PCR 
Master Mix 1 
59 2 35 
4.1 7 - 8 
TAGCACTAGACTG
TTTCCAGAGTCC 
GACAGTATCATGT
CTGTCTCATTCC 
3434 
 Extensor 
Long PCR 
Master Mix 1 
65 4 35 
4.2 9 
AGTGAATTGCCTA
CTGAGAAATGAG 
AGAGACAGGGTTT
CATCGTGTTAG 
1255 
 SequelPrep 
Enhancer A 
65 2 35 
5 10 
AATCATTTGACTG
TTCCATGTGC 
GTGTCCTGTGAAT
AGTCTCTGTGG 
1269 
 Extensor 
Long PCR 
Master Mix 1 
62 2 35 
6.1 11 - 14 
ACAGGCTCTACTG
ATGGACAGTTAC 
AGACAGAAGACTG
AGGTGTCCTAAC 
2111 
 Extensor 
Long PCR 
Master Mix 1 
65 3 35 
6.2 15 - 16 
AAAAGCCCTTCAT
CTGACTTTATG 
GTCTGTTTCTCAA
CAAGAGGTTCC 
1987 
 Extensor 
Long PCR 
Master Mix 1 
61 2 35 
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Table 51: MRE11A long PCR primers and conditions. 
Gene Amplicon Exons Forward Primer Reverse Primer 
Amplicon 
Size (bp) 
Long PCR Kit 
Annealing 
Temp (°C) 
Extension 
Time 
(min) 
Total 
no of 
cycles 
MRE11A 
1 1 - 3 
CAGACGTTCTAATT
CAAAAGTTCTAC 
AGCTTTGACAGTCAC
CTTACATTTC 
3960 
SequelPrep 
Enhancer A 
55 4 35 
2 4 
TAACAGTTTGCCTC
TTCCATTAGAG 
TGTCAACAAGAGTCC
ATAAACAAAG 
1250 
Extensor Long 
PCR Master Mix 1 
62 2 35 
3 5 - 7 
TCAAACTAATTGAA
ATGAATTGTCG 
TCTACCTTTTTGTTG
AATTGAGGAG 
3903 
SequelPrep 
Enhancer B 
55 4 40 
4 8 - 9 
CACTTGTCTGTGTC
CAATAAGTTTG 
TCCAGTATTCCTCTC
TCTCAATGAC 
1701 
SequelPrep 
Enhancer B 
59 2 35 
5 10 
AGGAAAGCCTTATT
GAAACATGAG 
AGACTGTGAGTGGT
GCTATAAGAGG 
2233 
SequelPrep 
Enhancer A 
55 3 35 
6 11 
CTTTCTCTTGAGGC
ACATCTCTAAG 
GAGGCCTCAGAAAT
AACAATGC 
2068 
Extensor Long 
PCR Master Mix 1 
68 3 35 
7 12 - 13 
TATGAACGAGAAAT
ACTGACTGTGG 
AGAGAAGATACTATC
CATGGGGAAC 
2067 
Extensor Long 
PCR Master Mix 1 
59 2 35 
8 14 
ACGATAATATATGG
CACATTGAAGG 
GGTTGCTAACTTGTA
GATTCAAACC 
1394 
Extensor Long 
PCR Master Mix 1 
62 2 40 
9 15 - 16 
ATAGCTCACTGCAG
CCTGTATCTC 
CTCTCTCTGTTGCTA
GGGTAGAGTC 
2448 
SequelPrep 
Enhancer B 
68 3 35 
10 17 - 18 
TCTCAATAAGCTGG
GAAATAATGAG 
GGAGAGAACACAGT
CTTCCATTAAG 
2223 
Extensor Long 
PCR Master Mix 1 
59 3 35 
11 19 
TTTTCAGAAGTGGA
AGATGGTAATG 
AGGCACATTACAAAG
AAGAAGACAC 
1369 
SequelPrep 
Enhancer B 
59 2 35 
12 20 
AAAATTACAGCTGT
TTCTGAGTTGG 
TTGAGATTGAGTTTC
ACTCTTGTTG 
3620 
SequelPrep 
Enhancer B 
62 4 40 
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Table 52: Long PCR primers and conditions for NGS resequencing of XPC. 
Gene Amplicon Exons Forward Primer Reverse Primer 
Amplicon 
Size (bp) 
Long PCR 
Kit 
Annealing 
Temp (°C) 
Extension 
Time 
(min) 
Total no 
of 
cycles 
XPC 
1 1 - 3 
TAACCTAACTCAAC
TGGTCCCTATG 
GTAAACAGCCTTC
TTTGGTAACTTG 
9800 
Phusion 
Flash 
68 5 401 
2 4 - 7 
GCTACTGTATACAA
GCAACGTAGGG 
TGTTTTATTCAGAC
AGAGCCTTACC 
4649 
Phusion 
Flash 
62 2 35 
3 8 - 10 
ACCCATAACCCAGT
ATATGGATGC 
TGTGGGGTGTGTT
TTATACTGC 
4394 
Phusion 
Flash 
62 2 35 
4 11 - 16 
CTTTACCCCATCCT
GATAGTCTGC 
GTCTGTTTCTCAA
CAAGAGGTTCC 
8079 
Phusion 
Flash 
68 4 401 
 
1 Phase 1 Denaturation and Annealing thermocycling steps were extended to 10 seconds each.  
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11.1.5.2. Conventional DNA sequencing primers 
Table 53: Conventional sequencing primers designed for specific MRE11A and XPC variants. 
Gene 
NCBI hg19 
position/ dbSNP 
rs number 
Variant base 
change 
Forward Primer Reverse Primer 
Amplicon 
Size (bp) 
Annealing 
Temp (°C) 
XPC 
rs111768011 C>G GAGGCCTGGTGGAGGTTG AACTGCCTTCTCCGAGTTCA 214 57 
rs59774494 A>G TTGGCCTCCTTTCTCTTCCT TAGTATCCGCGGGGTATCTG 188 57 
Chr 3: 14214734 G>A CCTGGCAGGAGGTTAGCTG AGCAACCAGCTCTCAGCTTC 165 57 
rs3731078 A>G TGTCCAGGCACAGCTATGTT TGGAATTTTTAAAACCCCTCCT 209 57 
rs3731123 C>G 
GCATGTTCCTGTTCTTCTACGA CAGAGCCCGGAGAATCAGTA 228 57 
Chr 3: 14201378 T>A 
rs3731137 C>T AGAGAAAAGTCGCAGGGTGA ATCTGTGGCTTGTGGCAACT 228 57 
rs77167750 A>G TTCTTCCTAGGCAAGGGTTG GTTTTTCCCCTGCCATTCTT 153 59 
Chr 3: 14192475 T>C 
CTTCCCAGCCTGAATCCAT AGGACAGTGGAGGCAAGAAA 300 59 
rs79619898 T>G 
rs115373819 C>T TGTCCCTGAAGTGGTGACAG CGTGGCCTCCATCACATATT 155 57 
rs181225959 G>A GAGGTTGAGGCGAGTGCAT CCTCTGCCTCCTGGGTTT 178 59 
rs7638104 C>T 
ATGATGGGTGAGGCTGGATA GATGTCAACCCTCGAACCTG 230 63 
Chr 3: 14189586 C>T 
Chr 3: 14189426 T>C AGATGTGGCCCACTGTCTTC GGCAGGAGCCTGCTGTATT 356 63 
Chr 3: 14186649 A>G GCTAAAATCAGGAAAGAAAAGGA AGCCTGCGCAAGACAGTAAG 242 57 
MRE11A 
rs11020802 G>T CACGGGCTCAGGAGTTCTTA CTCGCGACACTTCATGGATA 257 57 
rs1805363 G>A GGACTTGAAGCATCTACGTT ATGCGATTCCTAAATTACCC 224 57 
Chr 11: 94226459 C>T 
CCCAAACCTGGCTATTTTCA ATTTTCCTTTCCCGTGCTCT 314 57 
Chr 11: 94226398 A>T 
 258 
MRE11A 
rs496797 G>A CTGCAGATGCACTGTAAGCA 
TCAAATTACTGCAAGACTCCAAT
C 
216 57 
Chr 11: 94225305 deletion A 
CATGCCTGTAATCCCAGCTA 
TCCAAGAAGGTAGGTCAGATAC
TT 
337 53 
Chr 11: 94225127 G>A 
rs11404578 insertion T 
TTCAGATTAATTTTGAGGCTTAAATG TGAGAAGGCTAAACCCAGAGA 316 55 rs13447588 T>C 
rs13447590 G>C 
rs61893736 C>T CAAATTGAAACAATTCTGTGTTGG GTAACCCAGGCCCAAAAGTT 220 57 
rs10485020 T>A 
TTGAACTAGTGGTTAGGAAAACTGT GCAGAAGCTTTGACAGTCACC 597 57 Chr 11: 94223936 C>T 
Chr 11: 94223855 T>C 
Chr 11: 94218991 A>G TGATCAGTCAGTCAACTTTGGTTT CACTGCAACCTCTGCTTCTG 250 57 
rs3218740 C>T CAGGTGATACGATATTCATGCAG CGCAATCTTTGTGCTTCCTT 178 57 
Chr 11: 94211508 A>G CAAAACTGCACTTTGATATCTTGG 
TATTTCACTTCCTGCTCTTTCACT
T 
174 57 
Chr 11: 94210491 T>C GCAGTGTTGTCCACCCTTTT 
TGCAGAAATAAATATTAAAAGGG
ATG 
244 57 
Chr 11: 94210210 C>A 
GAATTTTACCATAGAAAACTCACATTT GGGTCTTGCTATGTTGTCCAG 498 57 rs13447619 G>A 
Chr 11: 94209866 G>T 
rs13447623 A>G TTTCTCTGAAAAAGTTTGAGC AATGGGATAAAGGAATGGAT 278 57 
rs115244417 C>G AAAGGGAGGAAGATGAATATG CCTTACAGGCTTCATGAGAA 275 55 
Chr 11: 94200953 T>C TTTTGAGATTGAAGAAATGCTTG CCGATGGTGATTGCTCTTCT 190 55 
Chr 11: 94200365 C>T CCAGTGCCCTGATTTCACTT TCTTTTCCACTGGTTATGGTGA 333 57 
Chr 11: 94199802 G>A 
TTCATGAAAATTTGAGAAGTACTGG TGGACAAAGGTTCCAGTGAA 572 57 Chr 11: 94199571 A>G 
Chr 11: 94199359 T>C 
rs104895017 A>G TCAGATGGTTTGCTTGGTAGG CGCTAGGAAACAACAATTTGC 270 57 
 259 
MRE11A 
rs640627 G>A TCAGATGGTTTGCTTGGTAGG CGCTAGGAAACAACAATTTGC 270 57 
Chr 11: 94197302 A>G 
GAACCTTTCAGTGTTCTTCG ATTCCCACTGTCAATTTGTT 242 57 rs641936 T>C 
Chr 11: 94197239 T>C 
rs13447654 A>G 
CCCGGTGTGTGATGTTCC TGCCCGTCAGAGAAATACAA 560 63 
Chr 11: 94196707 A>T 
Chr 11: 94196702 A>C 
Chr 11: 94196674 T>C 
Chr 11: 94196475 T>C 
Chr 11: 94195930 G>A TTGTTGTCATTGCTTTTGGTG AAGCAATGGGGAAAGGATTC 223 57 
Chr 11: 94193845 insertion CTC GCTGCACAGCAGGGAAAA 
AAGTTTCACTTAAGAATGTCCCT
GA 
145 57 
Chr 11: 94193208 A>C 
GTTTTGGCATGGCTGTCTTC TGGCAAAGAGGAACAAAGGT 278 57 
Chr 11: 94193178 C>T 
rs61749249 C>A ATGCCATTGAGGAATTAGTG ACCAACCATATGCAAGACTC 297 57 
Chr 11: 94189265 G>T 
AAGATGATGAAGTCCGTGAGG 
AGAGACAGGGTCTCACTCTGTT
G 
362 57 
Chr 11: 94189161 G>A 
rs13447695 A>C 
CATCGAGAGGAGGGTCTCAA CGTGACAAACACAGTGAAGC 280 57 
rs13447696 C>G 
Chr 11: 94179824 G>A 
AAAGTCAGTTTAAGAAAGAAAACTGC TGGTGAAACCCCACCTCTAC 515 57 
Chr 11: 94179497 A>G 
Chr 11: 94170115 A>G GCTGGAAGGAGCTTTACCAA 
TCTATAACCATTGAACTCACCTT
CA 
180 57 
rs61893706 G>A TGTGTTCCCTTAGGTGCTCA ATCACCTGGCAAGGAAACAA 235 57 
rs113009211 G>C TTGATGCAGCATTAGTACAAGGA TGGTGGTGCACGTCTGTAAT 226 57 
rs104895013 G>T CCCCGTTTTACAGATGAGGA CATCAAGTGTGCCTTTCTGG 205 61 
Chr 11: 94162799 T>C CAGGGAGTACATGTGCAGGTT GGAGGCCACTATCCTAAGCA 238 65 
 260 
MRE11A 
Chr 11: 94153102 G>A TTTCCTGAGCATAACTCCAT AACCCAGAACCTCTAGGAAA 279 57 
rs13447749 G>A 
AAAACAATTTATGCGAACCT CAATTTTTAACCCGTTTCCT 381 55 
Chr 11: 94152721 A>C 
Chr 11: 94152660 C>T 
rs11020777 T>C 
Chr 11: 94151932 T>C GCTGCCTCATATAGCACTTT GCTCTTCCCTGACTTAACCT 249 55 
rs104895004 G>T GACATAGCAGTTACAGAGGGTGA 
CATTCCTATACCAACAGGTCTGA
A 
226 55 
rs2155209 A>G 
TCCCTCTACAGGTCAAGAAA GAATGGATTTTCCTCTTTATGA 386 55 
Chr 11: 94150560 G>A 
rs13447762 T>G CCAGCTTGATAAATTTGCCTAT AGCGATTCTCCTGCCTCAG 287 55 
Chr 11: 94219326 deletion T ATCACCTTGTGTGGCCTGA TGTTTTCCTTGAGGGCTTATTT 315 55 
Chr 11: 94219035 A>T 
TGATCAGTCAGTCAACTTTGGTTT CACTGCAACCTCTGCTTCTG 250 57 
Chr 11: 94219035 deletion A 
Chr 11: 94218775 deletion A 
CTACTCGGGAAGCTGAGGTG AAGTCAAAAGACAAGCCATTGA 332 57 
Chr 11: 94218692 A>T 
Chr 11: 94218691 A>T 
Chr 11: 94218690 A>T 
Chr 11: 94218689 A>T 
Chr 11: 94218688 T>G 
Chr 11: 94218677 
insertion 
GAGATTTTTT 
Chr 11: 94212913 insertion A 
AGTGGTCATATGCCAATGTAGA TCATTTCCAAAATTCCAACAAA 254 55 
Chr 11: 94212912 insertion C 
Chr 11: 94210968 deletion C CCTCCACTTTCTAACCTTCAGTG AAACACTGGCAAAATTGAAGG 241 55 
Chr 11: 94209742 deletion A 
GCATGGTGGCTTATGCTTGT TTGTTTTCTTACTTCGGCTTAAAA 271 55 
Chr 11: 94209722 insertion A 
 261 
MRE11A 
Chr 11: 94189682 insertion T CCCATAGGGTATTAGAATTTTTCC GGGGCTACAATTAAGAAATGC 225 51 
Chr 11: 94189682 deletion T CCCATAGGGTATTAGAATTTTTCC GGGGCTACAATTAAGAAATGC 225 51 
Chr 11: 94170173 deletion T GCTGGAAGGAGCTTTACCAA 
TCTATAACCATTGAACTCACCTT
CA 
180 57 
Chr 11: 94163043 T>A 
TGAATTATGTAGTTCATTGTGTTTGTT TACCAAACCTCAGCATCACG 291 51 
Chr 11: 94162988 deletion T 
Chr 11: 94162335 A>G GGGTCAAATCGTAGCTCTGTT CAAAGCAGCCAACAAACAAA 244 55 
Chr 11: 94151564 insertion T 
TTAGGTGGGTCTGGGTGAGA AAAAAGGTTTCCCTGTCACG 261 59 
Chr 11: 94151561 T>A 
Chr 11: 94151548 insertion A 
Chr 11: 94151548 deletion A 
Chr 11: 94151547 T>A 
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Table 54: Conventional sequencing primers for exons of MUTYH and XPC. 
Gene Exon Forward Primer Right Primer 
Amplicon 
Size (bp) 
Annealing 
Temp (°C) 
MUTYH 
6 - 7 
TACCACCTTCAC
CCTTGACC 
GTTCCTACCCTC
CTGCCATC 
274 61 
8 - 9 
CCAGGAGTCTTG
GGTGTCTT 
AGCAGAGCTCCT
TTGCAGAC 
400 61 
10 - 11 
CAAAGGAGCTCT
GCTTCACA 
AGAACTGGAATG
GGGCTTCT 
394 61 
12 
AAAGCCCTCTTG
GCTTGAGT 
CCGATTCCCTCC
ATTCTCTC 
297 60 
16 
CCCCTCCCCCAA
CTACAAG 
CGAAACCAGTCT
GAGCAACA 
298 60 
XPC 
1 
GTATGGGGTGGA
GCTTCCTT 
AGCTACGCAGGA
GCTTGGAT 
484 65 
2 
CCTTCCACCCCT
CACCTTAT 
AATCTTCCATGGA
CCCCAGT 
341 65 
3 
TGTTGATGGAGG
AAGTGAGG 
TGCAATTAGTGAT
CTGACTCCA 
359 62 
4 
CATGCCTCACTT
CCTCCTTC 
CTCAGTCCTGGT
CCCCTACA 
328 65 
5.1 
AGGAAATAGCTG
GCTTGCAG 
AAATAAAGCCTC
GGTGAGCA 
319 65 
5.2 
TTTGGCAGCAAA
AATTCCTC 
ATGCCCACCACC
TGATACAT 
355 59 
6 
GCTGGGGAAAGT
AGGACAGA 
TGTCGGTAACAC
ACCTGGAA 
345 59 
7 
CTGGCTGTTTCC
AGCTTTTC 
GCTCGAAAGAAC
CCACACTC 
326 65 
8.1 
GGGGACATCTTG
ATGTATTGG 
GCCTCATCACTC
CCACTCTC 
450 63 
8.2 
GACAAGCAGGAG
AAGGCAAC 
ACCATCGCTGCA
CATTTTCT 
333 63 
8.3 
GACCCAAGCTTG
CCAGTG 
GCTGGGCATATA
TAAGGTGCTC 
478 59 
9 
GCTCCACCATCT
GTTGTCAG 
AAGGCTGCTAAT
CCCATGC 
327 64 
10 
GTCCACGTTCAA
GGCTGTTT 
GGGAGGCTCATC
ATCACTTC 
354 63 
11 
TTCTGAGGGTTC
ACCAGGTA 
GGGTGAGCAAGT
CAGCATTT 
320 60 
12 
AGCATCAGAAGG
GCTCAGG 
AGCTTTCCATCC
CCATCTCT 
319 63 
13 
AGATGTGGCCCA
CTGTCTTC 
GGCAGGAGCCTG
CTGTATT 
356 63 
14 
CTTGGTGTGAAG
GAGAGGCTA 
ACTTGAGGATGG
GGCAGAA 
320 65 
15.1 
ATTACTGACCCTC
GCCTGTG 
GTGCATGCTGCC
TCAGTTT 
397 63 
15.2 
CACTACAGGCCC
CACACCT 
ATGGTCCTAGGT
CCGCAAC 
422 63 
15.3 
AATGCGCTGATC
GTTTCTT 
AGAGCCAAATCT
TTAGATAAATGC 
420 61 
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11.1.6. Taqman SNP Genotyping Assays 
Table 55: Applied Biosystems Taqman SNP Genotyping Primers and Probes for MUTYH rare variants genotyped. 
   
Assay Assay ID Gene Variant Forward Primer Reverse Primer VIC Reporter 1 FAM Reporter 2 
Custom AHJ93TS 
MUTYH 
rs3219470 
C>T 
GGGTGATTGAATTT
GAAAGAGGTTCCT 
CCTCGGCCTCCCAAA
GTG 
CGGTGGCTCAC
GCC 
CGGTGGTTCA
CGCC 
Custom AHLI1Z0 
rs1140199 
G>A 
CTGGCCAACATGGT
GAAACC 
GCGCCCGCACCATAC 
CCGTCTCTACT
AAAAGTACAA 
CGTCTCTACT
AAAAATACAA 
Custom AHD1CYN 
c.IVS1+2246 
G>C 
CCTTGACCACAGTC
TTTAAAATTGCA 
AGCATAAAAAGCAAAA
ATTAGACCAAGAGG 
CCCACCTTGGC
ACTC 
CCCACCTTCG
CACTC 
Custom AHMRZ58 
rs34612342 
A>G 
CCACAGGAGGTGAA
TCAACTCT 
CCTTCCGAGCTCCCT
CCT 
CCTGGGCTACT
ATTCT 
CTGGGCTGCT
ATTCT 
Custom AHFAA4V 
c.1099 
C>T 
CCTGTGGAGAGCCT
GTGC 
CCCTTCCCCAGTAGG
CTTAC 
TCTCTGGCGTG
CCCG 
CTCTGGCATG
CCCG 
Pre-
designed 
C_27860252
_10 
rs36053993 
G>A 
    
Custom AHGI9A3 
c.1718 
C>T 
CAGGGTTCCAAAAG
GTCCCA 
GCTGTGTGCATCAGT
GGAGAT 
CACGGAGAGGA
CACC 
CACGGAAAGG
ACACC 
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Table 56: Applied Biosystems Taqman SNP Genotyping Primers and Probes for XPC rare variants genotyped. 
Assay Assay ID Gene Variant Forward Primer Reverse Primer VIC Reporter 1 FAM Reporter 2 
Custom AHN0YCG 
XPC 
c.172 
delAGGG 
AGAAATCCAAGGCCAA
GAGCAA 
GGCGTCTCCCGCGA
A 
CTCTCACCCTC
CTCCTC 
CGCTCTCACCT
CCTC 
Custom AHO9WIO 
rs3731072 
G>C 
GGAGAAGAGGAAGAA
CAGAGGGATA 
GGACTAGAGGCTGC
TGGAAAAG 
TCACTGCCAGT
ATCAG 
TCACTGCCACT
ATCAG 
Custom AHHR7HB 
c.IVS14+2 
T>G 
CAGGCAGTCATTGAAA
GGAAGGA 
GCTTCTGCTGTCCC
TCAGT 
CATATGCGCTT
ACCTCCT 
ATGCGCTTCCC
TCCT 
Custom AHI05NJ 
c.1271 
T>G 
CGACGTCCGCATGGC 
TCATCACTCCCACTC
TCCTCTTTAT 
TGGAGGCCACC
CGC 
TGGAGGCCCCC
CGC 
Custom AHJ93TR 
c.1624 
T>G 
AGTGGCTAGAGGTGTT
CTGTGA 
CACACCGTGCACAC
AGTCTA 
CACATACCCAC
TTTTC 
CACATACCCCC
TTTTC 
Custom AHLI1ZZ 
c.1655 
T>G 
TGTTCTGTGAGCAGGA
GGAAAAG 
GGCGTACTTGTAAC
AGGTCAGA 
CTGGCCCACCA
CACC 
CTGGCCCCCCA
CACC 
Custom AHMRZ57 
c.2240 
T>G 
ACTGGCAGACAGAGG
AGTATCAG 
CCTTCTGATGCTGC
CCTTACC 
TTCCCGTCCAC
GGCCA 
TTCCCGTCCCC
GGCCA 
Custom AHN0YCF 
c.2313 
T>G 
CTGCCCAGCATGATGC
CTAT 
CGGTGTAGATTGGG
CAGGTT 
CAGCTGGACAC
AGCCA 
CAGCTGGACCC
AGCCA 
Custom AHO9WIN 
c.2414 
A>C 
CTGTGTCCAGGCCATC
ACT 
CCTGTGTTTAGCCT
CCATCGAA 
CGGCTACTCCC
ATCCCGT 
CGGCTACTCCC
CTCCCGT 
Custom AHQIUOV 
c.*172 
T>G 
GGAGACGAGGCCAAG
CT 
AGCAAAAAGCTTTG
AAGGCTTCAC 
CTGCAGCACCT
CCT 
CTGCAGCCCCT
CCT 
Custom AHRRSU3 
c.*519 
A>C 
CCACTTACCTTCCCCT
GAGTCA 
ATGACCTGTACTTCT
CTGCTCTCT 
TGCCCTCACTG
CCTC 
TGCCCTCCCTG
CCTC 
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Table 57: Applied Biosystems Taqman SNP Genotyping Primers and Probes for DNA repair 3’UTR SNPs genotyped. 
 
 
 
 
 
 
 
 
 
 
Table 58: Applied Biosystems Taqman SNP Genotyping Primers and Probes for MRE11A rs1805363. 
Assay Assay ID Gene Variant Forward Primer Reverse Primer VIC Reporter 1 FAM Reporter 2 
Custom AHHR7HC ATM 
rs1137918 
A>G 
GGTGAAACCCTGTCT
CTACTAAAAATACA 
CCTCCCAGGTTCAA
GAGATTCTC 
AGTAGCTGGGA
TTACAG 
AGTAGCTGGGA
CTACAG 
Custom AHI05NK ATM 
rs227091 
T>C 
CCTCCTGGGTTCAAG
CAATTCTC 
TGGCACACGCCTGT
AGTC 
AGCTACTCGGG
AGGCT 
AGCTACTCAGG
AGGCT 
Pre-
designed 
C_3178688_10 BRCA1 
rs8176318 
G>T     
Pre-
designed 
C_29356_10 BRCA1 
rs12516 
C>T     
Pre-
designed 
C_11881871_10 LIG3 
rs4796030 
C>A     
Pre-
designed 
C_2440679_10 NBS1 
rs2735383 
G>C     
Pre-
designed 
C_9632806_10 PARP1 
rs8679 
T>C     
Pre-
designed 
C_29187507_10 RAD51 
rs7180135 
A>G     
Assay Assay ID Gene Variant Forward Primer Reverse Primer VIC Reporter 1 FAM Reporter 2 
Pre-
designed 
C_11474841_10 MRE11A 
rs1805363 
G>A     
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11.1.7. Illumina Sequencing Adaptors and Indexes 
Table 59: Illumina sequencing adaptor oligonucleotide sequences and index sequences (in brackets). 
Index 5'adaptor 3'adaptor 
Unindexed ACACTCTTTCCCTACACGACGCTCTTCCGATCT AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CAACCT) (GGTTGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
2 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(AACCAT) (TGGTTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
3 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(AAGGAT) (TCCTTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
4 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(AATTAT) (TAATTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
5 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(ACACAT) (TGTGTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
6 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GCATGT) (CATGCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
7 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TCGATT) (ATCGAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
8 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CGATCT) (GATCGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
9 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(AGCTAT) (TAGCTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
10 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GGTTGT) (CAACCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
11 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TGCATT) (ATGCAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
12 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GCCGGT) (CCGGCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
13 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GATCGT) (CGATCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
14 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CCTTCT) (GAAGGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
15 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TACGTT) (ACGTAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
16 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TCAGTT) (ACTGAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
17 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CAGTCT) (GACTGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
18 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CGTACT) (GTACGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
19 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TATATT) (ATATAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
20 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(AGTCAT) (TGACTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
21 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GAAGGT) (CCTTCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
22 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GACTGT) (CAGTCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
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Index 5'adaptor 3'adaptor 
23 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CATGCT) (GCATGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
24 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TCCTTT) (AAGGAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
25 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GCGCGT) (CGCGCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
26 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CCGGCT) (GCCGGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
27 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(ACGTAT) (TACGTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
28 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TCTCTT) (AGAGAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
29 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(ACTGAT) (TCAGTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
30 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GGAAGT) (CTTCCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
31 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TAATTT) (AATTAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
32 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CACACT) (GTGTGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
33 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GAGAGT) (CTCTCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
34 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CCAACT) (GTTGGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
35 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(ACCAAT) (TTGGTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
36 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GCTAGT) (CTAGCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
37 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(TGACTT) (AGTCAA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
38 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(AGAGAT) (TCTCTA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
39 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(GGCCGT) (CGGCCA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
40 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(CGCGCT) (GCGCGA)GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
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11.2. Appendix B 
11.2.1. Ethical Approval Letters 
11.2.1.1. Leeds (East) Local Research Ethical Committee 02/192 
11.2.1.2. Leeds (East) Local Research Ethical Committee studies 02/060 
11.2.1.3. Leeds (East) Local Research Ethical Committee 04/Q1206/62 
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11.2.2. Study Forms 
11.2.2.1. LBCS Case Study Information Letter 
 
 
 285 
 
  
 
The second study is looking at the differences in a person’s DNA, compared to other 
people’s, which may make them more likely to develop bladder tumours. This 
information might help us in the future to prevent bladder tumours developing in people 
at high risk of the disease. If you agree to take part in this study, we would ask you to 
consent to provide a further 5 ml of blood (at the same time as the other sample), and to 
fill in a simple questionnaire, regarding your smoking habits, jobs, and family history, 
which will be checked with you afterwards by a doctor or nurse.  
 
These studies will use samples from many patients treated in the Department of Urology 
and they are intended to provide valuable information about molecular changes in a 
large group of patients. The second study will also involve other hospital patients and 
relatives and friends of a similar age who do not have bladder tumours. 
 
Samples once donated are treated as a ‘gift’ to the hospital. They would be kept 
indefinitely within the hospital and laboratories (until they are used up), and may be 
used in this project and in future research. Scientific research is collaborative and this 
sometimes involves exchange of samples between laboratories worldwide.  We work 
with other laboratories in this way and may share samples to increase the range of 
measurements that can be made and increase their usefulness.  It is very important that 
you are sure you are happy for us to keep and use these samples, before you agree to 
donate them.  
 
All information collected about you during the study will be kept strictly confidential. 
Your questionnaire answers will be used by the researchers to link these facts with any 
findings we may make, so that we can evaluate our results. We would also like your 
permission to send results of the questionnaire data and blood analysis abroad to other 
researchers working in this field, but no one from outside the hospital could identify you 
from the reports. The results of studies arising from this research programme may be 
published in the medical literature but your identity and personal information will 
remain strictly confidential at all times. 
 
No special compensation arrangements have been made for this research programme. 
However, you rights to claim compensation from the hospital for injury or loss as a 
result of your treatment remain unaffected by your participation in this study. 
 
For further information, or if you have any questions, please contact: 
 
Professor M Knowles 
Division of Cancer Medicine 
Cancer Research UK Clinical Centre in Leeds 
Cancer Research Building 
St James’s University Hospital 
Beckett Street 
LEEDS LS9 7TF 
 
Tel 0113 206 4913 
Dr Anne Kiltie 
Molecular Radiobiology Group 
Section of Oncology 
Leeds Institute of Molecular Medicine 
Cancer Research Building 
St James’s University Hospital 
Beckett Street 
LEEDS LS9 7TF 
Tel 0113 206 7275 
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11.2.2.2. LBCS Case Study Consent Form 
 
 
  
 287 
 
  
Both studies 
I give permission for my medical records to be used and looked at and  
analysed in the strictest confidence. 
 
I understand that future research using the sample(s) I give may include  
genetic research aimed at understanding the genetic influences on disease,  
but that the results of these investigations are unlikely to have any  
implications for me personally, and findings will not be disclosed to me. 
 
 
 
 
I understand that I am free to change my mind about donating samples for research purposes at 
any time without having to give a reason and without it affecting my medical care in any way. 
 
I agree to take part in the above study. 
 
Signed: ……………………………………………………… Date ………………. 
 
(NAME IN BLOCK LETTERS) ……………………………………………………….. 
 
 
Person taking consent (signature) …………………………………. Date ……………….. 
 
(NAME IN BLOCK LETTERS) ……………………………………………………….. 
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11.2.2.3. LBCS Control Study Information Letter 
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No special compensation arrangements have been made for this research programme. 
However, your rights to claim compensation from the hospital for injury or loss as a 
result of your treatment remain unaffected by your participation in this study. 
 
For further information, or if you have any questions, please contact: 
 
Dr Anne Kiltie 
Molecular Radiobiology Group 
Section of Experimental Oncology 
Leeds Institute of Molecular Medicine 
Cancer Research Building 
St James’s University Hospital 
Beckett Street 
LEEDS LS9 7TF        Tel 0113 206 7275 
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11.2.2.4. LBCS Control Study Consent Form 
 
  
 291 
11.2.2.5. LBCS study questionnaire 
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11.2.2.6. MIBC study Pre-treatment Assessment Form 
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11.2.2.7. MIBC study Late Effects Assessment Form 
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11.3. Appendix C 
 
11.3.1. MUTYH & XPC rare variants 
 
All the below tables are in the file “Appendix C.xlsx” on the attached CD. 
11.3.1.1. MUTYH & XPC variants detected by unindexed multiplexed NGS 
(NextGene used for variant calling) 
11.3.1.2. XPC variants detected by indexed multiplexed NGS (Illuminator used 
for variant calling) 
11.3.1.3. MUTYH & XPC variants detected by unindexed multiplexed NGS 
(Syzygy used for variant calling) 
11.3.1.4. MUTYH & XPC rare variants single marker bladder cancer case-
control study results  
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11.3.2. Analyses of confirmed MRE11A variants identified by indexed multiplexed NGS 
11.3.2.1. Cancer-specific survival and late normal tissue radiotherapy toxicity 
Table 60: Analysis for all confirmed MRE11A variants for associations with cancer-specific survival and radiotherapy toxicity. A multivariate 
survival-adjusted Cochran-Armitage trend test was performed for cancer-specific survival and an ordered logistic regression for late bladder and 
bowel radiotherapy toxicity. 
     
Cancer-specific survival Late Bladder Toxicity Late Rectal Toxicity 
NCBI hg19  
position/  
dbSNP rs  
number 
Variant base 
change 
Gene Region 
dbSNP 
MAF 
Observed 
MAF 
Per-allele HR 
(95%CI) 
P-
value 
Per-allele OR 
(95%CI) 
P-
value 
Per-allele OR 
(95%CI) 
P-
value 
rs11020802 G>T 5'-upstream 0.33 0.30 1.08 (0.74 - 1.59) 0.68 1.07 (0.67 - 1.72) 0.78 1.41 (0.74 - 2.69) 0.30 
rs1805363 G>A 
Intron 1  
(Isoform 1)/  
5'UTR  
(Isoform 2) 
0.11 0.11 1.97 (1.26 - 3.07) 0.003 1.70 (0.92 - 3.12) 0.09 1.71 (0.80 - 3.65) 0.17 
rs524350 T>C Intron 1 0.39 0.40 0.90 (0.63 - 1.28) 0.55 1.01 (0.64 - 1.57) 0.98 1.27 (0.68 - 2.38) 0.45 
rs11825497 G>C Intron 1 0.06 0.10 0.65 (0.35 - 1.18) 0.16 0.86 (0.40 - 1.83) 0.69 0.81 (0.27 - 2.46) 0.71 
Chr 11: 94226459 C>T Intron 1 N/A 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94226398 A>T Intron 1 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs684507 C>T Intron 1 0.41 0.40 0.90 (0.63 - 1.28) 0.55 1.01 (0.64 - 1.57) 0.98 1.27 (0.68 - 2.38) 0.45 
rs497763 G>A Intron 2 0.4 0.40 0.90 (0.63 - 1.28) 0.55 1.01 (0.64 - 1.57) 0.98 1.27 (0.68 - 2.38) 0.45 
rs496797 G>A Intron 2 0.4 0.40 0.90 (0.63 - 1.28) 0.55 1.01 (0.64 - 1.57) 0.98 1.27 (0.68 - 2.38) 0.45 
rs493982 C>T Intron 2 0.39 0.40 0.90 (0.63 - 1.28) 0.55 1.01 (0.64 - 1.57) 0.98 1.27 (0.68 - 2.38) 0.45 
Chr 11: 94225127 G>A Intron 2 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs11404578 Insertion T Intron 2 0.44 0.003 Insufficient events Insufficient events Insufficient events 
rs13447588  T>C Intron 2 0.006 0.003 Insufficient events Insufficient events Insufficient events 
rs13447590  G>C Intron 2 0.006 0.02 1.11 (0.33 - 3.75) 0.86 0.86 (0.16 - 4.55) 0.86 1.19 (0.14 - 10.35) 0.88 
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rs61893736 C>T Intron 2 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs10485020 T>A Intron 2 0.008 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94223936 C>T Intron 3 N/A 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94218991 A>G Intron 4 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs11020799 G>A Intron 4 0.36 0.37 0.91 (0.63 - 1.30) 0.59 0.93 (0.59 - 1.46) 0.75 1.08 (0.57 - 2.03) 0.82 
rs11020798 T>G Intron 4 0.05 0.10 0.22 (0.39-1.30) 0.27 0.84 (0.38-1.84) 0.67 0.90 (0.30-2.74) 0.86 
rs13447601 
Insertion 
GAGATTTTTT 
Intron 4 0.25 0.20 0.90 (0.76-1.05) 0.19 0.93 (0.75-1.15) 0.50 0.84 (0.62-1.15) 0.28 
rs10501815 G>T Intron 5 0.06 0.10 0.68 (0.37 - 1.25) 0.22 0.80 (0.37 - 1.76) 0.59 0.87 (0.29 - 2.64) 0.81 
rs680695 T>C Intron 5 0.28 0.27 1.11 (0.74 - 1.67) 0.60 0.98 (0.60 - 1.59) 0.93 1.18 (0.61 - 2.29) 0.63 
rs535801 G>A Intron 5 0.33 0.27 1.11 (0.74 - 1.67) 0.60 0.98 (0.60 - 1.59) 0.93 1.18 (0.61 - 2.29) 0.63 
rs3218740 C>T Exon 6  0.002 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94211508 A>G Intron 6 N/A 0.008 0.48 (0.07 - 3.55) 0.48 Insufficient events Insufficient events 
rs5793683 Deletion C Intron 6 0.48 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94210491 T>C Intron 6 N/A 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94210210 C>A Intron 6 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs13447619 G>A Intron 6 0.01 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94209866 G>T Intron 6 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs13447623 A>G Intron 7 0.27 0.24 1.43 (1.00 - 2.08) 0.05 2.12 (1.30 - 3.45) 0.003 1.92 (1.02 - 3.61) 0.04 
rs610611 T>A Intron 8 0.32 0.61 0.81 (0.56 - 1.16) 0.25 0.56 (0.34 - 0.91) 0.02 0.45 (0.21 - 0.94) 0.03 
rs115244417 C>G Exon 9  N/A 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94200953 T>C Intron 10 N/A 0.003 3.01 (0.28 - 32.07) 0.36 Insufficient events Insufficient events 
rs78716391 G>C Intron 10 0.07 0.10 0.68 (0.37 - 1.25) 0.22 0.80 (0.37 - 1.76) 0.59 0.87 (0.29 - 2.64) 0.81 
Chr 11: 94200365 C>T Intron 10 N/A 0.03 0.65 (0.20 - 2.13) 0.48 2.26 (0.63 - 8.13) 0.21 0.78 (0.09 - 6.44) 0.82 
Chr 11: 94199802 G>A Intron 10 N/A 0.005 Insufficient events Insufficient events Insufficient events 
Chr 11: 94199571 A>G Intron 10 N/A 0.003 Insufficient events Insufficient events Insufficient events 
Chr 11: 94199359 T>C Intron 10 N/A 0.003 Insufficient events Insufficient events Insufficient events 
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rs533984 C>T Intron 10 0.39 0.37 0.83 (0.57 - 1.21) 0.34 1.09 (0.69 - 1.73) 0.71 1.56 (0.82 - 2.98) 0.18 
rs104895017 A>G Intron 10 0.01 0.01 Insufficient events 0.71 (0.07 - 7.00) 0.77 Insufficient events 
rs640627 G>A Intron 10 0.31 0.26 1.01 (0.67 - 1.54) 0.96 1.11 (0.67 - 1.85) 0.68 1.82 (0.92 - 3.62) 0.09 
Chr 11: 94197302 A>G Exon 11  N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs641936 T>C Intron 11 0.33 0.30 1.08 (0.74 - 1.59) 0.68 1.07 (0.67 - 1.72) 0.78 1.41 (0.74 - 2.69) 0.30 
Chr 11: 94197239 T>C Intron 11 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs13447654 A>G Intron 11 0.01 0.02 0.76 (0.18 - 3.20) 0.71 1.65 (0.36 - 7.61) 0.52 3.01 (0.55 - 16.50) 0.20 
rs13447655 A>G Intron 11 0.14 0.21 1.44 (0.99 - 2.09) 0.06 1.97 (1.20 - 3.24) 0.007 1.63 (0.85 - 3.13) 0.14 
Chr 11: 94196707 A>T Intron 11 N/A 0.008 0.99 (0.13 - 7.59) 0.99 Insufficient events Insufficient events 
Chr 11: 94196702 A>C Intron 11 N/A 0.008 0.99 (0.13 - 7.59) 0.99 Insufficient events Insufficient events 
Chr 11: 94196674 T>C Intron 11 N/A 0.003 4.54 (0.58 - 35.24) 0.15 Insufficient events Insufficient events 
Chr 11: 94196475 T>C Intron 11 N/A 0.003 6.95 (0.42 - 115.65) 0.18 Insufficient events Insufficient events 
rs657249 T>C Intron 11 N/A 0.27 1.11 (0.74 - 1.67) 0.60 0.98 (0.60 - 1.59) 0.93 1.18 (0.61 - 2.29) 0.63 
Chr 11: 94193845 Insertion CTC Intron 12 N/A 0.008 1.07 (0.55 - 2.08) 0.84 1.64 (0.73 - 3.68) 0.23 1.54 (0.68 - 3.48) 0.30 
rs10831230 G>T Intron 12 0.06 0.10 0.66 (0.36 - 1.20) 0.18 0.90 (0.42 - 1.92) 0.78 0.84 (0.28 - 2.55) 0.76 
rs592943 T>C Intron 12 0.27 0.61 1.22 (0.85 - 1.76) 0.28 1.76 (1.09 - 2.86) 0.02 2.20 (1.06 - 4.56) 0.04 
Chr 11: 94193208 A>C Intron 12 N/A 0.005 0.90 (0.12 - 6.74) 0.92 2.17 (0.13 - 35.34) 0.59 Insufficient events 
rs11020789 G>C Intron 12 0.06 0.10 0.66 (0.36 - 1.20) 0.18 0.90 (0.42 - 1.92) 0.78 0.84 (0.28 - 2.55) 0.76 
Chr 11: 94193178 C>T Intron 12 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs496190 T>C Intron 12 0.44 0.40 0.90 (0.63 - 1.29) 0.58 1.02 (0.65 - 1.60) 0.92 1.29 (0.69 - 2.40) 0.43 
rs61749249 C>A Exon 13  N/A 0.008 0.76 (0.10 - 5.69) 0.79 1.08 (0.10 - 12.13) 0.95 Insufficient events 
Chr 11: 94189265 G>T Intron 14 N/A 0.003 19.46 (1.18 - 321.29) 0.04 Insufficient events Insufficient events 
Chr 11: 94189161 G>A Intron 14 N/A 0.005 Insufficient events Insufficient events Insufficient events 
rs13447695 A>C Intron 15 0.05 0.03 1.16 (0.41 - 3.27) 0.78 0.80 (0.20 - 3.12) 0.74 Insufficient events 
rs13447696 C>G Intron 15 0.006 0.005 3.78 (0.48 - 29.98) 0.21 Insufficient events Insufficient events 
rs12222920 C>G Intron 15 0.06 0.10 0.66 (0.36 - 1.20) 0.18 0.90 (0.42 - 1.92) 0.78 0.84 (0.28 - 2.55) 0.76 
Chr 11: 94179824 G>A Intron 15 N/A 0.003 24.29 (2.85 - 206.91) 0.004 Insufficient events Insufficient events 
rs556477 C>T Intron 15 0.61 0.61 1.22 (0.85 - 1.76) 0.28 1.76 (1.09 - 2.86) 0.02 2.2 (1.06 - 4.56) 0.04 
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Chr 11: 94179497 A>G Intron 15 N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs1014666 A>G Intron 15 0.44 0.40 0.90 (0.63 - 1.29) 0.58 1.02 (0.65 - 1.60) 0.92 1.29 (0.69 - 2.40) 0.43 
Chr 11: 94170115 A>G Intron 17 N/A 0.02 1.49 (0.53 - 4.16) 0.45 0.42 (0.05 - 3.68) 0.43 Insufficient events 
rs530569 G>A Intron 17 0.3 0.27 1.11 (0.74 - 1.67) 0.60 0.98 (0.60 - 1.59) 0.93 1.18 (0.61 - 2.29) 0.63 
rs13447717 T>C Intron 17 0.06 0.09 0.70 (0.38 - 1.28) 0.24 0.84 (0.38 - 1.84) 0.67 0.90 (0.30 - 2.74) 0.86 
rs61893706 G>A Intron 17 N/A 0.03 2.68 (0.34 - 21.08) 0.35 Insufficient events Insufficient events 
rs113009211 G>C Intron 18 N/A 0.03 Insufficient events Insufficient events Insufficient events 
rs7126861 A>G Intron 18 0.07 0.10 0.66 (0.36 - 1.20) 0.18 0.90 (0.42 - 1.92) 0.78 0.84 (0.28 - 2.55) 0.76 
rs104895013 G>T Intron 18 N/A 0.008 1.01 (0.14 - 7.33) 1.00 4.42 (0.39 - 49.76) 0.23 3.66 (0.32 - 42.04) 0.30 
Chr 11: 94162799 T>C Intron 19 N/A 0.02 0.33 (0.05 - 2.41) 0.27 0.30 (0.04 - 2.46) 0.26 Insufficient events 
Chr 11: 94153102 G>A 
Exon 20  
3'UTR 
N/A 0.005 1.81 (0.25 - 13.21) 0.56 Insufficient events Insufficient events 
rs13447749 G>A 
Exon 20  
3'UTR 
0.06 0.05 0.83 (0.35 - 1.94) 0.67 2.11 (0.81 - 5.50) 0.13 1.38 (0.37 - 5.15) 0.63 
Chr 11: 94152721 A>C 
Exon 20  
3'UTR 
N/A 0.003 11.10 (1.24 - 99.79) 0.03 Insufficient events Insufficient events 
Chr 11: 94152660 C>T 
Exon 20  
3'UTR 
N/A 0.003 9.12 (1.13 - 73.54) 0.04 Insufficient events Insufficient events 
rs11020777 T>C 
Exon 20  
3'UTR 
0.11 0.08 0.90 (0.48 - 1.70) 0.75 0.86 (0.37 - 2.00) 0.73 1.06 (0.33 - 3.36) 0.92 
Chr 11: 94151932 T>C 
Exon 20  
3'UTR 
N/A 0.003 8.33 (1.08 - 64.00) 0.04 Insufficient events Insufficient events 
rs104895004 G>T 
Exon 20  
3'UTR 
N/A 0.003 Insufficient events Insufficient events Insufficient events 
rs2155209 A>G 
Exon 20  
3'UTR 
0.32 0.38 0.82 (0.57 - 1.18) 0.28 0.57 (0.35 - 0.92) 0.02 0.46 (0.22 - 0.95) 0.04 
Chr 11: 94150560 G>A 
Exon 20  
3'UTR 
N/A 0.003 2.46 (0.32 - 18.72) 0.38 Insufficient events Insufficient events 
rs13447762 T>G 3'-downstream 0.006 0.03 0.23 (0.03 - 1.66) 0.14 0.52 (0.11 - 2.54) 0.42 0.78 (0.09 - 6.44) 0.82 
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11.3.2.2. Bioinformatics functional predictions 
Table 61: Functional predictions for all confirmed MRE11A variants 
   
Coding Predicted miRNA binding 
Splicing/ Transcription 
factor binding site NCBI hg19 position/ 
dbSNP rs number 
Variant base 
change 
Gene Region 
Protein 
Change 
Polyphen SIFT 
miRNA-binding 
site 
ΔΔG (kJ/mol) 
rs11020802 G>T 5'-upstream Non-coding Non-coding 
ELF/BRCA1 transcription 
factor binding site 
rs1805363 G>A 
Intron 1  
(Isoform 1)/  
5'UTR  
(Isoform 2) 
Non-coding Nil 
5 bases 3' from  
Exon 1 GC donor splice 
site 
rs524350 T>C Intron 1 Non-coding Non-coding Nil 
rs11825497 G>C Intron 1 Non-coding Non-coding Nil 
Chr 11: 94226459 C>T Intron 1 Non-coding Non-coding Nil 
Chr 11: 94226398 A>T Intron 1 Non-coding Non-coding Nil 
rs684507 C>T Intron 1 Non-coding Non-coding Nil 
rs497763 G>A Intron 2 Non-coding Non-coding Nil 
rs496797 G>A Intron 2 Non-coding Non-coding Nil 
rs493982 C>T Intron 2 Non-coding Non-coding Nil 
Chr 11: 94225127 G>A Intron 2 Non-coding Non-coding Nil 
rs11404578 Insertion T Intron 2 Non-coding Non-coding Nil 
rs13447588  T>C Intron 2 Non-coding Non-coding Nil 
rs13447590  G>C Intron 2 Non-coding Non-coding Nil 
rs61893736 C>T Intron 2 Non-coding Non-coding Nil 
rs10485020 T>A Intron 2 Non-coding Non-coding Nil 
Chr 11: 94223936 C>T Intron 3 Non-coding Non-coding Nil 
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Chr 11: 94218991 A>G Intron 4 Non-coding Non-coding Nil 
rs11020799 G>A Intron 4 Non-coding Non-coding Nil 
rs11020798 T>G Intron 4 Non-coding Non-coding Nil 
rs13447601 
Insertion 
GAGATTTTTT 
Intron 4 Non-coding Non-coding Nil 
rs10501815 G>T Intron 5 Non-coding Non-coding Nil 
rs680695 T>C Intron 5 Non-coding Non-coding Nil 
rs535801 G>A Intron 5 Non-coding Non-coding 
6 bases 5' from  
Exon 6 AG receiver 
splice site 
rs3218740 C>T Exon 6  D142D (Synonymous) Nil Nil 
Chr 11: 94211508 A>G Intron 6 Non-coding Non-coding Nil 
rs5793683 Deletion C Intron 6 Non-coding Non-coding Nil 
Chr 11: 94210491 T>C Intron 6 Non-coding Non-coding Nil 
Chr 11: 94210210 C>A Intron 6 Non-coding Non-coding Nil 
rs13447619 G>A Intron 6 Non-coding Non-coding Nil 
Chr 11: 94209866 G>T Intron 6 Non-coding Non-coding Nil 
rs13447623 A>G Intron 7 Non-coding Non-coding Nil 
rs610611 T>A Intron 8 Non-coding Non-coding Nil 
rs115244417 C>G Exon 9  S334R Benign Tolerated Nil Nil 
Chr 11: 94200953 T>C Intron 10 Non-coding Non-coding Nil 
rs78716391 G>C Intron 10 Non-coding Non-coding Nil 
Chr 11: 94200365 C>T Intron 10 Non-coding Non-coding Nil 
Chr 11: 94199802 G>A Intron 10 Non-coding Non-coding Nil 
Chr 11: 94199571 A>G Intron 10 Non-coding Non-coding Nil 
Chr 11: 94199359 T>C Intron 10 Non-coding Non-coding Nil 
rs533984 C>T Intron 10 Non-coding Non-coding Nil 
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rs104895017 A>G Intron 10 Non-coding Non-coding Nil 
rs640627 G>A Intron 10 Non-coding Non-coding Nil 
Chr 11: 94197302 A>G Exon 11  H401R Benign Tolerated hsa-miR-892a -4.4 Nil 
rs641936 T>C Intron 11 Non-coding Non-coding Nil 
Chr 11: 94197239 T>C Intron 11 Non-coding Non-coding Nil 
rs13447654 A>G Intron 11 Non-coding Non-coding Nil 
rs13447655 A>G Intron 11 Non-coding Non-coding Nil 
Chr 11: 94196707 A>T Intron 11 Non-coding Non-coding Nil 
Chr 11: 94196702 A>C Intron 11 Non-coding Non-coding Nil 
Chr 11: 94196674 T>C Intron 11 Non-coding Non-coding Nil 
Chr 11: 94196475 T>C Intron 11 Non-coding Non-coding Nil 
rs657249 T>C Intron 11 Non-coding Non-coding Nil 
Chr 11: 94193845 Insertion CTC Intron 12 Non-coding Non-coding Nil 
rs10831230 G>T Intron 12 Non-coding Non-coding Nil 
rs592943 T>C Intron 12 Non-coding Non-coding Nil 
Chr 11: 94193208 A>C Intron 12 Non-coding Non-coding Nil 
rs11020789 G>C Intron 12 Non-coding Non-coding Nil 
Chr 11: 94193178 C>T Intron 12 Non-coding Non-coding Nil 
rs496190 T>C Intron 12 Non-coding Non-coding Nil 
rs61749249 C>A Exon 13  A492D 
Probably 
damaging 
Affect 
protein 
function 
hsa-miR-3659 6.6 Nil 
Chr 11: 94189265 G>T Intron 14 Non-coding Non-coding Nil 
Chr 11: 94189161 G>A Intron 14 Non-coding Non-coding Nil 
rs13447695 A>C Intron 15 Non-coding Non-coding Nil 
rs13447696 C>G Intron 15 Non-coding Non-coding Nil 
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rs12222920 C>G Intron 15 Non-coding Non-coding Nil 
Chr 11: 94179824 G>A Intron 15 Non-coding Non-coding Nil 
rs556477 C>T Intron 15 Non-coding Non-coding Nil 
Chr 11: 94179497 A>G Intron 15 Non-coding Non-coding Nil 
rs1014666 A>G Intron 15 Non-coding Non-coding Nil 
Chr 11: 94170115 A>G Intron 17 Non-coding Non-coding Nil 
rs530569 G>A Intron 17 Non-coding Non-coding Nil 
rs13447717 T>C Intron 17 Non-coding Non-coding Nil 
rs61893706 G>A Intron 17 Non-coding Non-coding Nil 
rs113009211 G>C Intron 18 Non-coding Non-coding Nil 
rs7126861 A>G Intron 18 Non-coding Non-coding Nil 
rs104895013 G>T Intron 18 Non-coding Non-coding Nil 
Chr 11: 94162799 T>C Intron 19 Non-coding Non-coding Nil 
Chr 11: 94153102 G>A Exon 20  3'UTR Non-coding Nil Nil 
rs13447749 G>A Exon 20  3'UTR Non-coding Nil Nil 
Chr 11: 94152721 A>C Exon 20  3'UTR Non-coding Nil Nil 
Chr 11: 94152660 C>T Exon 20  3'UTR Non-coding Nil Nil 
rs11020777 T>C Exon 20  3'UTR Non-coding Nil Nil 
Chr 11: 94151932 T>C Exon 20  3'UTR Non-coding Nil Nil 
rs104895004 G>T Exon 20  3'UTR Non-coding hsa-miR-338-5p 4.4 Nil 
rs2155209 A>G Exon 20  3'UTR Non-coding Nil Nil 
Chr 11: 94150560 G>A Exon 20  3'UTR Non-coding Nil Nil 
rs13447762 T>G 3'-downstream Non-coding Non-coding Nil 
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11.3.2.3. Linkage disequilibrium plot for all confirmed MRE11A variants  
(Figure in the file “Appendix C figures.pdf” on the attached CD”) 
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11.4. Appendix D 
11.4.1. DNA repair gene 3’UTR SNPs and predicted miRNA binding sites 
Table 62: All DNA repair gene 3’UTR SNPs identified located within a predicted miRNA 
binding site and predicted ∆G values. 
Gene, dbSNP 
ID & Allele 
Substitution 
Minor 
Allele 
Frequency 
Predicted 
miRNA 
binding 
Wildtype 
Allele 
∆G 
Variant 
Allele 
∆G 
∆∆G |ΔΔG| |ΔΔGtot|a 
XPC 
rs2229090 
C>G 
0.34 miR-339-3p -18.97 -28.82 9.85 9.85 113.27 
miR-520d-3p -19.02 -11.28 -7.74 7.74 
miR-934 -19.93 -13.4 -6.53 6.53 
miR-516b* -20.25 -15.45 -4.8 4.80 
miR-510 -26.57 -21.9 -4.67 4.67 
miR-877 -23.18 -18.7 -4.48 4.48 
miR-518e* -20.89 -16.66 -4.23 4.23 
miR-519c-5p -20.89 -16.66 -4.23 4.23 
miR-519b-5p -20.89 -16.66 -4.23 4.23 
miR-519a* -20.89 -16.66 -4.23 4.23 
miR-522* -20.89 -16.66 -4.23 4.23 
miR-523* -20.89 -16.66 -4.23 4.23 
miR-501-5p -18.36 -22.52 4.16 4.16 
miR-518c* -23.14 -19.02 -4.12 4.12 
miR-518d-5p -19.99 -15.88 -4.11 4.11 
miR-520c-5p -19.99 -15.88 -4.11 4.11 
miR-526a -19.99 -15.88 -4.11 4.11 
miR-150 -18.07 -22.17 4.1 4.10 
miR-373 -20.34 -16.35 -3.99 3.99 
miR-518f* -20.73 -16.79 -3.94 3.94 
miR-129-3p -24.73 -20.98 -3.75 3.75 
miR-186 -19.73 -23.31 3.58 3.58 
miR-196a -19.5 -15.97 -3.53 3.53 
miR-526b -18.47 -15.2 -3.27 3.27 
miR-140-5p -19.81 -16.76 -3.05 3.05 
miR-708 -22.71 -19.78 -2.93 2.93 
miR-939 -25.39 -22.48 -2.91 2.91 
miR-34c-3p -18.25 -21.13 2.88 2.88 
miR-302c -18.24 -15.36 -2.88 2.88 
miR-615-5p -25.71 -22.96 -2.75 2.75 
miR-658 -22.33 -19.71 -2.62 2.62 
miR-296-5p -22.9 -25.5 2.6 2.60 
miR-583 -23.85 -21.4 -2.45 2.45 
miR-675 -24.17 -21.75 -2.42 2.42 
miR-922 -21.85 -24.27 2.42 2.42 
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miR-874 -23.35 -20.95 -2.4 2.40 
miR-769-3p -20.66 -18.29 -2.37 2.37 
miR-491-5p -27.77 -29.81 2.04 2.04 
miR-520f -18.17 -16.16 -2.01 2.01 
miR-525-3p -19.18 -17.23 -1.95 1.95 
miR-205 -23.16 -25.05 1.89 1.89 
miR-525-5p -18.15 -16.26 -1.89 1.89 
miR-940 -24.91 -26.78 1.87 1.87 
miR-188-5p -19.11 -20.96 1.85 1.85 
miR-657 -23.51 -25.23 1.72 1.72 
miR-611 -30.32 -28.68 -1.64 1.64 
miR-518b -20.59 -22.1 1.51 1.51 
miR-181a -18.8 -17.46 -1.34 1.34 
miR-181d -20.75 -19.41 -1.34 1.34 
miR-486-3p -20.64 -19.4 -1.24 1.24 
miR-181b -20.14 -18.91 -1.23 1.23 
miR-936 -20.3 -21.5 1.2 1.20 
miR-184 -18.58 -19.67 1.09 1.09 
miR-376a -18.85 -19.9 1.05 1.05 
miR-212 -18.24 -17.39 -0.85 0.85 
miR-374b* -21.22 -20.46 -0.76 0.76 
miR-520c-3p -18.48 -17.8 -0.68 0.68 
miR-376c -19.05 -19.62 0.57 0.57 
miR-502-5p -24.41 -24.74 0.33 0.33 
miR-500 -23.04 -23.32 0.28 0.28 
miR-342-3p -20.8 -21.04 0.24 0.24 
miR-518a-3p -18.75 -18.77 0.02 0.02 
miR-188-3p -27.27 -27.27 0 0.00 
miR-637 -23.09 -23.09 0 0.00 
ATM rs227091 
T>C 
0.44 miR-217 -20.55 -15.14 -5.41 5.41 38.91 
miR-338-3p -19.43 -14.06 -5.37 5.37 
miR-199b-5p -18.31 -13.52 -4.79 4.79 
miR-939 -29.67 -34.39 4.72 4.72 
miR-199a-5p -20.72 -16.02 -4.7 4.70 
miR-24 -18.64 -14.81 -3.83 3.83 
miR-593* -18.39 -14.9 -3.49 3.49 
miR-196a -18.67 -22.01 3.34 3.34 
miR-134 -20.48 -17.22 -3.26 3.26 
miR-596 -30.88 -33.68 2.8 2.80 
miR-615-5p -22.73 -25.53 2.8 2.80 
miR-500 -21.21 -23.77 2.56 2.56 
miR-502-5p -18.7 -20.88 2.18 2.18 
miR-661 -25.15 -27.18 2.03 2.03 
miR-512-3p -18.26 -16.45 -1.81 1.81 
miR-125a-3p -19.45 -17.98 -1.47 1.47 
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miR-222 -19.98 -18.91 -1.07 1.07 
miR-142-3p -19.28 -18.29 -0.99 0.99 
miR-423-5p -18.46 -18.86 0.4 0.40 
miR-601 -18.5 -18.27 -0.23 0.23 
LIG3 
rs4796030 
C>A 
0.47 miR-612 -20.2 -14.84 -5.36 5.36 36.81 
miR-423-3p -20.98 -15.75 -5.23 5.23 
miR-346 -20.57 -15.4 -5.17 5.17 
miR-221 -19.39 -14.9 -4.49 4.49 
miR-888* -19.88 -15.52 -4.36 4.36 
miR-512-5p -19.69 -15.79 -3.9 3.90 
miR-615-3p -25.33 -21.63 -3.7 3.70 
miR-222 -24.35 -20.91 -3.44 3.44 
miR-525-3p -21.01 -17.71 -3.3 3.30 
miR-508-5p -20.99 -17.77 -3.22 3.22 
miR-377 -20.98 -18.13 -2.85 2.85 
miR-767-3p -20.08 -22.7 2.62 2.62 
miR-502-3p -18.04 -15.54 -2.5 2.50 
miR-941 -22.11 -19.82 -2.29 2.29 
miR-127-3p -21.14 -18.98 -2.16 2.16 
miR-619 -19.51 -21.66 2.15 2.15 
miR-188-3p -24.22 -22.14 -2.08 2.08 
miR-199b-5p -19.24 -21.29 2.05 2.05 
miR-191* -19.38 -21.02 1.64 1.64 
miR-342-3p -21.65 -20.07 -1.58 1.58 
miR-151-3p -18.83 -17.45 -1.38 1.38 
miR-572 -18.68 -20.04 1.36 1.36 
miR-501-3p -19.98 -18.73 -1.25 1.25 
miR-937 -23.01 -24.25 1.24 1.24 
miR-532-3p -29.00 -28.46 -0.54 0.54 
miR-220 -18.52 -18.54 0.02 0.02 
miR-199a-5p -21.55 -21.55 0 0.00 
miR-662 -20.71 -20.71 0 0.00 
BRCA1 
rs12516 C>T 
0.36 miR-874 -23.67 -13.75 -9.92 9.92 25.76 
miR-324-3p -21.78 -12.95 -8.83 8.83 
miR-623 -30.47 -23.46 -7.01 7.01 
miR-500 -22.59 -19.88 -2.71 2.71 
miR-501-5p -18.1 -15.39 -2.71 2.71 
miR-616 -19.93 -17.22 -2.71 2.71 
miR-181d -18.27 -15.56 -2.71 2.71 
miR-637 -25.74 -23.03 -2.71 2.71 
miR-199a-3p -19.4 -16.69 -2.71 2.71 
miR-199b-3p -19.4 -16.69 -2.71 2.71 
miR-639 -23.28 -21.34 -1.94 1.94 
miR-188-5p -27.88 -26.04 -1.84 1.84 
miR-146b-3p -19.27 -18.00 -1.27 1.27 
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miR-371-5p -20.75 -19.50 -1.25 1.25 
miR-942 -19.22 -18.69 -0.53 0.53 
miR-744 -23.85 -23.36 -0.49 0.49 
BRCA1 
rs8176318 
G>T 
0.35 miR-328 -22.49 -18.39 -4.1 4.10 21.82 
miR-565 -20.16 -16.21 -3.95 3.95 
miR-149 -20.88 -17.17 -3.71 3.71 
miR-146b-3p -20.4 -16.91 -3.49 3.49 
miR-345 -17.51 -14.21 -3.3 3.30 
miR-892b -18.94 -15.67 -3.27 3.27 
miR-639 -18.85 -20.36 1.51 1.51 
miR-423-5p -19.58 -19.58 0 0.00 
miR-518c* -20.46 -20.46 0 0.00 
PARP1 
rs8679 T>C 
0.17 miR-145 -20.54 -14.83 -5.71 5.71 17.42 
miR-105 -19.03 -14.12 -4.91 4.91 
miR-630 -19.73 -16.11 -3.62 3.62 
miR-302a -24.45 -27.63 3.18 3.18 
miR-302c -30.35 -32.43 2.08 2.08 
miR-302d -27.79 -29.86 2.07 2.07 
miR-302b -27.56 -25.9 -1.66 1.66 
miR-601 -20.81 -19.84 -0.97 0.97 
miR-500* -19.82 -20.46 0.64 0.64 
miR-502-3p -18.27 -18.84 0.57 0.57 
miR-151-5p -19.75 -19.75 0 0.00 
miR-196b -18.77 -18.77 0 0.00 
miR-199a-5p -23.83 -23.83 0 0.00 
miR-199b-5p -19.41 -19.41 0 0.00 
miR-296-5p -19.52 -19.52 0 0.00 
ATM 
rs1137918 
A>G 
0.22 miR-939 -23.78 -27.75 3.97 3.97 12.80 
miR-193a-5p -19.65 -15.96 -3.69 3.69 
miR-92a -18.15 -15.35 -2.8 2.80 
miR-508-5p -18.03 -20.39 2.36 2.36 
miR-565 -18.8 -20.67 1.87 1.87 
miR-516a-5p -19.82 -21.68 1.86 1.86 
miR-920 -18.52 -19.88 1.36 1.36 
miR-769-3p -23.3 -24.6 1.3 1.30 
miR-431 -19.4 -19.99 0.59 0.59 
miR-638 -26.1 -25.79 -0.31 0.31 
miR-299-3p -19.4 -19.09 -0.31 0.31 
miR-582-5p -18.67 -18.81 0.14 0.14 
miR-296-3p -21.94 -21.94 0 0.00 
miR-320 -21.02 -21.02 0 0.00 
miR-615-5p -25.13 -19.99 -5.14 5.14 
NBN (NBS1) 
rs2735383 
G>C 
0.32 miR-499 -14.03 -9.67 -4.36 4.36 8.70 
miR-508-3p -19.29 -14.95 -4.34 4.34 
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a|ΔΔGtot| is the sum of all |ΔΔG| values greater than 3kJ/mol only. 
NBN (NBS1) 
rs1063054 
A>C 
0.32 miR-24 -12.12 -15.99 3.87 3.87 6.92 
miR-191* -19.53 -16.48 -3.05 3.05 
miR-630 -22.65 -20.15 -2.5 2.50 
miR-145 -20.28 -18.61 -1.67 1.67 
miR-330-5p -18.7 -19.55 0.85 0.85 
miR-657 -24.59 -24.61 0.02 0.02 
miR-299-5p -18.75 -18.75 0 0.00 
RAD51 
rs7180135 
A>G 
0.47 miR-197 -18.32 -25.19 6.87 6.87 6.87 
miR-638 -19.23 -20.02 0.79 0.79 
miR-129-5p -18.62 -18.92 0.3 0.30 
miR-200a* -20.89 -20.62 -0.27 0.27 
LIG4 
rs3093772 
A>G 
0.11 miR-377 -11.34 -15.42 4.08 4.08 4.08 
BRCA2 
rs15869 A>C 
0.29 miR-653 -10.05 -10.05 0 0.00 0.00 
FEN-1 
rs4246215 
G>T 
0.39 miR-18a* -21.42 -19.54 -1.88 1.88 0.00 
miR-493* -15.71 -16.54 0.83 0.83 
LIG4 rs10131 
G>A 
0.10 miR-495 -5.38 -6.36 0.98 0.98 0.00 
MRE11A 
rs2155209 
A>G 
0.29 miR-744 -20.99 -20.02 -0.97 0.97 0.00 
miR-584 -18.6 -18.35 -0.25 0.25 
NBN (NBS1) 
rs9995 T>C 
0.32 miR-155 -18.22 -19.55 1.33 1.33 0.00 
miR-363* -18.62 -17.44 -1.18 1.18 
PARP2 
rs2700 A>C 
0.28 miR-9 -12.44 -12.14 -0.3 0.30 0.00 
miR-299-5p -12.26 -12.25 -0.01 0.01 
miR-330-5p -18.37 -18.37 0 0.00 
RAD23B 
(HR23B) 
rs11573727 
T>- 
0.34 miR-361-5p -8.26 -8.26 0 0.00 0.00 
RAD51 
rs11855560 
T>C 
0.47 miR-34a* -19.31 -21.24 1.93 1.93 0.00 
RAD51 
rs12593359 
T>G 
0.47 miR-766 -20.31 -18.32 -1.99 1.99 0.00 
miR-99b -20.51 -20.08 -0.43 0.43 
XPC 
rs1126547 
C>G 
0.12 miR-141 -15.16 -13.17 -1.99 1.99 0.00 
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